Generated by All in One SEO v4.9.5.1, this is an llms.txt file, used by LLMs to index the site.

# Oncotherm Kft.

## Sitemaps

- [XML Sitemap](https://oncotherm.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Bejegyzések

- [Medica 2025](https://oncotherm.com/medica-2025/) - From November 17 to 20, 2025, MEDICA in Düsseldorf once again gathered a large international audience of visitors and exhibitors from across the medical field. Oncotherm participated by presenting its hyperthermia technology and sharing updates on its clinical applications. Our booth provided an opportunity for constructive discussions with healthcare professionals and researchers interested in the
- [Medica 2025](https://oncotherm.com/hu/medica-2025/) - 2025. november 17. és 20. között a MEDICA Düsseldorf ismét nagyszámú nemzetközi látogatót és kiállítót gyűjtött össze az orvosi szektor minden területéről. Az Oncotherm részt vett az eseményen, bemutatva hipertermia technológiáját és ismertetve klinikai alkalmazásainak legfrissebb fejleményeit. Standunk lehetőséget biztosított konstruktív szakmai beszélgetésekre egészségügyi szakemberekkel és kutatókkal, akik érdeklődnek a hipertermia onkológiában történő alkalmazása iránt.
- [Health Asia 2025](https://oncotherm.com/de/health-asia-2025/) - Oncotherm war stolz darauf, erneut an der Health Asia 2025 teilzunehmen, Pakistans größter Gesundheits- und Medizinmesse, die vom 23. bis 25. Oktober 2025 im Karachi Expo Center stattfand. Diese jährliche Veranstaltung dient als zentrale Begegnungsplattform für Fachleute, Forscher und Führungskräfte im Gesundheitswesen und fördert die Zusammenarbeit sowie den Austausch von Ideen. Während der Messe präsentierte
- [Health Asia 2025](https://oncotherm.com/hu/health-asia-2025/) - Az Oncotherm büszkén vett részt ismét a Health Asia 2025 kiállításon, Pakisztán legnagyobb egészségügyi és orvosi ipari eseményén, amelyet 2025. október 23. és 25. között rendeztek a Karachi Expo Center-ben. Ez az éves rendezvény kulcsfontosságú találkozóhelyet biztosít az egészségügyi szektor szakemberei, kutatói és vezetői számára, elősegítve az együttműködést és az ötletek cseréjét. A kiállítás során
- [Medica 2025](https://oncotherm.com/de/medica-2025/) - Vom 17. bis 20. November 2025 versammelte die MEDICA in Düsseldorf erneut ein großes internationales Publikum von Besuchern und Ausstellern aus allen Bereichen der Medizin. Oncotherm nahm teil, um seine Hyperthermie-Technologie vorzustellen und aktuelle Informationen zu den klinischen Anwendungen zu teilen. Unser Stand bot die Gelegenheit zu konstruktiven Gesprächen mit Gesundheitsfachkräften und Forschern, die an
- [Philippinische FDA-Zulassung](https://oncotherm.com/de/philippines-fda/) - Oncotherm freut sich bekannt zu geben, dass sein onkologisches Hyperthermiegerät EHY-2030 die Zulassung der Philippinischen Food and Drug Administration (FDA) erhalten hat.Diese behördliche Genehmigung bestätigt, dass das EHY-2030 die geltenden Sicherheits-, Qualitäts- und Leistungsanforderungen erfüllt und somit für den klinischen Einsatz auf den Philippinen zugelassen ist. Die Zulassung stellt einen wichtigen Meilenstein in Oncotherms internationaler
- [Fülöp-szigeteki FDA engedély](https://oncotherm.com/hu/philippines-fda/) - Az Oncotherm örömmel jelenti be, hogy EHY-2030 onkológiai hipertermia készülékét jóváhagyta a Fülöp-szigeteki Élelmiszer- és Gyógyszerügyi Hatóság (FDA).Ez a szabályozási engedély megerősíti, hogy az EHY-2030 megfelel a vonatkozó biztonsági, minőségi és teljesítménybeli követelményeknek, így klinikai alkalmazása a Fülöp-szigeteken engedélyezett. Az engedély fontos mérföldkő az Oncotherm nemzetközi terjeszkedési stratégiájában, és erősíti a cég jelenlétét a délkelet-ázsiai
- [WHX Dubai 2026](https://oncotherm.com/whx-dubai-2026/) - February 9–12, 2026, the World Health Expo (WHX) Dubai brought together a record-breaking international audience of healthcare professionals, researchers, and innovators at the Dubai World Trade Centre and Dubai Exhibition Centre. This landmark event attracted over 235,000 registered visitors from more than 180 countries, alongside 4,300 exhibitors presenting the latest breakthroughs in medical technology, digital
- [WHX Dubai 2026](https://oncotherm.com/de/whx-dubai-2026/) - Vom 9. bis 12. Februar 2026 brachte die World Health Expo (WHX) Dubai ein rekordverdächtiges internationales Publikum aus Gesundheitsfachkräften, Forschern und Innovatoren im Dubai World Trade Centre und im Dubai Exhibition Centre zusammen. Diese bedeutende Veranstaltung zog über 235.000 registrierte Besucher aus mehr als 180 Ländern an, sowie 4.300 Aussteller, die die neuesten Durchbrüche in
- [WHX Dubai 2026](https://oncotherm.com/hu/whx-dubai-2026/) - 2026. február 9–12. között a World Health Expo (WHX) Dubai rekordlétszámú nemzetközi közönséget hozott össze egészségügyi szakemberekből, kutatókból és innovátorokból a Dubai World Trade Centre és a Dubai Exhibition Centre helyszínein. Ez a kiemelkedő esemény több mint 235 000 regisztrált látogatót vonzott 180-nál is több országból, valamint 4 300 kiállítót, akik az orvostechnológia, a digitális
- [Frohe Ostern!](https://oncotherm.com/de/happy-easter/) - Wir wünschen Ihnen und Ihren Liebsten ein frohes Osterfest voller Hoffnung, Erneuerung und neuer Anfänge.Möge diese besondere Zeit Ihnen Freude, Wärme und viele wertvolle Momente mit Ihren Nächsten bringen. Herzliche Ostergrüße vom gesamten Oncotherm Group Team!
- [Kellemes Húsvéti Ünnepeket!](https://oncotherm.com/hu/happy-easter/) - Kellemes húsvéti ünnepeket kívánunk Önnek és szeretteinek, tele reménnyel, megújulással és új kezdetekkel!Legyen ez a különleges időszak a boldogság, a meghittség és a közeli szeretteinkkel együtt töltött értékes pillanatok ideje. Az Oncotherm csapat minden munkatársa nevében kellemes húsvéti ünnepeket kívánunk!
- [Happy Easter!](https://oncotherm.com/happy-easter/) - Wishing you and your loved ones a joyful holiday filled with hope, renewal, and new beginnings. May this special time bring happiness, warmth, and moments to cherish with those closest to you. Warm Easter wishes from all of us at the Oncotherm Group.
- [Spotlight on Italy: Oncothermia Journal 37](https://oncotherm.com/oncothermia-journal-37/) - The latest special edition of the Oncothermia Journal vol. 37 shines a spotlight on the Italian market, reflecting the country’s growing role in the advancement of oncothermia. This issue brings together the highlights of the Oncotherm in Italy Conference, presenting cutting-edge clinical experiences and research. Also the central feature of this edition is the publication
- [Latest publications from Prof. András Szász](https://oncotherm.com/latest-publications-from-prof-andras-szasz/) - With continuous advancements in cancer treatment, we believe that Oncothermia (mEHT) holds the potential to revolutionize cancer care. Through recently published, groundbreaking research and presentations, we would like to offer our readers valuable insights into the role of Oncothermia in modern oncology, highlighting its transformative effect on current treatment approaches. Explore the latest Oncothermia,
- [Prof. Szász András legújabb publikációi](https://oncotherm.com/hu/prof-szasz-andras-legujabb-publikacioi/) - Ezekkel a közelmúltban publikált kiemelkedő kutatásokkal és előadásokkal arra törekszünk, hogy olvasóink megértsék az onkotermia szerepét a modern onkológiában, és rávilágítsunk a rákkezelés paradigmáira gyakorolt ​​átalakító hatására. Az Oncothermia, mEHT legfrissebb kiadványait itt találják: Szasz, A. (2024) Preclinical Verification of Modulated Electro-Hyperthermia — Part I. In Vitro Research International Journal of Clinical Medicine, 15, 257-298. Szasz,
- [Veröffentlichungen von Prof. András Szász](https://oncotherm.com/de/veroffentlichungen-von-prof-andras-szasz/) - Da die Krebsbehandlung immer weiter fortschreitet, glauben wir, dass der Ansatz der Oncothermie, der mEHT, das Potenzial hat, die Art und Weise, wie wir Krebs behandeln, zu verändern. Mit diesen kürzlich veröffentlichten herausragenden Forschungsergebnissen und Präsentationen möchten wir unseren Lesern ein Verständnis für die Rolle der Oncothermie in der modernen Onkologie vermitteln und ihren transformativen
- [Fókuszban Olaszország: Oncothermia Journal 37.](https://oncotherm.com/hu/oncothermia-journal-37/) - Az Oncothermia Journal legújabb különszáma (37. kötet) az olasz piacra irányítja a figyelmet, bemutatva az ország egyre fontosabb szerepét az onkotermia fejlődésében. A kiadvány összefoglalja az Oncotherm in Italy Conference legfontosabb előadásait, klinikai tapasztalatait és kutatási eredményeit. Kiemelt helyet kapott benne a nemrég alapított Società Italiana di Ipertermia Oncologica (SIIO) bemutatása is, amely mérföldkő az
- [Im Fokus: Italien – Oncothermia Journal Band 37](https://oncotherm.com/de/oncothermia-journal-37/) - Die neueste Sonderausgabe des Oncothermia Journal (Band 37) richtet den Blick auf den italienischen Markt und zeigt die wachsende Bedeutung Italiens für die Weiterentwicklung der Oncothermie. Diese Ausgabe fasst die Höhepunkte der Oncotherm in Italy Conference zusammen – mit neuesten klinischen Erfahrungen und Forschungsergebnissen. Ein zentrales Thema ist außerdem die Vorstellung der neu gegründeten Società
- [Philippines FDA Approval](https://oncotherm.com/philippines-fda/) - Oncotherm is pleased to announce that its EHY-2030 oncological hyperthermia device has received approval from the Philippines Food and Drug Administration (FDA). This regulatory clearance confirms that the EHY-2030 meets the applicable safety, quality, and performance requirements, allowing its clinical use in the Philippines. The approval represents an important milestone in Oncotherm’s international expansion strategy and strengthens the company’s presence
- [Health Asia 2025](https://oncotherm.com/health-asia-2025/) - Oncotherm was proud to once again take part in Health Asia 2025, Pakistan’s largest health and medical industry exhibition, held at the Karachi Expo Center from October 23-25 2025. This annual event serves as a key meeting point for professionals, researchers, and leaders across the healthcare sector, fostering collaboration and the exchange of ideas. During
- [Oncotherm in Italy presentations](https://oncotherm.com/oncotherm-in-italy-presentations/) - The Oncotherm in Italy seminar, held on April 2, 2025, at the Embassy of Hungary in Rome, was organized in partnership with the Hungarian Embassy and Oncotherm Kft. The event brought together leading experts in oncological hyperthermia - Prof. András Szász, Prof. Giammaria Fiorentini, Dr. Carrie Minnaar, and Dr. Elisabeth Arrojo - to present and
- [Oncothermia Journal Vol. 36 is here!](https://oncotherm.com/oncothermia-journal-vol-36-is-here/) - We are happy to announce that the Oncothermia Journal Vol. 36 is now available for download! We are pleased to announce the publication of the 36th volume of the Oncothermia Journal, featuring exciting new research and clinical insights from around the world! Read it by article here: Szász, A.: Peto’s “Paradox” and Six Degrees
- [Oncothermia Journal Band 36](https://oncotherm.com/de/oncothermia-journal-band-36/) - Wir freuen uns, Ihnen mitteilen zu können, dass das Oncothermia Journal Vol. 36 jetzt zum Download zur Verfügung steht! Wir freuen uns, die Veröffentlichung der 36. Ausgabe des Oncothermia Journal bekannt zu geben, die spannende neue Forschungsergebnisse und klinische Einblicke aus aller Welt präsentiert! Lesen Sie die Artikel einzeln hier: Szász, A.:
- [Oncothermia Journal Vol. 36](https://oncotherm.com/hu/oncothermia-journal-vol-36/) - Töltse le az Oncothermia Journl 36. kötetét! Örömmel jelentjük be az Oncothermia Journal 36. kötetének megjelenését, amely izgalmas új kutatási eredményeket és klinikai betekintéseket tartalmaz a világ minden tájáról! Szász, A.: Peto’s “Paradox” and Six Degrees of Cancer Prevalence Aloss, K. et al.: MEHT Accelerates Tumor Delivery and Improves Anticancer Activity of Doxorubicin Encapsulated
- [Oncotherm előadások Olaszországban](https://oncotherm.com/hu/oncotherm-eloadasok-olaszorszagban/) - 2025. április 2-án a Római Magyar Nagykövetség adott otthont az Oncotherm in Italy szemináriumnak, amelyet a nagykövetség és az Oncotherm Kft. közösen szervezett. Az eseményen a daganatterápiás hőkezelés nemzetközi szaktekintélyei – Prof. András Szász, Prof. Giammaria Fiorentini, Dr. Carrie Minnaar és Dr. Elisabeth Arrojo – mutatták be és vitatták meg a modulált elektro-hipertermia (mEHT) legfrissebb
- [Oncotherm-Präsentationen in Italien](https://oncotherm.com/de/oncotherm-prasentationen-in-italien/) - Am 2. April 2025 fand in der Ungarischen Botschaft in Rom das Oncotherm in Italy-Seminar statt, organisiert in Zusammenarbeit zwischen der Botschaft und Oncotherm Kft. Internationale Experten auf dem Gebiet der onkologischen Hyperthermie – Prof. András Szász, Prof. Giammaria Fiorentini, Dr. Carrie Minnaar und Dr. Elisabeth Arrojo – stellten dort die neuesten klinischen Erkenntnisse und
- [Oncothermia Journal 34. kötete](https://oncotherm.com/hu/oncothermia-journal-vol-34/) - Örömmel jelentjük be, hogy már elérhető az Oncothermia Journal 34. száma! Az Oncothermia Journal 34. száma megújult dizájnnal mutatja be a modulált elektro-hipertermia (mEHT) legfrissebb, különböző nagy hatású folyóiratokban megjelent publikációit. A kötet az első három cikkében a European Society of Hyperthermic Oncology (ESHO) legutóbbi, a németországi Kölnben tartott konferenciájának oncothermiás előadásait mutatja be. A konferencián
- [Oncothermia Journal Band 34](https://oncotherm.com/de/oncothermia-journal-vol-34/) - Wir freuen uns, Ihnen mitteilen zu können, dass das Oncothermia Journal Vol. 34 jetzt zum Download zur Verfügung steht! Mit neuem Design die 34. Ausgabe des Oncothermia Journals präsentiert die aktuellsten Informationen über modulierte Elektrohyperthermie (mEHT), die in verschiedenen hochrangigen Fachzeitschriften veröffentlicht wurden. In den ersten drei Artikeln werden die Oncothermie-Vorträge der jüngsten Konferenz der
- [Oncothermia Journal Vol. 34 is here!](https://oncotherm.com/oncothermia-journal-vol-34/) - We are happy to announce that the Oncothermia Journal Vol. 34 is now available for download! With a renewed design the 34th issue of the Oncothermia Journal presents the most updated information about modulated electro-hyperthermia (mEHT) published in various high-impact journals. In the first three articles, the volume presents the oncothermia presentations of the recent conference
- [Főelőadó: Prof. Szász András](https://oncotherm.com/hu/foeloado-prof-szasz-andras/) - Prof. Szász András volt a meghívott főelőadó a Cancer Research and Vaccination Summit 2025 című tudományos rendezvényen, amelyet az Egyesült Államokbeli Walthemben tartottak. Az eseményen onkológia, immunológia és biofizika szakértői gyűltek össze, hogy új, innovatív rákkezelési módszereket tárjanak fel. A Professzor előadásának középpontjában a Tumor-specifikus immunaktiváció és az abscopális hatás elektro-hipertermiával állt, amely során meggyőző
- [Hauptredner: Prof. András Szász](https://oncotherm.com/de/hauptredner-prof-andras-szasz/) - Prof. András Szász war der Hauptredner auf dem wissenschaftlichen Event Cancer Research and Vaccination Summit 2025, das in Walthem, USA, stattfand. Die Veranstaltung brachte Experten aus den Bereichen Onkologie, Immunologie und Biophysik zusammen, um neue Ansätze in der Krebsbehandlung zu erkunden. In seinem Hauptvortrag konzentrierte sich Prof. Szász auf die Tumorspezifische Immunaktivierung und den Abscopalen
- [Keynote speaker: Prof. András Szász](https://oncotherm.com/keynote-speaker-prof-andras-szasz/) - Prof. András Szász was the keynote speaker at the scientific event titled Cancer Research and Vaccination Summit 2025, in Walthem, USA, which brought together experts in oncology, immunology, and biophysics to explore novel approaches to cancer treatment. His keynote presentation focused on Tumor-Specific Immune Activation and the Abscopal Effect by Electro-Hyperthermia. His presentation provided compelling
- [We are MDR Approved](https://oncotherm.com/we-are-mdr-approved/) - Oncotherm achieves MDR Certification We are proud to share that Oncotherm has officially achieved Medical Device Regulation (Regulation (EU) 2017/745 on Medical Devices - MDR) certification under the European Union’s regulatory framework. This major milestone highlights our dedication to maintaining the highest standards of safety, quality, and innovation in the field of oncological medical technology.
- [MDR minősítést szereztünk](https://oncotherm.com/hu/oncotherm-mdr-minosites/) - Az Oncotherm mostantól MDR-minősítéssel rendelkezik! Örömmel osztjuk meg a hírt, hogy az Oncotherm hivatalosan is megszerezte az Európai Unió szigorú szabályozási rendszerének megfelelő MDR (Regulation (EU) 2017/745 on Medical Devices - MDR) tanúsítványt. Ez a jelentős mérföldkő megerősíti elkötelezettségünket a legmagasabb szintű biztonság, minőség és innováció iránt az onkológiai orvostechnika területén. Az MDR tanúsítás kulcsfontosságú
- [Oncotherm erhält MDR-Zertifizierung](https://oncotherm.com/de/oncotherm-erhalt-mdr-zertifizierung/) - Oncotherm erhält MDR-Zertifizierung Wir freuen uns sehr, bekannt geben zu dürfen, dass Oncotherm erfolgreich die Zertifizierung nach der Medical Device Regulation (Regulation (EU) 2017/745 on Medical Devices – MDR) der Europäischen Union erhalten hat. Dieser bedeutende Meilenstein unterstreicht unser konsequentes Engagement für höchste Standards in Sicherheit, Qualität und Innovation im Bereich der onkologischen Medizintechnologie. Die
- [Präsentationen von Veranstaltungen auf den Philippinen stehen zur Verfügung](https://oncotherm.com/de/prasentiationen-von-philippinen/) - Oncothermia Journal vol. 35 steht jetzt zum Download bereit, einschließlich der Präsentationen der Einführungsveranstaltung von Oncothermia auf den Philippinen! Die Präsentationen sind auch auf YOUTUBE verfügbar! Im Rahmen der umfassenden Veranstaltung wurden die jüngsten klinischen Erkenntnisse zur modulierten Elektro-Hyperthermie (mEHT) präsentiert. Dies umfasste eine Reihe von Fachvorträgen, unter anderem Vorträge von Prof. Dr. Pirus Ghadjar
- [Elérhetőek a Fülöp-szigeteki előadások](https://oncotherm.com/hu/philippines-event-presentations-available/) - Örömmel jelentjük be, hogy az Oncothermia Journal vol. 35 száma már letölthető a fülöp-szigeteki Oncothermia induló eseményének előadásaival együtt! Az előadások felvételét visszanézheti a YOUTUBE csatornánkon! A nagyszabású rendezvényen a modulált elektro-hipertermia (mEHT) legújabb klinikai eredményeit mutatták be olyan szakmai előadók, mint Prof. Dr. Pirus Ghadjar (Charité – Universitätsmedizin Berlin, Németország), Dr. Carrie Minnaar (University of
- [Philippines event presentations available](https://oncotherm.com/philippines-event-presentations-available/) - Oncothermia Journal vol. 35 is now available for download, including the presentations of the Launching event of Oncothermia in the Philippines! The presentations are also available on YOUTUBE! The large-scale event presented the latest clinical results of modulated electro-hyperthermia (mEHT) including a lineup of scientific presentations by Prof. Dr. Pirus Ghadjar (Charité – Universitätsmedizin Berlin,
- [Meet us at Arab Health 2025](https://oncotherm.com/meet-us-at-arab-health-2025/) - Join us at Arab Health 2025 in Dubai to connect with Oncotherm! Visit our booth SA.F56 at the Dubai World Trade Centre from January 27th to 30th, 2025! Explore the EHY-2030, our cutting-edge hyperthermia cancer treatment device, combining advanced technology with clinical expertise. Here’s what awaits you: Demonstrations of our innovative cancer treatment solutions Insights
- [Meet us at Arab Health 2025](https://oncotherm.com/hu/meet-us-at-arab-health-2025/) - Join us at Arab Health 2025 in Dubai to connect with Oncotherm! Visit our booth SA.F56 at the Dubai World Trade Centre from January 27th to 30th, 2025! Explore the EHY-2030, our cutting-edge hyperthermia cancer treatment device, combining advanced technology with clinical expertise. Here’s what awaits you: Demonstrations of our innovative cancer treatment solutions Insights
- [Meet us at Arab Health 2025](https://oncotherm.com/de/meet-us-at-arab-health-2025/) - Join us at Arab Health 2025 in Dubai to connect with Oncotherm! Visit our booth SA.F56 at the Dubai World Trade Centre from January 27th to 30th, 2025! Explore the EHY-2030, our cutting-edge hyperthermia cancer treatment device, combining advanced technology with clinical expertise. Here’s what awaits you: Demonstrations of our innovative cancer treatment solutions Insights
- [KOSG Symposium 2024](https://oncotherm.com/kosg-symposium-2024/) - On November 30, 2024, the Korean Oncologic-Hyperthermia Study Group (KOSG) Symposium took place at Inje University Haeundae Paik Hospital in the vibrant city of Busan, South Korea. The event brought together leading experts to explore advancements in oncological hyperthermia, focusing on its integration with cancer treatments such as radiotherapy and immunotherapy. Key sessions featured topics
- [KOSG Symposium 2024](https://oncotherm.com/hu/kosg-symposium-2024/) - On November 30, 2024, the Korean Oncologic-Hyperthermia Study Group (KOSG) Symposium took place at Inje University Haeundae Paik Hospital in the vibrant city of Busan, South Korea. The event brought together leading experts to explore advancements in oncological hyperthermia, focusing on its integration with cancer treatments such as radiotherapy and immunotherapy. Key sessions featured topics
- [KOSG Symposium 2024](https://oncotherm.com/de/kosg-symposium-2024/) - On November 30, 2024, the Korean Oncologic-Hyperthermia Study Group (KOSG) Symposium took place at Inje University Haeundae Paik Hospital in the vibrant city of Busan, South Korea. The event brought together leading experts to explore advancements in oncological hyperthermia, focusing on its integration with cancer treatments such as radiotherapy and immunotherapy. Key sessions featured topics
- [Oncotherm at Health Asia 2024](https://oncotherm.com/oncotherm-at-health-asia-2024/) - Oncotherm was proud to participate in Health Asia 2024, Pakistan's largest health and medical industry event, held at the Karachi Expo Center from 17th to 19th Ocotber, 2024 . This annual gathering brought together key stakeholders from across the healthcare industry. We showcased the EHY-2030 cancer treatment device, shared the proven benefits of Oncothermia (mEHT),
- [Oncotherm at Health Asia 2024](https://oncotherm.com/hu/oncotherm-at-health-asia-2024/) - Oncotherm was proud to participate in Health Asia 2024, Pakistan's largest health and medical industry event, held at the Karachi Expo Center from 17th to 19th Ocotber, 2024 . This annual gathering brought together key stakeholders from across the healthcare industry. We showcased the EHY-2030 cancer treatment device, shared the proven benefits of Oncothermia (mEHT),
- [Oncotherm at Health Asia 2024](https://oncotherm.com/de/oncotherm-at-health-asia-2024/) - Oncotherm was proud to participate in Health Asia 2024, Pakistan's largest health and medical industry event, held at the Karachi Expo Center from 17th to 19th Ocotber, 2024 . This annual gathering brought together key stakeholders from across the healthcare industry. We showcased the EHY-2030 cancer treatment device, shared the proven benefits of Oncothermia (mEHT),
- [Insights from Medica 2024](https://oncotherm.com/insights-from-medica-2024/) - From November 11 to 14, 2024, MEDICA in Düsseldorf brought together 80,000 visitors and over 5,000 exhibitors from 72 countries as the world’s leading medical trade fair. Oncotherm was proud to participate, presenting its oncological hyperthermia solutions to a global audience. Our booth became a focal point for meaningful discussions with healthcare professionals, researchers, and
- [Insights from Medica 2024](https://oncotherm.com/hu/insights-from-medica-2024/) - From November 11 to 14, 2024, MEDICA in Düsseldorf brought together 80,000 visitors and over 5,000 exhibitors from 72 countries as the world’s leading medical trade fair. Oncotherm was proud to participate, presenting its oncological hyperthermia solutions to a global audience. Our booth became a focal point for meaningful discussions with healthcare professionals, researchers, and
- [Insights from Medica 2024](https://oncotherm.com/de/insights-from-medica-2024/) - From November 11 to 14, 2024, MEDICA in Düsseldorf brought together 80,000 visitors and over 5,000 exhibitors from 72 countries as the world’s leading medical trade fair. Oncotherm was proud to participate, presenting its oncological hyperthermia solutions to a global audience. Our booth became a focal point for meaningful discussions with healthcare professionals, researchers, and
- [Oncothermie auf den Philippinen](https://oncotherm.com/de/oncothermie-auf-den-philippinen/) - Als bahnbrechenden Schritt im Kampf gegen den Krebs bereitet die Life1 Corporation, , ein führendes Vertriebsunternehmen auf den Philippinen, die Veranstaltung zur Einführung von Oncothermia am 1. Juni 2024 in der pulsierenden Stadt Makati auf den Philippinen vor. Die Veranstaltung, die in Zusammenarbeit mit Oncotherm organisiert wird, umfasst wissenschaftliche Präsentationen von angesehenen Fachleuten, die an
- [Launching at the Philippines](https://oncotherm.com/launching-at-the-philippines/) - Insights of the Philippines Launching event of Oncothermia Thank you to everyone who joined us on June 1st for the groundbreaking launch event of Oncothermia in the vibrant city of Makati, Philippines! It was an incredible day filled with innovation, inspiration, and a shared commitment to revolutionize cancer treatment. Hosted by Life1 Corporation, in collaboration
- [Beszámoló a Fülöp-szigeteki eseményről](https://oncotherm.com/hu/beszamolo-a-fulop-szigeteki-esemenyrol/) - Köszönjük mindenkinek, aki csatlakozott hozzánk június 1-jén az Oncothermia úttörő rendezvényén a Fülöp-szigeteki Makati nyüzsgő városában! A Life1 Corporation az Oncotherm-mel együttműködve, az Oncothermia kutatás vezető szakértőinek rangos sorát hívta össze, hogy egy konferencia keretein belül tudományos előadásokkal bemutassa azon ígéretes klinikai eredményeket, melyek központjában az oncotermia áll, bemutatva a potenciált, mely átalakíthatja az onkológia jövőjét
- [Auf den Philippinen gestartet](https://oncotherm.com/de/auf-den-philippinen-gestartet/) - Einblicke in das philippinische Launch-Event von Oncothermia Vielen Dank an alle, die am 1. Juni an der bahnbrechenden Eröffnungsveranstaltung von Oncothermia in der pulsierenden Stadt Makati auf den Philippinen teilgenommen haben! Es war ein unglaublicher Tag voller Innovation, Inspiration und gemeinsamer Verpflichtung, die Krebsbehandlung zu revolutionieren. Die Veranstaltung, die von der Life1 Corporation in Zusammenarbeit
- [In memoriam Mr. Ha-Chung Sung](https://oncotherm.com/in-memoriam-mr-ha-chung-sung/) - We learned with deep sorrow that Mr. Ha-Chung Sung, our esteemed partner and friend had recently passed away after a valiant battle with his illness. Though his battle may have been long and challenging, he faced each day with dignity, strength, and an unwavering sense of purpose. His passing leaves a deep void in our
- [In memoriam Ha-Chung Sung](https://oncotherm.com/hu/in-memoriam-mr-ha-chung-sung/) - Mély fájdalommal értesültünk arról, hogy Ha-Chung Sung úr, tisztelt partnerünk és barátunk hosszú küzdelem után betegségben elhunyt. Bár csatája hosszú és kihívásokkal teli volt, méltósággal, rendíthetetlen kitartással és céltudattal nézett szembe minden napjával. Elmúlása mély űrt hagy szívünkben és partnerségünkben. 17 éves partnerségünk során felbecsülhetetlen elkötelezettségével gazdagította együttműködésünket. Szerepének jelentősége nemcsak szakmai volt, hanem mélyen
- [Zum Gedenken an Herrn Ha-Chung Sung](https://oncotherm.com/de/zum-gedenken-an-herrn-ha-chung-sung/) - Mit tiefer Trauer haben wir erfahren, dass Herr Ha-Chung Sung, unser geschätzter Partner und Freund, kürzlich nach einem tapferen Kampf gegen seine Krankheit verstorben ist. Obwohl sein Kampf lang und schwer war, begegnete er jedem Tag mit Würde, Stärke und einem unerschütterlichen Sinn für Ziele. Sein Tod hinterlässt eine tiefe Lücke in unseren Herzen und
- [Neueste Veröffentlichungen](https://oncotherm.com/de/neueste-veroffentlichungen/) - Da die Krebsbehandlung immer weiter fortschreitet, glauben wir, dass der Ansatz der Oncothermie, der mEHT, das Potenzial hat, die Art und Weise, wie wir Krebs behandeln, zu verändern. Mit diesen kürzlich veröffentlichten herausragenden Forschungsergebnissen und Präsentationen möchten wir unseren Lesern ein Verständnis für die Rolle der Oncothermie in der modernen Onkologie vermitteln und ihren transformativen
- [Latest publications from 2024](https://oncotherm.com/latest-publications-from-2024/) - As cancer treatment is always advancing, we believe that the approach of Oncothermia, mEHT could be a potential to change the aspects of how we treat cancer. With these recently published outstanding research and presentations, we aim to provide our readers with an understanding of Oncothermia’s role in modern oncology, shedding light on its transformative
- [Legújabb publikációk](https://oncotherm.com/hu/legujabb-publikaciok-2024/) - Ezekkel a közelmúltban publikált kiemelkedő kutatásokkal és előadásokkal arra törekszünk, hogy olvasóink megértsék az onkotermia szerepét a modern onkológiában, és rávilágítsunk a rákkezelés paradigmáira gyakorolt ​​átalakító hatására. Az Oncothermia, mEHT legfrissebb kiadványait itt találja: Kim J-H, Shin J-Y, Lee S-Y. (2024) Treatment of pelvic and spinal bone metastases: Radiotherapy and hyperthermia alone vs. in combination
- [OncoSport Veranstaltungen](https://oncotherm.com/de/oncosport-veranstaltungen/) - Oncotherm ist stets bestrebt, die Freude am Freizeitsport und die Vorteile der Bewegung zu fördern. Wir nehmen aktiv an verschiedenen Sportveranstaltungen teil, sowohl als Einzelpersonen als auch in Teams, und vertreten Oncotherm mit Stolz. Auch im vergangenen Monat haben wir an außergewöhnlichen Veranstaltungen teilgenommen. OncoRun am NN Ultrabalaton 2024 Unsere unglaublichen Kolleginnen und Kollegen haben
- [OncoSport események](https://oncotherm.com/hu/oncosport-esemenyek/) - Az Oncotherm mindig örömmel támogatja a szabadidős sportok és a testmozgás előnyeit. Elkötelezettségünk mutatja, hogy aktívan részt veszünk különböző sporteseményeken egyénileg és csapatban is, büszkén képviselve az Oncotherm színeit. Az elmúlt hónapban is kiemelkedő eseményeken vettünk részt: OncoFutás az NN Ultrabalaton 2024 versenyen Hihetetlen kollégáink ismét sikeresen teljesítették 9 fős csapatban a 211 kilométeres Ultrabalaton
- [OncoSport events](https://oncotherm.com/oncosport-events/) - Oncotherm is always delighted to promote the enjoyment of leisure sports and the benefits of exercise. We actively participate in various sports events, both individually and in teams, proudly representing Oncotherm. In the past month, we have participated in extraordinary events as well. OncoRun at NN Ultrabalaton 2024 Our incredible colleagues have done it again!
- [Oncothermia in the Philippines](https://oncotherm.com/oncothermia-in-the-philippines/) - As a groundbreaking step in the fight against cancer, Life1 Corporation, leading distribution company in the Philippines, is preparing to host the launch event for Oncothermia on June 1, 2024 in the vibrant city of Makati, Philippines. Organized in collaboration with Oncotherm, the event will include a lineup of scientific presentations by esteemed professionals who
- [Oncothermia a Fülöp-szigeteken](https://oncotherm.com/hu/oncothermia-a-fulop-szigeteken/) - A rák elleni küzdelem úttörő lépéseként a Life1 Corporation, a Fülöp-szigetek egy vezető disztribútor vállalata egy napos konferenciát szervez az Oncothermia kezelésének bemutatására 2024. június 1-jén a Fülöp-szigeteken, a nyüzsgő Makati városában. Az Oncotherm-mel együttműködésben szervezett eseményen az Oncothermia kutatásában élenjáró, elismert szakemberek tudományos előadásait hallgathatják meg a résztvevők. Neves szakértők, köztük Prof. Dr. Szász
- [OncoRunners bei der Telekom Vivicitta 2024](https://oncotherm.com/de/oncorunners-bei-der-telekom-vivicitta-2024/) - Herzlichen Glückwunsch an unsere großartigen OncoRunners, die sich der Herausforderung gestellt haben, die 21 km lange Telekom Vivicittá – Budapests wichtigste Halbmarathondistanz für 2024 – zu erobern! Zum 39. Mal beteiligten sich am Wochenende über 23.000 Menschen am Lauffest. Fast 9.000 Amateur- und Profiläufer stellten sich bei schönem, sonnigem Laufwetter für die 21 Kilometer lange
- [OncoRunners at Telekom Vivicitta 2024](https://oncotherm.com/oncorunners-at-telekom-vivicitta-2024/) - Congratulations to our amazing OncoRunners for embracing the challenge of conquering the 21 km Telekom Vivicittá -Budapest's premier half-marathon distance for 2024! More than 23,000 people participated in the running festival for the 39th time over the weekend. Nearly 9,000 amateur and professional runners lined up for the 21-kilometer course in beautiful, sunny running weather,
- [OncoFutóink a Telekom Vivicitta-n 2024](https://oncotherm.com/hu/oncofutoink-a-telekom-vivicitta-2024/) - Gratulálunk kollégáinknak, akik sikeresen teljesítették 2024 első budapesti félmaratoni távját, a 21 km hosszú Telekom Vivicittát! Több mint 23 ezren vettek részt a hétvégén 39. alkalommal rendezett Telekom Vivicittá futófesztiválon, melyen közel 9000 amatőr és profi futó állt rajthoz a gyönyörű, napsütéses futóidőben, a cél a Margitszigeten volt. A versenynap április 21-éreesett, ahol kollégáink a
- [Interview mit Dr. Carrie Minnaar](https://oncotherm.com/de/interview-mit-dr-carrie-minnaar-2/) - Spannende Neuigkeiten in der Behandlung von Gebärmutterhalskrebs! Dr. Carrie Anne Minnaar, Expertin für hyperthermische Onkologie, enthüllt in ihrem aktuellen Interview bahnbrechende Erkenntnisse über die Anwendung der modulierten Elektrohyperthermie (mEHT) zur Behandlung von Gebärmutterhalskrebs. Dr. Minnaars Arbeit stellt einen bemerkenswerten Moment auf dem Weg dar, Onkothermie zugänglicher zu machen und die Behandlung von Gebärmutterhalskrebs zu verändern.
- [Interjú Dr. Carrie Minnaar-ral](https://oncotherm.com/hu/interju-dr-carrie-minnaar-ral/) - Izgalmas hírek a méhnyakrák kezelésében! Dr. Carrie Anne Minnaar, a hipertermiás onkológia szakértője a közelmúltban adott interjújában úttörő betekintést nyújt a modulált elektro-hipertermia (mEHT) méhnyakrák kezelésében történő alkalmazásába. Dr. Minnaar munkája figyelemre méltó pillanatot jelent az oncothermia hozzáférhetőbbé tételében és a méhnyakrák kezelésének átalakítására irányuló folyamatban. Az interú részleteit itt olvashatja!
- [Interview with Dr. Carrie Minnaar](https://oncotherm.com/interview-with-dr-carrie-minnaar/) - Exciting news in cervical cancer treatment! Dr. Carrie Anne Minnaar, expert in hyperthermic oncology, unveils groundbreaking insights into the application of modulated electro-hyperthermia (mEHT) for cervical cancer treatment in her recent interview. Dr. Minnaar's work marks a remarkable moment in the ongoing journey to make oncothermia more accessible and transforming cervical cancer treatment. Read the
- [Találkozzunk az Arab Health 2024 kiállításon!](https://oncotherm.com/hu/talalkozzunk-az-arab-health-2024-kiallitason/) - Get your ticket now! Találkozzon az Oncothermmel az Arab Health 2024 rendezvényén Dubaiban! Látogassa meg standunkat: SA.F56 a Dubai World Trade Centerben 2024. január 29. és február 1. között! Ismerje meg a klinikai szakértelmet technológiai innovációval ötvöző, EHY-2030 hipertermiás rákterápiás készülékünket. Mire számíthat? Készülékünk és rákkezelési megoldásunk bemutatása Betekintés a klinikai vizsgálati eredményekbe és a
- [Oncotherm az Arab Health 2024-en!](https://oncotherm.com/hu/insights-from-arab-healt-2024/) - Szeretnénk megköszönni mindenkinek, aki ellátogatott az Oncotherm standjára az Arab Health 2024 rendezvényen! Január 29. és február 1. között Dubaiban, az Egyesült Arab Emírségekben került megrendezésre az Arab Health 2024 rendezvénye, amelyen egészségügyi szakemberek és innovátorok széles skálája találkozott az együttműködések jegyében. Az Arab Health 2024 figyelemre méltó statisztikái: Több mint 3,450 kiállító a globális
- [Insights from Arab Healt 2024!](https://oncotherm.com/insights-from-arab-healt-2024/) - We would like to thank everyone who visited Oncotherm's booth at Arab Health 2024! From January 29th to February 1st in Dubai, UAE, Arab Health 2024 brought together a diverse array of healthcare professionals and innovators, creating an atmosphere of collaboration and discovery. The connections made and the collaborations initiated during this event have been
- [Einblicke in die Arab Health 2024!](https://oncotherm.com/de/einblicke-in-die-arab-health-2024/) - Wir möchten uns bei allen bedanken, die den Stand von Oncotherm auf der Arab Health 2024 besucht haben! Vom 29. Januar bis 1. Februar brachte die Arab Health 2024 in Dubai (VAE) eine Vielzahl von Fachleuten und Innovatoren aus dem Gesundheitswesen zusammen und schuf eine Atmosphäre der Zusammenarbeit und Entdeckung. Die auf dieser Veranstaltung geknüpften
- [ICHS and ESHO 2023 event coming soon!](https://oncotherm.com/ichs-and-esho-2023-event-coming-soon/) - Learn more about the event here! The next ICHS conference will be held with the annual meeting of ESHO – the European Society for Hyperthermic Oncology!The two events will take place at the same time and place, from 26 to 29 September in Cologne, Germany! As the object of both society is to promote the use
- [Hamarosan itt az ESHO és ICHS 2023 konferencia!](https://oncotherm.com/hu/hamarosan-itt-az-esho-es-ichs-2023-konferencia/) - ESHO 2023 A következő ICHS konferencia az ESHO – az European Society for Hyperthermic Oncology - éves konferenciájával kerül megrendezésre! A két rendezvény 2023. szeptember 26-29. között a németországi Kölnben, egy helyen és időben zajlik majd! ! Az alkalom kiváló lehetőséget jelenthet a különböző tudományágak közötti információcserére a rák kezelésében használt hőmérséklet biológiai hatásainak vizsgálatában.
- [Insights from ESHO-ICHS Meeting](https://oncotherm.com/insights-from-esho-ichs-meeting/) - Advancements in Hyperthermia and Immunotherapy Intersection We would like to thank those who participated in the latest event of ESHO-ICHS! The conference of the European Society for Hyperthermic Oncology was held along with the ICHS - the Conference of International Clinical Hyperthermia Society - this year and took place in the city of Cologne in
- [Betekintés az ESHO-ICHS találkozóba](https://oncotherm.com/hu/betekintes-az-esho-ichs-talalkozoba/) - Előrelépések a hipertermia és az immunterápia vizsgálatában Ezúton szeretnénk köszönetet mondani azoknak, akik részt vettek az ESHO-ICHS legutóbbi rendezvényén! A European Society for Hyperthermic Oncology konferenciája idén az ICHS - the Conference of International Clinical Hyperthermia Society – rendezvényével került megrendezésre a németországi Köln városában szeptember 26. és 29. között. E két találkozó konvergenciája, amelyek
- [Latest publications - ICHS and Research](https://oncotherm.com/latest-publications-ichs-and-research/) - As cancer treatment is always advancing, we believe that the approach of Oncothermia, mEHT could be a potential to change the aspects of how we treat cancer. With these recently published outstanding research and presentations, we aim to provide our readers with an understanding of Oncothermia's role in modern oncology, shedding light on its transformative
- [Legújabb publikációink - ICHS és kutatások](https://oncotherm.com/hu/legujabb-publikacioink-ichs-es-kutatasok/) - Ezekkel a közelmúltban publikált kiemelkedő kutatásokkal és előadásokkal arra törekszünk, hogy olvasóink megértsék az onkotermia szerepét a modern onkológiában, és rávilágítsunk a rákkezelés paradigmáira gyakorolt ​​átalakító hatására. Prezentációk és absztraktok az ESHO-ICHS eseményről: Minnaar,C.A.;Kotzen,J.A.: Modulated electro-hyperthermia added to chemoradiotherapy improves five-year survival: final results of a phase III randomised controlled trial, 35th Annual Meeting of
- [ICHS und ESHO 2023 Veranstaltung in Kürze!](https://oncotherm.com/de/ichs-und-esho-2023-veranstaltung-in-kuerze/) - ESHO 2023 Die nächste ICHS-Konferenz wird zusammen mit der Jahrestagung der ESHO - der Europäischen Gesellschaft für Hyperthermische Onkologie - stattfinden!Die beiden Veranstaltungen werden zur gleichen Zeit und am gleichen Ort stattfinden, vom 26. bis 29. September in Köln, Deutschland!! Da es das Ziel beider Gesellschaften ist, den Einsatz von Hyperthermie in der Krebstherapie zu
- [Einblicke von der ESHO-ICHS-Tagung](https://oncotherm.com/de/einblicke-von-der-esho-ichs-tagung/) - Fortschritte bei der Überschneidung von Hyperthermie und Immuntherapie Wir möchten uns bei allen bedanken, die an der letzten Veranstaltung der ESHO-ICHS teilgenommen haben! Die Konferenz der Europäischen Gesellschaft für Hyperthermische Onkologie wurde dieses Jahr zusammen mit der ICHS - der Konferenz der Internationalen Gesellschaft für Klinische Hyperthermie - abgehalten und fand vom 26. bis 29.
- [Neueste Veröffentlichungen - ICHS und Forschung](https://oncotherm.com/de/neueste-veroeffentlichungen-ichs-und-forschung-2/) - Da die Krebsbehandlung immer weiter fortschreitet, glauben wir, dass der Ansatz der Oncothermie, der mEHT, das Potenzial hat, die Art und Weise, wie wir Krebs behandeln, zu verändern. Mit diesen kürzlich veröffentlichten herausragenden Forschungsergebnissen und Präsentationen möchten wir unseren Lesern ein Verständnis für die Rolle der Oncothermie in der modernen Onkologie vermitteln und ihren transformativen
- [Oncotherm at Medica 2023](https://oncotherm.com/oncotherm-at-medica-2023/) - We would like to thank everyone who visited Oncotherm's booth at Medica 2023! Taking place from November 13th to 16th in Düsseldorf, Germany, Medica stands as one of the world's premier trade fairs for the medical sector. We appreciate the numerous outstanding meetings we've had with you and are optimistic that they will pave the
- [Publications for Sarcoma and Bone Cancer Awareness Month](https://oncotherm.com/publications-for-sarcoma-and-bone-cancer-awareness-month/) - Sarcoma and Bone Cancer Awareness Month is a global healthcare event observed for the entire month of July every year for the last 15 years, symbolized by the yellow ribbon. Around the globe, a wide range of activities are being carried out to increase awareness about these forms of cancer and to support research and
- [Meet us at Arab Health 2024!](https://oncotherm.com/meet-us-at-arab-health-2024/) - Join us at Arab Health 2024 in Dubai to connect with Oncotherm! Visit our booth SA.F56 at Dubai World Trade Centre from January 29th to February 1st, 2024! Discover the EHY-2030 hyperthermia cancer treatment device, a fusion of clinical expertise and technological innovation. What to expect: Demonstration of our device and cancer treatment solution Insights
- [Wir wünschen Ihnen ein frohes Weihnachtsfest!](https://oncotherm.com/de/wir-wuenschen-ihnen-ein-frohes-weihnachtsfest/) - Liebe geschätzte Partner, wir nähern uns den Festtagen und lassen das vergangene Jahr Revue passieren. Wir möchten Ihnen von ganzem Herzen für das Vertrauen, die Zusammenarbeit und die gemeinsamen Erfolge danken, die unsere Partnerschaft ausgemacht haben. Mögen die Erinnerungen an dieses Jahr für Sie, Ihre Kollegen und Ihre Lieben gleichermaßen in Ehren gehalten werden. Für
- [We wish you a Merry Christmas and a Happy New Year!](https://oncotherm.com/we-wish-you-a-merry-christmas-and-a-happy-new-year-2/) - Dear valued Partners, As we approach the festive season and reflect upon the year that has been, we want to extend our heartfelt gratitude for the trust, collaboration and shared successes that have defined our partnership. May the memories of this year be cherished for you, your colleagues, and your loved ones alike. Looking ahead,
- [Boldog Karácsonyt és Sikekben gazdag, boldog Új Évet kívánunk!](https://oncotherm.com/hu/boldog-karacsonyt-es-sikekben-gazdag-boldog-uj-evet-kivanunk/) - Kedves Partnereink! Az ünnepi időszakhoz közeledve és az elmúlt évre gondolva szeretnénk kifejezni hálánkat a bizalomért, az együttműködésért és a közös sikerekért, amelyek meghatározták partnerségünket. Előretekintve azt kívánjuk, hogy a következő év egészségben és boldogságban gazdag legyen Önnek és egész családjának. Boldog, szeretetben és nevetésben gazdag karácsonyi ünnepeket és új lehetőségekben, növekedésben és közös eredményekben
- [Besuchen Sie uns auf der Arab Health 2024!](https://oncotherm.com/de/talalkozzunk-az-arab-health-2024-kiallitason/) - Get your ticket now! Besuchen Sie uns auf der Arab Health 2024 in Dubai und lernen Sie Oncotherm kennen! Besuchen Sie unseren Stand SA.F56 im Dubai World Trade Centre vom 29. Januar bis 1. Februar 2024! Entdecken Sie unser Hyperthermie-Krebsbehandlungsgerät EHY-2030, eine Verschmelzung von klinischem Fachwissen und technologischer Innovation. Was Sie erwartet: Demonstration unseres Geräts
- [Oncotherm auf der Medica 2023](https://oncotherm.com/de/oncotherm-auf-der-medica-2023/) - Wir möchten uns bei allen bedanken, die den Stand von Oncotherm auf der Medica 2023 besucht haben! Die Medica findet vom 13. bis 16. November in Düsseldorf statt und gilt als eine der weltweit größten Fachmessen für den medizinischen Sektor. Wir freuen uns über die zahlreichen hervorragenden Gespräche mit Ihnen und sind optimistisch, dass diese
- [OncoRunning in der 38th Wizz Air Budapest Halbmarathon](https://oncotherm.com/de/oncorunning-in-der-38th-wizz-air-budapest-halbmarathon/) - Wir sind stolz auf unsere OncoRunner, die letztes Wochenende am 38. Wizz Air Budapest Halbmarathon teilgenommen haben. Die Route führte durch das Herz von Budapest, über mehrere Brücken und an den bekanntesten Sehenswürdigkeiten der Stadt vorbei. Unserer Kollegen absolvierten die 21 km einzeln, während die anderen sich die Distanz des Halbmarathons in der Gruppe teilten.
- [Medica 2023](https://oncotherm.com/de/medica-2023/) - Medica 2023 - Get your ticket! Oncotherm hat spannende Pläne für die Teilnahme an der MEDICA 2023, wo wir unser loko-regionales Hyperthermiegerät vorstellen werden, das klinische Expertise mit technologischer Innovation verbindet. Wir möchten Sie einladen, uns vom 13. bis 16. November 2023 in Halle 15, Stand A02, in der pulsierenden Stadt Düsseldorf, Deutschland, zu besuchen.
- [Juli ist Monat der Sarkom- und Knochenkrebs Aufklärung](https://oncotherm.com/de/juli-ist-monat-der-sarkom-und-knochenkrebs-aufklaerung/) - Der Monat der Sarkom- und Knochenkrebsaufklärung ist eine weltweite Gesundheitsaktion, die seit 15 Jahren jedes Jahr im Juli stattfindet und durch die gelbe Schleife symbolisiert wird. Rund um den Globus werden zahlreiche Aktivitäten durchgeführt, um das Bewusstsein für diese Krebsarten zu schärfen und die Forschung und Fortschritte bei der Behandlung zu unterstützen. Wir möchten allen
- [Neue klinische Phase-2- und Phase-3-Studie mit mEHT](https://oncotherm.com/de/neue-klinische-phase-2-und-phase-3-studie-mit-meht/) - Wir freuen uns, den Beginn einer randomisierten klinischen Studie der Phasen II und III bekannt zu geben, bei der die mEHT-Methode zur Behandlung von Brustkrebspatientinnen eingesetzt wird. Die Studie, die mit dem Oncotherm EHY-2030 Gerät durchgeführt wird, wird in der Abteilung für Onkologie, Abteilung für Innere Medizin und Onkologie an der Semmelweis Universität in Ungarn unter der
- [Oncotherm auf der SantExpo2023!](https://oncotherm.com/de/oncotherm-auf-der-santexpo2023/) - Wir sind sehr dankbar für alle, die den Stand von Oncotherm auf der SantExpo 2023 besucht haben! SantExpo ist die führende französische Veranstaltung des französischen Krankenhausverbands, die jedes Jahr die führenden Köpfe der Branche zusammenbringt, um die neuesten Fortschritte und Innovationen im Bereich der Gesundheitsversorgung zu diskutieren. Dieses Jahr fand die Messe vom 23. bis
- [Bewusstsein für die Krebsüberlebenshilfe schärfen](https://oncotherm.com/de/bewusstsein-fuer-die-krebsueberlebenshilfe-schaerfen/) - Der Juni ist der Monat der Krebsüberlebenden (National Cancer Survivor Month), in dem wir die von Krebs betroffenen Menschen ehren und ihrer gedenken, um das Bewusstsein für das Überleben von Krebs zu schärfen und diejenigen zu unterstützen, die derzeit mit der Krankheit kämpfen. Im Rahmen unseres Engagements für diese wichtige Sache haben wir eine Reihe
- [Oncothermia Journal Band 33](https://oncotherm.com/de/oncothermia-journal-band-33/) - Wir freuen uns, Ihnen mitteilen zu können, dass das Oncothermia Journal Vol. 33 jetzt zum Download zur Verfügung steht! Wir empfehlen unseren Lesern den 33. Band unseres Journals, da in diesem Band wesentliche neue Ergebnisse veröffentlicht und vorgestellt werden. Die Artikel behandeln Themen wie die Rolle von Resonanzen in der modulierten Elektro-Hyperthermie zur gezielten Bekämpfung
- [OncoRunners beim UltraBalaton 2023!](https://oncotherm.com/de/oncorunners-beim-ultrabalaton-2023/) - Unsere unglaublichen Kollegen haben gerade wieder etwas Außergewöhnliches vollbracht! Einige unserer Kollegen haben den NN Ultrabalaton 2023, einen fast 211 km langen Lauf um den Balaton am ersten Maiwochenende, erfolgreich abgeschlossen! Dieses Jahr war der 17. Jahrestag, an dem der Ein-Runden-Lauf rund um den Balaton stattfand, der gleichzeitig der längste Lauf in Mitteleuropa ist. Unzählige
- [OncoRunners bei der Telekom Vivicitta 2023](https://oncotherm.com/de/oncorunners-bei-der-telekom-vivicitta-2023/) - Herzlichen Glückwunsch an unsere OncoRunner-Kollegen, die sich der Herausforderung der 21,0975 km langen Telekom Vivicittá gestellt haben – der ersten Halbmarathon-Distanz des Jahres 2023 in Budapest! Am 23. April, dem ersten echten Frühlingswochenende des Jahres, nahmen wir an einem Staffellauf teil, während einige unserer Kollegen auch einzeln liefen und die Distanz erfolgreich absolvierten. Wir sind stolz auf
- [Oncotherm auf der SantExpo 2023](https://oncotherm.com/de/oncotherm-auf-der-santexpo-2023/) - Oncotherm freut sich, Sie auf die #Santexpo einzuladen, die vom 23. bis 25. Mai 2023 an der Pariser Porte de Versailles stattfindet. Wenn Sie daran interessiert sind, mehr über unsere Technologie zu erfahren und darüber, wie Ihre Patienten davon profitieren können, besuchen Sie uns an unserem Stand U23 in Halle 1! Was können Sie erwarten?
- [Veröffentlichungen für den Monat des Bewusstseins für Gehirn- und Melanomkrebs](https://oncotherm.com/de/veroeffentlichungen-fuer-den-monat-des-bewusstseins-fuer-gehirn-und-melanomkrebs/) - Der Mai ist ein wichtiger Monat, um das Bewusstsein für einige Krebsarten zu schärfen, von denen Millionen von Menschen auf der ganzen Welt betroffen sind. Es ist der Monat des Bewusstseins für Hirntumore, Melanome und Hautkrebs, da diese Krankheiten jedes Jahr unzählige Menschen betreffen. Für diesen speziellen Monat haben wir einige informative Veröffentlichungen und Studien
- [Frohe Ostern!](https://oncotherm.com/de/frohe-ostern/) - Oncotherm wünscht frohe Ostern! Wir wünschen Ihnen und Ihrer Familie ein frohes Osterfest, erfüllt mit dem Versprechen von Neuanfängen und den Segnungen von Wohlstand und Fülle!
- [Mirakle Integrated Health Centre wählt Oncotherm-Gerät](https://oncotherm.com/de/mirakle-integrated-health-centre-waehlt-oncotherm-geraet/) - Das Mirakle Integrated Health Centre feierte die Eröffnung seines Hyperthermie-Behandlungszentrums in Pollachi, Indien, das sich auf dem Mahalingapuram Nachimuthu Polytechnic University Campus befindet. Die Einrichtung ist mit dem neuesten Oncotherm-Gerät, dem EHY-2030, ausgestattet, um den Patienten eine gezielte und wirksame Krebsbehandlung zu ermöglichen. Die Eröffnungsfeier umfasste eine Präsentationszeremonie und Vorträge über die Vorteile der Hyperthermie
- [Veröffentlichungen zum Darmkrebs-Bewusstseinsmonat](https://oncotherm.com/de/veroeffentlichungen-zum-darmkrebs-bewusstseinsmonat/) - Zum Monat März, dem Monat des nationalen Bewusstseins für Darmkrebs, haben wir für unsere Leser einige informative Veröffentlichungen und Studien zu diesem Thema zusammengestellt. Diese Krankheit stellt weltweit ein großes Gesundheitsproblem dar und ist eine der Hauptursachen für krebsbedingte Todesfälle. Unser Ziel ist es, einen positiven Beitrag im Kampf gegen Darmkrebs zu leisten, denn diese
- [In Gedenken an Prof. Dr. med. Alexander Herzog](https://oncotherm.com/de/in-memoriam-prof-dr-med-alexander-herzog/) - Mit tiefer Trauer haben wir erfahren, dass Professor Herzog verstorben ist. Er war ein renommierter, geachteter, ausgezeichneter Arzt, der Chefarzt seiner Klinik. Seine klinische Tätigkeit und seine Therapien waren sehr erfolgreich, umgeben von der Liebe der Patienten. Die vielen Patienten, deren Leben er verlängert hat, denken mit großer Zuneigung an ihn. Kollegen suchten ihn oft
- [Wir wünschen Ihnen ein frohes Weihnachtsfest und ein gutes neues Jahr!](https://oncotherm.com/de/wir-wuenschen-ihnen-ein-frohes-weihnachtsfest-und-ein-gutes-neues-jahr/) - Liebe Partner, am Ende dieses besonderen Jahres möchten wir Ihnen unsere aufrichtige Wertschätzung für Ihr Vertrauen, Ihr Interesse, Ihre Zeit und Ihre Unterstützung zum Ausdruck bringen. Wir hoffen, dass dieses Jahr für Sie, Ihre Kollegen und Ihre Lieben ebenso unvergesslich war. Wir hoffen, dass das nächste Jahr Ihnen und Ihrer ganzen Familie Gesundheit und Glück bringen
- [Wohltätigkeit zu Weihnachten](https://oncotherm.com/de/wohltaetigkeit-zu-weihnachten/) - Zum sechsten Mal in Folge pflegen wir die Tradition, mit unseren lieben Kollegen an der Benefizaktion „Shoebox“ teilzunehmen! Unser OncoTeam in Ungarn hat 28 Schuhkartons mit einer Auswahl an Spielzeug, Hygieneartikeln, Büchern und anderen Geschenken für kleine Mädchen und Jungen in Not vorbereitet. Da die Spende diese Woche am Sonntag endet, ist noch Zeit und
- [Das 10. KOSG-Symposium 2022](https://oncotherm.com/de/das-10-kosg-symposium-2022/) - Bitte klicken Sie hier, um die Playlist zu öffnen! Das 10. KOSG-Symposium (Korean Oncologic-hyperthermia Study Group) fand am 3. Dezember dieses Jahres im Haeundae Paik-Krankenhaus der Inje-Universität (on- und offline) statt. Es diente als Forum für Experten, um ihre Ideen über den Einsatz der onkologischen Hyperthermie zu diskutieren und ihre Forschungen und klinischen Erfahrungen zu
- [In Gedenken an Dr. med. Friedrich Rudolf Douwes](https://oncotherm.com/de/in-memoriam-dr-med-friedrich-rudolf-douwes/) - Mit tiefer Trauer haben wir erfahren, dass unser Kooperationspartner, Kollege und Freund für viele von uns, Dr. Friedrich Douwes, verstorben ist. Er war ein großer Arzt mit Ideen, Innovationen und großer internationaler Erfahrung. Für ihn war der Patient als Mensch wichtig. Er behandelte nie nur den Tumor, sondern betrachtete den Tumorpatienten als Ganzes in seinem
- [Oncotherm auf der Medica 2022](https://oncotherm.com/de/oncotherm-auf-der-medica-2022/) - Medica 2022 Wir bedanken uns bei allen die den Stand von Oncotherm auf der Medica 2022 besucht haben! Eine der weltweit größten Fachmessen für die Medizinbranche fand letzte Woche vom 14. bis 17. November in Düsseldorf, Deutschland. Es war eine Freude, wieder persönliche Kontakte und Gespräche zu führen. Wir freuen uns auch über einige ausgezeichnete
- [Oncothermia Journal Volume 32 is avaliable](https://oncotherm.com/de/mar-letoltheto-az-oncothermia-journal-32-kotete/) - Wir freuen uns Ihnen mitzuteilen, dass der 32. Band des Oncothermia Journal ab sofort zum Download bereitsteht! OOncotherm hält es für sehr wichtig, diejenigen zu informieren, die an den neuesten Ergebnissen der Hyperthermie und den Trends auf dem aufstrebenden Gebiet der Onkologie interessiert sind. Die Artikel dieses Bandes umfassen zum Teil Präsentationen von Kliniken, die Hyperthermie anwenden
- [OncoRunning in der 37th Wizz Air Budapest Halbmarathon](https://oncotherm.com/de/oncorunning-in-der-37th-wizz-air-budapest-halbmarathon/) - Wir sind stolz auf unsere OncoRunner, die letztes Wochenende am 37. Wizz Air Budapest Halbmarathon teilgenommen haben. Die Route führte durch das Herz von Budapest, über mehrere Brücken und an den bekanntesten Sehenswürdigkeiten der Stadt vorbei. Drei unserer Kollegen absolvierten die 21 km einzeln, während die anderen sich die Distanz des Halbmarathons in der Gruppe
- [Medica 2022](https://oncotherm.com/de/medica-2022/) - Medica 2022 Wir freuen uns, Ihnen mitteilen zu können, dass Oncotherm in diesem Jahr an der Medica, einer der weltweit größten Messen für den medizinischen Sektor, teilnehmen wird. Wenn Sie mehr über unsere Methode und Geräte erfahren möchten, besuchen Sie uns an unserem Stand in Halle 15, Stand A32!
- [Neuer Artikel in Cellsben: Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field](https://oncotherm.com/de/neuer-artikel-in-cellsben-forcing-the-antitumor-effects-of-hsps-using-a-modulated-electric-field/) - https://www.mdpi.com/2073-4409/11/11/1838 Absztrakt The role of Heat Shock Proteins (HSPs) is a “double-edged sword” with regards to tumors. The location and interactions of HSPs determine their pro- or antitumor activity. The present review includes an overview of the relevant functions of HSPs, which could improve their antitumor activity. Promoting the antitumor processes could assist in the
- [Sonderausgabe in Cancers](https://oncotherm.com/de/sonderausgabe-in-cancers/) - Klicken Sie hier, um weitere Informationen zum Sonderheft zu erhalten Die Zeitschrift "Cancers" (IF>6) lud Professor Andras Szasz ein, Gastherausgeber einer Sonderausgabe über lokale Hyperthermie zu sein. Prof. Szasz bat zwei renommierte Hyperthermie-Experten (Prof. S. Bodis und Prof. NR. Datta), gemeinsam mit ihm Mitherausgeber zu sein. Die Sonderausgabe ist eine große Chance für den Bereich
- [Zivile Allianz für die Zivilbevölkerung](https://oncotherm.com/de/zivile-allianz-fuer-die-zivilbevoelkerung/) - Es bricht uns das Herz, unsere Nachbarn in solcher Not zu sehen. Tausende von müden und verängstigten Zivilisten sind in den letzten Tagen in Ungarn angekommen, hauptsächlich Kinder, Frauen und ältere Menschen, die alles zurückgelassen haben. Unsere Kollegen beschlossen zu handeln und organisierten eine Spendensammlung für Flüchtlinge, die vor dem Krieg in der Ukraine geflohen
- [Prof. Dr. Andras Szasz: Heterogeneous Heat Absorption Is Complementary to Radiotherapy](https://oncotherm.com/de/prof-dr-andras-szasz-heterogeneous-heat-absorption-is-complementary-to-radiotherapy/) - Ein weiterer Artikel von Prof. Dr. Andras Szasz ist in Cancers erschienen. Abstract: (1) Background: Hyperthermia in oncology conventionally seeks the homogeneous heating of the tumor mass. The expected isothermal condition is the basis of the dose calculation in clinical practice. My objective is to study and apply a heterogenic temperature pattern during the heating
- [Ausstellung des Förderprogramms für die Gesundheitsindustrie](https://oncotherm.com/de/ausstellung-des-foerderprogramms-fuer-die-gesundheitsindustrie/) - Wir haben an einer Ausstellung teilgenommen, die vom ungarischen Finanzministerium für die Teilnehmer des "Unterstützungsprogramms für die Gesundheitsindustrie" organisiert wurde, dass die Abhängigkeit von ausländischen Lieferanten in der Gesundheitsindustrie verringern soll. Balázs Ács, Geschäftsführer der Oncotherm Kft., hat Mihály Varga, Finanzminister und stellvertretender Ministerpräsident, und Gábor Gion, Staatssekretär für Finanzen, unsere Leistungen im ersten Jahr
- [Health Industry Support Program's exhibition](https://oncotherm.com/health-industry-support-programs-exhibition/) - We participated in an exhibition organized by the Hungarian Ministry of Finance for the participants of the "Health Industry Support Program" that was established to reduce the dependence on foreign suppliers in the health industry. Balázs Ács, Managing Director of Oncotherm Kft. demonstrated our achievements during the first year of the Support Program to Mihály
- [Russian Health Care Week 2021](https://oncotherm.com/de/russian-health-care-week-2021/) - Die Russische Woche des Gesundheitswesen ist das größte Gesundheitsprojekt in Russland, das internationale Fachmessen, Kongresse, Foren, Konferenzen und andere Veranstaltungen zusammenführt. Die Veranstaltung wird von russischen Behörden und Regierungen, gesetzgebenden, föderalen und regionalen Exekutivorganen in den Bereichen Gesundheitswesen, Produktion und Tourismus unterstützt. Oncotherm Kft. nahm an der Konferenz am Stand von HEPA im Dezember 2021
- [39. Konferenz der internationalen Gesellschaft für klinische Hyperthermie](https://oncotherm.com/de/39-konferenz-der-internationalen-gesellschaft-fuer-klinische-hyperthermie/) - Die 39. Konferenz der internationalen Gesellschaft für klinische Hyperthermie (ICHS) fand am 5. November 2021 auf Zoom statt. Es war erfreulich, dass 100 Teilnehmer aus 19 Ländern ihre Anwesenheit organisieren konnten: Griechenland, Nordmazedonien, Niederlande, Spanien, Italien, Südkorea, Brasilien, Deutschland, Japan, Australien, Pakistan, Großbritannien, Ungarn, Portugal, Schweiz, Belgien, Taiwan. Die Präsentationen werden demnächst auf unserem YouTube- Kanal
- [TeSzedd - Freiwilligenarbeit für eine sauberes Ungarn](https://oncotherm.com/de/teszedd-freiwilligenarbeit-fuer-eine-sauberes-ungarn/) - Im Namen des Umweltbewusstseins haben die Kollegen von Ocotherm am 23. Oktober an der Müllsammelaktion von TeSzedd teilgenommen. TeSzedd – die freiwillige Aktion für ein sauberes Ungarn, ist eine der größten Bewegungen in Ungarn. Seit neun Jahren werden im ganzen Land Gemeinschaftsreinigungen organisiert.
- [Die 39. Konferenz der International Clinical Hyperthermia Society](https://oncotherm.com/de/die-39-konferenz-der-international-clinical-hyperthermia-society/) - …Aufgrund der Pandemiesituation findet am 5. November 2021 die 39. Konferenz der International Clinical Hyperthermia Society online statt. Im Namen des ICHS-Vorstands und nach Wahlabstimmung 2019 wird Dr. Elisabeth Arrojo zur Präsidentin der 38. ICHS-Konferenz und aufgrund der Pandemiesituation auch zur 39. Konferenz ernannt. Wir hoffen, dass wir Sie auf der Konferenz treffen können! Zögern Sie nicht,
- [Preisgekrönter Spezialist im Bereich Hyperthermie - ESTRO 2021](https://oncotherm.com/de/preisgekroenter-spezialist-im-bereich-hyperthermie-estro-2021/) - Die Estro ist einer der wichtigsten Fachveranstaltungen Europas für Radioonkologie. Die jährliche Konferenz fand dieses Jahr vom 24. bis 31. August in Madrid statt. Wie jedes Jahr hat das Unternehmen an der großen Ausstellung der Konferenz teilgenommen. Interessenten konnten uns am imposanten Stand 680 besuchen und mehr über das Gerät sowie über die Methode erfahren.
- [ESTRO 2021](https://oncotherm.com/de/estro-2021/) - ESTRO 2021 Das jährliche Meeting der ESTRO (European Society for Radiotherapy and Oncology) findet dieses Jahr vom 27. bis 31. August in Madrid statt. Neben der Veranstaltung vor Ort gibt es auch ein Onlineangebot. 27. August, 10:30 bis 11:30 Uhr Dr. Carrie Minnaar, Modulated electro-hyperthermia improves three-year survival in locally advanced cervical cancer patients 27.
- [Therapeutic Basis of Electromagnetic Resonances and Signal-Modulation](https://oncotherm.com/de/therapeutic-basis-of-electromagnetic-resonances-and-signal-modulation/) - https://doi.org/10.4236/ojbiphy.2021.113011 Andras Szasz, Therapeutic Basis of Electromagnetic Resonances and Signal-Modulation The medical application of electromagnetic resonances is a controversial area of knowledge. Numerous unproven statements and some medical quackeries were published and distributed in informal channels among suffering patients. The fake information is hazardous in such severe diseases as cancer. The optimal, high efficacy energy transport
- [Vascular Fractality and Alimentation of Cancer](https://oncotherm.com/de/vascular-fractality-and-alimentation-of-cancer/) - https://doi.org/10.4236/ijcm.2021.127025 Andras Szasz, Vascular Fractality and Alimentation of Cancer Background: The basal metabolic rate has a scaling by tumor mass on the exponent of 3/4, while a simple surface-supplied volume of the mass would have a lower exponent, 2/3. The higher exponent can be explained by optimizing the overall energy distribution in the tumor, assuming that
- [The Capacitive Coupling Modalities for Oncological Hyperthermia](https://oncotherm.com/de/the-capacitive-coupling-modalities-for-oncological-hyperthermia/) - https://doi.org/10.4236/ojbiphy.2021.113010 Andras Szasz, The Capacitive Coupling Modalities for Oncological Hyperthermia The local-regional oncological hyperthermia has various electromagnetic methods for energy-transfer. The differences involve conceptual considerations and technical solutions. The most frequently applied energy transfer is capacitive coupling, concentrating the electric field to be the active heating component. The realization of the capacitive coupling set-up is divided
- [African Society for Hyperthermia in Oncology](https://oncotherm.com/de/african-society-for-hyperthermia-in-oncology/) - Registration 3 HOUR CONFERENCE ON-LINE 4 EXCITING INTERNATIONAL SPEAKERS 4 LOCAL SPEAKERS · Prof Peter Wust; Radiation Oncology and Radiation Therapy Clinic, Charité Medical University, Berlin, Germany · Prof Nilroy Datta; Department of Radiotherapy, Mahatma Ghandi Institute of Medical Sciences, India · Prof András Szász; Biotechnics Department; St. Istvan University; Budapest, Hungary · Dr Guy Cooper; 20+Years experience in International Medical Devices; Worked for
- [Modulierte Elektrohyperthermie mit wöchentlichem Paclitaxel oder Cisplatin bei Patienten mit rezidivierendem oder persistierendem epithelialem Ovarial-, Eileiter- oder primärem Peritonealkarzinom: die KGOG 3030-Studie](https://oncotherm.com/de/modulierte-elektrohyperthermie-mit-woechentlichem-paclitaxel-oder-cisplatin-bei-patienten-mit-rezidivierendem-oder-persistierendem-epithelialem-ovarial-eileiter-oder-primaerem-peritonealkarzinom-d/) - Kidong Kim, Jaee‑Hoon Kim, Seung Cheol Kim, Yong Beom Kim, Byung‑Ho Nam, Jae Hong No, Hanyboul Cho, Woong Ju, Dong Hoon Suh and Yun Hwanr Kim The study (KGOG 3030) aimed to evaluate the safety of modulated electro‑hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into
- [Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial](https://oncotherm.com/modulated-electro‑hyperthermia-with-weekly-paclitaxel-or-cisplatin-in-patients-with-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-the-kgog-3030-tr/) - Kidong Kim, Jaee‑Hoon Kim, Seung Cheol Kim, Yong Beom Kim, Byung‑Ho Nam, Jae Hong No, Hanyboul Cho, Woong Ju, Dong Hoon Suh and Yun Hwanr Kim The study (KGOG 3030) aimed to evaluate the safety of modulated electro‑hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into
- [Oncothermia Journal 30.](https://oncotherm.com/de/oncothermia-journal-30/) - Wir freuen uns Ihnen mitzuteilen, dass der 30. Band des Oncothermia Journal ab sofort zum Download bereitsteht.
- [A modulált elektro-hipertermia kiemelkedő helyi stresszreakciót és növekedésgátlást vált ki az egér mellrák-izotópokban](https://oncotherm.com/hu/a-modulalt-elektro-hipertermia-kiemelkedo-helyi-stresszreakciot-es-novekedesgatlast-valt-ki-az-eger-mellrak-izotopokban/) - Csaba András Schvarcz, Lea Danics, Tibor Krenács, Pedro Viana, Rita Béres, Tamás Vancsik, Ákos Nagy, Attila Gyenesei, József Kun, Marko Fonović, Robert Vidmar, Zoltán Benyó, Tamás Kaucsár and Péter Hama, Abstract: Modulated electro‐hyperthermia (mEHT) is a selective cancer treatment used in human oncology complementing other therapies. During mEHT, a focused electromagnetic field (EMF) is generated
- [Modulated Electro‐Hyperthermia Induces a Prominent Local Stress Response and Growth Inhibition in Mouse Breast Cancer Isografts](https://oncotherm.com/modulated-electro‐hyperthermia-induces-a-prominent-local-stress-response-and-growth-inhibition-in-mouse-breast-cancer-isografts/) - Csaba András Schvarcz, Lea Danics, Tibor Krenács, Pedro Viana, Rita Béres, Tamás Vancsik, Ákos Nagy, Attila Gyenesei, József Kun, Marko Fonović, Robert Vidmar, Zoltán Benyó, Tamás Kaucsár and Péter Hama, Abstract: Modulated electro‐hyperthermia (mEHT) is a selective cancer treatment used in human oncology complementing other therapies. During mEHT, a focused electromagnetic field (EMF) is generated
- [Modulierte Elektrohyperthermie induziert eine ausgeprägte lokale Stressreaktion und Wachstumshemmung bei Maus-Brustkrebs-Isotransplantaten](https://oncotherm.com/de/modulierte-elektrohyperthermie-induziert-eine-ausgepraegte-lokale-stressreaktion-und-wachstumshemmung-bei-maus-brustkrebs-isotransplantaten/) - Autoren: Csaba András Schvarcz, Lea Danics, Tibor Krenács, Pedro Viana, Rita Béres, Tamás Vancsik, Ákos Nagy, Attila Gyenesei, József Kun, Marko Fonović, Robert Vidmar, Zoltán Benyó, Tamás Kaucsár and Péter Hama, Abstract: Modulated electro‐hyperthermia (mEHT) is a selective cancer treatment used in human oncology complementing other therapies. During mEHT, a focused electromagnetic field (EMF) is
- [Klinische Studie zur modulierten Elektrohyperthermie bei fortgeschrittenem metastasiertem Brustkrebs](https://oncotherm.com/de/klinische-studie-zur-modulierten-elektrohyperthermie-bei-fortgeschrittenem-metastasiertem-brustkrebs/) - Autoren: Takuya Nagata, Masahiko Kanamori, Shinichi Sekine, Mie Arai, Makoto Moriyama und Tsutomu Fuji Das Ziel dieser Studie war es, die Ergebnisse einer Behandlung mit modulierter Elektrohyperthermie (mEHT) bei der Therapie von fortgeschrittenem Brustkrebs zu begutachten. Das Verfahren wurde bei 10 Patienten mit fortgeschrittenem metastasiertem und wiederkehrendem Brustkrebs, der gemäß der Standardtherapieprotokolle als unheilbar galt,
- [Veröffentlichung im Oncothermia Journal](https://oncotherm.com/de/publikacio-az-oncothermia-journalban/) - Das Oncothermia Journal ist eine offizielle Publikation der Oncotherm Group. Es erscheint dreimal im Jahr und bietet Ärzten und anderen Experten die Möglichkeit, ihre Studienergebnisse und praktischen Erfahrungen mit der Oncothermie zu teilen. So soll die Methode unterstützt und der Öffentlichkeit zugänglich gemacht werden. Wenn Sie selbst eine wissenschaftliche Arbeit im Oncothermia Journal veröffentlichen möchten,
- [Oncothermia Journal 29.](https://oncotherm.com/de/oncothermia-journal-29/) - Wir freuen uns Ihnen mitzuteilen, dass der 29. Band des Oncothermia Journal ab sofort zum Download bereitsteht.
- [Aktuelle Publikationen](https://oncotherm.com/de/aktuelle-publikationen-2/) - A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19 Autor: Andras Szasz Abstract The COVID-19 pandemic has experienced unprecedented limitations and extraordinary scientific efforts to address this exceptional situation. Despite blanket closures that have resulted in significant financial constraints and losses around the world, research has an “unlimited” budget, with an exceptional concentration of medical
- [Frohe Weihnachten und einen guten Rutsch ins neue Jahr!](https://oncotherm.com/de/we-wish-you-a-merry-christmas-and-a-happy-new-year/) - Da sich dieses “ereignisreiche” Jahr dem Ende neigt möchten wir uns an dieser Stelle die Zeit nehmen und uns für Ihr Interesse, Ihre Zeit und die Unterstützung unseres Unternehmens bedanken. Wir hoffen, dass Sie in den kommenden Tagen etwas Ruhe finden und auf die eine (persönlich) oder andere (virtuell) Art Zeit mit Ihrer Familie und
- [KOSG-Präsentationen](https://oncotherm.com/de/kosg-prezentaciok/) - KOSG Playliste Wir freuen uns Ihnen mitzuteilen, dass die Präsentationen der KOSG Konferenz ab sofort auf unserem YouTube-Kanal verfügbar sind. Die Playliste können Sie hier aufrufen.
- [mEHT und SARS-Cov-2](https://oncotherm.com/de/meht-and-sars-cov-2/) - Lesen Sie den Artikel hier Das „Frontiers in Oncology ” hat einen Artikel von Prof. András Szász zum Thema mEHT und SARS-Cov-2 veröffentlicht. A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19 Authors: Syed Muzzammil Masaud, Oliver Szasz, A. Marcell Szasz, Huma Ejaz, Rana Attique Anwar and Andras
- [KOSG Symposium 2020](https://oncotherm.com/de/kosg-symposium-2020/) - Das jährliche KOSG (Korean Oncologic-hyperthermia Study Group) Symposium wurde am 28. November 2020 online abgehalten. Es bot Experten ein Forum, in dem sie ihre Ideen zur Anwendung der onkologischen Hyperthermie diskutieren und ihre Forschungsergebnisse und klinischen Erfahrungen vorstellen konnten. Das Thema „Quo Vadis oncological hyperthermia (2020)?” wurde von Prof. András Szász präsentiert. “Heating as a medical intervention
- [36. MAOT und 11. Sino – Hungarian Medical Forum](https://oncotherm.com/de/36th-maot-and-11-sino-hungarian-medical-forum/) - MAOT Konferenz offizielle Website Prof. András Szász hat während dem 36. MAOT und dem 11. Sino – Hungarian Medical Forum online über das interessante Thema „Oncothermia as part of integrative medicine” gesprochen. “Hyperthermia in oncology has long-standing history, having roots in ancient medicine. Both the Eastern and Western medicine had used it in holistic (whole-body fever with herbal administration)
- [ICHS-Präsentationen auf unserem YouTube-Kanal](https://oncotherm.com/de/elerhetoek-az-ichs-eloadasok-youtube-csatornankon/) - ICHS-Playliste Wir freuen uns Ihnen mitzuteilen, dass die Präsentationen der 38. ICHS Konferenz ab sofort auf unserem YouTube-Kanal verfügbar sind. Die Playliste können Sie hier aufrufen.
- [Ein besonderes Event: die 38. ICHS Konferenz](https://oncotherm.com/de/ein-besonderes-event-die-38-ichs-konferenz/) - Offizielle Website der Konferenz Die 38. Konferenz der International Clinical Hyperthermia Society fand am 5. November 2020 statt und war ein Novum in der Geschichte der ICHS. Aufgrund der aktuellen Umstände wurde nach sorgfältiger Prüfung beschlossen, die Konferenz nicht wie geplant als Präsenzveranstaltung durchzuführen, sondern sie online stattfinden zu lassen. Wir freuen uns sehr über
- [ICHS-Programm ist online](https://oncotherm.com/de/ichs-programm-ist-online/) - Wir freuen uns, dass Programm der 38. ICHS Konferenz mit Ihnen zu teilen. Die Abstracts und der Guide für die Nutzung von Zoom können Sie ab sofort auf der offiziellen Website einsehen. Wenn Sie Interesse an der Teilnahme haben, senden Sie bitte eine E-Mail mit den folgenden Daten an info@ichs.eu Titel, Name, Institution, Abteilung, Adresse, Land und E-Mail-Adresse Die
- [ICHS 2020 Online-Konferenz](https://oncotherm.com/de/ichs-2020-online-konferenz/) - ICHS offical website: Offizielle Website der ICHS Wir freuen uns sehr Ihnen mitteilen zu können, dass die 38. ICHS Konferenz am 5. November 2020 online stattfinden wird. Im Namen des ICHS-Vorstandes und entsprechend des Wahlergebnisses wird Prof. Elisabeth Arrojo zur Präsidentin der Konferenz ernannt. Die Veranstaltung wird aus zwei Teilen bestehen, in denen Präsentationen zum Thema Hyperthermie gehalten werden. Zum einen
- [Auf dem Weg zur immunogenen hyperthermischen Wirkung](https://oncotherm.com/de/auf-dem-weg-zur-immunogenen-hyperthermischen-wirkung/) - Das „Clinical Oncology and Research Journal” hat einen Artikel von Prof. András Szász zum Thema modulierte Elektro-Hyperthermie veröffentlicht. Towards the Immunogenic Hyperthermic Action: Modulated ElectroHyperthermia Abstract Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use. Modulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a novel, cellularly selective
- [Data Mining and Evaluation of Single Arm Clinical Studies](https://oncotherm.com/de/data-mining-and-evaluation-of-single-arm-clinical-studies/) - In dem Buch „Recent Developments in Engineering Research Vol. 3” (Dr. Yong X. Gan, Professor am Department of Mechanical Engineering der California State Polytechnic University, Pomona, USA) wurde ein Artikel zum Thema Oncothermie veröffentlicht. Data Mining and Evaluation of Single Arm Clinical Studie Autoren: O Szasz, AM Szasz, GP Szigeti, A Szasz Abstract Lifetime analyses frequently apply
- [OncoRunning](https://oncotherm.com/de/oncorunning/) - Am 6. September 2020 haben unsere Läufer am 35. „Wizz Air Budapest Half Marathon” teilgenommen. Die Strecke verlief entlang der berühmtesten Sehenswürdigkeiten von Budapest und die Läufer konnten die Donau, die Budapester Burg und die Innenstadt bewundern. Zwei unserer Teammitglieder haben den Halbmarathon komplett absolviert, die anderen als Gruppe. Herzlichen Glückwunsch, liebe OncoRunners!
- [Oncothermia Journal Special Edition](https://oncotherm.com/de/oncothermia-journal-special-edition/) - Wir freuen uns Ihnen mitzuteilen, dass der Special Edition des Oncothermia Journals ab sofort unter dem folgendem Link heruntergeladen werden kann: https://oncotherm.com/oncothermia-journal/oncothermia-journal-special-edition Der Redakteur Prof. András Szász äußert sich zu dem aktuellen Band: "Liebe Leserinnen und Leser, liebe Kolleginnen und Kollegen aus Forschung und Praxis, der aktuelle Band des Oncothermia Journals ist eine besondere Ausgabe. Wir
- [Details zur Wirkungsweise von mEHT Monotherapie](https://oncotherm.com/de/details-zur-wirkungsweise-von-meht-monotherapie/) - Das „International Journal of Molecular Sciences” hat einen bedeutenden Artikel zum Thema modulierte Elektrohyperthermie veröffentlicht. Wir gratulieren den Autoren! Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models Autoren: Tibor Krenacs, Nora Meggyeshazi, Gertrud Forika, Eva Kiss, Peter Hamar, Tamas Szekely and Tamas Vancsik Abstract The benefits of high-fever range hyperthermia have been utilized in medicine
- [Experiment mit personalisierter Dosierung von Hyperthermie](https://oncotherm.com/de/experiment-mit-personalisierter-dosierung-von-hyperthermie/) - In dem Buch „Current Topics in Medicine and Medical Research Vol. 3” von Dr. Shigenori Ito (Abteilung für Kardiologie im Sankuro Hospital, Toyota, Japan und Direktor des Japan Cardiovascular Imaging Core Laboratory) wurde ein Artikel mit Bezug zur Oncothermie veröffentlicht. Experiment mit personalisierter Dosierung von Hyperthermie Autoren: Gyula Peter Szigeti, Oliver Szasz and Gabriella Hegyi Abstract
- [Artikel zum Thema Oncothermie](https://oncotherm.com/de/artikel-zum-thema-oncothermie-2/) - Für den ganzen Artikel klicken Sie bitte hier Es wird ein Artikel zum Thema Oncothermie veröffentlicht, zu dem wir den Autoren gratulieren möchten! Modulated Electro-Hyperthermia Resolves Radioresistance of Panc1 Pancreas Adenocarcinoma and Promotes DNA Damage and Apoptosis In Vitro Autoren: Gertrud Forika, Andrea Balogh, Tamás Vancsik, Attila Zalatnai, Gabor Petovari, Zoltan Benyo, Tibor Krenacs Abstract
- [Buchveröffentlichung](https://oncotherm.com/de/buchveroeffentlichung/) - Das Buch ist auf dieser Website verfügbar. In dem Buch „New Insights Into Physical Science“ wurden zwei interessante Artikel veröffentlicht. Einer davon, der das Thema Oncothermie behandelt, trägt den Titel „Development in Oncological Hyperthermia“ und wurde von Dr. Olivér Szász verfasst. Die onkologische Hyperthermie steht vor mehreren ungelösten medizinischen und technischen Problemen. Die Lösung liegt
- [Aktuelle Publikationen](https://oncotherm.com/de/aktuelle-publikationen/) - „Scientific Research” hat zwei Artikel von Prof. András Szász et al. veröffentlicht. The Growth of Healthy and Cancerous Tissues Authors: Gyula Peter Szigeti, Attila Marcell Szasz, Andras Szasz Abstract: The structure of the tissues is formed in a self-similar manner, forming fractal structures in their transport networks. The structure exhibits allometric forming and so-called scaling behavior.
- [Oncothermia Journal Band 28](https://oncotherm.com/oncothermia-journal-band-28/) - Wir freuen uns Ihnen mitzuteilen, dass der 28. Band des Oncothermia Journals ab sofort unter dem folgendem Link heruntergeladen werden kann: https://oncotherm.com/oncothermia-journal/oncothermia-journal-volume-28 Der Redakteur Prof. András Szász äußert sich zu dem aktuellen Band: „Das aktuelle Oncothermia Journal ist mittlerweile der 28. Band dieser Open-Access-Veröffentlichung. Wir haben im Jahr 2011 dieses Projekt ins Leben gerufen, um Oncothermie-Anwendern
- [Neue experimentelle Studie in „Scientific Reports”](https://oncotherm.com/de/neue-experimentelle-studie-in-scientific-reports/) - „Scientific Reports” hat einen Artikel in Verbindung mit modulierter Elektro-Hyperthermie veröffentlicht. Wir gratulieren den Autoren! Relationship between energy Dosage and Apoptotic cell Death by Modulated electro-Hyperthermia Authors: Patrick Hung-Ju Kao, Chia-Hung Chen, Yuk-Wah Tsang, Chen-Si Lin, Hsin-Chien Chiang, Cheng-Chung Huang, Mau-Shin Chi, Kai-Lin Yang, Wen-Tyng Li, Shang-Jyh Kao, Carrie Anne Minnaar, Kwan-Hwa Chi,& Yu-Shan Wan Abstract Modulated electro-hyperthermia (meHt)
- [Buchveröffentlichung: Challenges and Solutions of Oncological Hyperthermia](https://oncotherm.com/de/buchveroeffentlichung-challenges-and-solutions-of-oncological-hyperthermia/) - Klicken Sie hier, um das Buch zu kaufen. Das Buch „Challenges and Solutions of Oncological Hyperthermia“ wurde im Mai 2020 veröffentlicht und kann bei Cambridge Scholars Publishing (Website) erworben werden. Das vorliegende Buch ist eine einzigartige Fortsetzung des breiten Spektrums bestehender Veröffentlichungen und konzentriert sich auf die komplexen Mittel zur Unterstützung der natürlichen Prozesse bei
- [Neue Publikation von Prof. András Szász et al.](https://oncotherm.com/de/neue-publikation-von-prof-andras-szasz-et-al/) - Das International Journal of Clinical Medicine hat zwei Artikel von Prof. András Szász et al. Veröffentlicht. Parametrization of Survival Measures, Part I: Consequences of Self-Organizing Authors: Andras Szasz, Oliver Szasz Abstract: Lifetime analyses frequently apply a parametric functional description from measured data of the Kaplan-Meier non-parametric estimate (KM) of the survival probability. The cumulative Weibull distribution
- [Interview mit Dr. Carrie Minnaar](https://oncotherm.com/de/interview-mit-dr-carrie-minnaar/) - Für den ganzen Artikel klicken Sie bitte hier Das „Buddies For Life“ Magazin, ein Projekt der Breast Health Foundation hat ein Interview mit Dr. Carrie Minnaar veröffentlicht, in dem es unter anderem um Hyperthermie geht. „Hyperthermie und Brustkrebs: Lernen Sie mehr über Hyperthermie als neue Behandlungsmethode gegen Brustkrebs und über die Vorteile bei der gemeinsamen
- [Artikel zum Thema Oncothermie](https://oncotherm.com/de/artikel-zum-thema-oncothermie/) - Es wurden zwei Artikel zum Thema Oncothermie veröffentlicht, zu denen wir den Autoren gratulieren möchten! Der Artikel "Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients" wurde im "International Journal of Hyperthermia" veröffentlicht, der Artikel mit dem Thema "Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia
- [Erneuertes EG-Zertifikat veröffentlicht](https://oncotherm.com/de/erneuertes-eg-zertifikat-veroeffentlicht/) - Bitte klicken sie hier um auf die Seite unseres Qualitätsmanagements zu kommen BEKANNTMACHUNG Das erneuerte EG-Zertifikat der OncoTherm Kft. zur vollständigen Qualitätssicherung gemäß der Medizinprodukterichtlinie der Europäischen Union (MDD) wird nun von der benannten Stelle veröffentlicht. Es handelt sich um ein Langzeitzertifikat gemäß der MDD, welches spätestens bis zum 26. Mai 2024 gültig ist.
- [Oncothermiával kapcsolatos cikk a "Frontiers in Oncology" újságban](https://oncotherm.com/hu/oncothermiaval-kapcsolatos-cikk-a-frontiers-in-oncology-ujsagban/) - A teljes cikk ezen a linken érhető el Gratulálunk a szerzőknek a cikkhez! Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia Mau-Shin Chi, Minesh P. Mehta, Kai-Lin Yang, Hung-Chih Lai, Ying-Chu Lin, Hui-Ling Ko, Yu-Shan Wang, Kuang-Wen Liao and Kwan-Hwa Chi Purpose: True abscopal responses from radiation therapy are extremely rare; the combination
- [Article on abscopal effect in "Frontiers in Oncology"](https://oncotherm.com/article-on-abscopal-effect-in-frontiers-in-oncology/) - For the full article please visit this website Congratulations to the authors for the article! Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia Mau-Shin Chi, Minesh P. Mehta, Kai-Lin Yang, Hung-Chih Lai, Ying-Chu Lin, Hui-Ling Ko, Yu-Shan Wang, Kuang-Wen Liao and Kwan-Hwa Chi Purpose: True abscopal responses from radiation therapy are extremely rare;
- [Artikel zum abscopalen Effekt in "Frontiers in Oncology"](https://oncotherm.com/de/artikel-zum-abscopalen-effekt-in-frontiers-in-oncology/) - Um den ganzen Artikel zu lesen klicken sie bitte hier Wir beglückwünschen die Autoren zu diesem Artikel! Vermutlich abscopaler Effekt bei drei Pateinten durch Behandlung mit Kombination aus Strahlentherapie und modulierte Elektrohyperthermie Mau-Shin Chi, Minesh P. Mehta, Kai-Lin Yang, Hung-Chih Lai, Ying-Chu Lin, Hui-Ling Ko, Yu-Shan Wang, Kuang-Wen Liao and Kwan-Hwa Chi Purpose: True abscopal responses from radiation
- [11. Biennial Konferenz - Hyperthermische Onkologie & Medizin](https://oncotherm.com/de/11-biennial-konferenz-hyperthermische-onkologie-medizin/) - Gemeinsam mit Dr. Carrie Anne Minnaar nahm Prof. Dr. András Szász am 15. und 16. Februar 2020 an der 11. Biennial Konferenz in Mumbai, Indien, teil. Prof. Dr. Szász hielt eine Präsentation mit dem Titel „Modulierte Elektrohyperthermie zur immunogenen hyperthermischen Wirkung“ und Dr. Minnaar referierte unter dem Titel „Bericht zur lokalen Krankheitskontrolle, zu frühzeitigen Überlebensbefunden
- [Neue Erkenntnisse aus Südafrika im Tomography Journal](https://oncotherm.com/de/neue-erkenntnisse-aus-suedafrika-im-tomography-journal/) - For the full article please visit this website Wir beglückwünschen die Autoren des Artikels! Review der definierenden Merkmale der Knotenkrankheit auf PET/CT Scans bei HIV-positiven und -negativen Patientinnen mit fortgeschrittenem lokalen Gebärmutterhalskrebs in Südafrika Carrie Anne Minnaar, Ans Baeyens, Olusegun Akinwale Ayeni, Jeffrey Allan Kotzen, Mboyo-Di-Tamba Vangu Abstract Literature reports increased FDG nodal uptake in HIV-positive
- [Erfolgreiches 2019 für Oncotherm](https://oncotherm.com/de/erfolgreiches-2019-fuer-oncotherm/) - Nachdem 2020 mittlerweile einige Wochen alt ist, lohnt es sich, noch einmal den Blick auf das vergangene Jahr zu richten und eine Bilanz zu ziehen. Für die Oncotherm Group stellt 2019 ein erfolgreiches Geschäftsjahr dar, denn weltweit wurden über 50 Geräte ausgeliefert. Viele davon nach Südkorea, wo die Oncothermie großen Anklang findet und der entsprechende
- [Frohe Weihnachten und ein gutes neues Jahr!](https://oncotherm.com/de/frohe-weihnachten-und-ein-gutes-neues-jahr/) - Wir wünschen Ihnen besinnliche Feiertage! Verbringen Sie Weihnachten mit Ihren Liebsten und erschaffen Sie gemeinsame Erinnerungen. Frohe Weihnachten und für das neue Jahr Glück, Gesundheit und Freude! Ihr Oncotherm Team Das Büro in Ungarn ist vom 23. Dezember 2019 bis zum 03. Januar 2020 geschlossen. Sie erreichen uns wieder an dem 06. Januar 2020. Unser
- [We wish you Happy Holidays and a Happy New Year!](https://oncotherm.com/we-wish-you-happy-holidays-and-a-happy-new-year/) - Wishing you all the joys and happiness of the holiday season. May you be blessed with peace, love and joy. Christmas is about spending time with loved ones. Create happy memories together. Merry Christmas and Happy New Year to you and your family! Your Oncotherm Team The Hungarian office will be closed from 23rd December
- [Ein Artikel über Oncothermie wurde auf der "Frontiers in Oncology"-Homepage veröffentlicht](https://oncotherm.com/de/ein-artikel-ueber-oncothermie-wurde-auf-der-frontiers-in-oncology-homepage-veroeffentlicht/) - Um den ganzen Artikel zu lesen klicken Sie bitte hier Gratulation zu dieser interessanten Arbeit! Betrachtung der klinischen Befunde zur Methode der modulierten Elektro-Hyperthermie (mEHT): Ein Update für praktizierende Onkologen Attila M. Szasz1*†, Carrie Anne Minnaar2†, Gyongyver Szentmártoni1, Gyula P. Szigeti3 and Magdolna Dank1 Zusammenfassung Background: Modulated electro-hyperthermia (mEHT) is a variation of the conventional hyperthermia which selectively
- [Oncothermia related articel on website "Frontiers in Oncology"](https://oncotherm.com/oncothermia-related-articel-on-website-frontiers-in-oncology/) - For the full article please visit this website Congratulations to the authors for this exciting article! Review of the Clinical Evidences of Modulated Electro-Hyperthermia (mEHT) Method: An Update for the Practicing Oncologist Attila M. Szasz1*†, Carrie Anne Minnaar2†, Gyongyver Szentmártoni1, Gyula P. Szigeti3 and Magdolna Dank1 Roundup Background: Modulated electro-hyperthermia (mEHT) is a variation of the conventional hyperthermia
- [Conclusion of MEDICA 2019](https://oncotherm.com/conclusion-of-medica-2019/) - On Thursday, November 21st 2019, four successful days at the MEDICA 2019 in Dusseldorf came to an end for the Oncotherm team. During the trade fair an international audience came to our booth to gather information about the method of Oncothermia and our devices. New contacts were established and old ones consolidated. Among the new
- [Fazit zur MEDICA 2019](https://oncotherm.com/de/fazit-zur-medica-2019/) - Für das Team von Oncotherm gingen am Donnerstag, dem 21.11.2019, vier erfolgreiche Tage auf der MEDICA 2019 in Düsseldorf zu Ende. Während der Messe hat sich ein internationales Publikum an unserem Stand über die Methode der Oncothermie und unsere Geräte informiert. Es wurden nicht nur neue Kontakte geknüpft, sondern auch alte gefestigt. Die MEDICA 2019
- [Oncothermia Journal Volume 27](https://oncotherm.com/de/oncothermia-journal-volume-27/) - For the full volume please click on the link Volume 27 is now available! Fourteen hyperthermia related presentations from the 37th ICHS Conference are published in the 27th volume of Oncothermia Journal.
- [Unser Anwender Prof. Giammaria Fiorentini hat einen Artikel zum Thema Oncothermie veröfentlicht](https://oncotherm.com/de/unser-anwender-prof-giammaria-fiorentini-hat-einen-artikel-zum-thema-oncothermie-veroefentlicht/) - Please click here to the full version Glückwunsch zu dieser hervorragenden Forschung! Modulierte Elektro-Hyperthermie als Palliativbehandlung gegen Bauchspeicheldrüsenkrebs: eine retrospektive Beobachtungsstudie an 106 Patienten Giammaria Fiorentini, MD1 , Donatella Sarti, PhD1, Virginia Casadei, MD1, Carlo Milandri, MD2, Patrizia Dentico, MD2, Andrea Mambrini, MD3, Roberto Nani, MD4, Caterina Fiorentini, MD5, and Stefano Guadagni, MD6 Abstract: Background: Pancreatic adenocarcinoma
- [Ranking der Journals welche Artikel zur Oncothermie enthalten](https://oncotherm.com/de/ranks-of-the-journals-which-contain-oncothermia-articles/) - Erfahren Sie mehr über den Impact Factor „Der Impact Factor (IF), oder auch Journal Impact Factor (JIF), ist der szientometrische Index eines wissenschaftlichen Journals, welcher die durchschnittliche, jährliche Anzahl angibt, die ein Artikel in einem bestimmten Journal in später veröffentlichten Artikeln zitiert wird. Er wird oftmals als Maß für die relative Wichtigkeit eines Journals in
- [Das Oncotherm Laufteam beim „Crazy Sprint Run“](https://oncotherm.com/de/das-oncotherm-laufteam-beim-crazy-sprint-run/) - Der „Crazy Sprint Run“ ist ein herausfordernder Laufwettbewerb mit 19 Hindernissen, verteilt auf 2 km, der den Teilnehmern auch nach Beendigung des Laufs viele spannende Aktivitäten bietet. Er zählt zu den aufregendsten Läufen seiner Art in Ungarn. https://www.youtube.com/watch?v=_c68KUMRU7k&t=5s&ab_channel=CRAZY5K
- [Treffen in der amerikanischen Botschaft](https://oncotherm.com/de/treffen-in-der-amerikanischen-botschaft/) - Der Botschafter der Vereinigten Staaten von Amerika, David B. Cornsetin, lud Prof. Andras Szasz und die ungarischen Delegation des „Select USA Investment Summit 2019“ zu einem Gespräch am runden Tisch ein. Die Diskussionen fanden in einer offenen, freundlichen Atmosphäre statt. Der Botschafter interessierte sich für geschäftliche Aktivitäten und damit verbundenen Herausforderungen in den USA. Frau
- [34. MAOT Kongress](https://oncotherm.com/de/34-maot-kongresszus/) - Vom 4. bis 5. Oktober fand in Budapest der Kongress "One Belt-One Road" mit verschiedenen Themen aus dem Bereich der traditionellen chinesischen Medizin statt, der gleichzeitig auch der XXXIV. MAOT-Jahreskongress war. Die traditionelle chinesische Medizin ist in 122 Ländern auf der ganzen Welt anerkannt. Mehrere ausgezeichnete Studien bestätigen die Nützlichkeit der Behandlungsmethoden, die dem Interesse
- [3. Sport- und Innovationskonferenz](https://oncotherm.com/de/3-sport-und-innovationskonferenz/) - Die 3. Sport- und Innovationskonferenz fand vom 2. bis 3. Oktober in Budapest an der University of Physical Education statt. In Zusammenarbeit mit der University of Physical Education hat die XAX Kft. mit der Entwicklung eines Gerätes namens „SportAvail“ begonnen. Die XAX Kft. produziert gemäß der Lizenz von Oncotherm und nahm an der Konferenz als
- [Fazit zur 37. ICHS Konferenz](https://oncotherm.com/de/the-37th-ichs-conference-in-thessaloniki/) - Offizielle Website der 37. ICHS Konferenz Die 37. International Clinical Hyperthermia Society (ICHS) Konferenz fand vom 19. bis 21. September 2019 in Thessaloniki statt. Oncotherm fungierte dieses Jahr "Platinum Sponsor". Die international ausgerichtete Konferenz zog Teilnehmer aus vielen verschiedenen Ländern an: Brasilien, Ungar, Japan, USA, Deutschland, Australien, Süd Korea, England, Italien, Griechenland, Taiwan, Spanien, Russland,
- [Ein Artikel über Onkothermie wurde im Journal of Thermal Biology veröffentlicht](https://oncotherm.com/de/ein-artikel-ueber-onkothermie-wurde-im-journal-of-thermal-biology-veroeffentlicht/) - Für den Artikel besuchen Sie bitte die Website der Zeitschrift Gratulation zu dieser tollen Arbeit! Einfluss der Tumoreigenschaften auf Energieabsorption, Temperaturkartierung und Wärmedosis bei 13,56-MHz-Hochfrequenzhyperthermie Bibin Prasada, Subin Kimb, Woong Chob, Suzy Kimb, Jung Kyung Kimc,⁎ a Department of Mechanical Engineering, Graduate School, Kookmin University, Seoul 02707, Republic of Korea b Department of Radiation Oncology, SMG-Seoul National
- [Welttag des Lymphombewusstseins](https://oncotherm.com/de/welttag-des-lymphombewusstseins/) - Für weitere Informationen besuchen Sie bitte die folgende Website Der 15. September ist der weltweite Welttag des Lymphombewusstseins. Mehrere Konferenzen, Artikel und Tagungen machen die Menschen auf diesen Krebs mit hohem Risiko aufmerksam. "Lymphom" ist die allgemeine Bezeichnung für Krebsarten, die sich im Lymphsystem entwickeln. Das Lymphsystem besteht aus einem großen Gefäßnetz (ähnlich wie Blutgefäße), das
- [Látogatás a SORAM klinikán](https://oncotherm.com/hu/latogatas-a-soram-klinikan/) - Szász Professzor májusi dél-korai útja során meglátogatta a SORAM klinikát, ahol interjút készítettek vele, és körbevetették az új kórházban. A klinika ötvözi a nyugati és a kínai orvoslást. Jelenleg 6 darab EHY-2000+ készüléket használnak.
- [Besuch der SORAM Klinik](https://oncotherm.com/de/besuch-der-soram-klinik/) - Prof. Andras Szasz besuchte während seiner Reise nach Südkorea im Mai die SORAM-Klinik zum Interview. Die SORAM-Klinik bietet eine Kombinationstherapie aus westlicher und koreanischer Medizin an und verwendet derzeit sechs Onkothermie-Geräte (EHY-2000).
- [Visit of the SORAM Clinic](https://oncotherm.com/visit-of-the-soram-clinic/) - Prof. Andras Szasz visited SORAM clinic for interview during his trip to South Korea in May. SORAM clinic provides combination therapy of Western & Korean medicine and currently is using 6ea Oncothermia devices (EHY-2000).
- [Hyperthermie-Therapie für ältere Menschen](https://oncotherm.com/de/hyperthermia-therapy-for-the-elderly/) - Für den gesamten deutschen Artikel besuchen Sie bitte die folgende Seite In der US- Zeitung “New York Times” (vom 5.8.2019, Cancer Treatment at the End of Life.) spricht eine Expertin über die Behandlung von Krebs im Endstadium. In diesem Online-Artikel finden Sie eine Zusammenfassung des Originals und ein abschließendes Fazit. Dabei geht es um die
- [Aiblinger Gespräche 2019](https://oncotherm.com/de/aiblinger-gesprache-2019/) - Bitte klicken sie hier um den Flyer aufzurufen Am 13. und 14. September 2019 finden in der St. Georg Klinik die "Aiblinger Gespräche" statt. Thema der Veranstaltung: Komplementäre Onkologie - Möglichkeiten und Grenzen. Es wird eine Einblick in die folgenden Themen geboten: Präventionsdiagnostik: Herzvarianzanalyse – Stressmessung, AGE-Reader - Bewertung des kardiovaskulären Risikos, CRS-Analysesystem - Bestimmung
- [Aiblinger Gespräche 2019](https://oncotherm.com/aiblinger-gesprache-2019/) - Please click here to see the flyer On the 13th and 14th of September 2019 the "Aiblinger Gespräche" will take place in 2019 in the St. Georg Clinic. Theme of the event is: Complementary Oncology - Possibilities and Limits. It provides an insight into the following diagnostics to get to know each other: Prevention diagnostics:
- [KOSG Konferenz in Korea](https://oncotherm.com/de/kosg-konferenz-in-korea/) - Das KOSG-Symposium (Korean Oncologic-Hyperthermia Study Group) fand am 31. August 2019 in Korea statt. Referenten aus aller Welt, darunter Prof. Andras Szasz, Dr. Samuel Wang und Dr. Kai-lin Yang, nahmen teil und tauschten Erfahrungen zur Behandlung mit Hyperthermie in Europa, Asien und Korea aus.
- [KOSG Conference in Korea](https://oncotherm.com/kosg-conference-in-korea/) - KOSG (Korean Oncologic-Hyperthermia Study Group) Symposium was held at Catholic University on August 31st 2019 in Korea. Speakers from all over the world including Prof. Andras Szasz, Dr. Samuel Wang and Dr. Kai-lin Yang participated and shared experiences of hyperthermia treatment in Europe, Asia and Korea.
- [Aktivitäten in Thessaloniki während der ICHS-Konferenz](https://oncotherm.com/de/aktivitaeten-in-thessaloniki-waehrend-der-ichs-konferenz/) - Optionales Programm Programm 1 Abfahrt vom Hotel von 19.30 bis 20.30 Uhr. Besichtigungstour durch die Stadt und die Monumente. Abendessen 20:30 Uhr bei “HAMODRAKAS” (WWW.HAMODRAKAS.GR) Abfahrt 23-23: 30 zum Hotel. Kosten: 80 Euro pro Person Name: GALA DINNER und Stadtrundfahrt Datum: FREITAG 20.09.2019 Abfahrt vom Hotel um 19:30 Uhr Stadtrundfahrt 19:30 - 20:30 Uhr Programm 2 (Besichtigung von
- [Klinik Marinus am Stein in der Datenbank des International Medical Tourism Centre](https://oncotherm.com/de/klinik-marinus-am-stein-in-der-datenbank-des-international-medical-tourism-centre/) - Die offizielle Website der Klinik In der Datenbank des International Medical Tourism Centre (https://imedicaltourismcenter.com/) können Patienten mehrere Gesundheitszentren aus 27 Ländern auf dem Gebiet der Neurologie, Onkologie, Alternativmedizin, Chirurgie oder Urologie usw. finden. Die Klinik Marinus am Stein ist eine perfekte Lösung für die Krebsbehandlung von Patienten. Sie bieten auch Oncothermie. Über den folgenden Link können Sie den
- [Interview mit Dr. Aryan Tavakkoli](https://oncotherm.com/de/interview-mit-dr-aryan-tavakkoli/) - Die offizielle Website der Klinik Dr. Aryan Tavakkoli verwendet das EHY-2000Plus-Gerät in England in ihrer Klinik. Die Quantum Clinic (https://quantumclinic.co.uk/) in Lewes bietet verschiedene Arten von Krebsbehandlungen an, z. B. Onkothermie. Yes of Life ist die britische Wohltätigkeitsorganisation für integrative Krebsbehandlung, die ein Interview mit Dr. Tavakkoli über Onkothermie geführt hat. Für das gesamte Interview besuchen Sie bitte den
- [Fraktalphysiologiekurs in Thessaloniki](https://oncotherm.com/de/fraktalphysiologiekurs-in-thessaloniki/) - Die 37. ICHS-Konferenz in Thessaloniki, Griechenland, findet vom 19. bis 21. September statt. Als einzigartiges Programm wird Prof. Szász vor der Konferenz einen Fraktalphysiologie-Kurs abhalten. Dies ist das erste Mal, dass dieses Thema in Griechenland vorgestellt wird. Ort: Labor für Physiologie, Medizinische Fakultät, Aristoteles-Universität Thessalonik i http://physiology.med.auth.gr/content/dorothea-kapoukranidou-biographical-note Die Hautthemen des Vortrags sind die folgenden: Herausforderung der Komplexität Selbstorganisiertes Networking Strukturelle Komplexität
- [Updates zur ICHS-Konferenz](https://oncotherm.com/de/updates-zur-ichs-konferenz/) - Die offizielle Website der Konferenz Wir möchten Sie über die ICHS-Konferenz informieren, die vom 19. bis 21. September 2019 in Thessaloniki, Griechenland, stattfinden wird. Die Themen der Konferenz sind: Allgemeiner Status von Hyperthermie, Herausforderungen und Lösungen Begriffsbestimmungen - Konsens Klinische Ergebnisse der Hyperthermie Immunonkologie & Hyperthermie Integrative Onkologie und Hyperthermie Experimentelle und präklinische Hyperthermie, die molekulare Grundlage der Hyperthermie,
- [Opening of a new Korean hospital](https://oncotherm.com/opening-of-a-new-korean-hospital/) - Professor Seungjo Kim, a renowned expert in gynecology in Korea, former President of the Korean Gynecological Society, built a new Hospital for integrative medicine in cancer therapies, and oncothermia is among his therapy program. We congratulate Professor Kim on this beautiful, high-tech hospital. Professor Szasz visited the hospital and expressed his pleasure personally.
- [Eröffnung eines neuen koreanischen Krankenhauses](https://oncotherm.com/de/eroeffnung-eines-neuen-koreanischen-krankenhauses/) - Professor Seungjo Kim, ein renommierter Experte für Gynäkologie in Korea, ehemaliger Präsident der Koreanischen Gynäkologischen Gesellschaft, baute ein neues Krankenhaus für integrative Medizin. In seiner Krebstherapie gehört Oncothermie fest zu seiner Therapiemethode. Wir gratulieren Professor Kim zu diesem wunderschönen High-Tech-Krankenhaus. Professor Szasz besuchte das Krankenhaus und drückte seine Freude persönlich aus.
- [Dr. Carrie Minnaars randomisierte kontrollierte Phase-III-Studie wurde veröffentlicht](https://oncotherm.com/de/dr-carrie-minnaars-randomisierte-kontrollierte-phase-iii-studie-wurde-veroeffentlicht/) - Den gesamten Artikel finden Sie auf der Website der Zeitschrift Gratulation zu dieser tollen Arbeit! Nach zahlreichen retrospektiven und prospektiven Phase-II-Studien zu verschiedenen Tumorlokalisationen wurde heute im renommierten Journal PLOSOne die erste Phase-III-Studie zu Oncothermie veröffentlicht. Die eindeutigen Vorteile der Anwendung von Oncothermie zusätzlich zur Radiochemotherapie wurden in der randomisierten zweiarmigen Studie für fortgeschrittene Gebärmutterhalspatienten gezeigt. Die vorliegende
- [Eine klinische Phase-I / II-Studie zur Onkothermie wurde veröffentlicht](https://oncotherm.com/de/eine-klinische-phase-i-ii-studie-zur-onkothermie-wurde-veroeffentlicht/) - Den gesamten Artikel finden Sie auf der Website der Zeitschrift Klinische Phase-I / II-Studie zur modulierten Behandlung von Elektrohyperthermie bei Patienten mit rezidiviertem, refraktärem oder progressiv schwer behandelbarem Eierstockkrebs Heon Jong Yoo, Myong Cheol Lim, Sang-Soo Seo, Sokbom Kang, Jungnam Joo, and Sang-Yoon Park Abstract Objective: To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT)
- [New article on oncothermia was published in Journal of Radiation and Cancer Research](https://oncotherm.com/new-article-on-oncothermia-was-published-in-journal-of-radiation-and-cancer-research/) - For the whole article please visit the journal's website THERMAL AND NONTHERMAL EFFECTS OF RADIOFREQUENCY ON LIVING STATE AND APPLICATIONS AS AN ADJUVANT WITH RADIATION THERAPY Andras Szasz Abstract One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a
- [Új cikk jelent meg oncothermiával kapcsolatban a Journal of Radiation and Cancer Research újságban](https://oncotherm.com/hu/uj-cikk-jelent-meg-oncothermiaval-kapcsolatban-a-journal-of-radiation-and-cancer-research-ujsagban/) - Az angol nyelvű cikket itt találja THERMAL AND NONTHERMAL EFFECTS OF RADIOFREQUENCY ON LIVING STATE AND APPLICATIONS AS AN ADJUVANT WITH RADIATION THERAPY Andras Szasz Abstract One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a rarely applied oncotherapy
- [Ein neuer Artikel über Onkothermie wurde im Journal of Radiation and Cancer Research veröffentlicht](https://oncotherm.com/de/ein-neuer-artikel-ueber-onkothermie-wurde-im-journal-of-radiation-and-cancer-research-veroeffentlicht/) - Den gesamten Artikel finden Sie auf der Website der Zeitschrift THERMISCHE UND NICHTTHERMISCHE AUSWIRKUNGEN DER RADIOFREQUENZ AUF DEN LEBENSZUSTAND UND DIE ANWENDUNGEN ALS ZUSATZ ZUR STRAHLENBEHANDLUNG Andras Szasz Abstract One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a
- [Oncotherm beim Hindernislauf in Ungarn](https://oncotherm.com/de/oncotherm-beim-hindernislauf-in-ungarn/) - Offizielle Website der Veranstaltung Herzlichen Glückwunsch an unsere Läufer. Sie haben den Crazy5K-Laufwettbewerb in Dunakeszi am 02.06.2019 hervorragend abgeschlossen. CRAZY5K ist ein lustiger und herausfordernder Hindernislauf, bei dem man sich wieder jung fühlt. Die 10 riesigen aufblasbaren Hindernisse befinden sich auf einer 5 km langen Strecke. Der Wettbewerb wird in anderen Ländern und Städten wie Mailand, Rom,
- [Select USA Investment Summit](https://oncotherm.com/de/select-usa-investment-summit/) - Offizielle Website der Konferenz Prof. Andras Szasz hat auf Einladung des ungarischen Botschafters am Select USA Investment Summit teilgenommen. Die Veranstaltung von vom 10. bis 12. Juni in Washington, D.C. statt. Eine kurze, englischsprachige Zusammenfassung: “The U.S. government, through SelectUSA, assists companies seeking to establish or expand operations in the United States. The Summit is for
- [ESHO 2019](https://oncotherm.com/de/esho-2019-33rd-annual-meeting-of-the-european-society-for-hyperthermic-oncology-conference/) - Offizielle Website der ESHO Vom 22. bis 24. Mai fand das 33. jährliche Treffen der European Society for Hyperthermic Oncology in Warschau statt. Auch Oncotherm war auf der Konferenz vertreten. Es gab über 50 Präsentationen zum Thema Hyperthermie, im Folgenden sind die aufgelistet, die Oncothermie im Speziellen behandelt haben: Präsentationen; A. Szasz: Immune-effects with local hyperthermia S. Van Gool:
- [ESTRO 38](https://oncotherm.com/de/estro-38/) - Offizielle Website der ESTRO Dieses Jahr war auch Oncotherm auf der ESTRO 38 vertreten, die vom 26. bis 30. April 2019 in Mailand, Italien, stattfand. Die ESTRO 38 bot Fachleuten aus dem Bereich der Onkologie die Möglichkeit, Wissen auszutauschen und ihre neuesten Ergebnisse zu veröffentlichen. „Gemeinsam auf optimale Versorgung abzielen“ war das Thema von ESTRO
- [European SocieTy for Radiotherapy & Oncology in Milan](https://oncotherm.com/european-society-for-radiotherapy-oncology-in-milan/) - Official website of the ESTRO - European SocieTy for Radiotherapy & Oncology This year Oncotherm exhibited at ESTRO 38 which took place 26-30 April 2019 in Milan, Italy. ESTRO 38 offered professionals of oncology the chance to share knowledge and publish their latest results. ‘Targeting optimal care, together’ was the theme of ESTRO 38: working towards a common
- [Új 2030-as rákkezelő készülék telepítése a spanyolországi Valdecilla-ban](https://oncotherm.com/de/uj-2030-as-rakkezelo-keszulek-telepitese-a-spanyolorszagi-valdecilla-ban/) - Quelle Valdecilla hat als erstes öffentliches Krankenhaus in Spanien ein Oncothermiegerät im Rahmen eines Strahlentherapiesystems erhalten. Ab jetzt können sie damit auch Tumore mit schlechter Prognose behandeln. Die Gesundheitsministerin Luisa Real besuchte das Krankenhaus, um das neue Gerät zu sehen, das jetzt hauptsächlich für Patienten mit Gehirn-, Rektal- und Pankreastumoren verwendet wird. Das neue Oncothermie-Gerät
- [Österreichkongress für Radiotechnologie](https://oncotherm.com/de/oesterreichkongress-fuer-radiotechnologie/) - In Österreich findet vom 29. bis zum 30. März der Kongress der Radiotechnologen statt. Themen dieser Veranstaltung sind nicht nur die technologischen Methoden oder Therapiemöglichkeiten der Radiologie, sondern auch die komplementären Behandlungen. Diese können die Nebenwirkungen der konventionellen Krebstherapie lindern und die Heilung positiv unterstützen. Eine Art der Hyperthermie, die so genannte Oncothermie, wird am
- [European Oncology Convention 2019](https://oncotherm.com/de/european-oncology-convention-2019/) - Website der European Oncology Convention Die European Oncology Convention bringt die weltweit führenden Fachleute der Onkologiebranche zusammen. Mit einer unübertroffenen Auswahl von 100 CPD-akkreditierten Seminaren, interaktiven Workshops und hochmodernen Showcases exklusiv ausgewählter Aussteller verspricht diese Veranstaltung die revolutionären Methoden zur Erforschung und Behandlung von Krebs aufzuzeigen. Wir möchten Ihre Aufmerksamkeit auf das Seminar von Prof.
- [European Oncology Convention 2019](https://oncotherm.com/european-oncology-convention-2019/) - Website of European Oncology Convention European Oncology Convention brings the world’s leading professionals in the oncology industry together. Complete with an unrivalled line-up of 100 CPD accredited seminars, interactive workshops and state-of-the-art showcases from exclusively selected exhibitors, this event promises to show the revolutionary ways of studying and treating cancer. We would like to draw
- [European Oncology Convention 2019](https://oncotherm.com/hu/european-oncology-convention-2019/) - European Oncology Convention 2019 Konferencia honlapja Szász András Professzor előadást tart a "Modulated electrohyperthermia (mEHT) for advanced tumors" témakörben az European Oncology Convention 2019 konferencián. A konferenica március 26-27 között kerül megrendezésre Birminghamben. Az Oncotherm Kft. szeretettel várja az érdeklődőket a 362-es standnál. A konferencia angol nyelvű honlapja az alábbi linken érhető el: http://www.oncologyconvention.com/
- [Nützliche Informationen der 37. Konferenz der International Clinical Hyperthermia Society (ICHS)](https://oncotherm.com/de/nuetzliche-informationen-der-37-konferenz-der-international-clinical-hyperthermia-society-ichs/) - Weitere Informationen finden Sie auf der offiziellen Webseite der Veranstaltung Hier sind einige wichtige Informationen über die 37. ICHS Konferenz: Einreichung der Kurzfassungen ihrer Vorträge bis zum Juli 20. Juli 2019 zu senden an z.hahn@ichs.eu Veranstaltungsort: Hotel Panorama in Thessaloniki Hotelzimmerbuchung über folgende Optionen: info@hotelpanorama.gr oder +30 231 034 4871 Nützliche Links: Über den Veranstaltungsort: http://www.ichs-conference.org/venue/ Anforderungen an die Kurzfassungen: http://www.ichs-conference.org/abstract/ Sehenswürdigkeiten in Thessaloniki: https://www.tripadvisor.com/Attractions-g189473-Activities-Thessaloniki_Thessaloniki_Region_Central_Macedonia.html Wetter
- [Neue Publikation im Open Journal of Biophysics](https://oncotherm.com/de/neue-publikation-im-open-journal-of-biophysics-2/) - Die Publikation finden Sie hier Title: Bioelectromagnetic Paradigm of Cancer Treatment—Modulated Electro-Hyperthermia (mEHT) Autor: Olivér Szász Department of Biotechnics, St. Istvan University, Budaörs, Hungary ABSTRACT One of the most frequently applied bioelectromagnetic effects is the deep heating of the living species with EMF energy. Despite its long history, hyperthermia is a rarely applied oncotherapy. The
- [One of our EHY-2000plus users from South Korea is introducing Oncothermia and his practice on Korean TV](https://oncotherm.com/one-of-our-ehy-2000plus-users-from-south-korea-is-introducing-oncothermia-and-his-practice-on-korean-tv/) - Oncothermia and his practice on Korean TV Dr. Young Suck Lew, M.D., Ph.D is introducing Oncothermia and his practice on Korean TV. One of our EHY-2000plus users from South Korea, Woodridle hospital Dr. You used plasma light ball to explain Oncothermia's selectivity.
- [Egyik dél-koreai EHY-2000plus felhasználónk bemutatja az onkotermia működését a dél-koreai televízióban](https://oncotherm.com/hu/egyik-del-koreai-ehy-2000plus-felhasznalonk-bemutatja-az-onkotermia-mukodeset-a-del-koreai-televizioban/) - Onkotermia a gyakorlatban - dél-koreai televízió felvétele A dél-koreai televízióban Dr. Young Suck Lew, M.D., Ph.D bemutatta, hogyan működik az Oncothermia a gyakorlatban Egyik dél-koreai EHY-2000plus készülék felhasználója a Woodridle kórház orvosa, Dr. Young, plazmagömböt használva mutatta be az onkotermia módszer szelektivitásának képességét, amely bizonyítja, hogy az onkoterm rákkezelő készülékeivel a felhasználók célzottan csak a daganatot kezelik. A
- [Oncothermie Anwender aus Südkorea im koreanischen Fernsehen](https://oncotherm.com/de/oncothermie-anwender-aus-suedkorea-im-koreanischen-fernsehen/) - Oncothermie Anwender aus Südkorea im koreanischen Fernsehen Dr. Young Suck Lew, M.D., Ph.D, ein Oncothermie Anwender aus Südkorea, hat im koreanischen Fernsehen seine Praxis (Woodridle Hospital) vorgestellt und über das Thema Oncothermie gesprochen. Sie können sich das Video hier anschauen:
- [Oncothermie Studien](https://oncotherm.com/de/oncothermie-studien/) - Oncothermie Studien Die folgenden Oncothermie Studien sind auf der Clinical Trials Website (www.clinicaltrials.gov) gelistet. Weitere Informationen finden Sie unter https://www.clinicaltrials.gov/ct2/results?cond=&term=oncothermia&cntry=&state=&city=&dist=&Search=Search Study 1: Title: Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients Conditions: Cancer, Pancreas Interventions: Other: Oncothermia|Drug: FOLFIRINOX or Gemcitabine based chemotherapy Locations: Seoul National University Bundang Hospital, Seongnam,
- [Die 37. ICHS findet vom 19. - 21. September 2019 in Thessaloniki, Griechenland statt](https://oncotherm.com/de/die-37-ichs-findet-vom-19-21-september-2019-in-thessaloniki-griechenland-statt/) - ICHS official website Die nächste Jahrestagung der International Clinical Hyperthermia Society (ICHS) findet vom 19. - 21. September2019 in Thessaloniki, Griechenland statt. Vorstandsvorsitzender der Konferenz ist Dr. Aias-Theodoros Papastavrou. Die örtlichen Veranstalter der 37. ICHS Konferenz sind: The Hellenic Society of Oncologic Hyperthermia (Präsident Prof. Dr Vassilis Kouloulias) und The Hellenic Society for Integrative Oncology
- [Brandenburger Krebskongress](https://oncotherm.com/de/brandenburger-krebskongress/) - Einladung zum 6. Brandenburger Krebskongress in Potsdam Zum 6. Mal findet in Potsdam der Brandenburger Krebskongress statt. Das diesjährige Motto lautet „Onkologie im Land Brandenburg – immer in Bewegung“. Der Kongress richtet sich an onkologisch tätiges Fachpersonal aller Disziplinen und Berufsgruppen. Wir freuen uns auf Ihren Besuch! Wann: 22. - 23. Februar 2019 Wo: Dorint Hotel Potsdam
- [Neue Publikation im Open Journal of Biophysics](https://oncotherm.com/de/neue-publikation-im-open-journal-of-biophysics/) - Hier können Sie die Publikation herunterladen Open Journal of Biophysics, 2019, 9, 51-69 Title: Fluctuations Hypothesize the New Explanation of Meridians in Living Systems Gyula Peter Szigeti, Andras Szasz Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary Department of Biotechnics, St. Istvan University, Budaors, Hungary Abstract Biosystems are complex. Their physiology
- [Frohe Weichnachten und ein gutes neues Jahr!](https://oncotherm.com/de/frohe-weichnachten-und-ein-gutes-neues-jahr/) - Weihnachten steht vor der Tür und ein ereignisreiches Jahr geht zu Ende. Das gesamte Oncotherm Team wünscht Ihnen eine fröhliche und entspannende Weihnachtszeit. Für 2018 wünschen wir Ihnen und Ihrer Familie viel Glück, Gesundheit, Zufriedenheit und Erfolg, sowie einen guten Start ins neue Jahr. (Bitte beachten Sie, dass das deutsche Büro vom 24. bis 27.
- [Geräteinstallation in Lahore, Pakistan](https://oncotherm.com/de/geraeteinstallation-in-lahore-pakistan/) - Das Saira Memorial Hospital ist ein modernes Krankenhaus in Lahore, Pakistan. Im November wurde das EHY-3010 ML-Gerät in dem Krankenhaus installiert. Das EHY-3010 ist auf die simultane, multilokale Behandlung fortgeschrittener, metastasierender, maligner und solider Tumoren ausgerichtet. Innerhalb der bestehenden Palette von Oncothermie-Systemen stellt es einen absoluten Durchbruch im Bereich der multilokalen Tumorbehandlung dar. Anstelle einer
- [Neue Publikation im International Journal of Oncology](https://oncotherm.com/de/new-publication-appeared-in-the-international-journal-of-oncology/) - Bitte klicken Sie hier für die vollständige Publikation Wir freuen uns Ihnen die neue Publikation mit dem Titel "Oncological hyperthermia: The correct dosing in clinical applications“ vorzustellen. Autoren: Sun-Young Lee, Gyula Peter Szigeti, Attila Marcell Szasz Online veröffentlicht: 23. November 2018 Abstract The problem with the application of conventional hyperthermia in oncology is firmly
- [M5 TV Reportage über die Konferenz von 36. International Clinical Hyperthermia Society (ICHS)](https://oncotherm.com/de/m5-televizio-riportja-a-rakkezelesben-hipertermiat-alkalmazo-orvoskonferenciarol/) - TV Riport about the 36. International Clinical Hyperthermia Society (ICHS) Der ungarische M5 TV hat über die ICHS berichtet. Für weitere Informationen folgen Sie bitte diesem Link (Zeitbereich: 10:09 - 11:14): https://www.mediaklikk.hu/video/kulturalis-hirado-2018-09-28-i-adas/# Das Event wurde durch den NRDI Fonds finanziert.
- [MEDICA Messe 2018](https://oncotherm.com/de/medica-a-gyogyaszat-vilagforuma/) - Oncotherm wird auf der MEDICA Messe in Düsseldorf vertreten sein. Die Messe findet vom 12. – 15.11.2018 statt. Wir würden uns freuen Sie auf unserem Messestand 9B11 begrüßen zu dürfen. Weitere Informationen zur Messe finden Sie unter dem folgenden Link: https://www.medica-tradefair.com/
- [5. Europäischer Kongress für Immunologie](https://oncotherm.com/de/5-europaeischer-kongress-fuer-immunologie/) - 5. Europäischer Kongress für Immunologie Der 5. ECI wird alle Bereiche der modernen Immunologie abdecken, angefangen vom angeborenen Gedächtnis und der gewebespezifischen Regulation der Differenzierung von T- und B-Zellen, bis hin zu unbeaufsichtigten Analysen von Big Data für die Diagnostik und kombinatorische immunmodulatorische Biologika. Der besondere Schwerpunkt des 5. ECI wird auf dem „Bau von
- [5th European Congress of Immunology](https://oncotherm.com/5th-european-congress-of-immunology/) - 5th eci 2018 The 5th ECI will cover all fields of modern immunology, ranging from innate memory and tissue specific regulation of T and B cell differentiation to unsupervised analyses of big data for diagnostics and combinational immunomodulatory biologicals. The special focus of the 5th ECI will be ‘Building Bridges’. The Dutch take pride in being
- [Aiblinger Gespräche 2018](https://oncotherm.com/de/aiblinger-gespraeche-2018/) - Die „Aiblinger Gespräche“ bilden seit mehr als 20 Jahren ein interdisziplinäres Kommunikationsforum für Ärzte, Therapeuten, Sozial und Naturwissenschaftler, aber auch für Patienten und interessierte Laien. Ihnen wird die Möglichkeit geboten, sich über die neuesten Erkenntnisse aus der komplementären und biologischen Onkologie zu informieren. Auch in diesem Jahr werden wieder viele interessante Themen ins Programm einfließen,
- [Besuchen Sie uns auf der ESTRO 2018](https://oncotherm.com/de/besuchen-sie-uns-auf-der-estro-2018/) - ESTRO 37 ESTRO ist ein Verband, welcher sich auf Interdisziplinarität und Multidisziplinarität konzentriert. Auf der Konferenz haben Radioonkologen, Medizinphysiker, Radiobiologen und Strahlentherapeuten die Möglichkeit, sich mit anderen Onkologie-Organisationen auszutauschen, um die Wirksamkeit von Krebsbehandlungen zu verbessern. Thema der Konferenz dieses Jahr ist „Innovation for Value and Access“. Für weitere Informationen klicken Sie bitte hier Wir
- [Fakten zur Oncothermie](https://oncotherm.com/de/tenyek-az-onkotermiarol/) - Fakten zur Oncothermie Oncothermie kann für alle soliden Tumore angewandt werden. Nebenwirkungen treten nicht auf, es gibt nur wenige Kontraindikationen. Chemotherapien und Strahlentherapien werden durch die Behandlung unterstützt. Onkologen und anderes medizinisches Fachpersonal wenden diese Methode weltweit an. Tumorgewebe wird selektiv behandelt, die Malignität wird zerstört. Hemmt die Verbreitung des Tumors und stellt die interzellulären Verbindungen
- [Neue Veröffentlichung: "Hyperthermia Dosing and Depth of Effect"](https://oncotherm.com/de/neue-veroeffentlichung-hyperthermia-dosing-and-depth-of-effect/) - Autoren Szasz Oliver1, Szigeti Gyula Peter2, Vancsik Tamas3, Szasz Andras1 1Department of Biotechnics, St. Istvan University, Budapest, Hungary. 2Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary. 3Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. Zusammenfassung The penetration depth in the electromagnetic heating could be a crucial factor of
- [1,5 Milliarden-Forint Zuschuss für Tumortherapiegerät](https://oncotherm.com/de/1-5-milliarden-forint-zuschuss-fuer-tumortherapiegeraet/) - 1,5 Milliarden-Forint Zuschuss für Tumortherapiegerät Begünstigter: Oncotherm Kft. und Semmelweis Universität Projektname: „Improving the efficiency of the electromagnetic tumour therapy device and the preparation for its integration into commercial use” Betrag der vertraglichen Unterstützung: 1,472 Milliarden Forint Unterstützungs-Rate: 88,94% Geplanter Fertigstellungstermin: 31.12.2019 Projekt Identifikationsnummer: NVKP_16-1-2016-0042 Das Projekt “Improving the efficiency of the electromagnetic tumour therapy device and the preparation for
- [35. Jahrestagung von der Society for Thermal Medicine](https://oncotherm.com/de/35-jahrestagung-von-der-society-for-thermal-medicine/) - Die 35. Jahrestagung bietet weitere interessante Neuheiten über Entwicklungen im Bereich der Biologie, Physik, Technik und klinischen Anwendungen von Thermomedizin. Die Mission von der Society for Thermal Medicine besteht darin, die Behandlungsergebnisse der Patienten deutlich zu verbessern, durch die Förderung der wissenschaftlichen Entwicklung und Anwendung von Thermo-Therapie. thermaltherapy.org Wann: 7. Mai - 10. Mai 2018
- [35th Annual Meeting of the Society for Thermal Medicine](https://oncotherm.com/35th-annual-meeting-of-the-society-for-thermal-medicine/) - The 35th Annual Meeting features another outstanding line-up of the latest developments in biology, physics, engineering, and clinical applications of thermal medicine. The Society for Thermal Medicine’s mission is to significantly improve patient treatment outcomes by advancing the science, development and application of Thermal Therapy. Date: May 7 - May 10, 2018 Place: Tucson, Arizona
- [8. Kongress für komplementäre Krebstherapie](https://oncotherm.com/de/8-kongress-fuer-komplementaere-krebstherapie/) - Die Konferenz widmet sich dem übergeordneten Thema "Stand der komplementären Onkologie, aktuelle Diagnostik und Therapieoptionen". Wann: 20./ 21. April 2018 Wo: Konferenzzentrum München, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 München Programm - 8. Kongress für komplementäre Krebstherapie
- [Complementary Cancer Therapy Congress in Munich](https://oncotherm.com/complementary-cancer-therapy-congress-in-munich/) - The main topic of the conference will be "State of complementary oncology, current diagnostics and treatment options" ("Stand der komplementären Onkologie, aktuelle Diagnostik und Therapieoptionen"). When: 20./ 21. April 2018 Where: Conference Center Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich Programm - 8. Kongress für komplementäre Krebstherapie
- [Internationaler Kongress für klinische Studien](https://oncotherm.com/de/internationaler-kongress-fuer-klinische-studien/) - http://www.iacct2017.com/ IACCT2017 ist als multidisziplinäres Programm konzipiert, an dem Teilnehmer aus der ganzen Welt mitwirken. Es legt den Fokus auf den Wissensaustausch über die unzähligen Aspekte klinischer Studien. Dies ist eine großartige Gelegenheit, Kollegen aus Wissenschaft und klinischen Forschungseinrichtungen, sowie der pharmazeutischen, biomedizinischen und medizinischen Geräteindustrie zu treffen. Auf diesem Kongress haben Sie die Möglichkeit,
- [The International Annual Congress on Clinical Trials](https://oncotherm.com/the-international-annual-congress-on-clinical-trials/) - http://www.iacct2017.com/ IACCT2017 is designed to be a multidisciplinary program with participation of members from around the globe focused on exchanging knowledge about the countless aspects of clinical trials. This is a great opportunity to meet colleagues from the clinical trials community from academia, clinical research entities, pharmaceutical, biomedical and medical device industries. At this Congress you
- [9. Welthautkrebskongress](https://oncotherm.com/de/9-welthautkrebskongress/) - Welthautkrebskongress 2017 Der gemeinsame Kongress wird die weltweit führenden Melanomforscher und Ärzte zusammenbringen, um die neuesten Entwicklungen in Bezug auf Diagnose, Behandlung und Forschung vorzustellen. Dieser globale Gipfel wird die wissenschaftlichen und klinischen Untersuchungen zum Melanom beschleunigen und Delegierten aus multidisziplinären Bereichen die Möglichkeit bieten, sich in einem warmen Klima zum Austausch von Wissen und
- [9th World Congress of Melanoma](https://oncotherm.com/9th-world-congress-of-melanoma/) - World Congress of Melanoma 2017 The joint congress will bring together the world’s leading melanoma researchers and clinicians to showcase the latest developments in melanoma diagnosis, treatment and research. This global summit will accelerate scientific and clinical investigations into melanoma, providing an opportunity for delegates from multi-disciplinary fields to meet in a warm climate to
- [Deutschen Gesellschaft für Hyperthermie](https://oncotherm.com/de/deutschen-gesellschaft-fuer-hyperthermie/) - http://www.dght-ev.de/ Bei Krebsleiden und chronischen Krankheiten ist die Hyperthermie mittlerweile mehr als nur ein Hoffnungsschimmer zur Prognoseverbesserung. Denn Hyperthermie kann Leben retten, verlängern und erheblich verbessern. Innovationen und neueste Technologien machen es möglich. Randomisierte Studien belegen es. Der Stellenwert dieser Therapie sollte viel höher sein und braucht unbedingt mehr Aufmerksamkeit und Unterstützung. Diesem Ziel dient
- [Aiblinger Gespräche](https://oncotherm.com/de/aiblinger-gespraeche/) - Bei den "Aiblinger Gesprächen" handelt es sich um ein interdisziplinäres Kommunikationsforum für Ärzte, Therapeuten, Heilpraktiker, Sozial- und Naturwissenschaftler, aber auch für Patienten und Laien. Das Thema der diesjährigen Aiblinger Gespräche 2017 lautet: "Komplementärmedizin - der Blick aufs Ganze". Die Veranstaltung findet in der St. Georg Klinik statt und beginnt mit einem "Tag der offenen Tür".
- [10. Jahreskongress des Tumorzentrums München](https://oncotherm.com/de/10-jahreskongress-des-tumorzentrums-muenchen/) - In gewohnter Art werden die wichtigsten Entwicklungen der vorangegangenen zwölf Monate in ausgewählten Indikationsgebieten durch renommierte Experten bewertet und eingeordnet, um so praxisrelevantes onkologisches und hämatologisches Wissen zu vermitteln.
- [Ein einzigartiges Gerät gegen den Krebs, das EHY-2030](https://oncotherm.com/de/uj-innovacio-a-rakgyogyaszatban/) - Wir sind stolz darauf, ein einzigartiges Gerät gegen den Krebs einzuführen, eine brillante Lösung für den Patienten, das EHY-2030 Es enthält eine Reihe neuer Innovationen, die dazu beitragen, die gleiche hochwirksame modulierte Elektro-Hyperthermie-Behandlung mit einem neuen, patientenorientierteren Design effektiver zu gestalten. • Neugestaltetes Abstimmsystem, das schneller und genauer auf die weitergeleitete Leistung abzielt und das gesunde Gewebe schont.
- [Oncotherm lädt zur 35. ICHS ein](https://oncotherm.com/de/oncotherm-laedt-zur-35-ichs-ein/) - ICHS Conference 2017 In November 2017 the ICHS and Oncotherm will again welcome you to an interesting and scientifically challenging event. Like in 2013 this annual meeting will be organized by Prof. Dr. Clifford L.K. Pang in Guangzhou, China and be held together with the 5th Annual Conference of the World Federation of Chinese Medicine
- [Oncotherm will be present at 35. ICHS Annual Conference](https://oncotherm.com/oncotherm-will-be-present-at-35-ichs-annual-conference/) - ICHS Conference 2017 In November 2017 the ICHS and Oncotherm will again welcome you to an interesting and scientifically challenging event. Like in 2013 this annual meeting will be organized by Prof. Dr. Clifford L.K. Pang in Guangzhou, China and be held together with the 5th Annual Conference of the World Federation of Chinese Medicine
- [34. Jahrestagung der ÖGRO](https://oncotherm.com/de/34-jahrestagung-der-oegro/) - ÖGRO 2017 Der Kongress versucht Brücken zu schlagen zur medikamentösen sowie zur chirurgischen Tumortherapie. Eines der Hauptthemen wird die Kombination von lokaler Strahlentherapie mit neuen zielgerichteten Substanzen sein. Der vorgeschaltete dESO-Kurs (Deutschsprachig-Europäische Schule für Onkologie) widmet sich dem Thema der interdisziplinären Therapie von Kopf-Hals-Tumoren. Weitere Schwerpunkte werden die Hypofraktionierung in der Behandlung des Prostatakarzinoms, die
- [Konferenz der polnischen Hyperthermie-Gesellschaft](https://oncotherm.com/de/konferenz-der-polnischen-hyperthermie-gesellschaft/) - Die Polnische Hyperthermie-Gesellschaft (PTHO) ist eine NGO bestehend aus einem Kollektiv von über 50 Ärzten aus dem ganzen Land. Das Hauptziel der Gesellschaft ist die Förderung der thermischen Medizin in Polen. Die PTHO organisiert eine internationale medizinische Konferenz unter dem Motto "Der Stand der Hyperthermie in der polnischen Medizin".
- [Polish Hyperthermia Society Conference](https://oncotherm.com/polish-hyperthermia-society-conference/) - The Polish Hyperthermia Society (PTHO) is a non-governmental scientific organization with a collective of over 50 physicians from all over the country. The main goal of the society is to promote thermal medicine in Poland. PTHO organizes an international medical conference under the slogan "The Place of Hyperthermia in Polish Medicine".
- [ESHO 2017](https://oncotherm.com/de/esho-2017-2/) - ESHO 2017 Wir freuen uns, Sie im Namen der European Society for Hyperthermic Oncology (ESHO) und der Hellenic Society of Oncologic Hyperthermia vom 21. bis 23. Juni 2017 zum 31. Jahrestreffen der ESHO in Athen einzuladen. Anerkannte und angesehene Fachleute mit umfassender klinischer und wissenschaftlicher Erfahrung werden eingeladen, ihre Erfahrungen mit uns allen zu teilen. Es
- [ESHO 2017](https://oncotherm.com/esho-2017-2/) - ESHO 2017 On behalf of the European Society for Hyperthermic Oncology and of the Hellenic Society of Oncologic Hyperthermia, we are honored to invite you to join us for the 31st annual meeting of the European Society for Hyperthermic Oncology (ESHO 2017), which will be held in Athens-Greece, the “cradle of Democracy”, in June 21 - 23, 2017. Well acknowledged and reputable
- [21. Heilpraktiker-Symposium Dresden / Mitteldeutscher Heilpraktikertag](https://oncotherm.com/de/21-heilpraktiker-symposium-dresden-mitteldeutscher-heilpraktikertag/) - 21. Heilpraktiker-Symposium Kooperationspartner unserer Heilpraktikerkongresse sind der BDHN e.V. - Bund Deutscher Heilpraktiker und Naturheilkundiger - mit Sitz in München und der FVDH e.V. - Freier Verband Deutscher Heilpraktiker - mit Sitz in Münster. Wir sind Mitglied im DDH e.V. - Dachverband Deutscher Heilpraktikerverbände - sowie im BFB - Bundesverband Freier Berufe - mit Sitz
- [51. Medizinische Woche](https://oncotherm.com/de/51-medizinische-woche/) - 51. Medizinische Woche Immer mehr Menschen vertrauen alternativ oder ergänzend zur Schulmedizin auf die Naturheilkunde. Die Medizinische Woche Baden-Baden ist das Forum für Ärzte und Therapeuten, die aus voller Überzeugung naturheilkundliche Therapieverfahren anbieten. Und sie ist eine Plattform für alle Anbieter, die sich dem Erfolg der naturheilkundlichen Therapie verschrieben haben. Eine Fortbildungsveranstaltung zwischen Tradition und
- [VIII. Hyperthermie-Symposium](https://oncotherm.com/de/viii-hyperthermie-symposium/) - VIII. Hyperthermie-Symposium Zum Thema "Blick zurück nach vorn". Wir danken allen Referenten, Teilnehmern und Ausstellern für das Ermöglichen eines gelungenen Jubiläumskongresses im vergangenen Jahr. Wir freuen uns, auch in diesem Jahr wieder einen Kongress ausrichten zu können und freuen uns schon jetzt auf eine rege Resonanz. Sichern Sie sich schon jetzt Ihre Teilnahme.
- [20. Heilpraktiker-Kongress](https://oncotherm.com/de/20-heilpraktiker-kongress/) - 20. Heilpraktikerkongress Kooperationspartner unserer Heilpraktikerkongresse sind der BDHN e.V. - Bund Deutscher Heilpraktiker und Naturheilkundiger - mit Sitz in München und der FVDH e.V. - Freier Verband Deutscher Heilpraktiker - mit Sitz in Münster. Wir sind Mitglied im DDH e.V. - Dachverband Deutscher Heilpraktikerverbände - sowie im BFB - Bundesverband Freier Berufe - mit Sitz
- [23. Jahrestagung der Deutschen Gesellschaft für Radioonkologie](https://oncotherm.com/de/23-jahrestagung-der-deutschen-gesellschaft-fuer-radioonkologie/) - 23. Jahrestagung der DEGRO Die Zukunft gestalten: das ist eine Herausforderung für jede Fachdisziplin und jeden einzelnen Vertreter. In einem interdisziplinären Umfeld ist das nur möglich, wenn man die Stärken und Schwächen der eigenen Methoden und der Konkurrenzverfahren kennt und neue Entwicklungen und ihr Potenzial bewerten kann. Zunehmende Herausforderungen entstehen durch den Wunsch nach einer
- [18. Patienten-Arzt Kongress der GfBK](https://oncotherm.com/de/18-patienten-arzt-kongress-der-gfbk/) - 18. Patienten-Arzt-Kongress „Der Arzt behandelt, der menschliche Körper heilt.“ Mit einer Abwandlung des Satzes von Hippokrateseröffnete Professor Dr. med. Jörg Spitz, der Präsident der Gesellschaft für Biologische Krebsabwehr (GfBK) e. V., den 18. Patienten-Arzt-Kongress der Gesellschaft in Heidelberg. Selbstheilung war das zentrale Thema des Krebskongresses am 13. und 14. Mai in Heidelberg. Fast 900 Patienten,
- [Tag der offenen Tür Uni-Zentrum Naturheilkunde](https://oncotherm.com/de/tag-der-offenen-tuer-uni-zentrum-naturheilkunde/) - Tag der offenen Tür Am 18.3.2017 veranstaltet das Uni-Zentrum Naturheilkunde des Universitätsklinikum Freiburg einen Patiententag „Tag der offenen Tür“ Thema: Naturheilkunde bei Tumorerkrankungen Internationale anerkannte Referenten werden zu den Themen interdisziplinäre Onkologie, Hyperthermie, Mistel, Bewegungstherapie, Ernährung, Pflanzenstoffe, Enzyme, Vitamine, Spurenelemente, Kurzzeitfasten u.v.w. Vorträge halten.
- [5. Brandenburger Krebskongress](https://oncotherm.com/de/5-brandenburger-krebskongress/) - 5. Brandenburger Krebskongress Die Landearbeitsgemeinschaft Onkologische Versorgung Brandenburg e. V. (LAGO) und das Tumorzentrum Land Brandenburg e. V. (TZBB) veranstalten am 24. und 25. Februar 2017 im Dorint Hotel in Potsdam gemeinsam den 5. Brandenburger Krebskongress. Der Kongress zielt darauf ab, einen Überblick über das zu erhalten, was im Land Brandenburg für Krebspatienten verfügbar ist.
- [22. Joint Cancer Konferenz in Taiwan](https://oncotherm.com/de/22-joint-cancer-konferenz-in-taiwan/) - Die Konferenz hatte ein hochaktuelles Thema: Präzisionsmedizin. Fast 2000 Teilnehmer diskutierten die Themen während verschiedener Sitzungen intensiv. Pharmaunternehmen und anderen medizinischen Firmen zeigten ihre neuesten Produkte. Das Thema zog viele ausländische Teilnehmer ermöglichte einen intensiven Austausch über Präzisionsmedizin. Hauptorganisator war die taiwanesische Gesellschaft für gynäkologische Onkologie und sieben weitere Gesellschaften schlossen sich dieser interessanten Veranstaltung
- [The 22th Taiwan Joint Cancer Conference](https://oncotherm.com/the-22th-taiwan-joint-cancer-conference/) - The conference targeted a hot topic: Precision Medicine. Almost 2000 participants were intensively discussing the topics in various sessions. Exhibits of pharma and other medical companies had shown their newest products. The topic attracted many foreigner participants, making intensive discussions on the precision medicine. The main organizer was the Taiwanese Society of Gynecologic Oncology, but
- [7. Kongress für komplementäre Krebstherapie](https://oncotherm.com/de/7-kongress-fuer-komplementaere-krebstherapie/) - 7. Kongress für komplementäre Krebstherapie Die Konferenz widmet sich dem übergeordneten Thema "Stand der komplementären Onkologie, aktuelle Diagnostik und Therapieoptionen". Die Bedeutung der Umwelteinflüsse im Bereich der Krebsentstehung ist so eminent, dass wir uns entschlossen haben, einen eintägigen Schwerpunkt "Umweltmedizin" in den Kongress aufzunehmen.
- [ESTRO 2017](https://oncotherm.com/de/the-36th-european-society-for-radiotherapy-oncology/) - ESTRO 2017 Die ESTRO ist eine interdisziplinäre Gesellschaft, in der sich Radioonkologen, Medizinphysiker, Radiobiologen, Brachytherapeuten und Strahlentherapeuten mit anderen Organisationen im Bereich Onkologie, die die Vision der ESTRO von herausragender Krebsbehandlung teilen, zusammenschließen möchten. Bei der 36. ESTRO machen wir auf die multi- und interdisziplinären Komponenten unserer Praxis aufmerksam, wobei der Schwerpunkt auf den Möglichkeiten
- [The 36th European Society for Radiotherapy & Oncology](https://oncotherm.com/the-36th-european-society-for-radiotherapy-oncology/) - ESTRO 36 ESTRO is an interdisciplinary society where radiation oncologists, medical physicists, radiobiologists, brachytherapists and radiation therapists aspire to join forces with other organisations in the oncology field that share ESTRO’s vision of excellence in cancer treatment. At ESTRO 36, we draw attention to the multidisciplinary and interdisciplinary components of our practice, with emphasis on
- [Weltkongresses für Integrative Medizin & Gesundheit 2017 & 10. ECIM & 12. ICCMR Kongress](https://oncotherm.com/de/world-congress-integrative-medicine-health-2017-10th-ecim-12th-iccmr-congress/) - Weltkongresses für Integrative Medizin & Gesundheit 2017 Eines der geplanten Ziele des Weltkongresses für Integrative Medizin & Gesundheit ist die weitere Verbesserung der ganzheitlichen Patientenversorgung durch die Integration von Methoden aus der Komplementärmedizin. Die internationale Teilnehmergruppe bietet die idealen Voraussetzungen für einen umfassenden und sicherlich aufschlussreichen Austausch über den aktuellen Stand der integrativen Medizin -
- [World Congress Integrative Medicine & Health 2017, 10th ECIM, 12th ICCMR Congress](https://oncotherm.com/world-congress-integrative-medicine-health-2017-10th-ecim-12th-iccmr-congress/) - World Congress Integrative Medicine & Health 2017 One of the envisaged goals of your World Congress Integrative Medicine & Health is to further improve holistic patient care by integrating methods of complementary medicine. The international group of participants provides the ideal prerequisites for an extensive and certainly insightful exchange on the current state of integrative
- [34. Jahrestreffen der Society for Thermal Medicine](https://oncotherm.com/de/34th-annual-society-for-thermal-medicine-meeting/) - 34. Jahrestreffen der Society for Thermal Medicine Das 34. Jahrestreffen der Society for Thermal Medicine soll die wachsende weltweite Verbreitung wissenschaftlicher und klinischer Anwendungen von thermischer Medizin aufzeigen. Veranstaltungsort und Redner wurden sorgfältig ausgewählt, um den wissenschaftlichen Austausch zwischen Amerika, Europa und Asien zu fördern. Zu den Rednern gehören prominente Ärzte und führende Experten für Biologie, Medizin,
- [34th Annual Society for Thermal Medicine Meeting](https://oncotherm.com/34th-annual-society-for-thermal-medicine-meeting/) - 34th Annual Society for Thermal Medicine Meeting The 34th Annual Meeting is to highlight the growing global penetration of scientific and clinical applications of thermal medicine. The location and key invited speakers for the 34th Annual Meeting were carefully chosen to emphasize scientific exchange among the Americas, Europe, and Asia. Our roster of invited speakers includes prominent clinicians and
- [34. ICHS Conference / 4th International Oncothermia Symposium](https://oncotherm.com/34-ichs-conference-4th-international-oncothermia-symposium/) - ICHS Conference 2016 The 34th Conference will take place in the most beautiful Country of Europe: Italy, in Pesaro, the capital city of Music, Rossini’s home,and you can go for spectacular bicycle tours. Pesaro is easily to be reached from Bologna international airport, and Rimini, as well as Ancona airports. I am glad to invite
- [34. ICHS Konferenz & 4. Internationales Oncothermie Symposium](https://oncotherm.com/de/34-ichs-konferenz-4-internationales-oncothermie-symposium/) - ICHS Konferenz 2016 Wir freuen uns, Sie zur Teilnahme an der 34. Jahreskonferenz der International Clinical Hyperthermia Society (ICHS) und dem 4. Internationalen Oncothermie Symposium einladen zu können. Beide Veranstaltungen finden im schönsten Land Europas statt: Italien. Genau genommen in Pesaro, der Hauptstadt der Musik und Rossinis Heimat, in der man spektakuläre Radtouren machen kann. Pesaro
- [33. ICHS Konferenz & 3. Internationales Oncothermie Symposium](https://oncotherm.com/de/33-ichs-konferenz-3-internationales-oncothermie-symposium/) - ICHS Konferenz 2015 Die 33. ICHS Konferenz bietet Experten aus allen Bereichen der Hyperthermie die Möglichkeit, Erfahrungen auszutauschen und Studien zu präsentieren. Sie wird eine hervorragende Plattform für Forscher und Ärzte sein, um die Möglichkeit einer Hyperthermiebehandlung bei Krebs, aber auch bei anderen Krankheiten, kennenzulernen. Die Konferenz wird den technischen Hintergrund der Hyperthermiebehandlung sowie die Vor-
- [33. ICHS Conference 2015 / 3rd International Oncothermia Symposium](https://oncotherm.com/33-ichs-conference-2015-3rd-international-oncothermia-symposium/) - ICHS Conference 2015 The conference will offer the chance that experts of all fields of hyperthermia meet each other and present their experiences and studies. This will be an excellent platform for researchers and medical practitioners to explore the option of hyperthermia treatment in cancer but also in other diseases. The conference will be covering
- [Oncothermie ist ein Musterbeispiel für eine komplementärmedizinische Onkologie](https://oncotherm.com/de/oncothermie-ist-ein-musterbeispiel-fuer-eine-komplementaermedizinische-onkologie/) - http://www.openpr.de/news/794441.html Beim Patienten-Arzt-Forum der Gesellschaft für Biologische Krebsabwehr (GfBK) am 10. Mai 2014 in Berlin steht auch das Thema „Ganzheitliche Krebstherapie“ auf der Agenda. Vorgestellt werden sowohl die lokale Tiefenhyperthermie als auch die Ganzkörperhyperthermie, da die „Hyperthermie als eine weitere wichtige Therapiemöglichkeit in der komplementären Onkologie“ gilt. Beide Therapien, so die GfBK, können „zur Wirkungsverstärkung
- [Konferenz in Warschau: Hyperthermie ist Teil einer integrativen Medizin zur Prävention und Behandlung von Krebs](https://oncotherm.com/de/konferenz-in-warschau-hyperthermie-ist-teil-einer-integrativen-medizin-zur-praevention-und-behandlung-von-krebs/) - http://www.medcom24.de/content/Konferenz-Warschau-Hyperthermie-ist-Teil-einer-i… Die polnische Woman and Nature Foundation veranstaltete am 29. März 2014 in Warschau die erste Konferenz über den integrativen Ansatz in Prävention und Behandlung von Krankheiten (The Integrative Approach in the Prevention and Treatment of Diseases). Experten aus Polen, Italien, Ungarn und Deutschland diskutierten die Perspektiven eine Komplementärmedizin, die konventionelle und alternative Therapien kombiniert.
- [Darmkrebsmonat März 2014 – Lokoregionale Wärmetherapie als Komplementärmedizin](https://oncotherm.com/de/darmkrebsmonat-maerz-2014-lokoregionale-waermetherapie-als-komplementaermedizin/) - http://www.perspektive-mittelstand.de/Lokoregionale-Waermetherapie-als-Kompleme… „Wir wollen auf die Möglichkeiten hinweisen, die die Wärmetherapie bei einer komplementärmedizinischen Krebsbehandlung bieten kann“ (PM) Troisdorf/Köln, 26.03.2014 - „Der Felix Burda Stiftung ist zu danken, dass sie 2002 den Darmkrebsmonat ausgerufen hat, um die Öffentlichkeit für diese Krankheit zu sensibilisieren. So wissen immer mehr Menschen über Vorsorge- und Früherkennung“, sagt Prof. Dr. András
- [Synergien von Traditioneller Chinesischer Medizin und Wärmetherapie](https://oncotherm.com/de/synergien-von-traditioneller-chinesischer-medizin-und-waermetherapie/) - http://www.perspektive-mittelstand.de/Synergien-von-Traditioneller-Chinesischer… "Oncothermie und chinesische Medizin harmonieren, wenn sie das Gleichgewicht des Körpers wiederherstellen und ihn gegen Krebs stärken“ (PM) Troisdorf/Köln, 17.03.2014 - Auf synergetische Effekte zwischen der Oncothermie als spezieller Form der Wärmetherapie und der traditionellen chinesischen Medizin (TCM) weist Dr. Gabriella Hegyi, Pecs-Universität, Ungarn, in der Zeitschrift „Aktuelle Gesundheitsnachrichten, Ausgabe 14, hin. Hegyi, Vorsitzende
- [Hyperthermie als Thema auf dem Berliner Krebskongress](https://oncotherm.com/de/hyperthermie-als-thema-auf-dem-berliner-krebskongress/) - http://www.perspektive-mittelstand.de/Gut-dass-auch-Hyperthermie-ein-Thema-ist-… Das Motto des Kongresses: Intelligente Konzepte in der Onkologie. Hier kann sich auch die komplementärmedizinische Wärmetherapie positionieren“, sagt Prof. Dr. András Szász, Begründer der Oncothermie, einer speziellen Form der Hyperthermie. (PM) Troisdorf/Köln., 13.02.2014 - „Wir begrüßen es, dass der wichtigste deutschsprachige Kongress zu den Themen Krebsdiagnostik und Krebstherapie ebenfalls die Hyperthermie auf der Agenda
- [Hyperthermie in der Komplementärmedizin und Onkologie](https://oncotherm.com/de/hyperthermie-in-der-komplementaermedizin-und-onkologie/) - http://www.perspektive-mittelstand.de/Waermetherapie-vorurteilsfrei-einem-breit… (PM) Troisdorf, 15.01.2014 - „Es ist sehr positiv, wenn auflagenstarke, renommierte Zeitschriften wie die Apothekenumschau Ende 2013 die Wärmetherapie vorurteilsfrei für ein breites Publikum darstellen. Denn Krebs betrifft viele. Viele Patienten suchen zudem zusätzliche Wege der Behandlung. Und in der Onkologie ist die Wärmetherapie co-medikativ einsetzbar“, so Prof. Dr. András Szász, Begründer der Oncothermie,
- [32. ICHS Konferenz & 2. Internationales Oncothermie-Symposium](https://oncotherm.com/de/32-ichs-konferenz-2-internationales-oncothermie-symposium/) - ICHS Konferenz 2013 Im Namen des Organisationskomitees freuen wir uns, Sie zur Teilnahme an der 32. Jahreskonferenz der International Clinical Hyperthermia Society (ICHS) und den Internationalen Training Workshops zur klinischen Anwendung von Hyperthermie einzuladen, sowie zu der 3. Jahreskonferenz des Weltverbandes der Gesellschaften für Chinesische Medizin (Fachausschuss für Naturtherapie (WFCMS-SCNT)), welche alle vom 8. bis
- [32. ICHS Conference / 2nd International Oncothermia Symposium](https://oncotherm.com/32-ichs-conference-2nd-international-oncothermia-symposium/) - ICHS Conference 2013 On behalf of the organizing committee, we are glad to invite you to attend the 32nd Annual Conference of the International Clinical Hyperthermia Society (ICHS) -cum- International Training Workshops on Clinical Application of Hyperthermia and the 3rd Annual Conference of The World Federation of Chinese Medicine Societies - Specialty Committee of Natural
- [1. Internationales Oncothermie-Symposium](https://oncotherm.com/de/first-international-oncothermia-symposium/) - Besuchen Sie die Website des 1. Internationalen Oncothermie-Sypmosiums Das erste internationale Oncothermie-Symposium war ein voller Erfolg. Rund 120 Teilnehmer aus 21 Ländern tauschten zwei Tage lang ihre praktischen Erfahrungen und wissenschaftlichen Ergebnisse aus. Vorträge von 23 Experten aus aller Welt und 32 Poster zeigten die Wirkung und den Erfolg der Oncothermie-Behandlung. Die Vorträge und Poster
- [First International Oncothermia Symposium](https://oncotherm.com/first-international-oncothermia-symposium/) - Visit the Oncothermia Symposium 2013 website The First International Oncothermia-Symposium was a great success. About 120 participants from 21 countries came together for two days to share practical experiences and scientific results. 23 talks of experts from all over the world and 32 posters showed the effects and success of the Oncothermia treatment. The talks
- [31. ICHS Konferenz & 1. Internationales Oncothermie Symposium](https://oncotherm.com/de/31-ichs-konferenz-1-internationales-oncothermie-symposium/) - ICHS Conference 2012 Es ist uns eine große Freude, Sie zur 31. Konferenz der International Clinical Hyperthermia Society (ICHS) einzuladen, die vom 12. bis 14. Oktober 2012 in Budapest, Ungarn, stattfinden wird. Hyperthermie ist eine Methode aus dem Bereich der Onkologie, die ungiftig ist und gut personalisiert werden kann. Wir möchten die Hyperthermie weiterverbreiten, um
- [31. ICHS Conference / 1st International Oncothermia Symposium](https://oncotherm.com/31-ichs-conference-1st-international-oncothermia-symposium/) - ICHS Conference 2012 It is our great pleasure to invite you to the XXXI. Conference of the International Clinical Hyperthermia Society (ICHS), which will be held in Budapest, Hungary on 12-14 October, 2012. Hyperthermia is one of the methods in oncology, which in principle has proper conditions for individual treatments being statistically manageable at the
- [Internationaler Kongress: "Clinical Trials for Medical Devices" 2017](https://oncotherm.com/de/internationaler-kongress-clinical-trials-for-medical-devices-2017/) - Internationaler Kongress: "Clinical Trials for Medical Devices" 2017 Nach dem Erfolg von ctmd2015 in Wien und ctmd2016 in Berlin wird sich auch ctmd2017 auf die neuesten Entwicklungen und bevorstehenden Vorschriften für klinische Studien für Medizinprodukte auf internationaler Ebene konzentrieren.
- [Fizika a rákgyógyászatban: onkotermia](https://oncotherm.com/hu/fizika-a-rakgyogyaszatban-onkotermia/) - Fizika a rákgyógyászatban: onkotermia Az onkotermia, vagy szakszerűbben az EHY-2000 készüléket alkalmazó loko-regionális mély hipertermia, gyorsan fejlődő kiegészítő kezelési eljárás; a tumoros megbetegedések gyógykeze­lésére alkalmazzák. Dr. Szász András professzorral Hajduné Fábián Julianna beszélgetett. „A kutatás: látni, amit mindenki látott, és arra gondolni, amit még senki sem gondolt”. Szent-Györgyi Albert A módszer a klasszikus hipertermia elvein
- ['New' Prostate Cancer Treatment](https://oncotherm.com/uj-prosztatarak-kezelesi-mod/) - 'New' Prostate Cancer Treatment ARASOTA, Fla., April 15 /PRNewswire/ -- During a routine physical in September 2006, retired airline pilot Jeff Albulet's doctor thought he 'felt something' when he did a digital rectal exam, although Jeff's prostate specific antigen (PSA) was only 2. Six months later, Jeff's PSA rose to 3.5, and a biopsy showed pre-cancerous cells. In discussing
- [New Oncothermia user clinic in North America](https://oncotherm.com/new-oncothermia-user-clinic-in-north-america/) - Port Moody Health is one of just a few cancer centers in North America to offer… Port Moody Health is one of just a few cancer centers in North America to offer Hyperthermia (Modulated Electro-hyperthermia using the Oncotherm EHY-2000), an advanced technology from Germany and a major breakthrough in integrative cancer therapy. Now, Canadians no
- [The documentary "A New Standard of Care" coming soon](https://oncotherm.com/the-documentary-a-new-standard-of-care-coming-soon/) - The first documentary undertaken by WayMark Productions, “A New Standard of Care” (2017 targeted release date), investigates alternative cancer therapies. The World Health Organization statistics contend one-in-three women and one-in-two men will contract cancer in their lifetime, and that cancer is a leading cause of death worldwide — set to increase by 70 percent in
- [Gisunt Klinik Symposium](https://oncotherm.com/gisunt-klinik-symposium/) - http://www.gisunt-klinik.de/ Gisunt Klinik organised a one-day Symposium on integrative medicine at Hotel Kaiser in Wilhelmshaven on June 17th. The gisunt® clinic is a specialist hospital for integrative medicine with hyperthermia. It is the treatment center with internatiol reputation for chronically ill and cancer patients. Fever therapy, hyperthermia, oxygen therapies, acupuncture and naturopathic treatments are their
- [ESHO 2017](https://oncotherm.com/esho-2017/) - ONCOTHERM was PLATINUM SPONSOR of the ESHO 2017- Hellenic Society for Oncologic Hyperthermia We proudly inform you that Oncotherm attended the ESHO conference in Athens between 21 June and 23 June. We are honored to be platinum sponsor of such a successful event. The new device, EHY-2030 was presented during the conference and debut film was screened several times
- [EPT1 Greek National TV news about Oncothermia at ESHO 2017](https://oncotherm.com/ept1-greek-national-tv-news-about-oncothermia-at-esho-2017/) - EPT1 Greek National TV news about Oncothermia at ESHO 2017 We are very proud to publish the news of the EPT1 Greek National TV about the method of Oncothermia and the latest developed medical device: EHY-2030. The event was financed from the NRDI Fund.
- [1.5 billion-forint grant for tumour therapy device](https://oncotherm.com/1-5-billion-forint-grant-for-tumour-therapy-device/) - 1.5 billion-forint grant for tumour therapy device Beneficiary Name: Oncotherm Kft. and Semmelweis University Title of the project: „Improving the efficiency of the electromagnetic tumour therapy device and the preparation for its integration into commercial use” Amount of contracted support: 1,472 billion forints Support rate: 88.94% Projected completion date : 31.12.2019 Project ID number : NVKP_16-1-2016-0042 The tender
- [Saudi Arabia Approves Oncothermia, the Latest Technology in Cancer Treatment](https://oncotherm.com/saudi-arabia-approves-oncothermia-the-latest-technology-in-cancer-treatment/) - Saudi Arabia Approves Oncothermia, the Latest Technology in Cancer Treatment After being approved in over 30 countries, the Saudi Food and Drug Authority (SFDA) approved the use of Oncothermia (modulated electro-hyperthermia, mEHT), the latest complementary cancer treatment technology. The treatment gives cancer patients enhanced quality of life, improved survival rates, and comfort during the various
- [Unique device against cancer, the EHY-2030](https://oncotherm.com/unique-device-against-cancer-the-ehy-2030/) - https://www.youtube.com/watch?v=DJYLUPBAEjI&ab_channel=OncothermKft. we are proud to introduce a unique device against cancer, a brilliant solution for the patient, the EHY-2030 It features a number of new innovations that help deliver the same highly effective modulated electro-hyperthermia treatment more effectively using a new, more patient-oriented design. Redesigned tuning system which is capable of faster and more accurate targeting of
- [Új innováció a rákgyógyászatban](https://oncotherm.com/hu/uj-innovacio-a-rakgyogyaszatban/) - Büszkén mutatjuk be Önöknek az EHY-2030-as készülékünket, amely egyedülálló, kiegészítő rákgyógyászati eszközként számos technológiai innovációjával biztosítja a rendkívül hatékony, modulált Elektro-Hyperthermiás (mEHT) kezelést. Új, autonom hangolási rendszerével gyorsabb és pontosabb kihangolást biztosít Igazi áttörés az Onkológiai Hyperthermiában az Intelligens Elektróda Rendszer (Smart Electrode System), amely képes érzékelni a helyes illeszkedést a betegen és vizuális visszajelzést
- [Board inauguration at the Outsourcing Department of Biotechnics, at Oncotherm Kft.](https://oncotherm.com/board-inauguration-at-the-outsourcing-department-of-biotechnics-at-oncotherm-kft/) - Oncotherm Kft. is based in Budaörs, it was founded by Prof. Dr. András Szász in 1988. The company develops and manufactures supplementary oncological treatment tools which are exported to 32 countries. More than 200,000 treatments are performed with these devices annually to treat treat advanced tumor diseases. In Hungary, an international training and treatment center
- [ICHS Information - Facing forward to immuno-oncology!](https://oncotherm.com/ichs-information-facing-forward-to-immuno-oncology/) - ICHS website The 35th ICHS Annual Conference was held with the presence of a very large number of participants. The conference took place in China's best hospital in Clifford Hospital from 24th November until 26th of November 2017 in Ghuangzhou, China. List of lecture titles: Non-Toxic Integrative Cancer Treatment – the Health Preservation, Treating, and Rehabilitation
- [Cooperation of Academic and Industrial Partners to Fight Tumorous Diseases](https://oncotherm.com/cooperation-of-academic-and-industrial-partners-to-fight-tumorous-diseases/) - The objective of the National Competitiveness and Excellence Program (NVKP-16) was to provide funding for projects that aim at increasing the efficiency of the therapy of diseases of public health significance via Research, Development and Innovation (RDI). Our grant proposal entitled “Efficiency improvement, market introduction and preparations for integration into oncological therapeutic practice of an electromagnetic tumour
- [Oncological hyperthermia in crossroads - lecture in Lisbon](https://oncotherm.com/oncological-hyperthermia-in-crossroads-lecture-in-lisbon/) - Prof. András Szász with Mr. Soma Benke from RWU (our International Business Development Partner) visited Lisbon in September. Prof. András Szász held a lecture with the following title: Oncological hyperthermia in crossroads The lecture was attended by: Dra. Lurdes Batarda and Dr. Marco Possanzini from Fundacao Champalimaud (a Portuguese cancer foundation), Dr. Filipe Costa and Dra.
- [Modulated Electro-Hyperthermia as a chemoradiosensitizer for locally advanced cervical cancer](https://oncotherm.com/modulated-electro-hyperthermia-as-a-chemoradiosensitizer-for-locally-advanced-cervical-cancer/) - Dr. Carrie Anne Minnaar presented her poster at the 18th National Congress of South African Society of Clinical & Radiation Oncology ( SASCRO ) and South African Society of Medical Oncology (SASMO). She showed the latest results on cervical cancer. Conclusion: "The preliminary results continue to show a positive trend in local disease control and survival at 6
- [New installation in Granada, Spain](https://oncotherm.com/new-installation-in-granada-spain/) - New installation in Granada We are pleased to welcome CLINICA CHECA as a new Oncotherm user in Granada Spain. Take a look at the pictures of the modern designed clinic where the EHY-2000 device was installed in November.
- [Symposium for Hyperthermia in Cancer Treatment](https://oncotherm.com/symposium-for-hyperthermia-in-cancer-treatment/) - The symposium was organised in Chungnam University Hospital of Korea on 29.11.2017. Prof. Dr. András Szasz and Dr. Carrie Minnaar presented their lectures about: Basic principle and new results of Oncothermia The addition of mEHT to treatment protocols for locally advanced cervical cancer patients Please find some press release on the following sites: 중도일보 http://www.joongdo.co.kr/main/view.php?key=20171129010012190 대전일보 http://www.joongdo.co.kr/main/view.php?key=20171129010012190 충청뉴스 http://www.ccnnews.co.kr/news/articleView.html?idxno=97716 대전투데이 http://www.ccnnews.co.kr/news/articleView.html?idxno=97716 MBS http://www.mbstv.co.kr/news/articleView.html?idxno=129904 의계신문 http://www.medworld.co.kr/news/articleView.html?idxno=110468
- [FACTS about Oncothermia](https://oncotherm.com/facts-about-oncothermia/) - FACTS about Oncothermia Oncothermia is active in all solid tumors. No side effects, rare contraindications. Combined energy absorption with modulated electric field. Oncologists or other medical specialists treat with the method worldwide. Tumour tissue is selectively treated, the malignance is destroyed. Healthy tissue is unaffected. Efficacy of chemotherapy and radiotherapy is improved by the treatment. Reestablishes the
- [New publication: Hyperthermia Dosing and Depth of Effect](https://oncotherm.com/new-publication-hyperthermia-dosing-and-depth-of-effect/) - Hyperthermia Dosing and Depth of Effect Author(s) Szasz Oliver1, Szigeti Gyula Peter2, Vancsik Tamas3, Szasz Andras1 Affiliation(s) 1Department of Biotechnics, St. Istvan University, Budapest, Hungary. 2Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary. 3Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. ABSTRACT The penetration depth in the electromagnetic
- [New short film about the cancer treatment device manufacturer](https://oncotherm.com/kisfilmet-forgattak-az-onkotermia-modszeret-alkalmazo-rakkezelo-eszkozgyartorol/) - https://www.youtube.com/watch?v=5uKEGe_Z_6g&ab_channel=Buda%C3%B6rsiV%C3%A1rosiTelev%C3%ADzi%C3%B3
- [MEHT related article was chosen for the cover of the Journal of Cancer, a huge professional recognition](https://oncotherm.com/meht-related-article-was-chosen-for-the-cover-of-the-journal-of-cancer-a-huge-professional-recognition/) - MEHT related article in the Cancer of Journal It is a huge professional recognition that a mEHT related article was chosen for the cover of the Journal of Cancer. The title of the article: Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts Authors: Tamas Vancsik,1Csaba Kovago,2Eva Kiss,1Edina Papp,3Gertrud Forika,1Zoltan Benyo,4Nora Meggyeshazi,1,* and Tibor Krenacs1, 11st Department
- [Seminar in Lahore for recognized oncologists about Modulated electro-hyperthermia (mEHT)](https://oncotherm.com/seminar-in-lahore-for-recognized-oncologists-about-modulated-electro-hyperthermia-meht/) - Seminar in Lahore for recognized oncologists about Modulated electro-hypertherm… Oncothermia is a requested method worldwide. Dr. Oliver Szasz held a seminar in Lahore for recognized oncologists with the title: Modulated electro-hyperthermia (mEHT). Dr. Olivér Szász is an Associate professor at Biotechnics Department of St.Istvan University&CEO of Oncotherm Kft. (Hungary) and Oncotherm GmBH (Germany). For the riport please
- [New Installation of EHY-2000 Device - BioMed Clinic, Bad Bergzabern](https://oncotherm.com/ujabb-ehy-2000-es-keszuleket-telepitettunk-a-nemetorszagi-biomed-klinikan/) - BioMed clinic is a hospital for acute oncology cases, which combines conventional medicine with methods from complementary cancer therapy. Dr. H. Friedrich Migeod MD. is the chief physician of the BioMed-Hospital, Bad Bergzabern (see picture above). BioMed clinic is a longtime and a successful user of Oncotherm. BioMed has two EHY-2000+ devices and one EHY-2000
- [Meet us at ESTRO 37](https://oncotherm.com/talalkozzunk-az-estro-37-konferencian/) - ESTRO 37 ESTRO is a society focusing on interdisciplinarity and multidisciplinarity, giving radiation oncologists, medical physicists, radiobiologists, brachytherapists and radiation therapists (RTTs) the opportunity to engage with other oncology organisations with the collective aim of improving cancer treatment. This conference will convey the theme ‘Innovation for Value and Access’. Read the full welcome letter here by the
- [Oncotherm will be PLATINUM sponsor of the ESHO 2018](https://oncotherm.com/oncotherm-will-be-platinum-sponsor-of-the-esho-2018/) - ESHO 2018 We invite our partners to meet ONCOTHERM and its experts at ESHO, which is a great scientific platform to learn the advancement of hyperthermia research and improved clinical treatment from the world's leading hyperthermia experts. Dr. Olivér Szász will hold a lecture on 18.05 at 13:45 under the titel: Modulated electrohyperthermia from bench to clinic Dr. Olivér
- [36th International Clinical Hyperthermia Society](https://oncotherm.com/36th-international-clinical-hyperthermia-society/) - Official Website of the ICHS Invitation to the 36. Conference of the International Clinical Hyperthermia Society Date: from 28th- 29th September 2018 Place: Danubius Hotel Margitsziget, Budapest, Hungary We would like to invite you to take part as participant or as speaker. Show your new results for hyperthermia by oral or poster presentations. Your presence helps
- [M5 TV reported about the ICHS](https://oncotherm.com/m5-tv-reported-about-the-ichs/) - TV Riport about the 36.ICHS The Hungarian M5 TV reported about the ICHS. Please find in the following link this riport (time range: 10:09-11.14): https://www.mediaklikk.hu/video/kulturalis-hirado-2018-09-28-i-adas/# The event was financed from the NRDI Fund.
- [MEDICA- World Forum For Medicine](https://oncotherm.com/medica-a-gyogyaszat-vilagforuma/) - Oncotherm will participate at the MEDICA Düsseldorf 12–15.11.2018. We hope to see you at our booth 9B11. Please find more information about the exhibition via the following link: https://www.medica-tradefair.com/
- [New Oncotherm device installation in Pakistan, Lahore](https://oncotherm.com/new-oncotherm-device-installation-in-pakistan-lahore/) - Saira Memorial Hospital is a multi-disciplinary, tertiary care institution, with modern state of the art diagnostic and therapeutic facilities in Lahore. Since november the Oncothermia treatment is available here with the EHY-3010 ML device, designed for the simultaneous multi-local treatment of advanced, metastaticly disseminated, malignant solid tumors. Within the range of Oncothermia systems, it is
- [New publication appeared in the International Journal of Oncology](https://oncotherm.com/new-publication-appeared-in-the-international-journal-of-oncology/) - Please download the full publication here We draw your attention to the new publication with the title "Oncological hyperthermia: The correct dosing in clinical applications" Authors: Sun-Young Lee, Gyula Peter Szigeti, Attila Marcell Szasz Published online on: November 23, 2018 Abstract The problem with the application of conventional hyperthermia in oncology is firmly connected to
- [We wish you a Merry Christmas and a Happy New Year](https://oncotherm.com/kellemes-karacsonyi-unnepeket-es-boldog-uj-evet-kivanunk-2/) - Warmest thoughts and best wishes for a wonderful Christmas and a Happy New Year. May peace, love and prosperity follow you always! Wishing you and your family good health, happiness, success and prosperity in the coming year! Have a great start to a great year! (The Hungarian office will be closed from 19th December 2018 to
- ["Shoebox” project](https://oncotherm.com/shoebox-project/) - Oncotherm Kft. took part the “Shoebox” project organized by the Baptist Charity Service. We would like to make the Christmas of families and children in need more beautiful with the collected toys and food.
- [New publication appeared in the Open Journal of Biophysics](https://oncotherm.com/uj-publikacio-jelent-meg-az-open-journal-of-biophysics-en/) - Please download the publication here Open Journal of Biophysics, 2019, 9, 51-69 Title: Fluctuations Hypothesize the New Explanation of Meridians in Living Systems Gyula Peter Szigeti, Andras Szasz Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary Department of Biotechnics, St. Istvan University, Budaors, Hungary Abstract Biosystems are complex. Their physiology is
- ["6. Brandenburger Krebskongress" in Germany](https://oncotherm.com/6-brandenburgi-rakkongresszus-nemetorszagban/) - For more information please click here We are delighted to invite you to attend the 6. Brandenburger Krebskongress in Potsdam, Germany For the 6th time the Brandenburger Krebskongress (Brandenburger cancer conference) will take place in Potsdam. The conference is especially for oncology professionals of all disciplines and professions. We look forward to your visit! When: 22.
- [37.ICHS will be held in Thessaloniki, Greece on the 19th to the 21st of September 2019](https://oncotherm.com/37-ichs-will-be-held-in-thessaloniki-greece-on-the-19th-to-the-21st-of-september-2019/) - ICHS official website The 37. ICHS conference will be held in Thessaloniki, Greece on the 19th to the 21st of September 2019. Dr. Aias-Theodoros Papastavrou will be the chairman of the conference. The local organizers of the 37th ICHS conference will be: The Hellenic Society of Oncologic Hyperthermia (president Prof. Dr Vassilis Kouloulias) and The
- [Oncothermia trials](https://oncotherm.com/oncothermia-trials/) - Oncothermia trials The following oncothermia trials are registered in the https://www.clinicaltrials.gov, in the international database registered in USA. Via the following link please find more information of the trials: https://www.clinicaltrials.gov/ct2/results?cond=&term=oncothermia&cntry=&state=&city=&dist=&Search=Search Study 1: Title: Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients Conditions: Cancer, Pancreas Interventions: Other: Oncothermia|Drug: FOLFIRINOX or Gemcitabine based
- [An oncothermia related article was published in the Open Journal of Biophysics](https://oncotherm.com/an-oncothermia-related-article-was-published-in-the-open-journal-of-biophysics/) - Please find the article here Title: Bioelectromagnetic Paradigm of Cancer Treatment—Modulated Electro-Hyperthermia (mEHT) Author: Olivér Szász Department of Biotechnics, St. Istvan University, Budaörs, Hungary ABSTRACT One of the most frequently applied bioelectromagnetic effects is the deep heating of the living species with EMF energy. Despite its long history, hyperthermia is a rarely applied oncotherapy. The
- [Useful information of the 37. Conference of the International Clinical Hyperthermia Society (ICHS)](https://oncotherm.com/useful-information-of-the-37-conference-of-the-international-clinical-hyperthermia-society-ichs/) - For detailed information please visit the offical website of the conference Here are some handy information about the 37. ICHS Conference: Deadline of the abstract submisson: July 20, 2019 Send to your abstract to z.hahn@ichs.eu Venue: Hotel Panorama in Thessaloniki Hotel room booking via the following options: info@hotelpanorama.gr or +30 231 034 4871 Practical links: About the venue: http://www.ichs-conference.org/venue/ About the abstract requirements: http://www.ichs-conference.org/abstract/ Sightseeing programs in Thessaloniki: https://www.tripadvisor.com/Attractions-g189473-Activities-Thessaloniki_Thessaloniki_Region_Central_Macedonia.html Weather of
- [New installation of EHY-2030 in Spain, Valdecilla](https://oncotherm.com/uj-2030-as-rakkezelo-keszulek-telepitese-a-spanyolorszagi-valdecilla-ban/) - Source Valdecilla has become the first public hospital in Spain to have an oncothermia device within a radiotherapy service. Now they can treat tumors with bad prognosis. The Minister of Health, Ms. Luisa Real, visited the hospital to see the new equipment which is used now for patients with brain, rectal and pancreatic tumors. The new oncothermia device was installed in the
- [TeSzedd! - Volunteering for a clean Hungary with the participation of Oncotherm](https://oncotherm.com/teszedd-volunteering-for-a-clean-hungary-with-the-participation-of-oncotherm/) - Website of TeSzedd! - Volunteering for a clean Hungary TeSzedd! - Volunteering for a clean Hungary with the participation of Oncotherm's colleagues TeSzedd! – Volunteering for a clean Hungary is one of the largest volunteer movement of Hungary. This year, the waste picking day took place on the 8th occassion. Hungary joined the pan-European „Let’s Clean
- [ESHO 2019- 33rd Annual Meeting of the European Society for Hyperthermic Oncology Conference](https://oncotherm.com/esho-2019-33rd-annual-meeting-of-the-european-society-for-hyperthermic-oncology-conference/) - Official website of the conference May was the month of the 33rd Annual Meeting of the European Society for Hyperthermic Oncology Conference (ESHO 2019). The conference was held in Warsaw, Poland at the Warsaw Plaza Hotel 22-25 May, 2019. Oncotherm participated at the conference. More than 50 hyperthermia related lectures were presented by professional oncologists. The
- [Oncotherm Running Team reloaded](https://oncotherm.com/oncotherm-running-team-reloaded/) - Official website of the event Congratulate again to our runners. They completed the Crazy5K running competition in Dunakeszi on 02.06.2019. CRAZY5K is a fun and challenging obstacle run, which gives you the chance to feel like a child once again. The 10 gigantic inflatable obstacles are placed along a 5 km long track. The competition is organized
- [A Phase I/II clinical trial of oncothermia has been published](https://oncotherm.com/a-phase-i-ii-clinical-trial-of-oncothermia-has-been-published/) - For the whole article please visit the journal's website Congratulate on this nice work which was published at the Japanese Journal of Clinical Oncology Phase I/II clinical trial of modulated electrohyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer Heon Jong Yoo, Myong Cheol Lim, Sang-Soo Seo, Sokbom Kang, Jungnam Joo, and Sang-Yoon Park
- [Dr. Carrie Minnaar's phase III randomised controlled trial has been published](https://oncotherm.com/dr-carrie-minnaars-phase-iii-randomised-controlled-trial-has-been-published/) - For the whole article please visit the journal's website Congratulate on this nice work! After numerous retrospective and prospective Phase II studies of different tumor localizations, the first Phase III study by oncothermia had been published today in the prestigious Journal PLOSOne. The definite advantages of using oncothermia additionally to radiochemotherapy has been shown in the randomized
- [Support of the Szent Erzsébet Children Foundation](https://oncotherm.com/a-szent-erzsebet-gyermekalapitvany-tamogatasa/) - As the part of the CSR it is very important for us to support hospitals, children, foundations and those who are in need. Oncotherm Kft. aids the Szent Erzsébet Children Foundation every year. With our help they could buy new devices, new equipment’s for the children in several hospitals in Hungary.
- [Updates about the ICHS conference](https://oncotherm.com/updates-about-the-ichs-conference/) - The official website of the conference We would like to give you updates about the ICHS conference that will take place from the 19th – 21st September 2019 in Thessaloniki, Greece. The topics of the conference will be: General status of hyperthermia, challenges, and solutions Definitions of concepts - Consensus Clinical results of hyperthermia Immuno-oncology & hyperthermia Integrative
- [Interview with Dr. Aryan Tavakkoli](https://oncotherm.com/interju-dr-aryan-tavakkolival/) - The official website of the clinic Dr. Aryan Tavakkoli is using the EHY-2000Plus device in England in her clinic. Quantum Clinic (https://quantumclinic.co.uk/) in Lewes offers several types of cancer treatments, such as oncothermia. Yes of Life is the UK's integrative cancer care charity, which made an interview with Dr. Tavakkoli about oncothermia. For the whole
- [Fractal physiology course in Thessaloniki](https://oncotherm.com/fraktal-fiziologiai-kurzus-thessalonikiben/) - The 37th ICHS Conference in Thessaloniki, Greece will be held on 19-21 September. As a unique program, Prof. Szász will hold a Fractal physiology course before the conference. This is the first time that this topic will be presented in Greece. Place: Lab of Physiology, Medical School, Aristotle University of Thessaloniki http://physiology.med.auth.gr/content/dorothea-kapoukranidou-biographical-note The outline of the talk is the
- [Klinik Marinus am Stein in the database of International Medical Tourism Center](https://oncotherm.com/a-klinik-marinus-am-stein-korhaz-bekerult-a-international-medical-tourism-center-adatbazisaba/) - The official website of the clinic In the database of the International Medical Tourism Center (https://imedicaltourismcenter.com/) the patients should find several health centers in from 27 countries in the field of neurology, oncology, alternative medicine, surgery or urology, etc. Klinik Marinus am Stein is a perfect solution to the patients for cancer treatment. They offer oncothermia as
- [Satellite and free time activities in Thessaloniki during the ICHS Conference](https://oncotherm.com/satellite-and-free-time-activities-in-thessaloniki-during-the-ichs-conference/) - Satellite activities Satellite 1 Departure from hotel 19:30 -20:30. Sight seeing tour of the City and Monuments. Dinner 20:30 at “HAMODRAKAS” (WWW.HAMODRAKAS.GR) Departure 23-23:30 for the hotel. Cost: 80 Euros per person Name : GALA DINNER and City Tour Date: FRIDAY 20/09/2019 Departure from the hotel 19:30 City – Tour 19:30 – 20:30 Satellite 2
- [Oncothermia related article was published in the Journal of Thermal Biology](https://oncotherm.com/oncothermia-related-article-was-published-in-the-journal-of-thermal-biology/) - For the article please visit the journal's website Congratulate on this nice work! Effect of tumor properties on energy absorption, temperature mapping, and thermal dose in 13.56-MHz radiofrequency hyperthermia Bibin Prasada, Subin Kimb, Woong Chob, Suzy Kimb, Jung Kyung Kimc,⁎ a Department of Mechanical Engineering, Graduate School, Kookmin University, Seoul 02707, Republic of Korea b Department of Radiation Oncology,
- [World Lymphoma Awareness Day](https://oncotherm.com/world-lymphoma-awareness-day/) - For more please visit the following site September 15 is World Lymphoma Awareness Day all over the world. Several conferences, articles and meetings draw the people's attention of this high risk cancer type. "Lymphoma is the general term for cancers that develop in the lymphatic system. The lymphatic system is made up of a vast network
- [The 37th ICHS Conference in Thessaloniki](https://oncotherm.com/the-37th-ichs-conference-in-thessaloniki/) - The official website of the 37th ICHS Conference The beautiful Thessaloniki, Greece was the home of the 37th International Clinical Hyperthermia Society (ICHS) Conference between 19-21 September, 2019. For this successful event the Oncotherm Kft. was the PLATINUM SPONSOR. It was utterly an international conference. For instance the delegates from: Brazil Hungary Japan USA Germany Australia South-Korea
- [Hyperthermia therapy for the elderly](https://oncotherm.com/hyperthermia-therapy-for-the-elderly/) - For the whole German article please visit the following site An expert discusses the treatment of end-stage cancer in the New York Times (5 August 2019, Cancer Treatment at the End of Life.). In this online article you will find a summary of the original article and a conclusion. It deals with the motives of the
- [3rd Sport and Innovation Conference in Budapest](https://oncotherm.com/3rd-sport-and-innovation-conference-in-budapest/) - The 3rd Sport and Innovation Conference was held in Budapest, 2-3 October, at the University of Physical Education. XAX Kft. in cooperation with the University of Physical Education started to develop a new kind of device named SportAvail. XAX Kft. manufactures according to Oncotherm Kft.’s license. XAX Kft. participated at the conference as the representative of its distributor company,
- [34th MAOT Congress](https://oncotherm.com/34-maot-kongresszus/) - "One belt- One road" congress with a diverse range of TRADITIONAL CHINESE MEDICINE topics was held in Budapest between 4 and 5 of October, which was the XXXIV Annual MAOT Congress as well. The traditional Chinese medicine has acquired the right to exist in 122 countries around the world. Several excellent studies confirm the usefulness of this treatment among health care methods in
- [Select USA Investment Summit](https://oncotherm.com/select-usa-investment-summit/) - For more information of the event please visit the following site Prof. Andras Szasz participated at the Select USA Investment Summit event, which was held in Washington, D.C. June 10-12, 2019. He was invited by the American accredited ambassador of Hungary. A short summary of the event: “The U.S. government, through SelectUSA, assists companies seeking to establish
- [Oncothermia related article published in International Journal of Molecular Science](https://oncotherm.com/oncothermia-related-article-published-in-international-journal-of-molecular-science/) - For the full article please click here Congratulation on this excited article! Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects. Balázs Beszterceiy1.y, Tamás Vancsik 2,y, Anett Benedek 1, Enikő Major 1, Mbuotidem J. Thomas 1, Csaba A. Schvarcz 1, Tibor Krenács 2, Zoltán Benyó 1 and Andrea Balogh 1,* 1 Institute of Clinical Experimental Research, Semmelweis University, 1097 Budapest, Hungary 2 1st
- [Oncotherm Running Team at Crazy Sprint Run](https://oncotherm.com/oncotherm-running-team-at-crazy-sprint-run/) - Crazy Sprint Run is a 2km long intensive running competition with a lot of fun possibilities after the run. 19 challenges are waiting for you throughout the running period. This is one of the most exciting running programme in Hungary. https://www.youtube.com/watch?v=_c68KUMRU7k&t=5s&ab_channel=CRAZY5K
- [Our user, Prof. Giammaria Fiorentini just published a new article about Oncothermia](https://oncotherm.com/our-user-prof-giammaria-fiorentini-just-published-a-new-article-about-oncothermia/) - Please click here to the full version Congratulation on this great research! Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients Giammaria Fiorentini, MD1 , Donatella Sarti, PhD1, Virginia Casadei, MD1, Carlo Milandri, MD2, Patrizia Dentico, MD2, Andrea Mambrini, MD3, Roberto Nani, MD4, Caterina Fiorentini, MD5, and Stefano Guadagni, MD6
- [Meeting at the American Embassy](https://oncotherm.com/meeting-at-the-american-embassy/) - His Excellency the Ambassador of the United States of America, David B. Cornsetin invited Prof. Andras Szasz to a roundtable conversation with the 2019 Hungarian SelectUSA Investment Summit Delegation. The discussions were held in a frank, friendly atmosphere. His Excellency was interested in business activities and challenges in the USA. Ms Jennifer Kane-Zabolotskaya, Counselor for Commercial Affairs
- [Ranks of the journals which contain Oncothermia articles](https://oncotherm.com/ranks-of-the-journals-which-contain-oncothermia-articles/) - You should read more about the impact factor here "The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a proxy for the relative importance of a journal within its field; journals with
- [Oncothermia Journal Volume 27](https://oncotherm.com/oncothermia-journal-volume-27/) - For the full volume please click on the link Volume 27 is now available! Fourteen hyperthermia related presentations from the 37th ICHS Conference are published in the 27th volume of Oncothermia Journal.
- [Successful 2019 for Oncotherm](https://oncotherm.com/sikeres-2019-es-ev/) - With 2020 being a couple of weeks old it is worthwhile to look back at the past year and take stock. 2019 was a successful year for the Oncotherm Group since over 50 devices were delivered worldwide. Many of them went to South Korea, where Oncothermia is very popular and the corresponding market is booming, but
- [11th Biennial Conference on Hyperthermic Oncology & Medicine](https://oncotherm.com/11-biennial-konferencia/) - On 15th-16th February, 2020 the 11th Biennial Conference was held in India, Mumbai where Prof. András Szász participated together with Dr. Carrie Anne Minnaar. The professor had a presentation on the topic of “Modulated Electro-Hyperthermia towards the immunogenic Hyperthermic action” and Dr. Minnaar presented the topic of “Report on local disease control, early survival results, and
- [New results from South Africa](https://oncotherm.com/new-results-from-south-africa/) - For the full article please visit this website Congratulations to the authors for this article! Review of the Defining Characteristics of Nodal Disease on PET/CT Scans in Patients With HIV-Positive and-Negative Locally Advanced Cervical Cancer in South Africa Carrie Anne Minnaar, Ans Baeyens, Olusegun Akinwale Ayeni, Jeffrey Allan Kotzen, Mboyo-Di-Tamba Vangu Abstract Literature reports increased FDG nodal
- [Renewed EC Certificate is released](https://oncotherm.com/renewed-ec-certificate-is-released/) - Please click here to reach our Quality Management page ANNOUNCEMENT The renewed EC Certificate of OncoTherm Kft. about the full quality assurance system, according to the European Union Medical Device Directive (MDD) now is released by our Notified Body. It is an extended-time certificate according to MDD, which is valid until 2024-05-26 at the latest.
- [Oncothermia related articles](https://oncotherm.com/oncothermia-related-articles/) - Two articles related to the topic of Oncothermia were published. "Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients" in International Journal of Hyperthermia and "Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients" in Frontiers in Oncology. We would like to congratulate
- [Interview with Dr. Carrie Minnaar](https://oncotherm.com/riport-dr-carrie-minnaarral/) - ​​​​​​​For the full article please click here Buddies for life Magazine - A project of the Breast Health Foundation has published an interview with Dr. Carrie Minnaar related the topic of Hyperthermia. "Hyperthermia and breast cancer: We learn more about the new treatment, hyperthermia, and its benefits when applied in conjunction with chemotherapy and radiation for
- [New publications from Prof. András Szász et al.](https://oncotherm.com/new-publications-from-prof-andras-szasz-et-al/) - International Journal of Clinical Medicine published two articles written by Professor András Szász et al. Parametrization of Survival Measures, Part I: Consequences of Self-Organizing Authors: Andras Szasz, Oliver Szasz Abstract: Lifetime analyses frequently apply a parametric functional description from measured data of the Kaplan-Meier non-parametric estimate (KM) of the survival probability. The cumulative Weibull distribution function (WF)
- [Book Release: Challanges and Solutions of Oncological Hyperthermia](https://oncotherm.com/book-release-challanges-and-solutions-of-oncological-hyperthermia/) - Click here to buy the book Challenges and Solutions of Oncological Hyperthermia book has been released in May 2020, it can be purchased from Cambridge Scholars Publishing. The present book is a unique continuation of the broad set of existing publications, concentrating on the complex means of helping the natural processes to fight against cancer. This book collects together
- [New experimental study in Scientific Reports](https://oncotherm.com/uj-kiserleti-tanulmany-a-scientific-reportsban/) - Scientific Reports published an article related the topic of Modulated Electro-Hyperthermia. We would like to congratulate to the authors! Please find the abstract below. Relationship between energy Dosage and Apoptotic cell Death by Modulated electro-Hyperthermia Authors: Patrick Hung-Ju Kao, Chia-Hung Chen, Yuk-Wah Tsang, Chen-Si Lin, Hsin-Chien Chiang, Cheng-Chung Huang, Mau-Shin Chi, Kai-Lin Yang, Wen-Tyng Li, Shang-Jyh Kao, Carrie Anne Minnaar, Kwan-Hwa Chi,&
- [Oncothermia Journal Volume 28](https://oncotherm.com/oncothermia-journal-28/) - We are happy to announce that the Oncothermia Journal Volume 28 is available on the following link: https://oncotherm.com/oncothermia-journal/oncothermia-journal-volume-28 The editor, András Szász words' for this volume: "The recent volume of the Oncothermia Journal is the 28th now. We had started this open-access publication in 2011 intending to provide information for Oncothermia users and interested specialists about the current
- [The newest publications](https://oncotherm.com/the-newest-publications/) - Scientific Research published two articles written by Professor András Szász et al. The Growth of Healthy and Cancerous Tissues Authors: Gyula Peter Szigeti, Attila Marcell Szasz, Andras Szasz Abstract: The structure of the tissues is formed in a self-similar manner, forming fractal structures in their transport networks. The structure exhibits allometric forming and so-called scaling behavior. This
- [New Insights into Physical Science Vol. 1 book release](https://oncotherm.com/new-insights-into-physical-science-vol-1-book-release/) - Click here to buy the book In the New Insights Into Physical Science book two articles were published, one is related to the topic of Oncothermia “Development in Oncological Hyperthermia” authored by Olivér Szász. Oncological hyperthermia suffers from multiple unsolved medical and technical problems. The solution lies in strict selection and adequate action in nanoscopic range,
- [New Modulated Electro-Hyperthermia article](https://oncotherm.com/oncothermiaval-kapcsolatos-cikk/) - Please click here to read the article International Journal of Molecular Sciences has published an important article on the topic of modulated electro-hyperthermia, congratulations to the authors! Modulated Electro-Hyperthermia Resolves Radioresistance of Panc1 Pancreas Adenocarcinoma and Promotes DNA Damage and Apoptosis In Vitro Authors: Gertrud Forika, Andrea Balogh, Tamás Vancsik, Attila Zalatnai, Gabor Petovari, Zoltan Benyo,
- [Experiment with Personalised Dosing of Hyperthermia](https://oncotherm.com/szemelyre-szabott-hyperthermia/) - In Current Topics in Medicine and Medical Research Vol. 3 book (Dr. Shigenori Ito, Division of Cardiology, Sankuro Hospital, Toyota, Japan and Director of Japan Cardiovascular Imaging Core Laboratory, Japan) was puslished an article related to the topic of Oncothermia. Experiment with Personalised Dosing of Hyperthermia Authors: Gyula Peter Szigeti, Oliver Szasz and Gabriella Hegyi ABSTRACT Objective: Our objective is
- [Revealed details of the mechanism of mEHT monotherapy](https://oncotherm.com/revealed-details-of-the-mechanism-of-meht-monotherapy/) - International Journal of Molecular Sciences has published an important article on the topic of modulated electro-hyperthermia, congratulations to the authors! Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models Authors: Tibor Krenacs, Nora Meggyeshazi, Gertrud Forika, Eva Kiss, Peter Hamar, Tamas Szekely and Tamas Vancsik Abstract: The benefits of high-fever range hyperthermia have been utilized in medicine from the
- [Oncothermia Journal Special Edition](https://oncotherm.com/oncothermia-journal-special-edition/) - Oncothermia Journal Special Edition We are happy to announce that the Oncothermia Journal Volume Special Edition is available on the following link: https://oncotherm.com/oncothermia-journal/oncothermia-journal-special-edition The editor, András Szász words' for this volume: "Dear Readers, Dear Fellow Researchers, Dear Colleagues, Dear Friends, the recent volume of the Oncothermia Journal is special and exclusive. We collected two articles for the
- [OncoRunning](https://oncotherm.com/oncofutas/) - On the last weekend our runners participated in the 35th „Wizz Air Budapest Halfmarathon” Run, where the route led along the most famous sights of Budapest, so they could admire the breathtaking views of the Danube, the Buda Castle and the city center. Two of the team completed the half-marathon alone, the others in groups,
- [Data Mining and Evaluation of Single Arm Clinical Studies](https://oncotherm.com/data-mining-and-evaluation-of-single-arm-clinical-studies/) - In Recent Developments in Engineering Research Vol. 3 book (Dr. Yong X. Gan, Professor, Department of Mechanical Engineering, California State Polytechnic,University, Pomona, USA) was puslished an article related to the topic of Oncothermia. Data Mining and Evaluation of Single Arm Clinical Studies Authors: O Szasz, AM Szasz, GP Szigeti, A Szasz ABSTRACT Lifetime analyses frequently apply a parametric functional description
- [Towards the Immunogenic Hyperthermic Action](https://oncotherm.com/prof-szasz-andras-legujabb-publikacioja/) - Clinical Oncology and Research Journal has published Prof. András Szász's article on the topic of modulated electro-hyperthermia. Towards the Immunogenic Hyperthermic Action: Modulated ElectroHyperthermia Abstract Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use. Modulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm, introduces a novel, cellularly selective and immunogenic cell-ruination.
- [ICHS 2020 Online Conference](https://oncotherm.com/ichs-2020-online-conference/) - ICHS official website We are happy to announce that after careful consideration, it has been decided to arrange the 38th ICHS Conference ONLINE on 5th of November 2020. On behalf of the ICHS Board and according to the election vote Prof. Elisabeth Arrojo is appointed to be the president of the conference. There will be two sessions: clinical and
- [ICHS Program is available](https://oncotherm.com/ichs-program-is-available/) - Official website of the conference We are happy to share with you the 38th ICHS Online Conference Program. The abstracts and a helpful Zoom platform guide are also available on the official website: http://www.ichs-conference.org/ Registration is free. If you are interested please do no hesitate to send an email with your personal details (name, title, country,
- [A special event: the 38th Conference of ICHS](https://oncotherm.com/egy-kulonleges-esemeny-38-ichs-konferencia/) - The 38th Conference of the International Clinical Hyperthermia Society has ended. The international event held on 5th of November 2020 was very special, a new and unique happening in ICHS’s life. In these difficult circumstances after careful consideration, it has been decided to arrange the conference online, on Zoom platform. Despite the time zone differences
- [ICHS Presentations on our YouTube Channel](https://oncotherm.com/ichs-presentations-on-our-youtube-channel/) - ICHS playlist We are delighted to let you know that the recorded ICHS presentations are available on our YouTube Channel. Please click HERE to open the playlist.
- [36th MAOT and 11. Sino – Hungarian Medical Forum](https://oncotherm.com/36th-maot-and-11-sino-hungarian-medical-forum/) - MAOT Conference Official Website Prof. András Szász participated online on the 36th MAOT and 11. Sino – Hungarian Medical Forum with an interesting topic “Oncothermia as part of integrative medicine”. “Hyperthermia in oncology has long-standing history, having roots in ancient medicine. Both the Eastern and Western medicine had used it in holistic (whole-body fever with herbal administration) and
- [mEHT and SARS-CoV-2](https://oncotherm.com/meht-and-sars-cov-2/) - For the full article please click here Frontiers in Oncology has published an article an article on the topic of mEHT and SARS-CoV-2. A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19 Authors: Syed Muzzammil Masaud, Oliver Szasz, A. Marcell Szasz, Huma Ejaz, Rana Attique Anwar and Andras
- [KOSG Symposium 2020](https://oncotherm.com/kosg-symposium-2020/) - The Annual 2020 KOSG (Korean Oncologic-hyperthermia Study Group) Symposium, was held on 28th November Online. It was devoted to providing a forum for experts to discuss their ideas on the use of oncological hyperthermia and present their research and clinical experience. The topic “Quo Vadis oncological hyperthermia (2020)?” was presented by Prof. András Szász. “Heating as a
- [KOSG prezentációk](https://oncotherm.com/hu/kosg-prezentaciok/) - KOSG lejátszási lista Örömmel tudatjuk, hogy a KOSG konferencián felvett angol nyelvű előadások immáron elérhetőek Youtube csatornánkon. A konferencia lejátszási listája IDE kattintva érhető el.
- [KOSG Presentations on YouTube](https://oncotherm.com/kosg-presentations-on-youtube/) - KOSG Playlist We are delighted to let you know that the recorded KOSG presentations are available on YouTube. Please click here to open the playlist.
- [We wish you a Merry Christmas and a Happy New Year!](https://oncotherm.com/we-wish-you-a-merry-christmas-and-a-happy-new-year/) - As this special year comes to an end, we would like to take the time to thank you for your interest, your time and your support for our company. We hope that you will have some well-deserved time off that you can hopefully spend with your family and friends in one – face to face –
- [Publication in the Oncothermia Journal](https://oncotherm.com/publikacio-az-oncothermia-journalban/) - The Oncothermia Journal is an official publication of Oncotherm Group. The journal is published three times a year and gives an opportunity to doctors and other experts to share their study results or practical experiences with the method of Oncothermia. In this way the method is supported and is made accessible to the public. Scientific
- [Multi-dimensional thinking in breast oncology](https://oncotherm.com/tobbdimenzios-gondolkodas-a-mellrak-kezeleseben/) - A summary of the exchange on breast oncology between Fiorentini and Notter: Breast cancer classification and clinical grouping has been subject to a continuous change in the past decades. Based on extent and morphology with advent of gene expression analyses, we consider the disease a heterogeneous entity. Histologically the majority is classified as invasive carcinoma
- [New articles](https://oncotherm.com/megjelent-cikkek/) - A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19 Author: Andras Szasz Abstract The COVID-19 pandemic has experienced unprecedented limitations and extraordinary scientific efforts to address this exceptional situation. Despite blanket closures that have resulted in significant financial constraints and losses around the world, research has an “unlimited” budget, with an exceptional concentration of medical
- [Oncothermia Journal 29.](https://oncotherm.com/oncothermia-journal-29/) - We are happy to announce that the Oncothermia Journal Volume 29 is available on the following link.
- [Clinical study of modulated electro‑hyperthermia for advanced metastatic breast cancer](https://oncotherm.com/clinical-study-of-modulated-electro‑hyperthermia-for-advanced-metastatic-breast-cancer/) - Takuya Nagata, Masahiko Kanamori, Shinichi Sekine, Mie Arai, Makoto Moriyama, Tsutomu Fujii The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of
- [Oncothermia Journal 30.](https://oncotherm.com/oncothermia-journal-30/) - We are happy to announce that the Oncothermia Journal Volume 30 is available.
- [Bio-Electromagnetics without Fields: The Effect of the Vector Potential](https://oncotherm.com/bio-electromagnetics-without-fields-the-effect-of-the-vector-potential/) - Andras Szasz, Bio-Electromagnetics without Fields: The Effect of the Vector Pot… Numerous considerations deal with specialties of bioelectromagnetic effects, including the force-free and field-free interactions. The fact that bioelectromagnetic phenomena consist of effects without mechanical forces and even without measurable fields looks impossible in the simple considerations. However, the stochastic fluctuations cause surprising results, with
- [African Society for Hyperthermia in Oncology](https://oncotherm.com/african-society-for-hyperthermia-in-oncology/) - Registration 3 HOUR CONFERENCE ON-LINE 4 EXCITING INTERNATIONAL SPEAKERS 4 LOCAL SPEAKERS · Prof Peter Wust; Radiation Oncology and Radiation Therapy Clinic, Charité Medical University, Berlin, Germany · Prof Nilroy Datta; Department of Radiotherapy, Mahatma Ghandi Institute of Medical Sciences, India · Prof András Szász; Biotechnics Department; St. Istvan University; Budapest, Hungary · Dr Guy Cooper; 20+Years experience in International Medical Devices; Worked for
- [Therapeutic Basis of Electromagnetic Resonances and Signal-Modulation](https://oncotherm.com/therapeutic-basis-of-electromagnetic-resonances-and-signal-modulation/) - https://doi.org/10.4236/ojbiphy.2021.113011 Andras Szasz, Therapeutic Basis of Electromagnetic Resonances and Signal-Modulation The medical application of electromagnetic resonances is a controversial area of knowledge. Numerous unproven statements and some medical quackeries were published and distributed in informal channels among suffering patients. The fake information is hazardous in such severe diseases as cancer. The optimal, high efficacy energy transport
- [Vascular Fractality and Alimentation of Cancer](https://oncotherm.com/vascular-fractality-and-alimentation-of-cancer/) - https://doi.org/10.4236/ijcm.2021.127025 Andras Szasz, Vascular Fractality and Alimentation of Cancer Background: The basal metabolic rate has a scaling by tumor mass on the exponent of 3/4, while a simple surface-supplied volume of the mass would have a lower exponent, 2/3. The higher exponent can be explained by optimizing the overall energy distribution in the tumor, assuming that
- [The Capacitive Coupling Modalities for Oncological Hyperthermia](https://oncotherm.com/the-capacitive-coupling-modalities-for-oncological-hyperthermia/) - https://doi.org/10.4236/ojbiphy.2021.113010 Andras Szasz, The Capacitive Coupling Modalities for Oncological Hyperthermia The local-regional oncological hyperthermia has various electromagnetic methods for energy-transfer. The differences involve conceptual considerations and technical solutions. The most frequently applied energy transfer is capacitive coupling, concentrating the electric field to be the active heating component. The realization of the capacitive coupling set-up is divided
- [ESTRO 2021](https://oncotherm.com/estro-2021/) - ESTRO 2021 ESTRO’s (European Society for Radiotherapy and Oncology) annual meeting will take place August 27 – 31 in Madrid, Spain. The event is going to be held onsite and online as well. An entire clinical session is dedicated to the topic of hyperthermia. We would like to highlight the following lectures: August 27, 10:30 to 11:30
- [Award winning specialist in the field of hyperthermia - ESTRO 2021](https://oncotherm.com/award-winning-specialist-in-the-field-of-hyperthermia-estro-2021/) - ESTRO is the most important congress in Europe to the community of radiation oncology. The annual conference was held in Madrid between 27-31 of August. There is a great exhibition at the conference as well and our company participated just like in the previous years. The interested parties could visit our impressive booth 680, have
- [39th Conference of the International Clinical Hyperthermia Society](https://oncotherm.com/39th-conference-of-the-international-clinical-hyperthermia-society/) - Due to the pandemic situation the 39th Conference of the International Clinical Hyperthermia Society will be held online on 5 November 2021. On behalf of the ICHS Board and according to election vote in 2019 Dr. Elisabeth Arrojo is appointed to president of the 38th ICHS Conference and due to the pandemic situation to the 39th Conference
- [The 39th Conference of ICHS](https://oncotherm.com/the-39th-conference-of-ichs/) - The 39th Conference of the International Clinical Hyperthermia Society took place on Zoom on 5 November 2021. It was delightful that 100 participants could arrange their presence from 19 countries: Greece, North Macedonia, Netherlands, Spain, Italy, South Korea, Brasil, Germany, Japan, Australia, Pakistan, United Kingdom, Hungary, Portugal, Switzerland, Belgium, Taiwan. Presentations are going to be
- [TeSzedd - Volunteering for a clean Hungary](https://oncotherm.com/teszedd-volunteering-for-a-clean-hungary/) - In the name of environmental awareness Oncotherm colleagues took part in the TeSzedd garbage collection campaign on 23 October. TeSzedd - Volunteering for a clean Hungary is one of the biggest movements in Hungary. Community cleaning has been organized throughout the country for nine years.
- [Russian Health Care Week 2021](https://oncotherm.com/russian-health-care-week-2021/) - Russian Health Care Week is the largest health care project in Russia, which brings together international trade shows, congresses, forums, conferences and other events. The event is supported by Russian authorities and governments, legislative, federal and regional executive bodies in health care, manufacturing and tourism. Oncotherm Kft. took part on the conference at the stand
- [ICHS presentations on YouTube](https://oncotherm.com/ichs-presentations-on-youtube/) - The 39th ICHS conference were hold online on 5th November. If you did not have the opportunity to attandee on the live event, we have some great news: the presentations are available on YouTube. We hope that the international health situation make it possible to organise an onsite event and meet in person in 2022.
- [Mi is dobozolók vagyunk!](https://oncotherm.com/hu/mi-is-dobozolok-vagyunk/) - Az OncoTeam immár 5. alkalommal vett részt az országos Cipősdoboz Akcióban. Több, mint 20 gyönyörű dobozt állítottunk össze rászoruló kislányoknak és kisfiúknak. A dobozokban csizmák, melegítők, télikabátok, játékok, csokoládé, könyvek és sok más csodálatos dolog lapul. Ha van lehetősége arra, hogy részt vegyen az akcióban, kérjük, tegye meg, még van egy kis ideje erre! A
- [We are shoeboxers!](https://oncotherm.com/we-are-shoeboxers/) - Once again, for the 5th time, #OncoTeam has participated in the national "Shoebox" charity action. Our colleaguas have prepared more than 20 beautiful boxes for little girls and boys in need. The boxes contain boots, jumpers, coats, toys, books, chocolate and many other beautiful things. If you have the opportunity to participate, please do so, you still
- [Prof. Dr. Andras Szasz: Heterogeneous Heat Absorption Is Complementary to Radiotherapy](https://oncotherm.com/prof-dr-andras-szasz-heterogeneous-heat-absorption-is-complementary-to-radiotherapy/) - Another article by Prof. Dr. Andras Szasz has been published in Cancers. Abstract: (1) Background: Hyperthermia in oncology conventionally seeks the homogeneous heating of the tumor mass. The expected isothermal condition is the basis of the dose calculation in clinical practice. My objective is to study and apply a heterogenic temperature pattern during the heating
- [Civil alliance for civilians](https://oncotherm.com/civil-alliance-for-civilians/) - We are heartbroken to see our neighbors in such trouble. Thousands of tired and scared civilians have arrived to Hungary in the last few days, mostly children, women, and elderly people, who left everything behind. Our colleagues decided to take action, and they organized a company fundraising for refugees who fled from the war in Ukrain. With the help of
- [Special Issue in Cancers](https://oncotherm.com/special-issue-in-cancers/) - Click here for more details about the special issue A special issue about local hyperthermia in the journal of “Cancers” (IF>6) is a great opportunity for the field of hyperthermia in oncology. The final goal is to accept this method as a standard together with conventionally applied therapies. The issue highlights the recent developments and
- [New publication in Cellsben: Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field](https://oncotherm.com/new-publication-in-cellsben-forcing-the-antitumor-effects-of-hsps-using-a-modulated-electric-field/) - https://www.mdpi.com/2073-4409/11/11/1838 Absztrakt The role of Heat Shock Proteins (HSPs) is a “double-edged sword” with regards to tumors. The location and interactions of HSPs determine their pro- or antitumor activity. The present review includes an overview of the relevant functions of HSPs, which could improve their antitumor activity. Promoting the antitumor processes could assist in the
- [Medica 2022](https://oncotherm.com/medica-2022/) - Medica 2022 We are pleased to announce that this year Oncotherm is going to participate at Medica 2022, which is one of the largest trade fairs for the medical sector in the world. This annual exhibition will take place November 14-17 in Düsseldorf, Germany, offering a comprehensive overview of the latest technological advancements in the
- [OncoRunning in the 37th Wizz Air Budapest Half Marathon](https://oncotherm.com/oncorunning-in-the-37th-wizz-air-budapest-half-marathon/) - We are proud of our OncoRunners who participated in the 37th Wizz Air Budapest Half Marathon last weekend. The route led through the heart of Budapest, crossed several bridges, and passed the most well-known sites of the city. Three of our colleagues completed the 21 km individually while the others shared the distance of the
- [Oncothermia Journal Volume 32 is avaliable](https://oncotherm.com/mar-letoltheto-az-oncothermia-journal-32-kotete/) - We are happy to announce that the Oncothermia Journal Volume 32 is now available for download! Oncotherm considers it very important to inform those who are interested in the latest results of hyperthermia and the trends in the emerging field of oncology. The articles of this volume partly cover presentations of clinicians using hyperthermia and indicate
- [New business relations at the Hungarian-Uzbek Business Forum](https://oncotherm.com/new-business-relations-at-the-hungarian-uzbek-business-forum/) - This Monday, Balázs Ács, Managing Director of Oncotherm Kft. represented our company at the Hungarian-Uzbek Business Forum in Budapest. The purpose of the event was to encourage the business representatives of the two countries to establish new economic relations and business cooperation. A high-ranking diplomatic and business delegation from Uzbekistan was present and we had
- [Oncotherm at Medica 2022](https://oncotherm.com/oncotherm-at-medica-2022/) - Medica 2022 We would like to thank everyone who visited Oncotherm's booth at Medica 2022! One of the world's largest trade fair shows for the medical sector was held last week, 14-17. November in Düsseldorf, Germany. It was a pleasure to have personal contacts and conversations again. We are so grateful to have had several
- [In memoriam Dr. med. Friedrich Rudolf Douwes](https://oncotherm.com/in-memoriam-dr-med-friedrich-rudolf-douwes/) - With deep sorrow, we learn that our cooperative partner, colleague, and friend for many of us, Dr. Friedrich Douwes, has passed away. He was a great doctor with ideas, innovations, and substantial international experience. For him the patient as a person was important. He never treated only the tumour, he considered the tumorous patient as
- [The 10th KOSG Symposium 2022](https://oncotherm.com/the-10th-kosg-symposium-2022/) - Please click here for the presentations! The 10th KOSG Symposium (Korean Oncologic-hyperthermia Study Group) was held on 3rd December this year, at Inje University Haeundae Paik Hospital, on and offline. It was devoted to providing a forum for experts to discuss their ideas on the use of oncological hyperthermia and present their research and clinical
- [Christmas present in a shoebox](https://oncotherm.com/christmas-present-in-a-shoebox/) - For the 6th time in a row, we preserve the tradition of participating in the "Shoebox" charity action with our lovely colleagues! Our OncoTeam in Hungary has prepared 28 shoeboxes filled with a selection of toys, hygiene items, books, and other gifts for little girls and boys in need. There is still time as the donation ends this
- [We wish you a Merry Christmas and a Happy New Year!](https://oncotherm.com/kellemes-karacsonyi-unnepeket-es-boldog-uj-evet-kivanunk/) - Dear Partners, As this special year comes to an end, we would like to express our sincerest appreciation for all the trust, interest, time, and support you gave to our company. We hope that this year has been just as memorable for you, your colleagues, and your loved ones. We hope that the next year
- [In memoriam Prof. Dr. med. Alexander Herzog](https://oncotherm.com/in-memoriam-prof-dr-med-alexander-herzog/) - We learned with deep sorrow that Professor Herzog had passed away. He was a renowned, respected, excellent doctor, the chief physician of his clinic. His clinical activity and therapies were highly successful, surrounded by the love of patients. The many patients whose lives he extended think of him with great affection. Colleagues often approached him
- [Publications for Colorectal Cancer Awareness Month](https://oncotherm.com/publications-for-colorectal-cancer-awareness-month/) - As we enter the month of National Colorectal Cancer Awareness in March, we have collected some informative publications and studies on this topic for our Readers. This disease is a significant health concern worldwide and is one of the leading causes of cancer-related deaths. Our goal is to make a positive impact in the fight
- [Mirakle Integrated Health Centre chooses Oncotherm](https://oncotherm.com/mirakle-integrated-health-centre-chooses-oncotherm/) - The Mirakle Integrated Health Centre celebrated the opening of its hyperthermia treatment center in Pollachi, India, located at Mahalingapuram Nachimuthu Polytechnic University Campus. The facility is equipped with the latest Oncotherm device, the EHY-2030 to provide targeted and effective cancer treatment to their patients. The opening celebration included a presentation ceremony and lectures on the
- [Happy Easter!](https://oncotherm.com/kellemes-husveti-unnepeket-kivanunk/) - Az Oncotherm csapata kellemes Húsvéti ünnepet kíván Önnek és családjának, tele új kezdetek ígéretével, a jólét és a bőség áldásaival!
- [Publications for Brain and Melanoma cancer awareness month](https://oncotherm.com/publications-for-brain-and-melanoma-cancer-awareness-month/) - May is an important month for raising awareness about some types of cancer that affect millions of people around the world. It's Brain Cancer, and Melanoma & Skin Cancer Awareness Month as these diseases affect countless individuals every year. For this specific month we've collected some informative publications and studies as well, especially on the
- [Meet us at SantExpo 2023!](https://oncotherm.com/meet-us-at-santexpo-2023/) - Oncotherm is excited to invite you to join us at the SantExpo 2023! The event will be held from 23 to 25 May at Paris Expo, Porte de Versailles. If you're interested in learning more about our technology and how it can benefit your patients, come visit us at booth U23 in Hall 1! What to expect? Demonstration
- [OncoRunners at Telekom Vivicitta 2023](https://oncotherm.com/oncorunners-at-telekom-vivicitta-2023/) - Congratulations to our OncoRunner colleagues who took on the challenge of the 21.0975 km length Telekom Vivicittá - the first half-marathon distance of 2023 in Budapest! On April 23, which happened to be the first genuine spring weekend of the year, we participated in a relay race while some of our colleagues also ran individually and successfully completed the
- [OncoRunners completed the UltraBalaton 2023!](https://oncotherm.com/oncorunners-completed-the-ultrabalaton-2023/) - Our incredible colleagues have just accomplished something extraordinary again! Some of our colleagues have successfully completed the NN Ultrabalaton 2023, an almost 211 km kilometer long running race around lake Balaton on the first weekend of May! This year was the 17th anniversary of the one-lap race around Lake Balaton, which is also the longest
- [Oncothermia Journal Vol. 33 is avaliable!](https://oncotherm.com/oncothermia-journal-vol-33-is-avaliable/) - We are happy to announce that the Oncothermia Journal Vol. 33 is now available for download! We recommend the 33rd volume of our Journal to our readers' attention as essential new results are published and presented in this volume. The articles cover topics such as the role of resonances in modulated electro-hyperthermia for targeting malignant cells,
- [Oncotherm at SantExpo 2023!](https://oncotherm.com/oncotherm-a-santexpo-2023-kiallitason/) - We are grateful to those who visited Oncotherm's booth at SantExpo 2023! SantExpo is the leading French event of the French Hospital Federation, which brings together every year top industry leaders to discuss the latest advancements and innovations in the field of healthcare. This year the expo took place in Paris, France from the 23rd
- [Oncotherm a SantExpo 2023 kiállításon!](https://oncotherm.com/hu/oncotherm-a-santexpo-2023-kiallitason/) - Hálásak vagyunk azoknak, akik ellátogattak az Oncotherm standjára a SantExpo 2023-on! A SantExpo a Francia Kórházszövetség vezető francia rendezvénye, amely minden évben összehozza az iparág vezetőit, hogy megvitassák az egészségügy terén elért legújabb fejlesztéseiket és innovációkat. Az egészségügyi kiálllítást idén a francia fővárosban, Párizsban május 23-25. között rendezték meg , ahol az Oncotherm is képviseltette
- [Cancer Survivor Month](https://oncotherm.com/cancer-survivor-month/) - June is National Cancer Survivor Month, when we honor and remember those, who are affected by cancer to raise awareness for cancer survivorship and provide support for those currently battling the disease. As part of our commitment to this important cause, we have collected a series of publications that can offer valuable insights on the
- [New Phase II and Phase III clinical trial with mEHT](https://oncotherm.com/new-phase-ii-and-phase-iii-clinical-trial-with-meht/) - We are delighted to announce the initiation of a Phase II and Phase III randomized clinical trial, using the method of mEHT as a treatment for breast cancer patients. The trial, performed with the Oncotherm EHY-2030 device, is being conducted in the Division of Oncology, Department of Internal Medicine and Oncology at Semmelweis University in Hungary under
- [Meet at Medica 2023!](https://oncotherm.com/meet-at-medica-2023/) - Oncotherm has exciting plans to take part in MEDICA 2023, where we will demonstrate our loco-regional hyperthermia device that combines clinical expertise with technological innovation. We would like to invite you to join us at Hall 15, Booth A02, from November 13th to 16th, 2023, in the vibrant city of Düsseldorf, Germany. Our team will
- [OncoFutók a 38. Wizz Air Félmaratonon](https://oncotherm.com/hu/oncofutok-a-38-wizz-air-felmaratonon/) - Elismerésünket szeretnénk kifejezni OncoRunner kollégáink számára, akik a múlt hétvégén részt vettek a 38. Wizz Air Budapest Félmaratonon. Az útvonal Budapest nyüzsgő belvárosán vezetett keresztül, több hídon átívelve, és bepillantást engedve a város ikonikus nevezetességeibe. A 21 km-es félmaratoni távot idén 4 kollégánk teljesítette egyéni illetve váltó formájában. Gratulálunk OncoFutóinknak ehhez a kiemelkedő teljesítményhez!
- [OncoRunners at 38th Wizz Air Half Marathon](https://oncotherm.com/oncofutok-a-38-wizz-air-felmaratonon/) - We'd like to express our admiration for our OncoRunners who took part in the 38th Wizz Air Budapest Half Marathon last weekend. The route led through the vibrant center of Budapest, spanning multiple bridges and offering glimpses of the city's iconic landmarks. Four of our colleagues completed the 21-kilometer half-marathon distance. Congratulations to our OncoRunners
- [Lahorban tartott szemináriumot elismert onkológusok részére Dr.Szász Olivér](https://oncotherm.com/hu/lahorban-tartott-szeminariumot-elismert-onkologusok-reszere-dr-szasz-oliver/) - Oncothermia világszinten elismert kiegészítő rákterápiás módszer. Dr.Szász Olivér a modulált Elektro-Hipertermiáról (mEHT) tartott szemináriumot elismert onkológosok részére Pakisztán második legnagyobb városában, Lahorban.
- [Tudományosan igazolt rákkezelési módszerekről dokumentumfilm készül](https://oncotherm.com/hu/tudomanyosan-igazolt-rakkezelesi-modszerekrol-dokumentumfilm-keszul/) - Tudományosan igazolt rákterápiákról készítenek dokumentumfilmet A WayMark Productions által készített "New Standard of Care" (Új standard betegellátás) első dokumentumfilmje az alternatív rákterápiákat vizsgálja, bemutatóját 2017-re tervezik. Az Egészségügyi Világszervezet statisztikái szerint háromból egy nő, kettőből egy férfi lesz rákos megbetegedésben érintett, életük során. A rák a világon a halálok vezető oka - az elkövetkező két évtizedben 70
- [Rutineljárás lett a hőterápiás rákkezelés](https://oncotherm.com/hu/rutineljaras-lett-a-hoterapias-rakkezeles/) - Németországban már 11 éve rutinszerűen javallott a lokális hipertermia Rutineljárásnak minősítette a hipertermiás kezelés egy fajtáját a Sugárterápiás és Onkológiai Szakmai Kollégium (SOSZK), így lényegesen több beteg juthat az eddig csak klinikai kísérlet formájában elérhető gyógymódhoz. A külföldön már több helyütt, így Németországban már 11 éve rutinszerűen javallott lokális hipertermia, azaz hőterápia lényege, hogy a rákos szöveteket
- [Zöld utat kapott a rákellenes hőkezelés](https://oncotherm.com/hu/zold-utat-kapott-a-rakellenes-hokezeles/) - Zöld utat kapott a rákellenes hőkezelés A Sugárterápiás és Onkológiai Szakmai Kollégium rutineljárássá minősítette az úgynevezett lokális hipertermiás kezelést Magyarországon. A módszert - amely a rákos sejteket pusztítja el a test részleges felmelegítése révén - eddig csak klinikai próbaként alkalmazhatták, mostantól azonban hat onkológiai centrumban térítésmentesen érhető el a betegek számára. A hipertermia (hőkezelés, lázkezelés)
- [Magyar Innovációs Nagydíjban részesült az Oncotherm Kft.](https://oncotherm.com/hu/magyar-innovacios-nagydijban-reszesult-az-oncotherm-kft/) - http://www.innovacio.hu/ehirlevel/2010_7.html 2010. március 26-án, az Országházban adták át a 2009. évi Innovációs Díjakat. "A Magyar Innovációs Nagydíjat csak olyan vállalkozásnak lehet odaítélni, amely nemcsak nagy jelentőségű és hasznosult újítást valósított meg, hanem ezt az eredményt magyar vállalkozóként és Magyarországon érte el. " A kiemelt dicséretben részesült pályázatok okleveleit dr. Pakucs János, tiszteletbeli elnök, az Innovációs
- ["Új" prosztatarák kezelési mód](https://oncotherm.com/hu/uj-prosztatarak-kezelesi-mod/) - 'New' Prostate Cancer Treatment Dr. Friedrich Douwes szerint, - aki a németországi Bad Aiblingban található St. George Hospital orvosigazgatója és a Német Orvosi Társaság elnöke és egyben több száz tudományos cikk és könyv szerzője is - a transzurethrális prosztata hipertermia 100% kezdeti válaszarányt képvisel. Dr. Douwes sikeresen kezelt már több ezer prosztatarák beteget, közülük sokan az USA-ból érkeztek
- [Riport az Onkotermiáról az EgészségŐr című televíziós műsorban](https://oncotherm.com/hu/riport-az-onkotermiarol-az-egeszsegor-cimu-televizios-musorban/) - Az EgészségŐr c. televíziós műsorában megismerkedhetnek Prof. Dr. Szász Andrással, az Onkotermia módszerének megalkotójával, megtudhatják hogyan működik ez a rákkezelési mód és milyen rákbetegségeknél tud hatékony javulást előidézni. Az Oncotherm Kft. által fejlesztett, Magyarországon gyártott rákkezelő eszközöket a világ számos pontján nagy sikerrel alkalmazzák.
- [Új Oncothermia felhasználó Észak-Amerikában](https://oncotherm.com/hu/uj-oncothermia-felhasznalo-eszak-amerikaban/) - A Port Moody Health egyike Észak-Amerika rákközpontjai között, ahol hipertermiá… Észak-Amerikában már a Port Moody Health rákkezelő központjában is elérhető az onkotermiás kezelés az EHY-2000-es eszköz telepítésével. A kanadai betegeknek már nem kell a tengerentúlra utazni, hogy elérhesség az egyik legfejlettebb integratív rákterápiás eszközt, amely Németországban már több évtizede hatékonyan segíti a különböző típusú rákos megbetegedések kezelését,
- [Szimpózium a Gisunt Klinikán](https://oncotherm.com/hu/szimpozium-a-gisunt-klinikan/) - http://www.gisunt-klinik.de/ Gisunt Klinika egynapos szimpóziumot szervezett az Integrativ orvoslásról a wilhelmshaven-i Hotel Kaiserben, június 17-én. A Gisunk Klinika a krónikus és a rákos betegek körében nemzetközileg elismert, a hipertermiás és az integratív orvoslás specialistájaként működik. Fő kezelési módjai közé tartozik: a lázterápia, a hipertermia, az oxigénterápia, az akupunktúra és a naturopátiás kezelések. Klinikájukon az Oncotherm
- [ESHO 2017 - Az Oncotherm platinum szponzor](https://oncotherm.com/hu/esho-2017-az-oncotherm-platinum-szponzor/) - ONCOTHERM platinum szponzorként támogatta az ESHO 2017 (European Society for Hyperthermic Oncology) onkológiai konferenciát Örömmel tájékoztatjuk Önöket arról, hogy az Oncotherm Kft., platinum szponzorként vett részt az athéni, június 21-23 között megrendezett ESHO 2017 onkológiai konferencián. Ezen az eseményen mutattuk be a legújabb fejlesztésű rákkezelő eszközünket, az EHY-2030-at, és a működését bemutató kisfilmet, amelyet a szakmai, onkológusokból álló
- [EPT1 Görög Televízió is bemutatta az onkotermia rákkezelő módszerét](https://oncotherm.com/hu/ept1-gorog-televizio-is-bemutatta-az-onkotermia-rakkezelo-modszeret/) - Oncothermia bemutatása a Görög EPT1 Televízióban KIEGÉSZÍTŐ RÁKTERÁPIÁS MÓDSZERÜNK A GÖRÖG TELEVÍZIÓBAN Büszkék vagyunk arra, hogy bekerülhettünk a görög, EPT1 televízióba, ahol ismertették az onkotermiát, és a legújabb fejlesztésű eszközünket, az EHY-2030-at. A módszerről itt olvashat. A legújabb rákterápiás eszközről, az EHY-2030-ról itt olvashat.
- [Csaknem másfél milliárd forintos támogatás egy új daganatterápiás készülék fejlesztésére](https://oncotherm.com/hu/csaknem-masfel-milliard-forintos-tamogatas-egy-uj-daganatterapias-keszulek-fejlesztesere/) - NKFI Alap támogatásából megvalósuló fejlesztés A kedvezményezett neve: Oncotherm Kft., Semmelweis Egyetem A projekt címe: „Elektromágneses daganat-terápiás készülék hatékonyságának növelése, piaci bevezetése, és az onkológiai terápiás gyakorlatba történő integrálásának előkészítése” A szerződött támogatás összege: 1,472 milliárd forint A támogatás mértéke százalékban: 88.94% A projekt tervezett befejezési dátuma: 2019.12.31. A projekt azonosító száma: NVKP_16-1-2016-0042 A Semmelweis
- [Szaúd-Arábia engedélyezte az Oncothermia készülékek használatát, a rákkezelés legkorszerűbb kezelési módját](https://oncotherm.com/hu/szaud-arabia-engedelyezte-az-oncothermia-keszulekek-hasznalatat-a-rakkezeles-legkorszerubb-kezelesi-modjat/) - Szaúd-Arábia engedélyezte az Oncothermia készülékek használatát Közel 30 országban elfogadott az Oncothermiás kezelés, immáron már a szaúdi Élelmiszer-Biztonsági és Gyógyszerészeti Hivatal (Saudi Food and Drug Authority) is engedélyezte az Oncothermia készülékek használatát. A kezelésekkel javulhat a rákbetegek életminősége, növelheti az élettartamot és hozzájárulhat a betegek fizikai és szellemi jólétéhez. Az Oncothermia emellett kiegészítő rákkezelésként elősegítheti a
- [Táblaavatás az Oncotherm Kft.-nél, a Szent István Egyetem Kihelyezett Biotechnika Tanszékénél](https://oncotherm.com/hu/tablaavatas-az-oncotherm-kft-nel-a-szent-istvan-egyetem-kihelyezett-biotechnika-tanszekenel/) - A budaörsi központú Oncotherm Kft., melyet Prof. Dr. Szász András alapított 1988-ban, kiegészítő onkológiai kezelő eszközöket fejleszt, gyárt és 32 országba exportál. Ezekkel a berendezésekkel éves szinten több mint 200.000 kezelést végeznek előrehaladott daganatos betegségek gyógyítására. Hazánkban pályázati forrásból épül ki a Semmelweis Egyetem Onkológiai Központjában egy nemzetközi oktató és kezelő centrum a módszer nemzetközi
- [ICHS konferencia - Immunonkológia, az új fegyver!](https://oncotherm.com/hu/ichs-konferencia-immunonkologia-az-uj-fegyver/) - ICHS hivatalos oldala Óriási érdeklődés mellett került megrendezésre a 35.alkalommal megrendezett Nemzetközi Klinikai Hipertermia Társaság (ICHS) konferenciája, amelynek Kína első számú klinikája, a Clifford Hospital szolgált helyszínéül. Előadások: Non-Toxic Integrative Cancer Treatment – the Health Preservation, Treating, and Rehabilitation of Cancer Patients- Clifford L. K. Pang The application of gene-radiotherapy in combination with hyperthermia in
- [Akadémiai-ipari együttműködéssel a daganatos betegségek elleni küzdelemben](https://oncotherm.com/hu/akademiai-ipari-egyuttmukodessel-a-daganatos-betegsegek-elleni-kuzdelemben/) - A Semmelweis Egyetem vezetésével benyújtott „Elektromágneses daganat-terápiás készülék hatékonyságának növelése, piaci bevezetése, és az onkológiai terápiás gyakorlatba történő integrálásának előkészítése” című pályázat három évre 1,472 milliárd forint össztámogatásban részesült a 2016-ban kiírt Nemzeti Versenyképességi és Kiválósági Program (NVKP-16) keretében. Ennek célja olyan projektek támogatása volt, amelyek népegészségügyi szempontból is jelentős betegségek hatékonyabb gyógyításához járulnak hozzá
- [Modulált elektro-hipertermia, mint chemoradiosenzitizátor a lokálisan előrehaladott méhnyakrákra](https://oncotherm.com/hu/modulalt-elektro-hipertermia-mint-chemoradiosenzitizator-a-lokalisan-elorehaladott-mehnyakrakra/) - Dr. Carrie Anne Minnaar bemutatta a méhnyakrákkal kapcsolatos kutatásainak legújabb eredményeit a 18. dél-afrikai Klinikai és Sugárzás Onkológiai Társaság (SASCRO) és a dél-afrikai Orvosi Onkológiai Társaság (SASMO) részére, amelynek következtetése: " Az előzetes eredmények továbbra is pozitív trendet mutatnak az utánkövetésben és a 6 hónapos túlélési időben a vizsgált kezelési csoportban, váratlan mellékhatások és toxicitás nélkül. A
- [Onkológiai hyperthermia a középpontban - előadás Lisszabonban](https://oncotherm.com/hu/onkologiai-hyperthermia-a-kozeppontban-eloadas-lisszabonban/) - Prof. Dr. Szász András és Benke Soma (RWU Consulting - az Oncotherm nemzetközi, üzletfejlesztéséért felelős partnere) ellátogatott Lisszabonba, ahol Prof. Dr. Szász András előadást tartott: "Onkológiai hyperthermia a középpontban" címmel. A hallgatók között részt vettek Portugália neves orvosai úgy mint: Dra. Lurdes Batarda és Dr. Marco Possanzini - Fundacao Champalimaud (Portugál Rákalapítvány), Dr. Filipe Costa
- [Sikeres kiegészítő rákkezelés címmel jelent meg az Oncotherm Kft.-t bemutató cikk](https://oncotherm.com/hu/sikeres-kiegeszito-rakkezeles-cimmel-jelent-meg-az-oncotherm-kft-t-bemutato-cikk/) - A teljes cikk megtalálható a Budaörsi Napló 15. oldalán Sikeres kiegészítő rákkezelés címmel jelent meg a Budaörsi Napló 2017. októberi lapszámában az a cikk, amely bemutatja az Oncotherm Kft. tevékenységét és az Oncothermia módszer alapelveit.
- [Új Oncotherm készülék a granadai magánklinikán](https://oncotherm.com/hu/uj-oncotherm-keszulek-a-granadai-maganklinikan/) - Új készüléket installáltunk Granada városában Örömmel üdvözöljük felhasználóink között a spanyolországi CLINICA CHECA-t. Tekintse meg a modern stílusban berendezett klinikát, ahová novemberben telepítettük EHY-2000-es készülékünket.
- [Szimpózium a hipertermiás rákkezelésről](https://oncotherm.com/hu/szimpozium-a-hipertermias-rakkezelesrol/) - Koreában, Chungnam University Hospitalban került megrendezésre 2017. október 29-én az a szimpózium, ahol Prof. Dr. Szász András és Dr. Carrie Minnaar is előadást tartott a következő témákban: The basic principle and results of Oncothermia The addition of mEHT to treatment protocols for locally advanced cervical cancer patients Figyelmébe ajánlunk néhány megjelent sajtóanyagot a rendezvényről: 충청뉴스 http://www.ccnnews.co.kr/news/articleView.html?idxno=97716 대전투데이 http://www.ccnnews.co.kr/news/articleView.html?idxno=97716 MBS http://www.mbstv.co.kr/news/articleView.html?idxno=129904 의계신문 http://www.medworld.co.kr/news/articleView.html?idxno=110468 병원신문 http://www.khanews.com/news/articleView.html?idxno=133010 대전타임뉴스 http://www.timenews.co.kr/web/news/article/1220408
- [Tények az Onkotermiáról](https://oncotherm.com/hu/tenyek-az-onkotermiarol/) - Tények az Onkotermiáról Onkotermia minden szilárd tumorban aktívan fejti ki hatását. Nincs mellékhatása, igen ritka ellenjavallattal. Kombinált energiaelnyelés modulált elektromos térrel. Onkológus vagy más orvos szakember kezel a módszerrel világszerte. Tumorszövetet szelektíven kezelik, a malignitást (rosszindulatú sejtszaporulatot) elpusztítják. Egészséges szövetet érintetlenül hagyja. Radioterápia és a kemoterápia hatékonyságát javítja a kezelés, növeli a sejtkapcsolatokat, leállítja az
- [Új publikációnk jelent meg : Hyperthermia Dosing and Depth of Effect](https://oncotherm.com/hu/uj-publikacionk-jelent-meg-hyperthermia-dosing-and-depth-of-effect/) - Szerzők: Szasz Oliver1, Szigeti Gyula Peter2, Vancsik Tamas3, Szasz Andras1 Intézmény: 1Szent István Egyetem, Biotechnikai Tanszék, Budapest, Magyarország. 2Semmelweis Egyetem, Klinikai Kisérleti Kutató- és Humán Élettani Intézet, Budapest, Hungary. 3Semmelweis Egyetem I. Sz. Patológiai és Kísérleti Rákkutató Intézet, Budapest, Hungary. ABSTRACT The penetration depth in the electromagnetic heating could be a crucial factor of its application,
- [Kisfilmet forgattak az onkotermia módszerét alkalmazó rákkezelő eszközgyártóról](https://oncotherm.com/hu/kisfilmet-forgattak-az-onkotermia-modszeret-alkalmazo-rakkezelo-eszkozgyartorol/) - Kisfilm az Oncotherm Kft.-ről
- [Címlapra választotta a nemzetközileg elismert Journal of Cancer szaklap az MEHT-ról szóló publikációnkat](https://oncotherm.com/hu/cimlapra-valasztotta-a-nemzetkozileg-elismert-journal-of-cancer-szaklap-az-meht-rol-szolo-publikacionkat/) - MEHT related article in the Cancer of Journal Óriási szakmai elismerés, hogy az a mEHT-ról szóló publikációnk rákerülhetett a Journal of Cancer borítójára. A cikk címe: Modulated electro-hyperthermia induced loco-regional and systemic tumor destruction in colorectal cancer allografts Ezúton is gratulálunk a szerzőknek! Szerzők: Tamas Vancsik,1Csaba Kovago,2Eva Kiss,1Edina Papp,3Gertrud Forika,1Zoltan Benyo,4Nora Meggyeshazi,1,* and Tibor Krenacs1, 11st Department of Pathology and
- [Újabb EHY-2000-es készüléket telepítettünk a németországi BioMed Klinikán](https://oncotherm.com/hu/ujabb-ehy-2000-es-keszuleket-telepitettunk-a-nemetorszagi-biomed-klinikan/) - A németországi BioMed Klinikán akut rákkezeléssel foglalkoznak. Klinikájukon elérhetőek a hagyományos és a kiegészítő rákterápiák egyaránt. Az új EHY-2000-es készülék telepítésével immáron négy Oncotherm készülék is a betegek gyógyítását szolgálja a BioMed Klinikán. A képen Dr. H. Friedrich Migeod MD., a bad bergzabern-i klinka vezető orvosa látható.
- [Találkozzunk az ESTRO 37 konferencián](https://oncotherm.com/hu/talalkozzunk-az-estro-37-konferencian/) - ESTRO hivatalos oldala Az ESTRO egy olyan közösség, amely az interdiszciplinaritásra és a multidiszciplinaritásra összpontosít. Radiológusoknak, onkológusoknak, orvos fizikusoknak, radiobiológusoknak, brachytherapia szakorvosoknak kínál az egyéb onkológiai szervezetekkel egy közös platformot, ahol közösen mozdíthatják előre a rákterápia fejlődését. Ez a konferencia közvetíti az "Innovation for Value and Access" témát. A konferencia elnökének meghívóját itt olvashatja el Időpont:
- [Az ESHO PLATINUM fokozatú támogatója az Oncotherm](https://oncotherm.com/hu/az-esho-platinum-fokozatu-tamogatoja-az-oncotherm/) - Ezúton hívjuk meg jelenlegi és jövőbeni partnereinket a Berlinben tartandó ESHO konferenciára, ahol az Oncotherm csapatával és szakértőivel is találkozhat. Az ESHO egy nagyszerű platform arra, hogy a világ vezető hyperthermiás szakértőinek előadásait meghallgathassa, megismerve a legújabb kutatási eredményeket. Időpont: 2018. május 16–19. Hely: Berlin-Németország Szervezzünk találkozót (info@oncotherm.org) és hallgassa meg az oncothermia kutatási eredményeiről
- [Budapest szolgál helyszínéül a 36. International Clinical Hyperthermia Society konferenciának](https://oncotherm.com/hu/budapest-szolgal-helyszineul-a-36-international-clinical-hyperthermia-society-konferencianak/) - ICHS hivatalos oldala MEGHÍVÓ A 36. International Clinical Hyperthermia Society KONFERENCIÁJÁRA Időpont: 2018. szeptember 28-29. Helyszín: Danubius Hotel Margitsziget, Budapest, Magyarország Szeretnénk meghívni Önt, hogy látogasson el a Budapesten tartandó hipertermia konferenciára hallgatóként vagy éljen a lehetőséggel és mutassa be legújabb eredményeit prezentációval vagy kiállított poszter formájában. Önnel együtt tovább erősödhet a hipertermia elfogadottsága a hagyományos
- [M5 Televízió riportja a rákkezelésben hipertermiát alkalmazó orvoskonferenciáról](https://oncotherm.com/hu/m5-televizio-riportja-a-rakkezelesben-hipertermiat-alkalmazo-orvoskonferenciarol/) - M5 Televízió összeállítása a 36.ICHS konferenciáról Az International Clinical Hyperthermia Society 36. alkalommal rendezte meg éves konferenciáját, ezúttal Budapesten, a Margitszigeten. Az ICHS szervezetének célkitűzése, hogy a világszinten hipertermiát alkalmazó orvosok munkájának, kutatásainak eredményét elérhetővé tegye a szakemberek számára ezzel pedig lehetővé téve a még hatékonyabb kezeléseket a rákos megbetegedéssel élő betegek részére. A magyar
- [MEDICA - A gyógyászat világfóruma](https://oncotherm.com/hu/medica-a-gyogyaszat-vilagforuma/) - Az Oncotherm cégcsoport idén is kiállít a november 12-15-ig tartandó MEDICA szakkiállításon Düsseldorfban, ahol reméljük Önnel is találkozhatunk! Standunkat megtalálja a 9B11-es szám alatt. A rendezvényről ezen a linken olvashat bővebben: https://www.medica-tradefair.com/
- [Új Oncotherm készülék installáció a pakisztáni Lahore városának klinikáján](https://oncotherm.com/hu/uj-oncotherm-keszulek-installacio-a-pakisztani-lahore-varosanak-klinikajan/) - Saira Memorial Hospital egy olyan multidiszciplináris intézmény, amely modern diagnosztikai és terápiás eszközökkel felszerelten működik. November óta az Oncotherm EHY-3010 ML készülékének telepítésével már Lahore-ban is elérhető az Oncotherm kiegészítő rákterápiás kezelése. Az EHY-3010 az előrehaladott, metasztatikus, rosszindulatú daganatok egyidejű, multilokális kezelésére szolgál. Az Oncothermia rendszereken belül ez az eszköz egy úttörő áttörést hozott a
- [Új publikáció jelent meg az "Onkológiai hipertermiáról" az International Journal of Oncology-ban](https://oncotherm.com/hu/uj-publikacio-jelent-meg-az-onkologiai-hipertermiarol-az-international-journal-of-oncology-ban/) - A teljes publikációt itt töltheti le Örömmel hívjuk fel figyelmüket az International Journal of Oncology-ban nemrég megjelent új publikációra, "Oncological Hyperthermia: The correct dosing in clinical applications" címmel. Szerzők:: Sun-Young Lee, Gyula Peter Szigeti, Attila Marcell Szasz Közzétéve: 2018. november 23. Abstract The problem with the application of conventional hyperthermia in oncology is firmly connected to
- [A rák ellen, az emberért, a holnapért! Társadalmi Alapítvány Életigenlők c. magazinjában az Oncotherm módszeréről olvashat](https://oncotherm.com/hu/a-rak-ellen-az-emberert-a-holnapert-tarsadalmi-alapitvany-eletigenlok-c-magazinjaban-az-oncotherm-modszererol-olvashat/) - Oncothermről szóló interjú a 20-23.oldalon Már megjelent az ÉLETIGENLŐK portálján és időszakosan nyomtatottan magazinjának legutóbbi számában az az interjú, amit Prof.Dr.Szász Andrással készítettek. A cikkből megismerhető, hogy milyen előnyei vannak annak a speciális, onkológiai, daganatterápiás módszernek, amelyet oncothermiának hívnak. A teljes magazint ezen a linken érheti el: http://www.rakellen.hu/hu/magazines Interjú Prof.Dr.Szász Andrással az Életigenlők magazinban
- [Kellemes Karácsonyi Ünnepeket és Boldog Új Évet Kívánunk!](https://oncotherm.com/hu/kellemes-karacsonyi-unnepeket-es-boldog-uj-evet-kivanunk-2/) - Évente egyszer, egy csodás téli éjjel, bűvös, titkos álmok suhannak a szélben! Mindenki házába boldogság költözik. Szívünk örömmel megtelik! Mielőtt lefekszel, tárd ki az ablakod, elküldtem hozzád az én angyalom. Egy pillanatra kérlek, figyelj oda rá, mert a nevemben boldog, békés karácsonyt kíván! (A magyarországi irodánk 2018. december 19-től 2019. január 2-ig zárva tart. Német irodánk
- [Cipősdoboz akció](https://oncotherm.com/hu/ciposdoboz-akcio/) - A kezdeményezésről itt tud bővebben olvasni Az Oncotherm Kft. is részt vett a Baptista Szeretetszolgálat keretein belül rendezett Cipősdoboz akcióban. Az összegyűjtött játékokkal, élelmiszerekkel szeretnénk mások karácsonyát is szebbé tenni.
- [Új publikáció jelent meg az Open Journal of Biophysics-en](https://oncotherm.com/hu/uj-publikacio-jelent-meg-az-open-journal-of-biophysics-en/) - A publikációt itt töltheti le Open Journal of Biophysics, 2019, 9, 51-69 Cím: Fluctuations Hypothesize the New Explanation of Meridians in Living Systems Gyula Peter Szigeti, Andras Szasz Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary Department of Biotechnics, St. Istvan University, Budaors, Hungary Abstract Biosystems are complex. Their physiology is
- [37.ICHS konferencia Thessalonikiben, szeptember 19-21 között](https://oncotherm.com/hu/37-ichs-konferencia-thessalonikiben-szeptember-19-21-kozott/) - ICHS hivatalos weboldala Az idei, 37. ICHS konferencia a gyönyörű Thessaloniki városában kerül megrendezésre szeptember 19-21 között. Az esemény elnöke Dr. Aias-Theodoros Papastavrou. A helyi szervezésben közreműködik: Hellenic Society of Oncologic Hyperthermia - elnök: Prof. Dr Vassilis Kouloulias és Hellenic Society for Integrative Oncology - elnök: Dr. Alfred Barich További részleteket a rendezvény hivatalos lapján
- [6. Brandenburgi Rákkongresszus Németországban](https://oncotherm.com/hu/6-brandenburgi-rakkongresszus-nemetorszagban/) - For more information please click here Potsdamban kerül megrendezésre a 6. Brandenburgi Rákkongresszus, ahová örömmel várják az onkológiai szakembereket. Dátum: 2019.február 22-23. Helyszín: Dorint Hotel, Potsdam
- [Onkotermia - klinikai vizsgálatok](https://oncotherm.com/hu/onkotermia-klinikai-vizsgalatok/) - Onkotermia - klinikai vizsgálatok A következő onkotermia kísérleteket regisztrálták már az amerikai nemzetközi adatbázisban: https://www.clinicaltrials.gov/. Az alábbi linken keresztül bővebb információt találhat: https://www.clinicaltrials.gov/ct2/results?cond=&term=oncothermia&cntry=&state=&city=&dist=&Search=Search Stúdium 1: Title: Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients Conditions: Cancer, Pancreas Interventions: Other: Oncothermia|Drug: FOLFIRINOX or Gemcitabine based chemotherapy Locations: Seoul National University Bundang
- [Megjelent egy onkotermiával kapcsolatos cikk az Open Journal of Biophysics újságban](https://oncotherm.com/hu/megjelent-egy-onkotermiaval-kapcsolatos-cikk-az-open-journal-of-biophysics-ujsagban/) - Az angol nyelvű cikket itt találja Cím: Bioelectromagnetic Paradigm of Cancer Treatment—Modulated Electro-Hyperthermia (mEHT) Szerző: Szász Olivér Szent István Egyetem Biotechnikai Tanszék, Budaörs ABSZTRAKT One of the most frequently applied bioelectromagnetic effects is the deep heating of the living species with EMF energy. Despite its long history, hyperthermia is a rarely applied oncotherapy. The reason is its
- [Információk a 37. Conference of the International Clinical Hyperthermia Society (ICHS) konferenciáról](https://oncotherm.com/hu/informaciok-a-37-conference-of-the-international-clinical-hyperthermia-society-ichs-konferenciarol/) - A konferencia angol nyelvű honlapja Hasznos információk a 37. ICHS konferenciáról: Absztrakt leadási határidő: 2019. július 20 Az alábbi e-mail címre küldje az elkészült absztaktot: z.hahn@ichs.eu A konferencia helyszíne: Hotel Panorama Thessaloniki Szoba foglaláshoz használják a következő elérhetőségek egyikét: info@hotelpanorama.gr vagy +30 231 034 4871 Hasznos linkek: A helyszín: http://www.ichs-conference.org/venue/ Absztrakt leadási követelemények: http://www.ichs-conference.org/abstract/ Turisztikai látnivalók Thessalonikiben: https://www.tripadvisor.co.hu/Attractions-g189473-Activities-Thessaloniki_Thessaloniki_Region_Central_Macedonia.html Thessaloniki időjárása: https://www.accuweather.com/en/gr/thessaloniki/186405/september-weather/186405
- [TeSzedd! szemétgyűjtési akción az Oncotherm kollégái](https://oncotherm.com/hu/teszedd-szemetgyujtesi-akcion-az-oncotherm-kollegai/) - TeSzedd! – Önkéntesen a tiszta Magyarországért - weboldal TeSzedd! szemétgyűjtési akción az Oncotherm kollégái is tisztították az erdőt A TeSzedd! – Önkéntesen a tiszta Magyarországért akció ma hazánk legnagyobb önkéntes mozgalma, amelyet ebben az évben már nyolcadik alkalommal szerveztek meg. A szemétgyűjtési akció keretében egész Magyarország területén takarítottak a TeSzedd! önkéntesei. Gyönyörű, tavaszi napsütésben, a
- [Fraktál fiziológiai kurzus Thessalonikiben](https://oncotherm.com/hu/fraktal-fiziologiai-kurzus-thessalonikiben/) - A korábban már bemutatott ICHS Konferencia nyitásaként Szász Professzor Úr előadásában megrendezésre kerül az első fraktál fiziológiai kurzusThessalonikiben, Az elődás helyszíne a Thessoloniki Egyetem Fiziológiai Laboratóriuma (http://physiology.med.auth.gr/content/dorothea-kapoukranidou-biographical-note) Az előadás témái a követekzők lesznek: Challenge of complexity Self-organized networking Structural complexity Dynamical complexity Loss of complexity Perspectives A részvétel ingyenes. A szervezők mindenkit nagy szeretettel várnak.
- [Új 2030-as rákkezelő készülék telepítése a spanyolországi Valdecilla-ban](https://oncotherm.com/hu/uj-2030-as-rakkezelo-keszulek-telepitese-a-spanyolorszagi-valdecilla-ban/) - Forrás A Valdecilla lett az első állami kórház Spanyolországban, ahol a radioterápiás szolgáltatáson belüli onkotermiás kezelés is elérhető, amellyel rossz prognózisú tumorokat is kezelhetnek. Az egészségügyi miniszter, Luisa Real asszony is látogatást tett a kórházban, hogy megnézze az új készüléket, amelyeket jelenleg agydaganatos, végbél és a hasnyálmirigy-daganatos betegek kezelésére használnak. Az új onkotermiás eszközt a
- [ESHO 2019](https://oncotherm.com/hu/esho-2019/) - Május 22-25. között került megrendezésre a 33. ESHO - Annual Meeting of the European Society for Hyperthermic Oncology Konferencia. A helyszín idén Lengyelország, Varsó volt. Idén több, mint 50 előadás központi témája volt a hiperthermia, az alábbi előadások kapcsolódtak az onkotermiához: Előadások: A. Szasz: Immune-effects with local hyperthermia S. Van Gool: Can we monitor Immunogenic Cell
- [Az Oncotherm futócsapata újra bevetésen](https://oncotherm.com/hu/az-oncotherm-futocsapata-ujra-bevetesen/) - Az Oncotherm futócsapata teljesítette június 2.án, vasárnap Dunakeszin a Crazy 5K futóversenyt. Crazy5K egy szórakoztató futó akadályverseny, amely lehetővé teszi, hogy újra gyereknek érezd magad! A 10 óriási felfújható akadály egy 5 km hosszú pályán van elhelyezve. Ha eleged van a monoton futásból, ez egy remek alkalom, hogy új lendületet szerezz! Nem csak Magyarorszságon, hanem külföldön is részt
- [I/II fázisú klinikai eredmény jelent meg  Japanese Journal of Clinical Oncology újságban](https://oncotherm.com/hu/i-ii-fazisu-klinikai-eredmeny-jelent-meg-japanese-journal-of-clinical-oncology-ujsagban/) - Az angol nyelvű cikk itt olvasható el Gratulálunk a cikk szerzőinek a nagyszerű munkáért, amit az angol nyelvű Japanese Journal of Clinical Oncology újságban közöltek. Phase I/II clinical trial of modulated electrohyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer Heon Jong Yoo, Myong Cheol Lim, Sang-Soo Seo, Sokbom Kang, Jungnam Joo, and
- [Dr. Carrie Minnaar hármas fázisú méhnyakrákról szóló cikke megjelent](https://oncotherm.com/hu/dr-carrie-minnaar-harmas-fazisu-mehnyakrakrol-szolo-cikke-megjelent/) - Az angol nyelvű cikket itt találja A cikk a híres PLOSOne újságban jelent meg. Gratulálunk a szerzőknek a hármas fázisú vizsgálat eredményéhez.
- [A Szent Erzsébet Gyermekalapítvány támogatása](https://oncotherm.com/hu/a-szent-erzsebet-gyermekalapitvany-tamogatasa/) - Az alapítvány oldala A társadalmi felelősségvállalás részeként az Oncotherm Kft. fontosnak tartja a kórházak, gyermekalapítványok, egyesületek és, azok támogatását akik rászorulnak. Cégünk a Szent Erzsébet Alapítványt támogatja minden évben. A segítségünkkel új eszközöket, új berendezéseket tudnak vásárolni az ország számos kórháza számára.
- [Új onkológiai kórház nyílik Koreában](https://oncotherm.com/hu/uj-onkologiai-korhaz-nyilik-koreaban/) - Gratulálunk Seungjo Kim Professzor Úrnak, az új korháza megalapításához. A kórház építése jelenleg még folyamtban van, elkészülése után az onkotermia kezelés áll majd a központban. A kórház EHY-2000Plus készülékkel dolgozik majd. Szász Professzor Úr személyesen látogatta meg a kórházat és adta át jó kívánságait és gratulációját.
- [Friss információk az ICHS konferenciáról](https://oncotherm.com/hu/friss-informaciok-az-ichs-konferenciarol/) - A konferencia angol nyelvű hivatalos oldala A 37. ICHS Konferencia idén szeptember 19-21 között kerül megrendezésre Thessalonikiben, Görögországban. A konferencia témái a következők: General status of hyperthermia, challenges, and solutions Definitions of concepts - Consensus Clinical results of hyperthermia Immuno-oncology & hyperthermia Integrative oncology & hyperthermia Experimental and pre-clinical hyperthermia, the molecular basis of hyperthermia,
- [Interjú Dr. Aryan Tavakkolival](https://oncotherm.com/hu/interju-dr-aryan-tavakkolival/) - A klinika angol nyelvű honlapja Dr. Aryan Tavakkoli EHY-2000Plus felhasználó Angliában. Lewesben található Quantum Klinikájában a doktornő számos onkológiai terápiát alkalmaz, ezek közül egyik az onkothermia. A doktornővel a Yes of Life angliai, rákkezelési jótékonysági szervezet készített interjút, amit a következő angol nyelvű oldalon tud megtekinteni: https://yestolife.org.uk/blog/what-is-oncothermia-dr-aryan-tavakkoli/
- [A Klinik Marinus am Stein kórház bekerült a International Medical Tourism Center adatbázisába](https://oncotherm.com/hu/a-klinik-marinus-am-stein-korhaz-bekerult-a-international-medical-tourism-center-adatbazisaba/) - A klinika angol nyelvű honlapja International Medical Tourism Center (https://imedicaltourismcenter.com/) adatbázisában az érdeklődök számos kórház, klinika és egészségközpont között keresgélhetnek 27 különböző országban. A portfolióban a szépészeti beavatkozásoktól elkezdve a fogászati rendelésen át az onkológiai kezelések is megjelennek. A Klinik Marinus am Stein kórházban az onkotermia eljárást alkalmazzák az EHY-2000 készülékkel. Az alábbi angol nyelvű cikkben
- [Szababidős tevékenységek és választható programok az ICHS konferencia alatt Thessalonikiben](https://oncotherm.com/hu/szababidos-tevekenysegek-es-valaszthato-programok-az-ichs-konferencia-alatt-thessalonikiben/) - Választható programok Program 1 (Gála vacsora és városnézés) 19:30 -20:30 Városnézés 20:30-23:30 Gálavacsora at “HAMODRAKAS” (WWW.HAMODRAKAS.GR) Ár: 80 Euro/fő Dátum: 2019. 09.20. Péntek Program 2 (Kirándulás Vegrinára, Nagy Sándor szülőhelyére) Indulás a hotelból: 09:30 Érkezés Verginiára: 11:00 Angol nyelvű idegenvezetés: 11:30 Ebédidő: 13:00 (helyszín: www.ktima-Kalaitzi.gr) Indulás a reptérre:14:45 Érkezés a reptérre: 15:30 Ár: 90 Euro/fő Dátum: 2019.09.22. Vasárnap Szabadidős
- [Oncothermiával kapacsolatos cikk jelent meg a Journal of Thermal Biology újságban](https://oncotherm.com/hu/oncothermiaval-kapacsolatos-cikk-jelent-meg-a-journal-of-thermal-biology-ujsagban/) - A cikk az újság honlapján érhető el Gratulálunk a cikk megjelenéséhez! Effect of tumor properties on energy absorption, temperature mapping, and thermal dose in 13.56-MHz radiofrequency hyperthermia Bibin Prasada, Subin Kimb, Woong Chob, Suzy Kimb, Jung Kyung Kimc,⁎ a Department of Mechanical Engineering, Graduate School, Kookmin University, Seoul 02707, Republic of Korea b Department of Radiation Oncology,
- [Limfóma Világnap](https://oncotherm.com/hu/limfoma-vilagnap/) - További információkat az alábbi linken talál A Limfóma Világnapja szeptember 15.e világszerte. Számos konferencia, cikk, tudományos irat hívja fel a figyelmünket a betegség jelentőségére. "A limfóma a nyirokrendszer sejtjeit, a fehérvérsejteket, vagy más néven limfocitákat érintő betegség. Limfóma esetén a limfociták rákos sejtekként kezdenek viselkedni, ellenőrizetlenül növekednek és osztódnak, illetve nem pusztulnak el kellő mértékben."
- [Hiperthermia kezelés az idős korosztály számára](https://oncotherm.com/hu/hiperthermia-kezeles-az-idos-korosztaly-szamara/) - A teljes német cikk az alábbi oldalon található Egy orvosszakértő a New York Times (Cancer Treatment at the End of Life című cikk. Megjelenés: 2019. 08.05.) újságban tárgyalja a végstádiumú rák kezelését. A német nyelvű cikkben olvasható a teljes anyag összefoglalója. A végstádiumban szenvedő betegek, sokszor nem is tudatosítják magukban a betegségük súlyosságát, míg másik reménykednek, hogy
- [37. ICHS Konferencia](https://oncotherm.com/hu/37-ichs-konferencia/) - Idén a káprázatosan szép Thessalonikiben, Görögország kiemelt üdülővárosában került megrendezésre a 37. ICHS Konferencia szeptember 19-21 között. Az Oncotherm Kft. az esemény PLATINUM SZPONZORA volt. A konferencia nemcsak nevében viseli a nemzetközi szót, hanem ez a résztvevők sokszínűségéből is látszik. Vendégeink a következő országokból érkeztek a konferenciára: Brazília Magyarország Japán USA Németország Ausztrália Dél-Korea Egyesült Királyság Olaszország Görögország
- [Budapesten került megrendezésre a 3. Sport és Innováció konferencia](https://oncotherm.com/hu/budapesten-kerult-megrendezesre-a-3-sport-es-innovacio-konferencia/) - Testnevelési Egyetem honlapja Idén harmadik alkalommal, október 2-3. között került megrendezésre a Sport és Innováció konferencia Budapesten, a Testnevelési Egyetemen. A Testnevelési Egyetem és a XAX Kft. közös munkájának eredménye egy új típusú kezelő készülék, a SportAvail; egy olyan eszköz, mely a véráramlás befolyásolásával és a vázizom sejtjeiben nagyobb mennyiségű mitokondrium fejlesztésével, valamint a magas fizikai terhelések
- [34. MAOT Kongresszus](https://oncotherm.com/hu/34-maot-kongresszus/) - Szász András Professzor interjúja 3:28mp-től megtekinthető Október 4-5. között Budapesten megrendezésre került a "One belt- One road" elnevezésű hagyományos kínai orvoslás témakörét érintő kongresszusa, amely egyben a XXXIV. MAOT kongresszusa is. A kínai orvoslás a világ 122 országában szerzett már létjogosultságot. Számos kiváló tanulmány igazolja beépíthetőségét az egészségügyi ellátásba a betegek megsegítése érdekében. Szász András Professzor is
- [Select USA Investment Summit konferencia Washingtonban](https://oncotherm.com/hu/select-usa-investment-summit-konferencia-washingtonban/) - Az esemény angol nyelvű oldala itt érhető el Szász András Professzor részt vett az Amerikában, Washingon D.C.-ben megrendezett Select USA Investment Summit konferencián. A Professzor Úr a magyarországi amerikai nagykövet hívására vett részt az eseményen június 10-12 között. A konferencián minden évben részt vesznek kis-nagy és multinacionális cégek is, akiknek segítségével a nem amerikai, külföldi cégek bejuthatnak az amerikai
- [Oncotherm futócsapata a Crazy2k futóversenyen](https://oncotherm.com/hu/oncotherm-futocsapata-a-crazy2k-futoversenyen/) - A hivatlos videóért kérlek kattintson ide A Crazy Sprint Run egy 2 kilóméteres szórakoztató futóverseny, ahol a csapatok 19 akadállyal néznek szembe a verseny ideje alatt. A következő esemény Szolnokon kerül megrendezésre október 12-én. A szervezők várják a lelkes jelentkezőket. Mindenkit bíztatunk, hogy vegyen részt Magyyarország egyik legélménydúsabb futóversenyén.
- [Oncothermiával kapcsolatos cikk jelent meg az International Journal of Molecular Sciences újságban](https://oncotherm.com/hu/oncothermiaval-kapcsolatos-cikk-jelent-meg-az-international-journal-of-molecular-sciences-ujsagban/) - Az angol nyelvű teljes cikkhez kattintson a linkre Gratulálunk a szerzőknek a cikk megjelenéséhez! Stress-Induced, p53-Mediated Tumor Growth Inhibition of Melanoma by Modulated Electrohyperthermia in Mouse Models without Major Immunogenic Effects. Balázs Beszterceiy1.y, Tamás Vancsik 2,y, Anett Benedek 1, Enikő Major 1, Mbuotidem J. Thomas 1, Csaba A. Schvarcz 1, Tibor Krenács 2, Zoltán Benyó 1 and Andrea Balogh1,* 1 Institute of Clinical Experimental Research, Semmelweis University, 1097 Budapest,
- [Az egyik felhasználónk, Prof. Giammaria Fiorentini új publikációja jelent meg](https://oncotherm.com/hu/az-egyik-felhasznalonk-prof-giammaria-fiorentini-uj-publikacioja-jelent-meg/) - A teljes angol cikkhez kattintson ide Gratulálunk a szerzőknek az új kutatáshoz! Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients Giammaria Fiorentini, MD1 , Donatella Sarti, PhD1, Virginia Casadei, MD1, Carlo Milandri, MD2, Patrizia Dentico, MD2, Andrea Mambrini, MD3, Roberto Nani, MD4, Caterina Fiorentini, MD5, and Stefano Guadagni, MD6 Abstract: Background:
- [Kerekasztal-beszélgetés a budapesti Amerikai Nagykövetségen](https://oncotherm.com/hu/kerekasztal-beszelgetes-a-budapesti-amerikai-nagykovetsegen/) - Az Amerikai Egyesült Államok nagykövete, David B. Cornsetin Úr meghívta Szász Professzort egy kerekasztal-beszélgetésre az Amerikai Nagykövetségre Budapesten. A beszélgetésen, amely barátságos légkörben került megrendezésre, még részt vett a 2019, évi SelectUSA befektetési delegációja is. A találkozón több témát is érintettek, legfontosabbak az Amerikai Egyesült Államok üzleti tevékenységei és kihatásai voltak. Ebben segítséget kaptak Jennifer Kane-Zabolotskaya-tól, aki
- [Folyóiratok rangsora, amelyekben Oncothermiával kapcsolatos cikkek lettek publikálva](https://oncotherm.com/hu/folyoiratok-rangsora-amelyekben-oncothermiaval-kapcsolatos-cikkek-lettek-publikalva/) - Itt tud többet olvasni az impakt faktokról "Az impakt faktor(IF) a Thomson Reuters által indexelt folyóiratok tudományos színvonalának fokmérője: megmutatja, hogy adott folyóirat cikkeit más folyóiratok milyen mértékben idézték. Az IF érték a folyóirat hatásmutatója, melyből a tudományos közösség hajlamos az adott cikk (és szerző) minőségére következtetni, helytelenül." Oncothermiával kapcsolatos cikke sokasága lett publikáklva magas
- [Oncothermia Journal Volume 27](https://oncotherm.com/hu/oncothermia-journal-volume-27/) - A teljes kiadványért kérem kattintson a linkre A 27-es példány már elérhető! Tizennégy darab hyperthermiával kapcsolatos előadás olvasható ebben a kiadásban. A prezentációk a 37. ICHS Konferencián kerültek bemutatásra. Az előadások angol nyelven érhetők el.
- [Sikeres 2019-es év](https://oncotherm.com/hu/sikeres-2019-es-ev/) - Magunk mögött hagyva 2020 első pár hetét, az előző évre visszatekintve szeretnénk összegezni pár sorban a cégben zajlott eseményeket. A Oncotherm Group történetében 2019 kiemelkedően sikeres év volt, amit nem más bizonyít, mint az 50 világszerte eladott készülék. A vállalat a legtöbb gépet Dél-Koreában értékesítette- ahol az Oncothermia kimagaslóan népszerű – azonban Kelet-Ázsia országaiban és Európában
- [11. Biennial Konferencia](https://oncotherm.com/hu/11-biennial-konferencia/) - 2020. február 15-16. között India, Mumbaiban került megrendezésre a 11. Biennial Konferencia, melyen Professzor Szász András Dr. Carrie Minneaarral közösen vett részt . A professzor előadásának címe “Modulated Electro-Hyperthermia towards the immunogenic Hyperthermic action”, melynek absztraktja angol nyelven lejjebb található, Dr. Minnaar pedig bemutatta a“Report on local disease control, early survival results, and toxicity, following the addition of modulated electro-hyperthermia to
- [Új eredmények Dél-Afrikából](https://oncotherm.com/hu/uj-eredmenyek-del-afrikabol/) - A teljes cikkhez kérem kattinson ide Gratulálunk a szerzőknek a cikkhez! Téma: Defining Characteristics of Nodal Disease on PET/CT Scans in Patients With HIV-Positive and-Negative Locally Advanced Cervical Cancer in South Africa Szerzők: Carrie Anne Minnaar, Ans Baeyens, Olusegun Akinwale Ayeni, Jeffrey Allan Kotzen, Mboyo-Di-Tamba Vangu Abstract Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim
- [Megújított EC tanúsítvány](https://oncotherm.com/hu/megujitott-ec-tanusitvany/) - Kattintson ide a minőségirányítás oldal eléréséhez KÖZLEMÉNY: Megújított EC tanúsítvány Az OncoTherm Kft. megújított EC tanusítványát a tanusító szervezetünk kibocsátotta, amely igazolja az “Európai Unió Tanácsának 93/42/EGK irányelve az orvostechnikai eszközökről” szóló irányelv szerinti teljes körű minőségirányítási rendszert. A tanúsítvány angol és német nyelven az alábbi linken elérhető: https://oncotherm.com/hu/minosegiranyitas
- [Oncothermiával kapcsolatos cikkek](https://oncotherm.com/hu/oncothermiaval-kapcsolatos-cikkek/) - Márciusban két angol nyelvű cikk is megjelent Oncothermiával kapcsolatban. Az "Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients" az International Journal of Hyperthermia-ban publikálták, a "Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients" pedig a Frontiers in Oncologyban. Angol nyelvű absztraktok
- [Riport Dr. Carrie Minnaarral](https://oncotherm.com/hu/riport-dr-carrie-minnaarral/) - A teljes angol nyelvű cikkért kattintson ide! A "Buddies for life Magazine - A project of the Breast Health Foundation" újság publikált egy riportot Dr. Carrie Minnaarral Hyperthermia témában. "Hyperthermia és a mellrák: Tudjunk meg többet az új kezelésről, a hyperthermiáról és annak előnyeiről, ha kemoterápiával és sugárterápiával együtt alkalmazzák az emlőrák kezelésére. " A teljes
- [Új publikációk Professzor Szász Andrástól](https://oncotherm.com/hu/uj-publikaciok-professzor-szasz-andrastol/) - Az International Journal of Clinical Medicine májusban két cikket publikált, mely Professzor Szász András munkássága más szerzőkkel együtt. Cím: Parametrization of Survival Measures, Part I: Consequences of Self-Organizing Szerzők: Andras Szasz, Oliver Szasz Abstract: Lifetime analyses frequently apply a parametric functional description from measured data of the Kaplan-Meier non-parametric estimate (KM) of the survival probability. The cumulative
- [Megjelent a legújabb Oncothermia témájú könyv](https://oncotherm.com/hu/megjelent-a-legujabb-oncothermia-temaju-konyv/) - A könyv megvásárlásához kattintson ide! 2020 májusában "Challenges and Solutions of Oncological Hyperthermia" címmel megjelent a legújabb Oncothermia témájú könyv, mely megvásárolható angol nyelven a Cambridge Scholars Publishing kiadótól. A könyv 19 publikációt foglal magában, melyek a 36. alkalommal, Budapesten megrendezett ICHS (International Clinical Hyperthermia Society) konferencián lettek ismertetve. Egyik fejezete, egy régóta várt gyakorlati útmutató,
- [Új kísérleti tanulmány a Scientific Reportsban](https://oncotherm.com/hu/uj-kiserleti-tanulmany-a-scientific-reportsban/) - A Scientific Reports júniusban publikálta a legújabb Oncothermiával kapcsolatos kísérleti tanulmányt. Gratulálunk a szerzőknek! Az angol nyelvű absztrakt lejjebb olvasható. Relationship between energy Dosage and Apoptotic cell Death by Modulated electro-Hyperthermia Szerzők: Patrick Hung-Ju Kao, Chia-Hung Chen, Yuk-Wah Tsang, Chen-Si Lin, Hsin-Chien Chiang, Cheng-Chung Huang, Mau-Shin Chi, Kai-Lin Yang, Wen-Tyng Li, Shang-Jyh Kao, Carrie Anne Minnaar, Kwan-Hwa Chi,& Yu-Shan
- [Oncothermia Journal 28](https://oncotherm.com/hu/oncothermia-journal-28/) - Kattintson ide az Oncothermia Journal Volume 28 eléréséhez Örömmel tudatjuk, hogy az Oncothermia Journal legújabb száma angol nyelven elérhető a következő linken: https://oncotherm.com/oncothermia-journal/oncothermia-journal-volume-28 Professzor Szász András szavai e kötethez: "The recent volume of the Oncothermia Journal is the 28th now. We had started this open-access publication in 2011 intending to provide information for Oncothermia users and interested
- [Legújabb publikációink](https://oncotherm.com/hu/legujabb-publikacioink/) - A Scientific Research publikált két cikket, melyeknek szerzői között többek között Professzor Szász András is szerepel. Az angol nyelvű absztraktok lejjebb találhatóak. The Growth of Healthy and Cancerous Tissues Szerzők: Gyula Peter Szigeti, Attila Marcell Szasz, Andras Szasz Abstract: The structure of the tissues is formed in a self-similar manner, forming fractal structures in their transport networks.
- [New Insights into Physical Science Vol. 1 könyvmegjelenés](https://oncotherm.com/hu/new-insights-into-physical-science-vol-1-konyvmegjelenes/) - Ide kattintva megvásárolhatja az angol nyelvű könyvet! A New Insights Physical Science könyvben két angol nyelvű cikkünk jelent meg. Az egyik az Oncothermia témájú “Development in Oncological Hyperthermia”, szerzője Szász Olivér. Az onkológiai hipertermia többszörös megoldatlan medikai és technikai problémával küzd. A megoldás a szigorú szelekcióban és a nanoszkópos tartomány megfelelő működésében rejlik, anélkül hogy ösztönözné a robusztus transzportmechanizmusokat,
- [Oncothermiával kapcsolatos cikk](https://oncotherm.com/hu/oncothermiaval-kapcsolatos-cikk/) - Az angol nyelvű teljes cikk ide kattintva érhető el A International Journal of Molecular Sciences publikált egy Oncothermiával kapcsolatos cikket, ezúttal szeretnénk gratulálni a szerzőknek a munkájukhoz! Modulated Electro-Hyperthermia Resolves Radioresistance of Panc1 Pancreas Adenocarcinoma and Promotes DNA Damage and Apoptosis In Vitro Szerzők: Gertrud Forika, Andrea Balogh, Tamás Vancsik, Attila Zalatnai, Gabor Petovari, Zoltan
- [Személyre szabott Hyperthermia](https://oncotherm.com/hu/szemelyre-szabott-hyperthermia/) - A Current Topics in Medicine and Medical Research Vol. 3 könyvben (Dr. Shigenori Ito, Division of Cardiology, Sankuro Hospital, Toyota, Japan and Director of Japan Cardiovascular Imaging Core Laboratory, Japan) megjelent egy Oncothermiával kapcsolatos cikk, melynek angol nyelvű absztraktja lejjebb olvasható. Experiment with Personalised Dosing of Hyperthermia Szerzők: Gyula Peter Szigeti, Oliver Szasz and Gabriella Hegyi ABSTRACT Objective: Our objective
- [Oncothermia mechanizmusának feltárása](https://oncotherm.com/hu/oncothermia-mechanizmusanak-feltarasa/) - Egy magyar kutatócsoport feltárta az Oncothermia mechanizmusát és molekuláris hátterét, amit az International Journal of Molecular Sciences által publikált cikkben részleteznek, angol nyelvű absztraktra lejjebb olvasható. Gratulálunk a szerzőknek! Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models Authors: Tibor Krenacs, Nora Meggyeshazi, Gertrud Forika, Eva Kiss, Peter Hamar, Tamas Szekely and Tamas Vancsik Abstract: The benefits of high-fever range
- [Oncothermia Journal Special Edition](https://oncotherm.com/hu/oncothermia-journal-special-edition/) - Oncothermia Journal Special Edition Örömmel tudatjuk, hogy az Oncothermia Journal legújabb száma angol nyelven elérhető a következő linken: https://oncotherm.com/oncothermia-journal/oncothermia-journal-special-edition Professzor Szász András szavai e kötethez: "Dear Readers, Dear Fellow Researchers, Dear Colleagues, Dear Friends, the recent volume of the Oncothermia Journal is special and exclusive. We collected two articles for the practicing medical staff (physicians and trained
- [OncoFutás](https://oncotherm.com/hu/oncofutas/) - Szeptember első hetében futóink részt vettek a 35. "Wizzair Budapest Félmaraton" futáson, ahol Budapest egyik legszebb útvonalán futhattak, így verseny közben megcsodálhatták a rakpartot, a Budai Várat és a belvárost. Ketten a csapatból egyedül, a többiek váltóban teljesítették a félmaratont, gratulálunk nekik ehhez a lenyűgöző teljesítményhez! ?
- [Data Mining and Evaluation of Single Arm Clinical Studies](https://oncotherm.com/hu/data-mining-and-evaluation-of-single-arm-clinical-studies/) - A Recent Developments in Engineering Research Vol. 3 könyvben (Dr. Yong X. Gan, Professor, Department of Mechanical Engineering, California State Polytechnic,University, Pomona, USA) egy Oncothermiával kapcsolatos cikk került publikálásra angol nyelven. Cím: Data Mining and Evaluation of Single Arm Clinical Studies Szerzők: O Szasz, AM Szasz, GP Szigeti, A Szasz ABSTRACT Lifetime analyses frequently apply a parametric functional
- [Prof. Szász András legújabb publikációja](https://oncotherm.com/hu/prof-szasz-andras-legujabb-publikacioja/) - Kattintson ide az angol nyelvű cikkért! A Clinical Oncology and Research Journal publikálta Professzor Szász András legújabb cikkjét, mely a modulált elektro-hipertermiáról szól. Towards the Immunogenic Hyperthermic Action: Modulated ElectroHyperthermia Abstract Hyperthermia treatment for solid tumors is a long-used, but poorly accepted method in clinical use. Modulated electro-hyperthermia (mEHT, trade name: oncothermia®) changes the paradigm,
- [ICHS 2020 Online Konferencia](https://oncotherm.com/hu/ichs-2020-online-konferencia/) - ICHS hivatalos honlapja Örömmel jelentjük be, hogy az idei ICHS Konferenciát november 5-én ONLINE formában rendezzük meg. Az ICHS vezetőség és az előző konferencia szavazása alapján az elnök Elisabeth Arrojo Professzor. A konferencia két részből áll: klinikai majd kísérleti tanulmányok bemutatása hypertermiával kapcsolatban. A regisztráció ingyenes. Amennyiben szeretne részt venni, kérem küldjön egy emailt az adataival (név, titulus, klinika, részleg, cím,
- [ICHS Programfüzet](https://oncotherm.com/hu/ichs-programfuzet/) - A konferencia angol nyelvű hivatalos oldala Örömmel tudatjuk, hogy az ICHS Online Konferencia programfüzete az előadók absztraktjaival már elérhető a honlapon, illetve PDF formában letölthető a cikk végén. A hivatalos oldalon megtalálható egy hasznos Zoom leírás is, amely segítséget nyújt a program használatában. A regisztráció ingyenes, várunk minden kedves érdeklődőt. Amennyiben szeretne részt venni, kérem küldjön egy emailt
- [Egy különleges esemény: 38. ICHS Konferencia](https://oncotherm.com/hu/egy-kulonleges-esemeny-38-ichs-konferencia/) - A konferencia angol nyelvű hivatalos oldala Véget ért a 38. "International Clinical Hyperthermia Society" Konferencia. A 2020. november 5-én megrendezett nemzetközi esemény egy különleges és egyedi történés volt az ICHS életében. Az utóbbi körülményekre való tekintettel, fontos meggondolás után, az egyesület úgy döntött, hogy a konferenciát online formában, a Zoom felület segítségével rendezi meg. A különböző
- [Elérhetőek az ICHS előadások YouTube csatornánkon](https://oncotherm.com/hu/elerhetoek-az-ichs-eloadasok-youtube-csatornankon/) - ICHS lejátszási lista Örömmel tudatjuk, hogy az ICHS konferencián felvett angol nyelvű előadások immáron elérhetőek Youtube csatornánkon. A konferencia lejátszási listája IDE kattintva érhető el.
- [MAOT Konferencia](https://oncotherm.com/hu/maot-konferencia/) - MAOT Konferencia hivatalos oldala Prof. Szász András részt vett az online megrendezett 36. MAOT és 11. Sino – Hungarian Medical Fórumon és a következő témában adott elő: “Oncothermia as part of integrative medicine”. “Hyperthermia in oncology has long-standing history, having roots in ancient medicine. Both the Eastern and Western medicine had used it in holistic (whole-body fever with herbal administration)
- [KOSG Symposium 2020](https://oncotherm.com/hu/kosg-symposium-2020/) - Kattintson ide az angol nyelvű cikkért Az éves KOSG (Korean Oncologic-hyperthermia Study Group) Symposium november 28-án került megrendezésre online felületen. Az esemény célja, hogy a szakértők számára egy megfelelő fórumot biztosítson, ahol megvitathatják elképzeléseiket az onkológiai hipertermia alkalmazásáról, valamint bemutathatják kutatásaikat, klinikai tapasztalataikat. Prof. Szász András a “Quo Vadis oncological hyperthermia (2020)?” téméban adott elő, melynek angol nyelvű
- [Oncothermia és SARS-CoV-2](https://oncotherm.com/hu/oncothermia-es-sars-cov-2/) - Kattintson ide az angol nyelvű cikkért A Frontiers in Oncology újság publikálta az mEHT és SARS-CoV-2 témájában íródott cikket. A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19 Szerzők: Syed Muzzammil Masaud, Oliver Szasz, A. Marcell Szasz, Huma Ejaz, Rana Attique Anwar and Andras Szasz Introduction: Right now, we
- [Kellemes Ünnepeket kívánunk!](https://oncotherm.com/hu/2020-12-16-1507-vallalati-hirek-kellemes-unnepeket-kivanunk/) - E különleges év végéhez közeledve szeretnénk megragadni az alkalmat, hogy megköszönjük mindazt az érdeklődést, időt és támogatást, melyet cégünknek nyújtottak. Reméljük, hogy a jól megérdemelt pihenést mindenki ki tudja majd élvezni és lehetősége adódik ezt az időt családdal és barátokkal tölteni, akár személyesen, akár online formában. Kívánjuk, hogy a következő év egészséget és boldogságot hozzon Önöknek és családjuknak! Kellemes
- [Megjelent cikkek](https://oncotherm.com/hu/megjelent-cikkek/) - A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19 Szerző: Andras Szasz Absztrakt The COVID-19 pandemic has experienced unprecedented limitations and extraordinary scientific efforts to address this exceptional situation. Despite blanket closures that have resulted in significant financial constraints and losses around the world, research has an “unlimited” budget, with an exceptional concentration of medical
- [Többdimenziós gondolkodás a mellrák kezelésében](https://oncotherm.com/hu/tobbdimenzios-gondolkodas-a-mellrak-kezeleseben/) - A summary of the exchange on breast oncology between Fiorentini and Notter: Breast cancer classification and clinical grouping has been subject to a continuous change in the past decades. Based on extent and morphology with advent of gene expression analyses, we consider the disease a heterogeneous entity. Histologically the majority is classified as invasive carcinoma
- [Oncothermia Journal 29.](https://oncotherm.com/hu/oncothermia-journal-29/) - Örömmel tudatjuk, hogy az Oncothermia Journal legújabb száma angol nyelven elérhető ezen a linken.
- [Publikáció az Oncothermia Journalban](https://oncotherm.com/hu/publikacio-az-oncothermia-journalban/) - Az Oncothermia Journal az Oncotherm Csoport hivatalos, évente három alkalommal megjelenő kiadványa, amelyben orvosok és kutatók tehetik közzé az Oncothermia területén elért kutatási eredményeiket és gyakorlati tapasztalataikat. Az évente három alkalommal megjelenő kiadvány a tudományos szerzők munkáinak közzétételén felül, hirdetések megjelenésére is lehetőséget kínál. Tudományos munkákat várunk az info@oncotherm.org e-mail címre.
- [Modulált elektro-hipertermia klinikai vizsgálata előrehaladott áttétes emlőrák esetén](https://oncotherm.com/hu/modulalt-elektro-hipertermia-klinikai-vizsgalata-elorehaladott-attetes-emlorak-eseten/) - Takuya Nagata, Masahiko Kanamori, Shinichi Sekine, Mie Arai, Makoto Moriyama, Tsutomu Fujii The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of
- [Oncothermia Journal 30.](https://oncotherm.com/hu/oncothermia-journal-30/) - Örömmel tudatjuk, hogy az Oncothermia Journal legújabb száma angol nyelven elérhető ezen a linken.
- [Bio-Electromagnetics without Fields: The Effect of the Vector Potential](https://oncotherm.com/hu/bio-electromagnetics-without-fields-the-effect-of-the-vector-potential/) - Andras Szasz, Bio-Electromagnetics without Fields: The Effect of the Vector Pot… Numerous considerations deal with specialties of bioelectromagnetic effects, including the force-free and field-free interactions. The fact that bioelectromagnetic phenomena consist of effects without mechanical forces and even without measurable fields looks impossible in the simple considerations. However, the stochastic fluctuations cause surprising results, with
- [Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial](https://oncotherm.com/hu/modulated-electro‑hyperthermia-with-weekly-paclitaxel-or-cisplatin-in-patients-with-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-the-kgog-3030-tr/) - Kidong Kim, Jaee‑Hoon Kim, Seung Cheol Kim, Yong Beom Kim, Byung‑Ho Nam, Jae Hong No, Hanyboul Cho, Woong Ju, Dong Hoon Suh and Yun Hwanr Kim The study (KGOG 3030) aimed to evaluate the safety of modulated electro‑hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into
- [African Society for Hyperthermia in Oncology](https://oncotherm.com/hu/african-society-for-hyperthermia-in-oncology/) - Registration 3 HOUR CONFERENCE ON-LINE 4 EXCITING INTERNATIONAL SPEAKERS 4 LOCAL SPEAKERS · Prof Peter Wust; Radiation Oncology and Radiation Therapy Clinic, Charité Medical University, Berlin, Germany · Prof Nilroy Datta; Department of Radiotherapy, Mahatma Ghandi Institute of Medical Sciences, India · Prof András Szász; Biotechnics Department; St. Istvan University; Budapest, Hungary · Dr Guy Cooper; 20+Years experience in International Medical Devices; Worked for
- [The Capacitive Coupling Modalities for Oncological Hyperthermia](https://oncotherm.com/hu/the-capacitive-coupling-modalities-for-oncological-hyperthermia/) - https://doi.org/10.4236/ojbiphy.2021.113010 Andras Szasz, The Capacitive Coupling Modalities for Oncological Hyperthermia The local-regional oncological hyperthermia has various electromagnetic methods for energy-transfer. The differences involve conceptual considerations and technical solutions. The most frequently applied energy transfer is capacitive coupling, concentrating the electric field to be the active heating component. The realization of the capacitive coupling set-up is divided
- [Vascular Fractality and Alimentation of Cancer](https://oncotherm.com/hu/vascular-fractality-and-alimentation-of-cancer/) - https://doi.org/10.4236/ijcm.2021.127025 Andras Szasz, Vascular Fractality and Alimentation of Cancer Background: The basal metabolic rate has a scaling by tumor mass on the exponent of 3/4, while a simple surface-supplied volume of the mass would have a lower exponent, 2/3. The higher exponent can be explained by optimizing the overall energy distribution in the tumor, assuming that
- [Therapeutic Basis of Electromagnetic Resonances and Signal-Modulation](https://oncotherm.com/hu/therapeutic-basis-of-electromagnetic-resonances-and-signal-modulation/) - https://doi.org/10.4236/ojbiphy.2021.113011 Andras Szasz, Therapeutic Basis of Electromagnetic Resonances and Signal-Modulation The medical application of electromagnetic resonances is a controversial area of knowledge. Numerous unproven statements and some medical quackeries were published and distributed in informal channels among suffering patients. The fake information is hazardous in such severe diseases as cancer. The optimal, high efficacy energy transport
- [ESTRO 2021](https://oncotherm.com/hu/estro-2021/) - ESTRO 2021 Az ESTRO (European Society for Radiotherapy and Oncology) éves konferenciáját 2021. augusztus 27. és 31. között rendezik meg Spanyolországban, Madridban. Az eseményen idén online és a helyszínen is részt lehet venni. Az idei konferencián egy teljes klinikai szekciót szentelnek a hipertermia témájának, mi pedig a következő két előadást szeretnénk kiemelni: Augusztus 27., 10:30 -11:30 Dr.
- [Díjnyertes hyperthermia specialista az ESTRO-n](https://oncotherm.com/hu/dijnyertes-hyperthermia-specialista-az-estro-n/) - Az ESTRO a sugárterápia és onkológia szakmai közösségének legnagyobb európai konferenciája. Az idei eseményt Madridban tartották augusztus 27. és 31. között. Az előadások mellett nagy hangsúlyt kap a kiállítás, melyen a korábbi évek hagyományához hasonlóan cégünk is részt vett. Az érdeklődők a 680-as impozáns standnál tekinthették meg készülékünket, tudhattak meg többet az oncothermia metódusáról. Az
- [39. ICHS Konferencia](https://oncotherm.com/hu/39-ichs-konferencia/) - A pandémiás helyzet miatt a 39. ICHS konferencia online kerül megrendezésre 2021. november 5-én. Az ICHS Tanács szavazata alapján Dr. Elisabeth Arrojo lett kinevezve a 38. ICHS Konferencia, és a kialakult helyzet miatt a szintén online térben megrendezésre kerülő 39. ICHS Konferencia elnökének. Az esemény lehetőséget kínál megismerni az oncothermiát, illetve a legújabb tudományos eredményeket a területen.
- [TeSzedd! – Oncotherm Volunteer](https://oncotherm.com/hu/teszedd-oncotherm-volunteer/) - A környezettudatosság jegyében 2021.10.23-án az Oncotherm kollégái ismét részt vettek a TeSzedd szemétgyűjtési akcióban. A TeSzedd! – Önkéntesen a tiszta Magyarországért akció hazánk egyik legnagyobb mozgalma. Kilenc éve szerveznek közösségi takarítást az ország egész területén.
- [Lezajlott a 39. ICHS Konferencia](https://oncotherm.com/hu/lezajlott-a-39-ichs-konferencia/) - A 39. ICHS konferencia online került megrendezésre 2021. November 5-én Zoomon. Örömünkre szolgált, hogy közel 100 érdeklő vet részt az eseményen összesen 18 országból: Görögországból, Észak-Macedóniából, Hollandiából, Spanyolországból, Olaszországból, Dél-Koreából, Brazíliából, Németországból, Japánból, Ausztráliából, Pakisztánból, az Egyesült Királyságból, Magyarországról, Portugáliából, Svájcból, Belgiumból, Tajvanból. Az előadások hamarosan elérhetőek lesznek az Oncotherm YouTube csatornáján. Addig is, tekintse
- [Russian Health Care Week 2021](https://oncotherm.com/hu/russian-health-care-week-2021/) - A Russian Health Care Week a legnagyobb egészségügyi rendezvény Oroszországban. Russian Health Care Week is the largest health care project in Russia, amely magában foglal egy nemzetközi szakmai kiállítást, fórumokat, konferenciákat, és egyéb eseményeket. 2021 decemberében az Oncotherm Kft. is részt vehetett ezen a nagyszabású eseményen a HEPA magyar iroda standján. A helyszínen több orosz
- [ICHS presentations on YouTube](https://oncotherm.com/hu/ichs-presentations-on-youtube/) - November 5-én került megrendezésre a 39. ICHS konferencia. Ha nem volt lehetősége részt venni az eseményen, van egy nagyszerű hírünk: az előadások már elérhetőek a YouTube csatornánkon. Reméljük, hogy a nemzetközi egészségügyi helyzet lehetővé teszi, hogy 2022-ben élőben kerüljön megrendezésre a konferencia, és hogy lehetőségünk nyíljon személyesen is találkozni.
- [Prof. Dr. Szász András : Heterogeneous Heat Absorption Is Complementary to Radiotherapy](https://oncotherm.com/hu/prof-dr-szasz-andras-heterogeneous-heat-absorption-is-complementary-to-radiotherapy/) - Professzor Dr. Szász András újabb cikke jelent meg a Cancersben. Abstract: (1) Background: Hyperthermia in oncology conventionally seeks the homogeneous heating of the tumor mass. The expected isothermal condition is the basis of the dose calculation in clinical practice. My objective is to study and apply a heterogenic temperature pattern during the heating process and
- [Civil alliance for civilians](https://oncotherm.com/hu/civil-alliance-for-civilians/) - Az egész világot megrázó háború eseményeit kollégáink is nyomon követték, és céges adománygyűjtést szerveztek a háború elől hazánkba menekülők számára. Az összefogásnak köszönhetően több ezer olyan alapvető terméket tudtunk vásárolni mint élelmiszer, pelenka, nedves törlőkendő, fogkefe, fogkrém, szappan. Ha módjában áll, segítsen Ön is! Ha szeretné megtudni, milyen formában támogathatja a bajba jutottokat, forduljon Magyarország
- [Lokális hipertermia különszám a Cancers-ben](https://oncotherm.com/hu/lokalis-hipertermia-kulonszam-a-cancers-ben/) - Kattintson ide a különszám további részleteiért A „Cancers” folyóirat (IF>6) felkérte professzor Szász Andrást, hogy legyen vendégszerkesztője a következő különszámnak, melynek témája a lokális hipertermia lesz. Szász professzor élve a lehetőséggel, további két neves hipertermiás szakértőt (Prof. S. Bodis és Prof. NR. Datta) kért fel társszerkesztőnek. A különszám remek lehetőséget nyújt a rákkezelésben használt hipertermiának,
- [Új cikk a Cellsben: Forcing the Antitumor Effects of HSPs Using a Modulated Electric Field](https://oncotherm.com/hu/uj-cikk-a-cellsben-forcing-the-antitumor-effects-of-hsps-using-a-modulated-electric-field/) - https://www.mdpi.com/2073-4409/11/11/1838 Absztrakt The role of Heat Shock Proteins (HSPs) is a “double-edged sword” with regards to tumors. The location and interactions of HSPs determine their pro- or antitumor activity. The present review includes an overview of the relevant functions of HSPs, which could improve their antitumor activity. Promoting the antitumor processes could assist in the
- [Medica 2022](https://oncotherm.com/hu/medica-2022/) - Medica 2022 Örömmel jelentjük be, hogy az Oncotherm Kft idén részt vesz a világ egyik legnagyobb egészségügyi szakkiállításán, a Medica 2022 rendezvényén. Az évente megrendezésre kerülő kiállításnak 2022-ben a németországi Düsseldorf ad otthont, november 14-17. között, amely átfogó áttekintést nyújt az eglszségügyi szektor legújabb technológiai víványairól. Ha szeretne többet is megtudni eszközeinkről és tudományos hátterünkről,
- [Már letölthető az Oncothermia Journal 32. kötete!](https://oncotherm.com/hu/mar-letoltheto-az-oncothermia-journal-32-kotete/) - Örömmel tudatjuk, hogy az Oncothermia Journal legújabb száma angol nyelven elérhető és letölthető! Az Oncothermnél fontosnak tartjuk, hogy tájékoztassuk érdeklődőinket a hipertermia legfrissebb eredményeiről és az onkológia feltörekvő területének trendjeiről, hiszen célunk, hogy releváns és naprakész információkat biztosítsunk. Reméljük, hogy értékes megfigyeléseivel ez a kötet hasznos lesz a napi kezelési döntései során!
- [A Magyar-Üzbég Üzleti Fórum új üzleti lehetősége](https://oncotherm.com/hu/a-magyar-uzbeg-uzleti-forum-uj-uzleti-lehetosege/) - 2022. október 3-án hétfőn került megrendezésre a Magyar-Üzbég Üzleti Fórum Budapesten, melyen az Oncotherm Kft. részéről ügyvezető igazgatónk, Ács Balázs képviselte vállalatunkat. Az esemény személyes tárgyalások keretében ösztönözte a két ország üzleti szereplői között új gazdasági kapcsolatok kialakítását és a meglévő kapcsolatok erősítését. A fórumon Üzbegisztán magas rangú diplomáciai és üzleti delegációja is jelen volt,
- [Oncotherm a Medica 2022 kiállításon](https://oncotherm.com/hu/oncotherm-a-medica-2022-kiallitason/) - Medica 2022 Ezúton is köszönjük minden kedves résztvevőnek, aki a 2022. évi Medica kiállításon ellátogatott az Oncotherm standjához! Öröm volt ismét személyes kapcsolatokat kialakítani partnereinkkel. A kiállítás számos kiváló üzleti találkozónak adott lehetőséget, melyek bízunk benne, hogy gyümölcsöző együttműködéshez vezetnek! MEDICA 2022 számokban kifejezve: 5.000 kiállító 70 résztvevő nemzet 81.000 látogató az egészségügyi ipar különböző
- [In memoriam Dr. med. Friedrich Rudolf Douwes](https://oncotherm.com/hu/in-memoriam-dr-med-friedrich-rudolf-douwes/) - Mély fájdalommal tudatjuk, hogy sokunk együttműködő partnere, kollégája és barátja, Dr. Friedrich Douwes elhunyt. Kiváló orvos volt ötletekkel, újításokkal és jelentős nemzetközi tapasztalatokkal. Számára a beteg, mint ember volt a fontos, nem a tumort kezelte, hanem a daganatos beteget. Az integratív gyógyászat úttörője volt, nemcsak onkológiai betegeit, hanem számos társbetegséget és más, jelenleg kevésbé gyógyítható
- [10. KOSG Szimpózium 2022](https://oncotherm.com/hu/10-kosg-szimpozium-2022/) - Az angol nyelvű előadásokért kattintson ide! A 10. KOSG Szimpózium (Korean Oncologic-hyperthermia Study Group) idén, 2022-ben december 3-án került megrendezésre, melynek helyszínét az Inje University Haeundae Paik Hospital adta. Az esemény célja, hogy a szakértők számára egy megfelelő fórumot biztosítson, ahol megvitathatják elképzeléseiket az onkológiai hipertermia alkalmazásáról, valamint bemutathatják kutatásaikat, klinikai tapasztalataikat. Örömmel tudatjuk, hogy
- [Egy cipősdoboznyi Karácsony](https://oncotherm.com/hu/egy-ciposdoboznyi-karacsony/) - Immáron 6. alkalommal őrizzük kedves kollégáinkkal a jótékonysági Cipősdoboz akcióban való részvétel hagyomáyát. Az idei alkalomra OncoTeam-ünk 28 cipősdobozt állított össze válogatott játékokkal, higiéniai cikkekkel, könyvekkel és egyéb ajándékokkal, hogy megajándékozzuk a rászoruló kisgyermekeket. Még mindig van idő a csomagok elkészítésére, hiszen az adomány akció most vasárnap ér véget! Arra bíztatjuk Önöket is, hogy vegyenek részt
- [Kellemes Karácsonyi Ünnepeket és Boldog Új Évet Kívánunk!](https://oncotherm.com/hu/kellemes-karacsonyi-unnepeket-es-boldog-uj-evet-kivanunk/) - Kedves Partnereink! Ennek a különleges évnek a végéhez közeledve szeretnénk kifejezni őszinte köszönetünket Önöknek bizalmukért, idejükért és támogatásukért, mellyel 2022-ben megajándékoztak minket! Reméljük, hogy az idei év is kellemes élményekben gazdag és emlékezetes volt Önöknek, kollégáiknak és szerettekinek, és bízunk benne, hogy a következő év egészséget és boldogságot hoz Önnek és egész családjának. Kellemes Karácsonyi
- [In memoriam Prof. Dr. med. Alexander Herzog](https://oncotherm.com/hu/in-memoriam-prof-dr-med-alexander-herzog/) - Mély fájdalommal értesültünk, hogy Prof. Dr. med. Alexander Herzog elhunyt. Neves, megbecsült, kiváló orvos volt, klinikájának főorvosa. Klinikai tevékenysége és terápiái rendkívül sikeresek voltak, a betegek szeretete övezte. Betegei, akinek meghosszabbította az életét, nagy szeretettel gondol rá. A kollégák gyakran fordultak hozzá tanácsért és konzultációért. Egyetemi előadásai és különböző konferenciákon tartott előadásai nagy népszerűségnek örvendtek.
- [Publikációgyüjtemény a vastag- és végbélrák elleni küzdelem hónapjára](https://oncotherm.com/hu/publikaciogyujtemeny-a-vastag-es-vegbelrak-elleni-kuzdelem-honapjara/) - Március hagyományosan a vastagbélrák elleni küzdelem hónapja, melynek alkalmából összegyűjtöttünk Olvasóinknak néhány tájékoztató kiadványt és tanulmányt erről a témáról. A rák ezen típusa világszerte jelentős egészségügyi probléma, és a daganatos betegségekkel összefüggő halálozások egyik vezető okaként tartják számon. Célunk, hogy pozitív hatást fejtsünk ki a vastag- és végbélrák elleni küzdelemben, mivel ezek a vizsgálatok ígéretes
- [A Mirakle Integrated Health Centre az Oncotherm készülékét választotta](https://oncotherm.com/hu/a-mirakle-integrated-health-centre-az-oncotherm-keszuleket-valasztotta/) - Az indiai Pollachi városában található Mirakle Integrated Health Centre február 26-án ünnepélyes megnyitó keretében át a első hipertermia kezelési központját. A Mahalingapuram Nachimuthu Polytechnic University Campusán található létesítményt az Oncotherm EHY-2030 készülékével felszerelkezve nyújt célzott és hatékony rákkezelési lehetőséget pácienseinek. A megnyitó ünnepségen informatív előadások hangzottak el többek közt a hipertermia előnyeiről a rákterápiában, valamint
- [Kellemes húsvéti ünnepeket kívánunk!](https://oncotherm.com/hu/kellemes-husveti-unnepeket-kivanunk/) - Az Oncotherm csapata kellemes Húsvéti ünnepet kíván Önnek és családjának, tele új kezdetek ígéretével, a jólét és a bőség áldásaival!
- [Publikációgyüjtemény az agydaganat elleni küzdelem hónapjára](https://oncotherm.com/hu/publikaciogyujtemeny-az-agydaganat-elleni-kuzdelem-honapjara/) - Május szintén fontos hónapot jelent a rákellenes küzdelemben, mivel ez az időszak az agydaganat, melanoma és bőrrák tudatosításáról szól, hiszen ezek a betegségek évente számos embert érintenek. Célunk, hogy pozitív hatást gyakoroljunk a rákkal szembeni küzdelemben. Ehhez összegyűjtöttünk néhány tájékoztató publikációt és tanulmányt a témában, amelyek az oncothermia kezelésekkel kapcsolatos ígéretes eredményeket mutatják be. Szasz
- [Oncotherm a SantExpo 2023 konferencián](https://oncotherm.com/hu/oncotherm-a-santexpo-2023-konferencian/) - Az Oncotherm örömmel meghívja Önt Párizsba a SantExpo-ra, amely 2023. május 23. és 25. között kerül megrendezésre a Paris Porte de Versailles-ban! A SantExpo az egészségügyi, egészségügyi és szociális szolgáltatások éves találkozója, amelyen az iparág vezető vezetői találkoznak, hogy megvitassák a terület legújabb fejlesztéseit és innovációit. Ha többet szeretne megtudni technológiánkról, és arról, hogy az milyen
- [OncoFutóink a Telekom Vivicitta félmaratonon](https://oncotherm.com/hu/oncofutoink-a-telekom-vivicitta-felmaratonon/) - Gratulálunk kollégáinknak, akik sikeresen teljesítették 2023 első budapesti félmaratoni távját, a 21.0975 km hosszú Telekom Vivicittát! A versenynap április 23-ára, az év első igazi tavaszi hétvégéjére esett, ahol kollégáink a félmaratoni távban egyéni futóként és váltócsapatokként is teljesítettek. Büszkék vagyunk kollégáink kivételes teljesítményére és elkötelezettségükre, hogy ilyen jeles sporteseményeken vesznek részt! Gratulálunk Nekik!
- [OncoFutóink sikeresen teljesítették az UltraBalatont!](https://oncotherm.com/hu/oncofutoink-sikeresen-teljesitettek-az-ultrabalatont/) - Kollégáink sikeresen teljesítették a közel 211 km-es Balaton-körüli futóversenyt, az NN Ultrabalatont! 2023-ban volt a 17. évfordulója az egykörös Balaton körüli versenynek, amely egyben Közép-Európa leghosszabb futóversenye. Az eseményre számtalan sportoló érkezett Európa minden tájáról, hogy a Magyarország közepén található tó partja mentén futhasson. A teljes távot az Oncotherm mindössze 6 elszánt kollégából álló csapata váltóversenyen
- [Már letölthető az Oncothermia Journal 33. kötete!](https://oncotherm.com/hu/mar-letoltheto-az-oncothermia-journal-33-kotete/) - Örömmel jelentjük be, hogy már elérhető az Oncothermia Journal 33. száma! Az Oncothermnél fontosnak tartjuk, hogy tájékoztassuk érdeklődőinket a hipertermia legfrissebb eredményeiről és az onkológia feltörekvő területének trendjeiről, hiszen célunk, hogy releváns és naprakész információkat biztosítsunk. Legújabb kötetünkben olyan témákról olvashat, mint a rezonanciák szerepe a modulált elektro-hipertermiában a rosszindulatú sejtek megcélzásakor, az mEHT kiegészítő alkalmazása
- [Június a Rák túlélők hónapja!](https://oncotherm.com/hu/junius-a-rak-tulelok-honapja/) - Június a nemzeti rákot túlélők hónapja, amikor is a daganatos betegség által érintettek előtt tisztelegünk és emlékezünk meg. Ezen időszak célja, hogy felhívjuk a figyelmet a betegségre, valamint támogatást nyújtsunk a jelenleg daganatos betegséggel küzdőknek. E fontos ügy iránti elkötelezettségünk részeként összegyűjtöttünk egy olyan kiadványsorozatot, amely értékes betekintést nyújthat az oncothermia kezelésekbe. A lenti publikációk
- [Új Phase II és Phase III klinikai vizsgálat indult mEHT-vel](https://oncotherm.com/hu/uj-phase-ii-es-phase-iii-klinikai-vizsgalat-indult-meht-vel/) - Örömmel osztjuk meg olvasóinkkal, hogy az emlőrákos betegek mEHT kezelésének témakörében új Phase II. és Phase III. randomizált klinikai vizsgálat indult. Az Oncotherm EHY-2030 készülékével végzett vizsgálat a Semmelweis Egyetem Belgyógyászati ​​és Onkológiai Klinika Onkológiai Osztályán, Dr. Szász Marcell koordinálásával,és Prof. Dank Magdolna kutatásvezető együttműködésével zajlik. A tanulmány célja, hogy az egyidejű modulált elektro-hipertermia alkalmazását és annak előnyösségét vizsgálja neoadjuváns kemoterápiás
- [Publikációk a Szarkóma és Csontrák hónapjára](https://oncotherm.com/hu/publikaciok-a-szarkoma-es-csontrak-honapjara/) - A szarkóma és a csontrák elleni küzdelem hónapja - melyet a sárga színű szalag jelképez - egy globális egészségügyi esemény, amelyet az elmúlt 15 évben minden év júliusában tartanak. Világszerte számos tevékenységet folytatnak a rák e formáival kapcsolatos tudatosság növelése, valamint a kutatások és a kezelésük terén elért előrelépések támogatása érdekében. Szeretnénk kifejezni támogatásunkat és
- [Találkozzunk a MEDICA-n!](https://oncotherm.com/hu/talalkozzunk-a-medica-n/) - Az Oncotherm örömmel meghívja Önt a MEDICA 2023 kiállítására, amely 2023. november 13. és 16. között kerül megrendezésre a németországi Düsseldorf városában! Ha többet szeretne megtudni technológiánkról, és arról, hogy az milyen előnyökben részesülhetnek páciensei a készülékünk által, látogasson el hozzánk az A02-es standunkhoz a 15-es csarnokban! Növelje Ön is rákkezelési megoldásainak hatékonyságát az EHY-2030
- [Oncotherm a Medica 2023 kiállításon](https://oncotherm.com/hu/oncotherm-a-medica-2023-kiallitason/) - Köszönjük, hogy ellátogattak az Oncotherm standjára a Medica 2023 kiállításon! Az idén november 13. és 16. között a németországi Düsseldorfban megrendezésre kerülő Medica kiállítás a világ egyik vezető egészségügyi szakkiállítása. Nagyra értékeljük érdeklődésüket, az idei évben is számos kiemelkedő találkozóra volt lehetőségünk, melyek bízunk benne, hogy gyümölcsöző együttműködéshez vezetnek! A Medica 2023 számokban mérve: 5.300+
- [OncoFutás a 37. Wizz Air Budapest Félmaratonon](https://oncotherm.com/hu/oncofutas-a-37-wizz-air-budapest-felmaratonon/) - Büszkék vagyunk, hogy OncoFutóink múlt hétvégén részt vettek a 37. Wizz Air Budapest Félmaratonon. A verseny útvonala igazi városnézést jelentett, hiszen Budapest szívében, a főváros legismertebb helyszíneit, nevezetességeit érintve futhattak indulóink. A teljes, 21 km-es távot három kollégánk egyénileg, míg a többiek váltóban teljesítették. Gratulálunk Nekik ehhez a lenyűgöző teljesítményhez!

## Oldalak

- [Főoldal](https://oncotherm.com/hu/) - A Módszer Alapelvei Az Oncothermia, vagyis a loko-regionális mély hyperthermia egy olyan rohamosan fejlődő, kiegészítő eljárás, amelyet a daganatos megbetegedések gyógykezelésére alkalmaznak. A módszer a klasszikus Hyperthermia elméletén alapszik. Fő cél: a hőbevitel által a sejtkörüli folyadékban történő energiaelnyelés elérése, valamint a rákos sejtek membránjainak roncsolása. Oncothermia Klinikáink 500 készülék + 30 ország + 400
- [Home](https://oncotherm.com/) - News Kellemes Húsvéti Ünnepeket! 2026 április 02. February 9-12, 2026 WHX Dubai 2026 2026 február 24. Fülöp-szigeteki FDA engedély 2026 január 29. 17-20. November 2025 Medica 2025 2025 november 23. 23-25. October 2025 Health Asia 2025 2025 október 30. Fókuszban Olaszország: Oncothermia Journal 37. 2025 szeptember 17. 2. April 2025 Oncotherm előadások Olaszországban 2025 szeptember
- [Hauptseite](https://oncotherm.com/de/) - News Kellemes Húsvéti Ünnepeket! 2026 április 02. February 9-12, 2026 WHX Dubai 2026 2026 február 24. Fülöp-szigeteki FDA engedély 2026 január 29. 17-20. November 2025 Medica 2025 2025 november 23. 23-25. October 2025 Health Asia 2025 2025 október 30. Fókuszban Olaszország: Oncothermia Journal 37. 2025 szeptember 17. 2. April 2025 Oncotherm előadások Olaszországban 2025 szeptember
- [Our projects implemented with co-financing from the European Union](https://oncotherm.com/our-projects-implemented-with-co-financing-from-the-european-union/) - Our projects implemented with co-financing from the European Union Improving the adaptability and productivity of employees and companies through workforce development Name of beneficiary: Oncotherm Kft. Programme identifier: GINOP_Plusz-3.2.1-21 Improving the adaptability and productivity of employees and companies through workforce development Project identification number: PEM/01/001986-1/2025 Contracted grant amount: HUF 10,972,044 Name, objective and detailed description
- [Unsere Projekte, die mit Kofinanzierung der Europäischen Union umgesetzt werden](https://oncotherm.com/de/unsere-projekte-die-mit-kofinanzierung-der-europaeischen-union-umgesetzt-werden/) - Unsere Projekte, die mit Kofinanzierung der Europäischen Union umgesetzt werden Verbesserung der Anpassungsfähigkeit und Produktivität von Arbeitnehmern und Unternehmen durch die Entwicklung der Arbeitskräfte Name des Begünstigten: Oncotherm GmbH Programmkennung: GINOP_Plusz-3.2.1-21 Verbesserung der Anpassungsfähigkeit und Produktivität von Arbeitnehmern und Unternehmen durch die Entwicklung der Arbeitskräfte Projektidentifikationsnummer: PEM/01/001986-1/2025 Vertraglich zugesicherte Fördermittel: 10.972.044 HUF Bezeichnung, Ziel und
- [About Us](https://oncotherm.com/about-us/) - Oncotherm Team Timeline of Oncotherm Corporate Social Responsibility Tenders Contact You're never wrong to do the right thing – Mark Twain – Oncotherm Team Oncotherm is proud of its team of highly trained and dedicated professionals who provide the highest level of collaboration and service to both patients and physicians. Relying on the latest knowledge
- [Über uns](https://oncotherm.com/de/uber-uns/) - Oncotherm Team Zeitleiste von Oncotherm Corporate Social Responsibility Tenders Kontakt Es ist nie falsch, das zu tun, was richtig ist. – Mark Twain – Oncotherm Team Oncotherm ist stolz auf sein Team von hochqualifizierten und engagierten Fachleuten, die Patienten und Ärzten ein Höchstmaß an Zusammenarbeit und Service bieten. Basierend auf den neuesten Erkenntnissen können wir
- [A Pézügyminisztérium által finanszírozott projektjeink](https://oncotherm.com/hu/a-pezugyminiszterium-altal-finanszirozott-projektjeink/) - A Pézügyminisztérium által finanszírozott projektjeink Vészhelyzeti lélegeztető és ImmunoBooster prototípus fejlesztése Kedvezményezett neve: Oncotherm Kft. A projekt címe: „Vészhelyzeti lélegeztető és ImmunoBooster prototípus fejlesztése” Szerződéses támogatás összege: 462 242 443 Ft Támogatásintenzitás: 77,97% Tervezett befejezési dátum: 2022.12.31. Projekt azonosító száma: PM/15237-13/2020 Jelenleg a lélegeztető gépek piacán több nagy gyártó is kínál termékeket, azonban a COVID-19 járvány kapcsán kiderült, hogy a gyártók nem
- [Az Európai Unió társfinanszírozásával megvalósuló projektjeink](https://oncotherm.com/hu/az-europai-unio-tarsfinanszirozasaval-megvalosulo-projektjeink/) - Az Európai Unió társfinanszírozásával megvalósuló projektjeink A munkavállalók és vállalatok alkalmazkodóképességének és termelékenységének javítása a munkaerő fejlesztésén keresztül Kedvezményezett neve: Oncotherm Kft. Program azonosítója: GINOP_Plusz-3.2.1-21. A munkavállalók és vállalatok alkalmazkodóképességének és termelékenységének javítása a munkaerő fejlesztésén keresztül Projekt azonosító száma: PEM/01/001986-1/2025 Szerződéses támogatás összege: 10.972.044,- Ft A projekt keretében megvalósuló képzések elnevezése, célja és részletes leírása: Haladok
- [Rólunk](https://oncotherm.com/hu/rolunk/) - Az Oncotherm büszke magasan képzett és elkötelezett szakemberekből álló csapatára, akik a legmagasabb szintű együttműködést és szolgáltatást biztosítják mind a betegek, mind az orvosok számára. A legfrissebb tudásra való támaszkodás lehetővé teszi, hogy széles spektrumú, személyre szabott terápiás megoldást nyújtsunk. Hiszünk abban, hogy a folyamatos fejlődés és a tudásunk bővítése kulcsfontosságú a betegek jobb egészségének és gyógyulásának elérése érdekében.
- [Zertifikate](https://oncotherm.com/de/zertifikate/) - Zertifikate Die Qualitätspolitik von Oncotherm Oncotherm hat sich ganz der Entwicklung und Herstellung von sicheren und zuverlässigen "komplementären Therapie-Medizinprodukten" verschrieben und zielt darauf ab, eine Therapie anzubieten, die die Lebensqualität der Patienten erhöht. ISO 13485:2016 MDR Certificate - Regulation (EU) 2017/745 on Medical Devices
- [Tanúsítványok](https://oncotherm.com/hu/tanusitvanyok/) - TANÚSÍTVÁNYOK Oncotherm Minőségpolitikája Az OncoTherm Group vezetősége és összes dolgozója elkötelezi magát a vonatkozó nemzetközi szabványoknak, EU direktíváknak és az CMDR (Canadian Medical Devices Regulations) megfelelő, a betegek közérzetét, életminőségét javító, illetőleg gyógyulásuk esélyét hatékonyan növelő, biztonságos és megbízható orvosi berendezések kifejlesztése, gyártása mellett. Cégünk ennek érdekében végzi kutató – fejlesztő munkáját, és kialakította ehhez
- [Certificates](https://oncotherm.com/certificates/) - Our certificates Quality Policy of Oncotherm Oncotherm is entirely committed to the development and manufacture of safe and reliable “complementary therapy medical devices” and aims at providing a therapy, that increases the quality of life of patients ISO 13485:2016 MDR Certificate - Regulation (EU) 2017/745 on Medical Devices
- [Projects financed by the Hungarian Ministry of Finance](https://oncotherm.com/de/projects-financed-by-the-hungarian-ministry-of-finance/) - Projects financed by the Hungarian Ministry of Finance Development of emergency ventilator and ImmunoBooster prototype Beneficiary Name: Oncotherm Kft. Title of the project: „Development of emergency ventilator and ImmunoBooster prototype” Amount of contracted support: 462.242.443 forints Support rate: 77,97% Projected completion date: 31.12.2022 Project ID number: PM/15237-13/2020 In the course of this project, our company
- [Projects financed by the Hungarian Ministry of Finance](https://oncotherm.com/projects-financed-by-the-hungarian-ministry-of-finance/) - Projects financed by the Hungarian Ministry of Finance Development of emergency ventilator and ImmunoBooster prototype Beneficiary Name: Oncotherm Kft. Title of the project: „Development of emergency ventilator and ImmunoBooster prototype” Amount of contracted support: 462.242.443 forints Support rate: 77,97% Projected completion date: 31.12.2022 Project ID number: PM/15237-13/2020 In the course of this project, our company
- [Arab Health 2025](https://oncotherm.com/qr_oncotherm/) - Oncotherm has been developing, manufacturing and marketing cancer treatment systems since 1988 applying the patented oncothermia technology to treat malignant tumors. The technology of oncothermia - modulated-electro-hyperthermia, mEHT® - is a modern enhancement of one of the oldest cancer treatment methods, classical hyperthermia. Oncothermia is a personalized, non-toxic therapy that uses an electric field to
- [Arab Health 2025 T-shirt](https://oncotherm.com/qr_oncotherm_draft/) - Oncothermia method Clinical knowledge Our mission Oncothermia Method Oncothermia, i. e. modulated-electro-hyperthermia for oncological use, is a fast developing supportive, complementary treatment method. The principles are based on the classical method of Hyperthermia, but in contrast to the homogeneous heating of classical hyperthermia, oncothermia (modulated electro-hyperthermia (mEHT®)) heats the malignant cells selectively, concentrating the energy
- [Arab Health 2025](https://oncotherm.com/oncotherm_arab_health_2025/) - Oncotherm has been developing, manufacturing and marketing cancer treatment systems since 1988 applying the patented oncothermia technology to treat malignant tumors. The technology of oncothermia - modulated-electro-hyperthermia, mEHT® - is a modern enhancement of one of the oldest cancer treatment methods, classical hyperthermia. Oncothermia is a personalized, non-toxic therapy that uses an electric field to
- [Collection of experimental publications](https://oncotherm.com/collection-of-experimental-publications/) - Collection of experimental publications Oncotherm is keen to prepare studies and publish those in relevant scientific and medical literature. Our philosophy covers a complex interation between the various levels of research and applications. The basic researches (theoretical considerations and in-silico studies) are followed by the laboratory experiments in-vitro and in-vivo completed with preclinical and afterwards
- [Datenschutzbestimmungen](https://oncotherm.com/de/datenschutzbestimmungen/) - Datenschutzbestimmungen 1. Purpose of the General Privacy Policy By publishing this Privacy Policy, Oncotherm Kft, OncoPet Kft, SCA Holding Kft, SCA Medical Trading Kft, SCA Pro Med Service Kft, SCA Oncology Kft, Oncotherm GmbH and XAX Kft (hereinafter collectively referred to as the Company or Data Controller) comply with the preliminary data processing requirements of
- [Adatvédelmi tájékoztató](https://oncotherm.com/hu/adatvedelmi-tajekoztato/) - ADATVÉDELMI TÁJÉKOZTATÓ 1. Az Általános Adatkezelési Politika célja Az OncoTherm Kft., az SCA Holding Kft, az SCA Medical Trading Kft, az SCA Pro Med Service Kft, az SCA Oncology Kft, az OncoPet Kft az Oncotherm GmbH és a XAX Kft (a továbbiakban együtt: a Vállalkozás vagy Adatkezelő) a jelen Adatkezelési Politika közzététele útján tesz eleget
- [Privacy Policy](https://oncotherm.com/privacy-policy/) - Privacy Policy 1. Purpose of the General Privacy Policy By publishing this Privacy Policy, Oncotherm Kft, OncoPet Kft, SCA Holding Kft, SCA Medical Trading Kft, SCA Pro Med Service Kft, SCA Oncology Kft, Oncotherm GmbH and XAX Kft (hereinafter collectively referred to as the Company or Data Controller) comply with the preliminary data processing requirements
- [Impresszum](https://oncotherm.com/hu/impresszum/) - IMPRESSZUM Oncotherm Kft. Gyár u. 2. 2040 Budaörs, Magyarország Telefon: +36 (23)-555-510 Fax: +36 (23)-555-515 E-mail: info@oncotherm.org Adószám: HU10228018 Kerületi Bíróság: Budapest Cg.: 13-09-125195 Ügyvezető igazgató: Ács Balázs Kutatási igazgató: Prof. Dr. Szász András Társtulajdonos, tanácsadó: Dr. Szász Olivér Oncotherm GmbH Belgische Allee 9 53842 Troisdorf Germany Telefon: +49 (2241)-319920 Fax: +49 (2241)-3199211 E-mail: info@oncotherm.de
- [Impressum](https://oncotherm.com/de/impresszum/) - IMPRESSUM Oncotherm Kft. Gyár u. 2. 2040 Budaörs, Ungarn Telefon: +36 (23)-555-510 Fax: +36 (23)-555-515 E-mail: info@oncotherm.org Steuernummer: HU10228018 Amtsgericht: Budapest Handelsregisternummer: 13-09-125195 Geschäftsführer: Eng. Balázs ÁCS Gründer, Berater: Prof. Dr. András SZÁSZ Miteigentümer, Berater: Dr. Olivér SZÁSZ Oncotherm GMBH Belgische Allee 9 53842 Troisdorf Deutschland Telefon: +49 (2241)-319920 Fax: +49 (2241)-3199211 E-mail: info@oncotherm.de Steuernummer:
- [Impressum](https://oncotherm.com/impressum/) - IMPRESSUM Oncotherm Kft. Gyár u. 2. 2040 Budaörs, Hungary Telephone: +36 (23)-555-510 Fax: +36 (23)-555-515 E-mail: info@oncotherm.org VAT: HU10228018 District Court: Budapest Company registration number: 13-09-125195 Chief Executive Officer: Eng. Balázs ÁCS Founder, consultant: Prof. Dr. András SZÁSZ Co-owner, consultant: Dr. Olivér SZÁSZ Oncotherm GmbH Belgische Allee 9 53842 Troisdorf Germany Telephone: +49 (2241)-319920 Fax:
- [A Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal által finanszírozott projektjeink](https://oncotherm.com/hu/a-nemzeti-kutatasi-fejlesztesi-es-innovacios-hivatal-altal-finanszirozott-projektjeink/) - A Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal által finanszírozott projektjeink Elektromágneses daganat-terápiás készülék hatékonyságának növelése, piaci bevezetése, és az onkológiai terápiás gyakorlatba történő integrálásának előkészítése A kedvezményezett neve: Oncotherm Kft., Semmelweis Egyetem A projekt címe: „Elektromágneses daganat-terápiás készülék hatékonyságának növelése, piaci bevezetése, és az onkológiai terápiás gyakorlatba történő integrálásának előkészítése” A szerződött támogatás összege: 1,472
- [Quality Management](https://oncotherm.com/minosegiranyitas/) - MINŐSÉGIRÁNYÍTÁS Oncotherm Minőségpolitikája Az OncoTherm Group vezetősége és összes dolgozója elkötelezi magát a vonatkozó nemzetközi szabványoknak, EU direktíváknak és az CMDR (Canadian Medical Devices Regulations) megfelelő, a betegek közérzetét, életminőségét javító, illetőleg gyógyulásuk esélyét hatékonyan növelő, biztonságos és megbízható orvosi berendezések kifejlesztése, gyártása mellett. Cégünk ennek érdekében végzi kutató – fejlesztő munkáját, és kialakította ehhez
- [Karriere](https://oncotherm.com/de/karriere/) - Kommen Sie zu uns und werden Sie Teil unseres Oncotherm-Teams! Möchten Sie an der Entwicklung und Produktion von Medizinprodukten zur Krebsbehandlung mitwirken und in einem innovativen, international anerkannten Unternehmen arbeiten? LASSEN SIE UNS ZUSAMMENARBEITEN! Wer sind wir? Oncotherm Kft. ist seit mehr als 35 Jahren mit innovativen Lösungen auf dem Gebiet der Onkologie tätig. Unser
- [Karrier](https://oncotherm.com/hu/karrier/) - Csatlakozz csapatunkhoz, tegyünk együtt a küldetésünkért! Szeretnél egy innovatív, nemzetközileg is elismert vállalat tagjaként részt venni daganatterápiás orvostechnikai eszközök fejlesztésében és gyártásában? DOLGOZZ VELÜNK! Kik vagyunk mi? Az Oncotherm Kft. immár több mint 30 éve van jelen innovatív megoldásaival az onkológia területén. Vállalkozásunkból mára a világpiacon is meghatározó, piacvezető szereplő vált, a csapatunk által fejlesztett
- [Career](https://oncotherm.com/career/) - Join us and be a part of our Oncotherm Team! Would you like to participate in the development and production of cancer treatment medical devices and join to an innovative, internationally recognized company? LET’S WORK TOGETHER! Who are We? Oncotherm Kft. has been present with its innovative solutions in the field of oncology for more
- [Oncothermia](https://oncotherm.com/oncothermia/) - Oncothermia method Clinical knowledge Our mission Oncothermia Method Oncothermia, i. e. modulated-electro-hyperthermia for oncological use, is a fast developing supportive, complementary treatment method. The principles are based on the classical method of Hyperthermia, but in contrast to the homogeneous heating of classical hyperthermia, oncothermia (modulated electro-hyperthermia (mEHT®)) heats the malignant cells selectively, concentrating the energy
- [FAQ für Patienten](https://oncotherm.com/de/faq-fuer-patienten/) - FAQ für Patienten Wo finde ich alle Orte, an denen die Behandlung angeboten wird? Auf unsere Webseite können Sie alle Oncothermie Anwender und Ihre Kontaktinformationen finden. Auf Anfrage stellen wir Ihnen auch gerne eine Liste zur Verfügung. Ist die Oncothermie eine weitverbreitete Behandlung? Ja, die Behandlung wird immer häufiger genutzt. Die meisten Konferenzen im Bereich
- [LabEHY](https://oncotherm.com/de/labehy/) - EHY-2030 LabEHY LabEHY Ein elektro-hyperthermisches Gerät, das speziell für Forschungszwecke entwickelt wurde. Das LabEHY-Gerät wurde entwickelt, um verschiedene Arten von Zelllinien- (in vitro) und Kleintierexperimenten (in vivo) mit der Oncothermie-Methode (mEHT) durchzuführen, die zur nicht-invasiven Behandlung von malignem Gewebe eingesetzt wird. Der Unterschied in der komplexen Dielektrizitätskonstante (komplexe Impedanz) von bösartigem und gesundem Gewebe ermöglicht
- [EHY-2030](https://oncotherm.com/hu/ehy-2030/) - EHY-2030 LabEHY EHY-2030 Lokoregionális modulált elektro-hypertermia (mEHT) készülék a rosszindulatú daganatok kezelésére EHY-2030 a legújabb, lokoregionális daganatterápiás eszközünk. A legfrissebb fejlesztésű eszközünk új, Intelligens Elektródatartó Rendszerrel (SES), integrált Patient Management Rendszerrel (PMS-100) és felhasználóbarát érintőképernyővel irányítható rendszerrel került kifejlesztésre. Az új, megemelt teljesítményű RF generátor, az intelligens módon vezérelt, fokozatos motorhangolású rendszer hozzájárul a gyorsabb
- [LabEHY](https://oncotherm.com/hu/labehy/) - EHY-2030 LabEHY LabEHY Kifejezetten kutatási célokra fejlesztett elektro-hyperthermiás eszköz A LabEHY készülék különféle típusú sejtvonal (in vitro) és kisállat (in vivo) kísérletek elvégzésére került kifejlesztésre az onkotermia (mEHT) módszerének felhasználásával, amely a rosszindulatú szövetek non-invazív kezelésére szolgál. A rosszindulatú és az egészséges szövetek komplex dielektromos állandója (komplex impedanciája) közötti különbség lehetővé teszi azok megkülönböztetését, így
- [Oncothermia](https://oncotherm.com/hu/oncothermia/) - ONCOTHERMIA MÓDSZER TUDOMÁNYOS HÁTTÉR KÜLDETÉSÜNK A Módszer Alapelvei Az Oncothermia, vagyis a loko-regionális mély hyper-thermia egy olyan rohamosan fejlődő, kiegészítő eljárás, amelyet a daganatos megbetegedések gyógykezelésére alkalmaznak. A módszer a klasszikus Hyperthermia elméletén alapszik. Fő cél: a hőbevitel által a sejtkörüli folyadékban történő energiaelnyelés elérése, valamint a rákos sejtek membránjainak roncsolása. Az Oncothermia hatása szinergikus
- [Oncothermia](https://oncotherm.com/de/oncothermia/) - Oncothermie Methode Klinisches Wissen Unser Ziel Oncothermie Methode Die Oncothermie, d. h. die modulierte Elektro-Hyperthermie für den onkologischen Einsatz, ist eine sich schnell entwickelnde unterstützende, komplementäre Behandlungsmethode. Die Prinzipien basieren auf der klassischen Methode der Hyperthermie, aber im Gegensatz zur homogenen Erwärmung der klassischen Hyperthermie erwärmt die Oncothermie (modulierte Elektro-Hyperthermie (mEHT®)) die bösartigen Zellen selektiv
- [Kísérleti Onkotermia publikációgyűjtemény](https://oncotherm.com/hu/kiserleti-onkotermia-publikaciogyujtemeny/) - KÍSÉRLETI ONKOTERMIA PUBLIKÁCIÓGYŰJTEMÉNY Az Oncotherm rendszeresen tesz közzé publikációkat a releváns tudományos és orvosi szaklapokban, weboldalakon. Filozófiánk kiterjed a különböző kutatási szintek és alkalmazások közötti komplex interakcióra. Az alapkutatásokat (elméleti megfontolások és in-silico modellek) a laboratóriumi kísérletek követik in vitro és in vivo, preklinikai és utólagos klinikai publikációkkal. Minden lépés nemcsak a következő előrelépésekkel lép
- [Sammlung von experimentellen Publikationen](https://oncotherm.com/de/sammlung-von-experimentellen-publikationen/) - Sammlung von experimentellen Publikationen Oncotherm ist bestrebt, Studien durchzuführen und diese in der einschlägigen wissenschaftlichen und medizinischen Literatur zu veröffentlichen. Unsere Philosophie beinhaltet eine komplexe Interaktion zwischen den verschiedenen Ebenen der Forschung und Anwendung. Der Grundlagenforschung (theoretische Überlegungen und in-silico-Studien) folgen Laborexperimente in vitro und in vivo, ergänzt durch präklinische und klinische Studien. Alle Schritte
- [Newsletter abonnieren](https://oncotherm.com/de/newsletter-abonnieren/) - Newsletter abonnieren Wenn Sie unseren monatlichen Newsletter mit den neuesten Nachrichten erhalten möchten, melden Sie sich bitte unten an. Arbeitsgebiet- Keine -DoktorKrankenschwester /-pflegerService MitarbeiterMarketing MitarbeiterBüro- und VerwaltungPatientSonstige Ich akzeptiere die Bestimmungen und Bedingungen der Datenschutzerklärung. Please leave this field empty.
- [Projects financed by the Hungarian National Research, Development and Innovation Office](https://oncotherm.com/de/projects-financed-by-the-hungarian-national-research-development-and-innovation-office/) - Projects financed by the Hungarian National Research, Development and Innovation Office Improving the efficiency of the electromagnetic tumour therapy device and the preparation for its integration into commercial use Beneficiary Name: Oncotherm Kft. and Semmelweis University Title of the project: „Improving the efficiency of the electromagnetic tumour therapy device and the preparation for its integration
- [EHY-2030](https://oncotherm.com/de/ehy-2030/) - EHY-2030 LabEHY EHY-2030 Loko-regionale modulierte Elektro-Hyperthermie (mEHT)-Gerät Das Gerät EHY-2030 ist für die adjuvante Behandlung von Glioblastomen in Kombination mit Chemo- und/oder Strahlentherapie vorgesehen. Das neu konzipierte Gerät umfasst das Smart Electrode System und das integrierte Patientenmanagementsystem (PMS) sowie ein benutzerfreundliches Touchscreen-Display mit vollständiger Systemsteuerung. Der neue HF-Generator mit Impulsmodus und erhöhter Spitzenleistung wurde mit
- [FAQ für Distributoren](https://oncotherm.com/de/faq-fur-distributoren/) - FAQ für Distributoren Ich möchte Vertriebspartner werden. Was ist der erste Schritt? Um die beste Form der Zusammenarbeit vorzuschlagen, wenden Sie sich bitte an unser Büro: HU-2040 Budaörs, Gyár u. 2. Tel.: +36 23 555510 info@oncotherm.org Wer kann Vertriebspartner werden? Die Distributoren werden von uns sorgfältig ausgewählt. Unsere Distributoren und Händler müssen zeigen, dass sie
- [FAQ für Fachleute](https://oncotherm.com/de/faq-fur-fachleute/) - FAQ für Fachleute Wie kann ich ein Gerät bestellen? Geräte können direkt bei der Oncotherm-Zentrale in Deutschland oder Ungarn bestellt werden, oder bei einem zuständigen Distributor bzw. Handelsvertreter. Wie hoch ist der Preis von einem Gerät? Kontaktieren Sie bitte unsere Zentrale für Informationen. Oncotherm Kft. HU-2040 Budaörs, Gyár u. 2. Tel.: +36 23 555510 info@oncotherm.org
- [Partnerek](https://oncotherm.com/hu/partnerek/) - GYIK BETEGEKNEK Hol érhetőek el a kezelések? A weboldalunkon a Klinikáknál találhat egy listát a kezelőhelyekről: Oncothermia klinikák Ezen felül irodáinkon keresztül is szívesen megadjuk az Önhöz legközelebb található klinika elérhetőségeit. Általánosan használt kezelés-e az Oncothermia? Igen, egyre inkább ismert kezelési módszernek számít. A jelentősebb, kiegészítő onkológiás terápiákról szóló konferenciák jelentős részén az Oncothermia módszerei, eredményei előadások
- [EHY-2030](https://oncotherm.com/ehy-2030/) - EHY-2030 LabEHY EHY-2030 Loco-regional modulated electro-hyperthermia (mEHT) device The EHY-2030 device is intended for the adjuvant treatment of glioblastoma in a combination regimen with chemotherapy and/or radiation therapy. The newly designed device includes the Smart Electrode system and the integrated Patient Management System (PMS) and a user-friendly touch screen display with full system control. The
- [Kérdések és válaszok Szakembereknek](https://oncotherm.com/hu/kerdesek-es-valaszok-szakembereknek/) - Kérdések és válaszok Szakembereknek Hol vásárolhatom meg a készülékeket? A készülék elsődleges értékesítője az SCA Medical Trading Kft., azonban a készülékek megrendelhetőek közvetlenül a Oncotherm Kft. budaörsi központjától, amelynek elérhetőségei: Kapcsolat: Magyarország, 2040 Budaörs, Gyár utca 2. Telefon: +36 23 555510 info@oncotherm.org Mennyibe kerülnek a készülékek? Kérjük, hogy árajánlatkérésével forduljon a központi irodánkhoz, vagy keresse
- [FAQ Professional](https://oncotherm.com/faq-professional/) - FAQ Professional How can I order the device? The device can be ordered directly from the Oncotherm headquarter in Hungary or depending on your location from the responsible distributor. What is the price of the device? Please contact our headquarter office or the responsible distributor what is depend on your location. Oncotherm Kft. HU-2040 Budaörs,
- [LabEHY](https://oncotherm.com/labehy/) - EHY-2030 LabEHY LabEHY An electro-hyperthermic device specially developed for research purposes The LabEHY device was developed to perform various types of cell line (in vitro) and small animal (in vivo) experiments using the oncothermia (mEHT) method, which is used for the non-invasive treatment of malignant tissues. The difference between the complex dielectric constant (complex impedance)
- [Projects financed by the Hungarian National Research, Development and Innovation Office](https://oncotherm.com/projects-financed-by-the-hungarian-national-research-development-and-innovation-office/) - Projects financed by the Hungarian National Research, Development and Innovation Office Improving the efficiency of the electromagnetic tumour therapy device and the preparation for its integration into commercial use Beneficiary Name: Oncotherm Kft. and Semmelweis University Title of the project: „Improving the efficiency of the electromagnetic tumour therapy device and the preparation for its integration
- [Kérdések és válaszok Betegeknek](https://oncotherm.com/hu/kerdesek-es-valaszok-betegeknek/) - Kérdések és válaszok Betegeknek Hol érhetőek el a kezelések? A weboldalunkon a Klinikáknál találhat egy listát a kezelőhelyekről: Oncothermia klinikák Ezen felül irodáinkon keresztül is szívesen megadjuk az Önhöz legközelebb található klinika elérhetőségeit. Általánosan használt kezelés-e az Oncothermia? Igen, egyre inkább ismert kezelési módszernek számít. A jelentősebb, kiegészítő onkológiás terápiákról szóló konferenciák jelentős részén az Oncothermia
- [Kérdések és válaszok Disztribútoroknak](https://oncotherm.com/hu/kerdesek-es-valaszok-disztributoroknak/) - Kérdések és válaszok Disztribútoroknak Szeretnék a cég disztribútora lenni, mi az első lépés ehhez? A legjobb együttműködési forma megtalálásához kérjük vegye fel a kapcsolatot központi irodánkkal az alábbi elérhetőségek egyikén: Kapcsolat: Magyarország, 2040 Budaörs, Gyár utca 2. Telefon: +36 23 555510 info@oncotherm.org Ki lehet kereskedelmi partner? Viszonteladóinkat nagy körültekintéssel választjuk ki. Forgalmazóinknak nemcsak színvonalasan kell
- [FAQ Patient](https://oncotherm.com/faq-patient/) - FAQ Patient Where can I find places where the treatment is provided? Our website lists the Oncothermia users and their contact details for your convenience. You can also request a list from our office. Is Oncothermia a common treatment? "Yes, since it is becoming more and more known. Most of the conferences held in the
- [FAQ Distributor](https://oncotherm.com/faq-distributor/) - FAQ Distributor I would like to become a distributor. What is the first step? For suggesting the best form of cooperation please contact our office: HU-2040 Budaörs, Gyár u. 2. Tel.: +36 23 555510 info@oncotherm.org Who can become a distributor, dealer? The distributors are caerfully chosen by us. Our distributors and dealers have to show,
- [Hírlevél feliratkozás](https://oncotherm.com/hu/hirlevel-feliratkozas/) - HÍrlevél feliratkozás Ha szeretne értesülni legújabb híreinkről, kérjük iratkozzon fel havonta megjelenő hírlevelünkre. Munkakör- Nincs -orvosápolószervízmarketingtitkárságbetegegyéb Az adatvédelmi szabályzat feltételeit megismertem, megértettem és elfogadom. Please leave this field empty.
- [Sign up for newsletter](https://oncotherm.com/sign-up-for-newsletter/) - Sign up for newsletter If you want to receive our monthly Newsletter about the latest news, please sign up below. Working area- None -DoctorNurseService personMarketing personSecretaryPatientOther I accept the terms and conditions of the privacy policy. Please leave this field empty.

## Oncothermia Journal

- [Volume 37](https://oncotherm.com/hu/oncothermia-journal/volume-37/)
- [Volume 37](https://oncotherm.com/de/oncothermia-journal/volume-37/)
- [Volume 37](https://oncotherm.com/oncothermia-journal/volume-37/)
- [Volume 36](https://oncotherm.com/oncothermia-journal/volume-36/)
- [Volume 35](https://oncotherm.com/oncothermia-journal/volume-35/)
- [Volume 33](https://oncotherm.com/de/oncothermia-journal/volume-33/)
- [Volume 33](https://oncotherm.com/oncothermia-journal/volume-33/)
- [Volume 33](https://oncotherm.com/hu/oncothermia-journal/volume-33/)
- [Volume 34](https://oncotherm.com/oncothermia-journal/volume-34/)
- [Volume 34](https://oncotherm.com/hu/oncothermia-journal/volume-34/)
- [Volume 34](https://oncotherm.com/de/oncothermia-journal/volume-34/)
- [Volume 18](https://oncotherm.com/hu/oncothermia-journal/volume-18/)
- [Volume 18](https://oncotherm.com/oncothermia-journal/volume-18/)
- [Volume 18](https://oncotherm.com/de/oncothermia-journal/volume-18/)
- [Volume 17](https://oncotherm.com/hu/oncothermia-journal/volume-17/)
- [Volume 17](https://oncotherm.com/oncothermia-journal/volume-17/)
- [Volume 17](https://oncotherm.com/de/oncothermia-journal/volume-17/)
- [Volume 16](https://oncotherm.com/hu/oncothermia-journal/volume-16/)
- [Volume 16](https://oncotherm.com/oncothermia-journal/volume-16/)
- [Volume 16](https://oncotherm.com/de/oncothermia-journal/volume-16/)
- [Volume 15](https://oncotherm.com/hu/oncothermia-journal/volume-15/)
- [Volume 15](https://oncotherm.com/oncothermia-journal/volume-15/)
- [Volume 15](https://oncotherm.com/de/oncothermia-journal/volume-15/)
- [Volume 14](https://oncotherm.com/hu/oncothermia-journal/volume-14/)
- [Volume 14](https://oncotherm.com/oncothermia-journal/volume-14/)
- [Volume 14](https://oncotherm.com/de/oncothermia-journal/volume-14/)
- [Volume 13](https://oncotherm.com/hu/oncothermia-journal/volume-13/)
- [Volume 13](https://oncotherm.com/oncothermia-journal/volume-13/)
- [Volume 13](https://oncotherm.com/de/oncothermia-journal/volume-13/)
- [Volume 12](https://oncotherm.com/hu/oncothermia-journal/volume-12/)
- [Volume 12](https://oncotherm.com/oncothermia-journal/volume-12/)
- [Volume 12](https://oncotherm.com/de/oncothermia-journal/volume-12/)
- [Volume 11](https://oncotherm.com/hu/oncothermia-journal/volume-11/)
- [Volume 11](https://oncotherm.com/oncothermia-journal/volume-11/)
- [Volume 11](https://oncotherm.com/de/oncothermia-journal/volume-11/)
- [Volume 10](https://oncotherm.com/hu/oncothermia-journal/volume-10/)
- [Volume 10](https://oncotherm.com/oncothermia-journal/volume-10/)
- [Volume 10](https://oncotherm.com/de/oncothermia-journal/volume-10/)
- [Volume 9](https://oncotherm.com/hu/oncothermia-journal/volume-9/)
- [Volume 9](https://oncotherm.com/oncothermia-journal/volume-9/)
- [Volume 9](https://oncotherm.com/de/oncothermia-journal/volume-9/)
- [Volume 8](https://oncotherm.com/hu/oncothermia-journal/volume-8/)
- [Volume 8](https://oncotherm.com/oncothermia-journal/volume-8/)
- [Volume 8](https://oncotherm.com/de/oncothermia-journal/volume-8/)
- [Volume 7](https://oncotherm.com/hu/oncothermia-journal/volume-7/)
- [Volume 7](https://oncotherm.com/oncothermia-journal/volume-7/)
- [Volume 7](https://oncotherm.com/de/oncothermia-journal/volume-7/)
- [Volume 4](https://oncotherm.com/hu/oncothermia-journal/volume-4/)
- [Volume 4](https://oncotherm.com/oncothermia-journal/volume-4/)
- [Volume 4](https://oncotherm.com/de/oncothermia-journal/volume-4/)
- [Volume 6](https://oncotherm.com/hu/oncothermia-journal/volume-6/)
- [Volume 6](https://oncotherm.com/oncothermia-journal/volume-6/)
- [Volume 6](https://oncotherm.com/de/oncothermia-journal/volume-6/)
- [Volume 5](https://oncotherm.com/hu/oncothermia-journal/volume-5/)
- [Volume 5](https://oncotherm.com/oncothermia-journal/volume-5-2/)
- [Volume 5](https://oncotherm.com/de/oncothermia-journal/volume-5-2/)
- [Volume 1](https://oncotherm.com/hu/oncothermia-journal/volume-1/)
- [Volume 1](https://oncotherm.com/oncothermia-journal/volume-1/)
- [Volume 1](https://oncotherm.com/de/oncothermia-journal/volume-1/)
- [Volume 2](https://oncotherm.com/hu/oncothermia-journal/volume-2/)
- [Volume 2](https://oncotherm.com/oncothermia-journal/volume-2/)
- [Volume 2](https://oncotherm.com/de/oncothermia-journal/volume-2/)
- [Volume 3](https://oncotherm.com/hu/oncothermia-journal/volume-3/)
- [Volume 3](https://oncotherm.com/oncothermia-journal/volume-3/)
- [Volume 3](https://oncotherm.com/de/oncothermia-journal/volume-3/)
- [Volume 19](https://oncotherm.com/hu/oncothermia-journal/volume-19/)
- [Volume 19](https://oncotherm.com/oncothermia-journal/volume-19/)
- [Volume 19](https://oncotherm.com/de/oncothermia-journal/volume-19/)
- [Volume 20](https://oncotherm.com/hu/oncothermia-journal/volume-20/)
- [Volume 20](https://oncotherm.com/oncothermia-journal/volume-20/)
- [Volume 20](https://oncotherm.com/de/oncothermia-journal/volume-20/)
- [Volume 21](https://oncotherm.com/hu/oncothermia-journal/volume-21/)
- [Volume 21](https://oncotherm.com/oncothermia-journal/volume-21/)
- [Volume 21](https://oncotherm.com/de/oncothermia-journal/volume-21/)
- [Volume 22](https://oncotherm.com/hu/oncothermia-journal/volume-22/)
- [Volume 22](https://oncotherm.com/oncothermia-journal/volume-22/)
- [Volume 22](https://oncotherm.com/de/oncothermia-journal/volume-22/)
- [Volume 23](https://oncotherm.com/hu/oncothermia-journal/volume-23/)
- [Volume 23](https://oncotherm.com/oncothermia-journal/volume-23/)
- [Volume 23](https://oncotherm.com/de/oncothermia-journal/volume-23/)
- [Volume 24](https://oncotherm.com/hu/oncothermia-journal/volume-24/)
- [Volume 24](https://oncotherm.com/oncothermia-journal/volume-24/)
- [Volume 24](https://oncotherm.com/de/oncothermia-journal/volume-24/)
- [Volume 25](https://oncotherm.com/hu/oncothermia-journal/volume-25/)
- [Volume 25](https://oncotherm.com/oncothermia-journal/volume-25/)
- [Volume 25](https://oncotherm.com/de/oncothermia-journal/volume-25/)
- [Volume 26](https://oncotherm.com/hu/oncothermia-journal/volume-26/)
- [Volume 26](https://oncotherm.com/oncothermia-journal/volume-26/)
- [Volume 26](https://oncotherm.com/de/oncothermia-journal/volume-26/)
- [Volume 27](https://oncotherm.com/hu/oncothermia-journal/oncothermia-journal-volume-27/)
- [Volume 27](https://oncotherm.com/oncothermia-journal/oncothermia-journal-volume-27/)
- [Volume 27](https://oncotherm.com/de/oncothermia-journal/oncothermia-journal-volume-27/)
- [Volume 28](https://oncotherm.com/hu/oncothermia-journal/volume-28/)
- [Volume 28](https://oncotherm.com/oncothermia-journal/volume-28/)
- [Volume 28](https://oncotherm.com/de/oncothermia-journal/volume-28/)
- [Volume 29](https://oncotherm.com/hu/oncothermia-journal/volume-29/)
- [Volume 29](https://oncotherm.com/oncothermia-journal/volume-29/)
- [Volume 29](https://oncotherm.com/de/oncothermia-journal/volume-29/)
- [Volume 30](https://oncotherm.com/hu/oncothermia-journal/volume-30/)
- [Volume 30](https://oncotherm.com/oncothermia-journal/volume-30/)
- [Volume 30](https://oncotherm.com/de/oncothermia-journal/volume-30/)
- [Volume 31](https://oncotherm.com/hu/oncothermia-journal/volume-31/)
- [Volume 31](https://oncotherm.com/oncothermia-journal/volume-31/)
- [Volume 31](https://oncotherm.com/de/oncothermia-journal/volume-31/)
- [Volume 32](https://oncotherm.com/hu/oncothermia-journal/volume-32/)
- [Volume 32](https://oncotherm.com/oncothermia-journal/volume-32/)
- [Volume 32](https://oncotherm.com/de/oncothermia-journal/volume-32/)

## Térképek

- [Sanctura Centre](https://oncotherm.com/maps/sanctura-centre/)
- [Sanctura Centre](https://oncotherm.com/hu/terkepek/sanctura-centre/)
- [Sanctura Centre](https://oncotherm.com/de/karte/sanctura-centre/)
- [Oncotherm Ireland](https://oncotherm.com/maps/oncotherm-ireland/)
- [Oncotherm Ireland](https://oncotherm.com/hu/terkepek/oncotherm-ireland/)
- [Oncotherm Ireland](https://oncotherm.com/de/karte/oncotherm-ireland/)
- [A. Zarate General Hospital](https://oncotherm.com/maps/a-zarate-general-hospital/)
- [A. Zarate General Hospital](https://oncotherm.com/hu/terkepek/a-zarate-general-hospital/)
- [A. Zarate General Hospital](https://oncotherm.com/de/karte/a-zarate-general-hospital/)
- [Cancer Specialist Clinic](https://oncotherm.com/maps/cancer-specialist-clinic/)
- [Cancer Specialist Clinic](https://oncotherm.com/hu/terkepek/cancer-specialist-clinic/)
- [Cancer Specialist Clinic](https://oncotherm.com/de/karte/cancer-specialist-clinic/)
- [Lebanese German Oncothermia](https://oncotherm.com/maps/lebanese-german-oncothermia/)
- [Lebanese German Oncothermia](https://oncotherm.com/de/karte/lebanese-german-oncothermia/)
- [Lebanese German Oncothermia](https://oncotherm.com/hu/terkepek/lebanese-german-oncothermia/)
- [Synthesis Clinic](https://oncotherm.com/maps/synthesis-clinic/)
- [Synthesis Clinic](https://oncotherm.com/hu/terkepek/synthesis-clinic/)
- [Synthesis Clinic](https://oncotherm.com/de/karte/synthesis-clinic/)
- [Oncotherm MENA](https://oncotherm.com/maps/oncotherm-mena/)
- [Oncotherm MENA](https://oncotherm.com/hu/terkepek/oncotherm-mena/)
- [Oncotherm MENA](https://oncotherm.com/de/karte/oncotherm-mena/)
- [Marqués de Valdecilla University Hospital](https://oncotherm.com/maps/marques-de-valdecilla-university-hospital/)
- [Marqués de Valdecilla University Hospital](https://oncotherm.com/de/karte/marques-de-valdecilla-university-hospital/)
- [Marqués de Valdecilla University Hospital](https://oncotherm.com/hu/terkepek/marques-de-valdecilla-university-hospital/)
- [Charité – Universitätsmedizin Berlin](https://oncotherm.com/hu/terkepek/charite-universitatsmedizin-berlin/)
- [Charité – Universitätsmedizin Berlin](https://oncotherm.com/maps/charite-universitatsmedizin-berlin/)
- [Charité – Universitätsmedizin Berlin](https://oncotherm.com/de/karte/charite-universitatsmedizin-berlin/)
- [Integrative Oncology, IHF Outpatient Clinic](https://oncotherm.com/hu/terkepek/integrative-oncology-ihf-outpatient-clinic/)
- [Integrative Oncology, IHF Outpatient Clinic](https://oncotherm.com/maps/integrative-oncology-ihf-outpatient-clinic/)
- [Integrative Oncology, IHF Outpatient Clinic](https://oncotherm.com/de/karte/integrative-oncology-ihf-outpatient-clinic/)
- [Dr James Laporta Institute – Hyperthermia Clinics International](https://oncotherm.com/maps/dr-james-laporta-institute-hyperthermia-clinics-international/)
- [Dr James Laporta Institute – Hyperthermia Clinics International](https://oncotherm.com/hu/terkepek/dr-james-laporta-institute-hyperthermia-clinics-international/)
- [Dr James Laporta Institute – Hyperthermia Clinics International](https://oncotherm.com/de/karte/dr-james-laporta-institute-hyperthermia-clinics-international/)
- [Biotherapy International](https://oncotherm.com/hu/terkepek/biotherapy-international/)
- [Biotherapy International](https://oncotherm.com/maps/biotherapy-international/)
- [Biotherapy International](https://oncotherm.com/de/karte/biotherapy-international/)
- [Oncotherm Kft.](https://oncotherm.com/maps/oncotherm-kft/)
- [Oncotherm Kft.](https://oncotherm.com/de/karte/oncotherm-kft/)
- [Oncotherm GmbH](https://oncotherm.com/maps/oncotherm-gmbh/)
- [Oncotherm GmbH](https://oncotherm.com/de/karte/oncotherm-gmbh/)
- [Life1 Corporation](https://oncotherm.com/maps/life1-corporation/)
- [Life1 Corporation](https://oncotherm.com/hu/terkepek/life1-corporation/)
- [Life1 Corporation](https://oncotherm.com/de/karte/life1-corporation/)
- [Spedali Civili di Brescia](https://oncotherm.com/maps/spedali-civili-di-brescia/)
- [Spedali Civili di Brescia](https://oncotherm.com/de/karte/spedali-civili-di-brescia/)
- [Tagesklinik Erzgesund](https://oncotherm.com/maps/tagesklinik-erzgesund/)
- [Tagesklinik Erzgesund](https://oncotherm.com/de/karte/tagesklinik-erzgesund/)
- [Tsukiji Clinic COSMOS](https://oncotherm.com/maps/tsukiji-clinic-cosmos/)
- [Tsukiji Clinic COSMOS](https://oncotherm.com/de/karte/tsukiji-clinic-cosmos/)
- [Stichting Hyperthermie / Baron G.A.](https://oncotherm.com/maps/stichting-hyperthermie-baron-g-a/)
- [Stichting Hyperthermie / Baron G.A.](https://oncotherm.com/de/karte/stichting-hyperthermie-baron-g-a/)
- [Singal Baekse Hospital](https://oncotherm.com/maps/singal-baekse-hospital/)
- [Singal Baekse Hospital](https://oncotherm.com/de/karte/singal-baekse-hospital/)
- [Singyeongju Hospital](https://oncotherm.com/maps/singyeongju-hospital/)
- [Singyeongju Hospital](https://oncotherm.com/de/karte/singyeongju-hospital/)
- [Russian Scientific Center of Roengenology and Radiology (RSCRR)](https://oncotherm.com/maps/russian-scientific-center-of-roengenology-and-radiology-rscrr/)
- [Russian Scientific Center of Roengenology and Radiology (RSCRR)](https://oncotherm.com/de/karte/russian-scientific-center-of-roengenology-and-radiology-rscrr/)
- [Zhongmei Hospital](https://oncotherm.com/maps/zhongmei-hospital/)
- [Zhongmei Hospital](https://oncotherm.com/de/karte/zhongmei-hospital/)
- [Zentrum für Naturheilverfahren Dr. Hartung](https://oncotherm.com/maps/zentrum-fur-naturheilverfahren-dr-hartung/)
- [Zentrum für Naturheilverfahren Dr. Hartung](https://oncotherm.com/de/karte/zentrum-fur-naturheilverfahren-dr-hartung/)
- [Hospi Care Co. Ltd.](https://oncotherm.com/hu/terkepek/hospi-care-co-ltd/)
- [Bionext Systems Pte. Ltd.](https://oncotherm.com/hu/terkepek/bionext-systems-pte-ltd/)
- [TEK GRUP Saglik Hizmetleri A.S.](https://oncotherm.com/hu/terkepek/tek-grup-saglik-hizmetleri-a-s/)
- [TEK GRUP Saglik Hizmetleri A.S.](https://oncotherm.com/maps/tek-grup-saglik-hizmetleri-a-s/)
- [TEK GRUP Saglik Hizmetleri A.S.](https://oncotherm.com/de/karte/tek-grup-saglik-hizmetleri-a-s/)
- [Bionext Systems Pte. Ltd.](https://oncotherm.com/maps/bionext-systems-pte-ltd/)
- [Bionext Systems Pte. Ltd.](https://oncotherm.com/de/karte/bionext-systems-pte-ltd/)
- [Hospi Care Co. Ltd.](https://oncotherm.com/maps/hospi-care-co-ltd/)
- [Hospi Care Co. Ltd.](https://oncotherm.com/de/karte/hospi-care-co-ltd/)
- [Oncotherm GmbH](https://oncotherm.com/hu/terkepek/oncotherm-gmbh/)
- [CORIS MEDICA SRL](https://oncotherm.com/hu/terkepek/coris-medica-srl/)
- [Ascendio Praxis SRL](https://oncotherm.com/hu/terkepek/ascendio-praxis-srl/)
- [Instituto Médico De Oncología Avanzada INMOA](https://oncotherm.com/hu/terkepek/instituto-medico-de-oncologia-avanzada-inmoa/)
- [Ewha Womans University Cancer Center](https://oncotherm.com/hu/terkepek/ewha-womans-university-cancer-center/)
- [Keimyung University](https://oncotherm.com/hu/terkepek/keimyung-university/)
- [Yonsei University Medical Center](https://oncotherm.com/hu/terkepek/yonsei-university-medical-center/)
- [Handong Global University](https://oncotherm.com/hu/terkepek/handong-global-university/)
- [University of Maryland](https://oncotherm.com/hu/terkepek/university-of-maryland/)
- [University of Pittsburgh](https://oncotherm.com/hu/terkepek/university-of-pittsburgh/)
- [London Immunotherapy, The London Welbeck Hospital](https://oncotherm.com/hu/terkepek/london-immunotherapy-the-london-welbeck-hospital/)
- [Keimyung University](https://oncotherm.com/maps/keimyung-university/)
- [Keimyung University](https://oncotherm.com/de/karte/keimyung-university/)
- [Handong Global University](https://oncotherm.com/maps/handong-global-university/)
- [Handong Global University](https://oncotherm.com/de/karte/handong-global-university/)
- [Yonsei University Medical Center](https://oncotherm.com/maps/yonsei-university-medical-center/)
- [Yonsei University Medical Center](https://oncotherm.com/de/karte/yonsei-university-medical-center/)
- [University of Maryland](https://oncotherm.com/maps/university-of-maryland/)
- [University of Maryland](https://oncotherm.com/de/karte/university-of-maryland/)
- [University of Pittsburgh](https://oncotherm.com/maps/university-of-pittsburgh/)
- [University of Pittsburgh](https://oncotherm.com/de/karte/university-of-pittsburgh/)
- [London Immunotherapy, The London Welbeck Hospital](https://oncotherm.com/maps/london-immunotherapy-the-london-welbeck-hospital/)
- [London Immunotherapy, The London Welbeck Hospital](https://oncotherm.com/de/karte/london-immunotherapy-the-london-welbeck-hospital/)
- [Ewha Womans University Cancer Center](https://oncotherm.com/maps/ewha-womans-university-cancer-center/)
- [Ewha Womans University Cancer Center](https://oncotherm.com/de/karte/ewha-womans-university-cancer-center/)
- [Instituto Médico De Oncología Avanzada INMOA](https://oncotherm.com/maps/instituto-medico-de-oncologia-avanzada-inmoa/)
- [Instituto Médico De Oncología Avanzada INMOA](https://oncotherm.com/de/karte/instituto-medico-de-oncologia-avanzada-inmoa/)
- [Ascendio Praxis SRL](https://oncotherm.com/maps/ascendio-praxis-srl/)
- [Ascendio Praxis SRL](https://oncotherm.com/de/karte/ascendio-praxis-srl/)
- [CORIS MEDICA SRL](https://oncotherm.com/maps/coris-medica-srl/)
- [CORIS MEDICA SRL](https://oncotherm.com/de/karte/coris-medica-srl/)
- [University of the Witwatersrand](https://oncotherm.com/hu/terkepek/university-of-the-witwatersrand/)
- [Korea Institute of Radiological & Medical Sciences](https://oncotherm.com/hu/terkepek/korea-institute-of-radiological-medical-sciences/)
- [CHA University](https://oncotherm.com/hu/terkepek/cha-university/)
- [Chonbuk National University Hospital](https://oncotherm.com/hu/terkepek/chonbuk-national-university-hospital/)
- [Korea University of Science and Technology](https://oncotherm.com/hu/terkepek/korea-university-of-science-and-technology/)
- [Seoul National University](https://oncotherm.com/hu/terkepek/seoul-national-university/)
- [Arcadia Praxisklinik](https://oncotherm.com/hu/terkepek/arcadia-praxisklinik/)
- [Arichae Hospital](https://oncotherm.com/hu/terkepek/arichae-hospital/)
- [ARTOI - Associazione Ricerca Terapie Oncologiche Integrate](https://oncotherm.com/hu/terkepek/artoi-associazione-ricerca-terapie-oncologiche-integrate/)
- [Artsenpraktijk Duchateau Jean-Marie](https://oncotherm.com/hu/terkepek/artsenpraktijk-duchateau-jean-marie/)
- [Baek Hospital](https://oncotherm.com/hu/terkepek/baek-hospital/)
- [BioMed-Klinik Betriebs GmbH](https://oncotherm.com/hu/terkepek/biomed-klinik-betriebs-gmbh/)
- [Artsenpraktijk Duchateau Jean-Marie](https://oncotherm.com/maps/artsenpraktijk-duchateau-jean-marie/)
- [Artsenpraktijk Duchateau Jean-Marie](https://oncotherm.com/de/karte/artsenpraktijk-duchateau-jean-marie/)
- [ARTOI - Associazione Ricerca Terapie Oncologiche Integrate](https://oncotherm.com/maps/artoi-associazione-ricerca-terapie-oncologiche-integrate/)
- [ARTOI - Associazione Ricerca Terapie Oncologiche Integrate](https://oncotherm.com/de/karte/artoi-associazione-ricerca-terapie-oncologiche-integrate/)
- [Arichae Hospital](https://oncotherm.com/maps/arichae-hospital/)
- [Arichae Hospital](https://oncotherm.com/de/karte/arichae-hospital/)
- [Arcadia Praxisklinik](https://oncotherm.com/maps/arcadia-praxisklinik/)
- [Arcadia Praxisklinik](https://oncotherm.com/de/karte/arcadia-praxisklinik/)
- [BioMed-Klinik Betriebs GmbH](https://oncotherm.com/maps/biomed-klinik-betriebs-gmbh/)
- [BioMed-Klinik Betriebs GmbH](https://oncotherm.com/de/karte/biomed-klinik-betriebs-gmbh/)
- [Baek Hospital](https://oncotherm.com/maps/baek-hospital/)
- [Baek Hospital](https://oncotherm.com/de/karte/baek-hospital/)
- [University of the Witwatersrand](https://oncotherm.com/maps/university-of-the-witwatersrand/)
- [University of the Witwatersrand](https://oncotherm.com/de/karte/university-of-the-witwatersrand/)
- [Chonbuk National University Hospital](https://oncotherm.com/maps/chonbuk-national-university-hospital/)
- [Chonbuk National University Hospital](https://oncotherm.com/de/karte/chonbuk-national-university-hospital/)
- [CHA University](https://oncotherm.com/maps/cha-university/)
- [CHA University](https://oncotherm.com/de/karte/cha-university/)
- [Korea University of Science and Technology](https://oncotherm.com/maps/korea-university-of-science-and-technology/)
- [Korea University of Science and Technology](https://oncotherm.com/de/karte/korea-university-of-science-and-technology/)
- [Seoul National University](https://oncotherm.com/maps/seoul-national-university/)
- [Seoul National University](https://oncotherm.com/de/karte/seoul-national-university/)
- [Korea Institute of Radiological & Medical Sciences](https://oncotherm.com/maps/korea-institute-of-radiological-medical-sciences/)
- [Korea Institute of Radiological & Medical Sciences](https://oncotherm.com/de/karte/korea-institute-of-radiological-medical-sciences/)
- [AnthroMed Berlin-Brandenburg GmbH](https://oncotherm.com/hu/terkepek/anthromed-berlin-brandenburg-gmbh/)
- [Australian Clinic of Biological Medicine](https://oncotherm.com/hu/terkepek/australian-clinic-of-biological-medicine/)
- [Azienda Ospedaliera Marche Nord - Department of Oncology- Hematology](https://oncotherm.com/hu/terkepek/azienda-ospedaliera-marche-nord-department-of-oncology-hematology/)
- [Oncotherm Kft.](https://oncotherm.com/hu/terkepek/oncotherm-kft/)
- [Shenzhen Plan Medical Technology Development Co., Ltd](https://oncotherm.com/hu/terkepek/shenzhen-plan-medical-technology-development-co-ltd/)
- [Szent István University](https://oncotherm.com/hu/terkepek/szent-istvan-university/)
- [University of Pécs](https://oncotherm.com/hu/terkepek/university-of-pecs/)
- [1st Department of Pathology and Experimental Cancer Research-Semmelweis University](https://oncotherm.com/hu/terkepek/1st-department-of-pathology-and-experimental-cancer-research-semmelweis-university/)
- [University of Szeged](https://oncotherm.com/hu/terkepek/university-of-szeged/)
- [Institute of Clinical Experimental Research-Semmelweis University](https://oncotherm.com/hu/terkepek/institute-of-clinical-experimental-research-semmelweis-university/)
- [Department of Biophysics and Radiation Biology-Semmelweis University](https://oncotherm.com/hu/terkepek/department-of-biophysics-and-radiation-biology-semmelweis-university/)
- [Department of Oncology -Semmelweis University](https://oncotherm.com/hu/terkepek/department-of-oncology-semmelweis-university/)
- [Department of Oncology -Semmelweis University](https://oncotherm.com/maps/department-of-oncology-semmelweis-university/)
- [Department of Oncology -Semmelweis University](https://oncotherm.com/de/karte/department-of-oncology-semmelweis-university/)
- [Department of Biophysics and Radiation Biology-Semmelweis University](https://oncotherm.com/maps/department-of-biophysics-and-radiation-biology-semmelweis-university/)
- [Department of Biophysics and Radiation Biology-Semmelweis University](https://oncotherm.com/de/karte/department-of-biophysics-and-radiation-biology-semmelweis-university/)
- [Institute of Clinical Experimental Research-Semmelweis University](https://oncotherm.com/maps/institute-of-clinical-experimental-research-semmelweis-university/)
- [Institute of Clinical Experimental Research-Semmelweis University](https://oncotherm.com/de/karte/institute-of-clinical-experimental-research-semmelweis-university/)
- [University of Szeged](https://oncotherm.com/maps/university-of-szeged/)
- [University of Szeged](https://oncotherm.com/de/karte/university-of-szeged/)
- [1st Department of Pathology and Experimental Cancer Research-Semmelweis University](https://oncotherm.com/maps/1st-department-of-pathology-and-experimental-cancer-research-semmelweis-university/)
- [1st Department of Pathology and Experimental Cancer Research-Semmelweis University](https://oncotherm.com/de/karte/1st-department-of-pathology-and-experimental-cancer-research-semmelweis-university/)
- [University of Pécs](https://oncotherm.com/maps/university-of-pecs/)
- [University of Pécs](https://oncotherm.com/de/karte/university-of-pecs/)
- [Szent István University](https://oncotherm.com/maps/szent-istvan-university/)
- [Szent István University](https://oncotherm.com/de/karte/szent-istvan-university/)
- [Shenzhen Plan Medical Technology Development Co., Ltd](https://oncotherm.com/maps/shenzhen-plan-medical-technology-development-co-ltd/)
- [Shenzhen Plan Medical Technology Development Co., Ltd](https://oncotherm.com/de/karte/shenzhen-plan-medical-technology-development-co-ltd/)
- [Azienda Ospedaliera Marche Nord - Department of Oncology- Hematology](https://oncotherm.com/maps/azienda-ospedaliera-marche-nord-department-of-oncology-hematology/)
- [Azienda Ospedaliera Marche Nord - Department of Oncology- Hematology](https://oncotherm.com/de/karte/azienda-ospedaliera-marche-nord-department-of-oncology-hematology/)
- [Australian Clinic of Biological Medicine](https://oncotherm.com/maps/australian-clinic-of-biological-medicine/)
- [Australian Clinic of Biological Medicine](https://oncotherm.com/de/karte/australian-clinic-of-biological-medicine/)
- [AnthroMed Berlin-Brandenburg GmbH](https://oncotherm.com/maps/anthromed-berlin-brandenburg-gmbh/)
- [AnthroMed Berlin-Brandenburg GmbH](https://oncotherm.com/de/karte/anthromed-berlin-brandenburg-gmbh/)
- [Azienda Ospedaliera Marche Nord - Department of Oncology- Hematology](https://oncotherm.com/hu/terkepek/azienda-ospedaliera-marche-nord-department-of-oncology-hematology-2/)
- [University of Toyama](https://oncotherm.com/hu/terkepek/university-of-toyama/)
- [University of Miyazaki](https://oncotherm.com/hu/terkepek/university-of-miyazaki/)
- [University of Tsukuba](https://oncotherm.com/hu/terkepek/university-of-tsukuba/)
- [Unidad Oncothermia Barcelona](https://oncotherm.com/hu/terkepek/unidad-oncothermia-barcelona/)
- [Chung Yuan Christian University](https://oncotherm.com/hu/terkepek/chung-yuan-christian-university/)
- [National Yang-Ming University](https://oncotherm.com/hu/terkepek/national-yang-ming-university/)
- [Fu Jen Catholic University](https://oncotherm.com/hu/terkepek/fu-jen-catholic-university/)
- [National Taiwan University](https://oncotherm.com/hu/terkepek/national-taiwan-university/)
- [Bundang CHA Hospital](https://oncotherm.com/hu/terkepek/bundang-cha-hospital/)
- [Bundang Jesaeng Hospital](https://oncotherm.com/hu/terkepek/bundang-jesaeng-hospital/)
- [Busan Adventist Hospital](https://oncotherm.com/hu/terkepek/busan-adventist-hospital/)
- [Busan Adventist Hospital](https://oncotherm.com/maps/busan-adventist-hospital/)
- [Busan Adventist Hospital](https://oncotherm.com/de/karte/busan-adventist-hospital/)
- [Bundang Jesaeng Hospital](https://oncotherm.com/maps/bundang-jesaeng-hospital/)
- [Bundang Jesaeng Hospital](https://oncotherm.com/de/karte/bundang-jesaeng-hospital/)
- [Bundang CHA Hospital](https://oncotherm.com/maps/bundang-cha-hospital/)
- [Bundang CHA Hospital](https://oncotherm.com/de/karte/bundang-cha-hospital/)
- [Fu Jen Catholic University](https://oncotherm.com/maps/fu-jen-catholic-university/)
- [Fu Jen Catholic University](https://oncotherm.com/de/karte/fu-jen-catholic-university/)
- [National Taiwan University](https://oncotherm.com/maps/national-taiwan-university/)
- [National Taiwan University](https://oncotherm.com/de/karte/national-taiwan-university/)
- [National Yang-Ming University](https://oncotherm.com/maps/national-yang-ming-university/)
- [National Yang-Ming University](https://oncotherm.com/de/karte/national-yang-ming-university/)
- [Chung Yuan Christian University](https://oncotherm.com/maps/chung-yuan-christian-university/)
- [Chung Yuan Christian University](https://oncotherm.com/de/karte/chung-yuan-christian-university/)
- [Unidad Oncothermia Barcelona](https://oncotherm.com/maps/unidad-oncothermia-barcelona/)
- [Unidad Oncothermia Barcelona](https://oncotherm.com/de/karte/unidad-oncothermia-barcelona/)
- [University of Tsukuba](https://oncotherm.com/maps/university-of-tsukuba/)
- [University of Tsukuba](https://oncotherm.com/de/karte/university-of-tsukuba/)
- [University of Miyazaki](https://oncotherm.com/maps/university-of-miyazaki/)
- [University of Miyazaki](https://oncotherm.com/de/karte/university-of-miyazaki/)
- [University of Toyama](https://oncotherm.com/maps/university-of-toyama/)
- [University of Toyama](https://oncotherm.com/de/karte/university-of-toyama/)
- [Azienda Ospedaliera Marche Nord - Department of Oncology- Hematology](https://oncotherm.com/maps/azienda-ospedaliera-marche-nord-department-of-oncology-hematology-2/)
- [Azienda Ospedaliera Marche Nord - Department of Oncology- Hematology](https://oncotherm.com/de/karte/azienda-ospedaliera-marche-nord-department-of-oncology-hematology-2/)
- [Catholic Kwandong University International St. Mary’s Hospital](https://oncotherm.com/hu/terkepek/catholic-kwandong-university-international-st-marys-hospital/)
- [CelluMed High Clinic](https://oncotherm.com/hu/terkepek/cellumed-high-clinic/)
- [Center of Medical Oncology/Euroclinic Dr. Volovat](https://oncotherm.com/hu/terkepek/center-of-medical-oncology-euroclinic-dr-volovat/)
- [Central Clinic Hospital](https://oncotherm.com/hu/terkepek/central-clinic-hospital/)
- [Centre for Natural Pain Solutions](https://oncotherm.com/hu/terkepek/centre-for-natural-pain-solutions/)
- [Centro Aktis](https://oncotherm.com/hu/terkepek/centro-aktis/)
- [Centro Bellessere Terni](https://oncotherm.com/hu/terkepek/centro-bellessere-terni/)
- [Centro Biocel](https://oncotherm.com/hu/terkepek/centro-biocel/)
- [CHA Bundang Medical Center](https://oncotherm.com/hu/terkepek/cha-bundang-medical-center/)
- [Changwon Convalescent Hospital](https://oncotherm.com/hu/terkepek/changwon-convalescent-hospital/)
- [Charlotte Maxeke Johannesburg Academic Hospital](https://oncotherm.com/hu/terkepek/charlotte-maxeke-johannesburg-academic-hospital/)
- [Chiwamitra Cancer Hospital](https://oncotherm.com/hu/terkepek/chiwamitra-cancer-hospital/)
- [Chiwamitra Cancer Hospital](https://oncotherm.com/maps/chiwamitra-cancer-hospital/)
- [Chiwamitra Cancer Hospital](https://oncotherm.com/de/karte/chiwamitra-cancer-hospital/)
- [Charlotte Maxeke Johannesburg Academic Hospital](https://oncotherm.com/maps/charlotte-maxeke-johannesburg-academic-hospital/)
- [Charlotte Maxeke Johannesburg Academic Hospital](https://oncotherm.com/de/karte/charlotte-maxeke-johannesburg-academic-hospital/)
- [Changwon Convalescent Hospital](https://oncotherm.com/maps/changwon-convalescent-hospital/)
- [Changwon Convalescent Hospital](https://oncotherm.com/de/karte/changwon-convalescent-hospital/)
- [CHA Bundang Medical Center](https://oncotherm.com/maps/cha-bundang-medical-center/)
- [CHA Bundang Medical Center](https://oncotherm.com/de/karte/cha-bundang-medical-center/)
- [Centro Biocel](https://oncotherm.com/maps/centro-biocel/)
- [Centro Biocel](https://oncotherm.com/de/karte/centro-biocel/)
- [Centro Bellessere Terni](https://oncotherm.com/maps/centro-bellessere-terni/)
- [Centro Bellessere Terni](https://oncotherm.com/de/karte/centro-bellessere-terni/)
- [Centro Aktis](https://oncotherm.com/maps/centro-aktis/)
- [Centro Aktis](https://oncotherm.com/de/karte/centro-aktis/)
- [Centre for Natural Pain Solutions](https://oncotherm.com/maps/centre-for-natural-pain-solutions/)
- [Centre for Natural Pain Solutions](https://oncotherm.com/de/karte/centre-for-natural-pain-solutions/)
- [Central Clinic Hospital](https://oncotherm.com/maps/central-clinic-hospital/)
- [Central Clinic Hospital](https://oncotherm.com/de/karte/central-clinic-hospital/)
- [Center of Medical Oncology/Euroclinic Dr. Volovat](https://oncotherm.com/maps/center-of-medical-oncology-euroclinic-dr-volovat/)
- [Center of Medical Oncology/Euroclinic Dr. Volovat](https://oncotherm.com/de/karte/center-of-medical-oncology-euroclinic-dr-volovat/)
- [CelluMed High Clinic](https://oncotherm.com/maps/cellumed-high-clinic/)
- [CelluMed High Clinic](https://oncotherm.com/de/karte/cellumed-high-clinic/)
- [Catholic Kwandong University International St. Mary’s Hospital](https://oncotherm.com/maps/catholic-kwandong-university-international-st-marys-hospital/)
- [Catholic Kwandong University International St. Mary’s Hospital](https://oncotherm.com/de/karte/catholic-kwandong-university-international-st-marys-hospital/)
- [Chonbuk National University Hospital](https://oncotherm.com/hu/terkepek/chonbuk-national-university-hospital-2/)
- [Chosun University Hospital](https://oncotherm.com/hu/terkepek/chosun-university-hospital/)
- [Chungnam National University Hospital](https://oncotherm.com/hu/terkepek/chungnam-national-university-hospital/)
- [Clifford Hospital](https://oncotherm.com/hu/terkepek/clifford-hospital/)
- [Clínica Checa](https://oncotherm.com/hu/terkepek/clinica-checa/)
- [Clínica ME TÓ DI CA Córdoba](https://oncotherm.com/hu/terkepek/clinica-me-to-di-ca-cordoba/)
- [Clinica Medicina Integrativa](https://oncotherm.com/hu/terkepek/clinica-medicina-integrativa/)
- [Clinica Villa Salaria](https://oncotherm.com/hu/terkepek/clinica-villa-salaria/)
- [Clinicum St. Georg GmbH & Co. KG](https://oncotherm.com/hu/terkepek/clinicum-st-georg-gmbh-co-kg/)
- [Daehan Convalescence Hospital](https://oncotherm.com/hu/terkepek/daehan-convalescence-hospital/)
- [Daehan Convalescence Hospital](https://oncotherm.com/maps/daehan-convalescence-hospital/)
- [Daehan Convalescence Hospital](https://oncotherm.com/de/karte/daehan-convalescence-hospital/)
- [Clinicum St. Georg GmbH & Co. KG](https://oncotherm.com/maps/clinicum-st-georg-gmbh-co-kg/)
- [Clinicum St. Georg GmbH & Co. KG](https://oncotherm.com/de/karte/clinicum-st-georg-gmbh-co-kg/)
- [Clinica Villa Salaria](https://oncotherm.com/maps/clinica-villa-salaria/)
- [Clinica Villa Salaria](https://oncotherm.com/de/karte/clinica-villa-salaria/)
- [Clinica Medicina Integrativa](https://oncotherm.com/maps/clinica-medicina-integrativa/)
- [Clinica Medicina Integrativa](https://oncotherm.com/de/karte/clinica-medicina-integrativa/)
- [Clínica ME TÓ DI CA Córdoba](https://oncotherm.com/maps/clinica-me-to-di-ca-cordoba/)
- [Clínica ME TÓ DI CA Córdoba](https://oncotherm.com/de/karte/clinica-me-to-di-ca-cordoba/)
- [Clínica Checa](https://oncotherm.com/maps/clinica-checa/)
- [Clínica Checa](https://oncotherm.com/de/karte/clinica-checa/)
- [Clifford Hospital](https://oncotherm.com/maps/clifford-hospital/)
- [Clifford Hospital](https://oncotherm.com/de/karte/clifford-hospital/)
- [Chungnam National University Hospital](https://oncotherm.com/maps/chungnam-national-university-hospital/)
- [Chungnam National University Hospital](https://oncotherm.com/de/karte/chungnam-national-university-hospital/)
- [Chosun University Hospital](https://oncotherm.com/maps/chosun-university-hospital/)
- [Chosun University Hospital](https://oncotherm.com/de/karte/chosun-university-hospital/)
- [Chonbuk National University Hospital](https://oncotherm.com/maps/chonbuk-national-university-hospital-2/)
- [Chonbuk National University Hospital](https://oncotherm.com/de/karte/chonbuk-national-university-hospital-2/)
- [Daejeon Wellness Rehabilitation Hospital](https://oncotherm.com/hu/terkepek/daejeon-wellness-rehabilitation-hospital/)
- [Daesoonjinrihoe Senior Specialty Hospital](https://oncotherm.com/hu/terkepek/daesoonjinrihoe-senior-specialty-hospital/)
- [Dar Al-shifa Tumor Treatment Center](https://oncotherm.com/hu/terkepek/dar-al-shifa-tumor-treatment-center/)
- [David Lambotn Naturopathic Clinic and Associates](https://oncotherm.com/hu/terkepek/david-lambotn-naturopathic-clinic-and-associates/)
- [Department of Oncology -Semmelweis University](https://oncotherm.com/hu/terkepek/department-of-oncology-semmelweis-university-2/)
- [Ditmanson Chia-Yi Christian Hospital](https://oncotherm.com/hu/terkepek/ditmanson-chia-yi-christian-hospital/)
- [Ditmanson Chia-Yi Christian Hospital](https://oncotherm.com/maps/ditmanson-chia-yi-christian-hospital/)
- [Ditmanson Chia-Yi Christian Hospital](https://oncotherm.com/de/karte/ditmanson-chia-yi-christian-hospital/)
- [Department of Oncology -Semmelweis University](https://oncotherm.com/maps/department-of-oncology-semmelweis-university-2/)
- [Department of Oncology -Semmelweis University](https://oncotherm.com/de/karte/department-of-oncology-semmelweis-university-2/)
- [David Lambotn Naturopathic Clinic and Associates](https://oncotherm.com/maps/david-lambotn-naturopathic-clinic-and-associates/)
- [David Lambotn Naturopathic Clinic and Associates](https://oncotherm.com/de/karte/david-lambotn-naturopathic-clinic-and-associates/)
- [Dar Al-shifa Tumor Treatment Center](https://oncotherm.com/maps/dar-al-shifa-tumor-treatment-center/)
- [Dar Al-shifa Tumor Treatment Center](https://oncotherm.com/de/karte/dar-al-shifa-tumor-treatment-center/)
- [Daesoonjinrihoe Senior Specialty Hospital](https://oncotherm.com/maps/daesoonjinrihoe-senior-specialty-hospital/)
- [Daesoonjinrihoe Senior Specialty Hospital](https://oncotherm.com/de/karte/daesoonjinrihoe-senior-specialty-hospital/)
- [Daejeon Wellness Rehabilitation Hospital](https://oncotherm.com/maps/daejeon-wellness-rehabilitation-hospital/)
- [Daejeon Wellness Rehabilitation Hospital](https://oncotherm.com/de/karte/daejeon-wellness-rehabilitation-hospital/)
- [Dongnae St. Mary's Hospital](https://oncotherm.com/hu/terkepek/dongnae-st-marys-hospital/)
- [Eden Adventist Hospital](https://oncotherm.com/hu/terkepek/eden-adventist-hospital/)
- [EunBit Love Hospital](https://oncotherm.com/hu/terkepek/eunbit-love-hospital/)
- [Ewha Womans University Cancer Center For Woman (EUMC)](https://oncotherm.com/hu/terkepek/ewha-womans-university-cancer-center-for-woman-eumc/)
- [Ewha Womans University Cancer Center For Woman (EUMC)](https://oncotherm.com/maps/ewha-womans-university-cancer-center-for-woman-eumc/)
- [Ewha Womans University Cancer Center For Woman (EUMC)](https://oncotherm.com/de/karte/ewha-womans-university-cancer-center-for-woman-eumc/)
- [EunBit Love Hospital](https://oncotherm.com/maps/eunbit-love-hospital/)
- [EunBit Love Hospital](https://oncotherm.com/de/karte/eunbit-love-hospital/)
- [Eden Adventist Hospital](https://oncotherm.com/maps/eden-adventist-hospital/)
- [Eden Adventist Hospital](https://oncotherm.com/de/karte/eden-adventist-hospital/)
- [Dongnae St. Mary's Hospital](https://oncotherm.com/maps/dongnae-st-marys-hospital/)
- [Dongnae St. Mary's Hospital](https://oncotherm.com/de/karte/dongnae-st-marys-hospital/)
- [Family Hospital](https://oncotherm.com/hu/terkepek/family-hospital/)
- [Funato Clinic](https://oncotherm.com/hu/terkepek/funato-clinic/)
- [Gangnam Severance Hospital](https://oncotherm.com/hu/terkepek/gangnam-severance-hospital/)
- [gisunt Klinik für integrative Medizin](https://oncotherm.com/hu/terkepek/gisunt-klinik-fur-integrative-medizin/)
- [Good Sunlin Hospital](https://oncotherm.com/hu/terkepek/good-sunlin-hospital/)
- [Good World Anti Cancer Center](https://oncotherm.com/hu/terkepek/good-world-anti-cancer-center/)
- [Habichtswald Reha-Klinik](https://oncotherm.com/hu/terkepek/habichtswald-reha-klinik/)
- [Hama Psoriasis Center](https://oncotherm.com/hu/terkepek/hama-psoriasis-center/)
- [Hansarang Medical Clinic](https://oncotherm.com/hu/terkepek/hansarang-medical-clinic/)
- [Hansarang Medical Clinic](https://oncotherm.com/maps/hansarang-medical-clinic/)
- [Hansarang Medical Clinic](https://oncotherm.com/de/karte/hansarang-medical-clinic/)
- [Hama Psoriasis Center](https://oncotherm.com/maps/hama-psoriasis-center/)
- [Hama Psoriasis Center](https://oncotherm.com/de/karte/hama-psoriasis-center/)
- [Habichtswald Reha-Klinik](https://oncotherm.com/maps/habichtswald-reha-klinik/)
- [Habichtswald Reha-Klinik](https://oncotherm.com/de/karte/habichtswald-reha-klinik/)
- [Good World Anti Cancer Center](https://oncotherm.com/maps/good-world-anti-cancer-center/)
- [Good World Anti Cancer Center](https://oncotherm.com/de/karte/good-world-anti-cancer-center/)
- [Good Sunlin Hospital](https://oncotherm.com/maps/good-sunlin-hospital/)
- [Good Sunlin Hospital](https://oncotherm.com/de/karte/good-sunlin-hospital/)
- [gisunt Klinik für integrative Medizin](https://oncotherm.com/maps/gisunt-klinik-fur-integrative-medizin/)
- [gisunt Klinik für integrative Medizin](https://oncotherm.com/de/karte/gisunt-klinik-fur-integrative-medizin/)
- [Gangnam Severance Hospital](https://oncotherm.com/maps/gangnam-severance-hospital/)
- [Gangnam Severance Hospital](https://oncotherm.com/de/karte/gangnam-severance-hospital/)
- [Funato Clinic](https://oncotherm.com/maps/funato-clinic/)
- [Funato Clinic](https://oncotherm.com/de/karte/funato-clinic/)
- [Family Hospital](https://oncotherm.com/maps/family-hospital/)
- [Family Hospital](https://oncotherm.com/de/karte/family-hospital/)
- [HealthSource Integrative Medical Centre](https://oncotherm.com/hu/terkepek/healthsource-integrative-medical-centre/)
- [Helios Cäcilien-Hospital Hüls](https://oncotherm.com/hu/terkepek/helios-cacilien-hospital-huls/)
- [Hufelandklinik für ganzheitliche immunbiologische Therapie](https://oncotherm.com/hu/terkepek/hufelandklinik-fur-ganzheitliche-immunbiologische-therapie/)
- [Hwasun Silver's Specialty Hospital](https://oncotherm.com/hu/terkepek/hwasun-silvers-specialty-hospital/)
- [Hyperthermie Zentrum Hannover](https://oncotherm.com/hu/terkepek/hyperthermie-zentrum-hannover/)
- [Hyperthermiezentrum Hochwald](https://oncotherm.com/hu/terkepek/hyperthermiezentrum-hochwald/)
- [Inje University Haeundae Paik Hospital](https://oncotherm.com/hu/terkepek/inje-university-haeundae-paik-hospital/)
- [INMOA Bilbao](https://oncotherm.com/hu/terkepek/inmoa-bilbao/)
- [Institut OncoLight](https://oncotherm.com/hu/terkepek/institut-oncolight/)
- [Instituto Médico De Oncología Avanzada INMOA](https://oncotherm.com/hu/terkepek/instituto-medico-de-oncologia-avanzada-inmoa-2/)
- [Instituto Toscano Tumori / Ospedale San Giuseppe](https://oncotherm.com/hu/terkepek/instituto-toscano-tumori-ospedale-san-giuseppe/)
- [Instituto Toscano Tumori / Ospedale San Giuseppe](https://oncotherm.com/maps/instituto-toscano-tumori-ospedale-san-giuseppe/)
- [Instituto Toscano Tumori / Ospedale San Giuseppe](https://oncotherm.com/de/karte/instituto-toscano-tumori-ospedale-san-giuseppe/)
- [Instituto Médico De Oncología Avanzada INMOA](https://oncotherm.com/maps/instituto-medico-de-oncologia-avanzada-inmoa-2/)
- [Instituto Médico De Oncología Avanzada INMOA](https://oncotherm.com/de/karte/instituto-medico-de-oncologia-avanzada-inmoa-2/)
- [Institut OncoLight](https://oncotherm.com/maps/institut-oncolight/)
- [Institut OncoLight](https://oncotherm.com/de/karte/institut-oncolight/)
- [INMOA Bilbao](https://oncotherm.com/maps/inmoa-bilbao/)
- [INMOA Bilbao](https://oncotherm.com/de/karte/inmoa-bilbao/)
- [Inje University Haeundae Paik Hospital](https://oncotherm.com/maps/inje-university-haeundae-paik-hospital/)
- [Inje University Haeundae Paik Hospital](https://oncotherm.com/de/karte/inje-university-haeundae-paik-hospital/)
- [Hyperthermiezentrum Hochwald](https://oncotherm.com/maps/hyperthermiezentrum-hochwald/)
- [Hyperthermiezentrum Hochwald](https://oncotherm.com/de/karte/hyperthermiezentrum-hochwald/)
- [Hyperthermie Zentrum Hannover](https://oncotherm.com/maps/hyperthermie-zentrum-hannover/)
- [Hyperthermie Zentrum Hannover](https://oncotherm.com/de/karte/hyperthermie-zentrum-hannover/)
- [Hwasun Silver's Specialty Hospital](https://oncotherm.com/maps/hwasun-silvers-specialty-hospital/)
- [Hwasun Silver's Specialty Hospital](https://oncotherm.com/de/karte/hwasun-silvers-specialty-hospital/)
- [Hufelandklinik für ganzheitliche immunbiologische Therapie](https://oncotherm.com/maps/hufelandklinik-fur-ganzheitliche-immunbiologische-therapie/)
- [Hufelandklinik für ganzheitliche immunbiologische Therapie](https://oncotherm.com/de/karte/hufelandklinik-fur-ganzheitliche-immunbiologische-therapie/)
- [Helios Cäcilien-Hospital Hüls](https://oncotherm.com/maps/helios-cacilien-hospital-huls/)
- [Helios Cäcilien-Hospital Hüls](https://oncotherm.com/de/karte/helios-cacilien-hospital-huls/)
- [HealthSource Integrative Medical Centre](https://oncotherm.com/maps/healthsource-integrative-medical-centre/)
- [HealthSource Integrative Medical Centre](https://oncotherm.com/de/karte/healthsource-integrative-medical-centre/)
- [Instytut Immunoterapii Nowotworów i Chorób Przewleklych ImmunoMedica Sp. z o. o. Sp. k.](https://oncotherm.com/hu/terkepek/instytut-immunoterapii-nowotworow-i-chorob-przewleklych-immunomedica-sp-z-o-o-sp-k/)
- [Integrated Health Clinic](https://oncotherm.com/hu/terkepek/integrated-health-clinic/)
- [Integrative Medical Center Sp. z o. o.](https://oncotherm.com/hu/terkepek/integrative-medical-center-sp-z-o-o/)
- [IOZK - Immunologisch-Onkologisches Zentrum Köln](https://oncotherm.com/hu/terkepek/iozk-immunologisch-onkologisches-zentrum-koln/)
- [Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.](https://oncotherm.com/hu/terkepek/istituto-tumori-giovanni-paolo-ii-i-r-c-c-s/)
- [Jangdeuk Oriental Hospital](https://oncotherm.com/hu/terkepek/jangdeuk-oriental-hospital/)
- [Jinyounghanseo Hospital](https://oncotherm.com/hu/terkepek/jinyounghanseo-hospital/)
- [Joeun Gumgang Hospital](https://oncotherm.com/hu/terkepek/joeun-gumgang-hospital/)
- [Kemotermi](https://oncotherm.com/hu/terkepek/kemotermi/)
- [Keunnamu Care Hospital](https://oncotherm.com/hu/terkepek/keunnamu-care-hospital/)
- [Klinik im LEBEN](https://oncotherm.com/hu/terkepek/klinik-im-leben/)
- [Klinik Öschelbronn](https://oncotherm.com/hu/terkepek/klinik-oschelbronn/)
- [Klinik Öschelbronn](https://oncotherm.com/maps/klinik-oschelbronn/)
- [Klinik Öschelbronn](https://oncotherm.com/de/karte/klinik-oschelbronn/)
- [Klinik im LEBEN](https://oncotherm.com/maps/klinik-im-leben/)
- [Klinik im LEBEN](https://oncotherm.com/de/karte/klinik-im-leben/)
- [Keunnamu Care Hospital](https://oncotherm.com/maps/keunnamu-care-hospital/)
- [Keunnamu Care Hospital](https://oncotherm.com/de/karte/keunnamu-care-hospital/)
- [Kemotermi](https://oncotherm.com/maps/kemotermi/)
- [Kemotermi](https://oncotherm.com/de/karte/kemotermi/)
- [Joeun Gumgang Hospital](https://oncotherm.com/maps/joeun-gumgang-hospital/)
- [Joeun Gumgang Hospital](https://oncotherm.com/de/karte/joeun-gumgang-hospital/)
- [Jinyounghanseo Hospital](https://oncotherm.com/maps/jinyounghanseo-hospital/)
- [Jinyounghanseo Hospital](https://oncotherm.com/de/karte/jinyounghanseo-hospital/)
- [Jangdeuk Oriental Hospital](https://oncotherm.com/maps/jangdeuk-oriental-hospital/)
- [Jangdeuk Oriental Hospital](https://oncotherm.com/de/karte/jangdeuk-oriental-hospital/)
- [Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.](https://oncotherm.com/maps/istituto-tumori-giovanni-paolo-ii-i-r-c-c-s/)
- [Istituto Tumori "Giovanni Paolo II" I.R.C.C.S.](https://oncotherm.com/de/karte/istituto-tumori-giovanni-paolo-ii-i-r-c-c-s/)
- [IOZK - Immunologisch-Onkologisches Zentrum Köln](https://oncotherm.com/maps/iozk-immunologisch-onkologisches-zentrum-koln/)
- [IOZK - Immunologisch-Onkologisches Zentrum Köln](https://oncotherm.com/de/karte/iozk-immunologisch-onkologisches-zentrum-koln/)
- [Integrative Medical Center Sp. z o. o.](https://oncotherm.com/maps/integrative-medical-center-sp-z-o-o/)
- [Integrative Medical Center Sp. z o. o.](https://oncotherm.com/de/karte/integrative-medical-center-sp-z-o-o/)
- [Integrated Health Clinic](https://oncotherm.com/maps/integrated-health-clinic/)
- [Integrated Health Clinic](https://oncotherm.com/de/karte/integrated-health-clinic/)
- [Instytut Immunoterapii Nowotworów i Chorób Przewleklych ImmunoMedica Sp. z o. o. Sp. k.](https://oncotherm.com/maps/instytut-immunoterapii-nowotworow-i-chorob-przewleklych-immunomedica-sp-z-o-o-sp-k/)
- [Instytut Immunoterapii Nowotworów i Chorób Przewleklych ImmunoMedica Sp. z o. o. Sp. k.](https://oncotherm.com/de/karte/instytut-immunoterapii-nowotworow-i-chorob-przewleklych-immunomedica-sp-z-o-o-sp-k/)
- [Klinikum Altenburger Land](https://oncotherm.com/hu/terkepek/klinikum-altenburger-land/)
- [Korea Cancer Center Hospital](https://oncotherm.com/hu/terkepek/korea-cancer-center-hospital/)
- [Korea University Ansan Hospital](https://oncotherm.com/hu/terkepek/korea-university-ansan-hospital/)
- [Korean University Guro Hospital](https://oncotherm.com/hu/terkepek/korean-university-guro-hospital/)
- [KRH Klinikum Siloah](https://oncotherm.com/hu/terkepek/krh-klinikum-siloah/)
- [Kukmin Health Center](https://oncotherm.com/hu/terkepek/kukmin-health-center/)
- [LaserMedical](https://oncotherm.com/hu/terkepek/lasermedical/)
- [London Immunotherapy, The London Welbeck Hospital](https://oncotherm.com/hu/terkepek/london-immunotherapy-the-london-welbeck-hospital-2/)
- [Loving Care Clinic](https://oncotherm.com/hu/terkepek/loving-care-clinic/)
- [Manduk Hill Hospital](https://oncotherm.com/hu/terkepek/manduk-hill-hospital/)
- [Manduk Hill Hospital](https://oncotherm.com/maps/manduk-hill-hospital/)
- [Manduk Hill Hospital](https://oncotherm.com/de/karte/manduk-hill-hospital/)
- [Loving Care Clinic](https://oncotherm.com/maps/loving-care-clinic/)
- [Loving Care Clinic](https://oncotherm.com/de/karte/loving-care-clinic/)
- [London Immunotherapy, The London Welbeck Hospital](https://oncotherm.com/maps/london-immunotherapy-the-london-welbeck-hospital-2/)
- [London Immunotherapy, The London Welbeck Hospital](https://oncotherm.com/de/karte/london-immunotherapy-the-london-welbeck-hospital-2/)
- [LaserMedical](https://oncotherm.com/maps/lasermedical/)
- [LaserMedical](https://oncotherm.com/de/karte/lasermedical/)
- [Kukmin Health Center](https://oncotherm.com/maps/kukmin-health-center/)
- [Kukmin Health Center](https://oncotherm.com/de/karte/kukmin-health-center/)
- [KRH Klinikum Siloah](https://oncotherm.com/maps/krh-klinikum-siloah/)
- [KRH Klinikum Siloah](https://oncotherm.com/de/karte/krh-klinikum-siloah/)
- [Korean University Guro Hospital](https://oncotherm.com/maps/korean-university-guro-hospital/)
- [Korean University Guro Hospital](https://oncotherm.com/de/karte/korean-university-guro-hospital/)
- [Korea University Ansan Hospital](https://oncotherm.com/maps/korea-university-ansan-hospital/)
- [Korea University Ansan Hospital](https://oncotherm.com/de/karte/korea-university-ansan-hospital/)
- [Korea Cancer Center Hospital](https://oncotherm.com/maps/korea-cancer-center-hospital/)
- [Korea Cancer Center Hospital](https://oncotherm.com/de/karte/korea-cancer-center-hospital/)
- [Klinikum Altenburger Land](https://oncotherm.com/maps/klinikum-altenburger-land/)
- [Klinikum Altenburger Land](https://oncotherm.com/de/karte/klinikum-altenburger-land/)
- [Marsden Centre for Naturopathic Excellence](https://oncotherm.com/hu/terkepek/marsden-centre-for-naturopathic-excellence/)
- [mea vita Praxis](https://oncotherm.com/hu/terkepek/mea-vita-praxis/)
- [Medical Corporation Zuiseikai Kuramae naika Clinic](https://oncotherm.com/hu/terkepek/medical-corporation-zuiseikai-kuramae-naika-clinic/)
- [MEDIZIESE - Naturarztpraxis Wolfgang Ziese](https://oncotherm.com/hu/terkepek/mediziese-naturarztpraxis-wolfgang-ziese/)
- [Mirakle Integrated Health Centre](https://oncotherm.com/hu/terkepek/mirakle-integrated-health-centre/)
- [Miwa Central Clinic](https://oncotherm.com/hu/terkepek/miwa-central-clinic/)
- [Moscow P.A. Gertsen Research Institute of Oncology](https://oncotherm.com/hu/terkepek/moscow-p-a-gertsen-research-institute-of-oncology/)
- [Mudeung Mountain Eco Hospital](https://oncotherm.com/hu/terkepek/mudeung-mountain-eco-hospital/)
- [MVM - Medizinische Verwaltungs- & Managementgesellschaft mbH](https://oncotherm.com/hu/terkepek/mvm-medizinische-verwaltungs-managementgesellschaft-mbh/)
- [MVZ Prof. Dr. Adamietz GmbH - Strahlentherapie am EvK Witten](https://oncotherm.com/hu/terkepek/mvz-prof-dr-adamietz-gmbh-strahlentherapie-am-evk-witten/)
- [National Cancer Institute](https://oncotherm.com/hu/terkepek/national-cancer-institute/)
- [National Cancer Institute](https://oncotherm.com/maps/national-cancer-institute/)
- [National Cancer Institute](https://oncotherm.com/de/karte/national-cancer-institute/)
- [MVZ Prof. Dr. Adamietz GmbH - Strahlentherapie am EvK Witten](https://oncotherm.com/maps/mvz-prof-dr-adamietz-gmbh-strahlentherapie-am-evk-witten/)
- [MVZ Prof. Dr. Adamietz GmbH - Strahlentherapie am EvK Witten](https://oncotherm.com/de/karte/mvz-prof-dr-adamietz-gmbh-strahlentherapie-am-evk-witten/)
- [MVM - Medizinische Verwaltungs- & Managementgesellschaft mbH](https://oncotherm.com/maps/mvm-medizinische-verwaltungs-managementgesellschaft-mbh/)
- [MVM - Medizinische Verwaltungs- & Managementgesellschaft mbH](https://oncotherm.com/de/karte/mvm-medizinische-verwaltungs-managementgesellschaft-mbh/)
- [Mudeung Mountain Eco Hospital](https://oncotherm.com/maps/mudeung-mountain-eco-hospital/)
- [Mudeung Mountain Eco Hospital](https://oncotherm.com/de/karte/mudeung-mountain-eco-hospital/)
- [Moscow P.A. Gertsen Research Institute of Oncology](https://oncotherm.com/maps/moscow-p-a-gertsen-research-institute-of-oncology/)
- [Moscow P.A. Gertsen Research Institute of Oncology](https://oncotherm.com/de/karte/moscow-p-a-gertsen-research-institute-of-oncology/)
- [Miwa Central Clinic](https://oncotherm.com/maps/miwa-central-clinic/)
- [Miwa Central Clinic](https://oncotherm.com/de/karte/miwa-central-clinic/)
- [Mirakle Integrated Health Centre](https://oncotherm.com/maps/mirakle-integrated-health-centre/)
- [Mirakle Integrated Health Centre](https://oncotherm.com/de/karte/mirakle-integrated-health-centre/)
- [MEDIZIESE - Naturarztpraxis Wolfgang Ziese](https://oncotherm.com/maps/mediziese-naturarztpraxis-wolfgang-ziese/)
- [MEDIZIESE - Naturarztpraxis Wolfgang Ziese](https://oncotherm.com/de/karte/mediziese-naturarztpraxis-wolfgang-ziese/)
- [Medical Corporation Zuiseikai Kuramae naika Clinic](https://oncotherm.com/maps/medical-corporation-zuiseikai-kuramae-naika-clinic/)
- [Medical Corporation Zuiseikai Kuramae naika Clinic](https://oncotherm.com/de/karte/medical-corporation-zuiseikai-kuramae-naika-clinic/)
- [mea vita Praxis](https://oncotherm.com/maps/mea-vita-praxis/)
- [mea vita Praxis](https://oncotherm.com/de/karte/mea-vita-praxis/)
- [Marsden Centre for Naturopathic Excellence](https://oncotherm.com/maps/marsden-centre-for-naturopathic-excellence/)
- [Marsden Centre for Naturopathic Excellence](https://oncotherm.com/de/karte/marsden-centre-for-naturopathic-excellence/)
- [Natural Love Deogyusan Care Hospital](https://oncotherm.com/hu/terkepek/natural-love-deogyusan-care-hospital/)
- [Naturheilpraxis Dr. Langner](https://oncotherm.com/hu/terkepek/naturheilpraxis-dr-langner/)
- [Naturheilpraxis Gronau - Wieger Rekker - Praxis für Naturheilverfahren](https://oncotherm.com/hu/terkepek/naturheilpraxis-gronau-wieger-rekker-praxis-fur-naturheilverfahren/)
- [New Anti Cancer Hospital](https://oncotherm.com/hu/terkepek/new-anti-cancer-hospital/)
- [New Breath Hospital](https://oncotherm.com/hu/terkepek/new-breath-hospital/)
- [New Hope Hospital](https://oncotherm.com/hu/terkepek/new-hope-hospital/)
- [Novac Clinic](https://oncotherm.com/hu/terkepek/novac-clinic/)
- [OncoClinic Ltd](https://oncotherm.com/hu/terkepek/oncoclinic-ltd/)
- [Onkologische Tagesklinik Dr. med. Ferdinand Wurms](https://oncotherm.com/hu/terkepek/onkologische-tagesklinik-dr-med-ferdinand-wurms/)
- [OptiMed Clinic in National Cancer Institute of Ukraine](https://oncotherm.com/hu/terkepek/optimed-clinic-in-national-cancer-institute-of-ukraine/)
- [Optimum Wellness Naturopathic Medical Clinic](https://oncotherm.com/hu/terkepek/optimum-wellness-naturopathic-medical-clinic/)
- [Ospedale Civico di Carrara](https://oncotherm.com/hu/terkepek/ospedale-civico-di-carrara/)
- [Özel Tansan Onkoloji Polikliniği](https://oncotherm.com/hu/terkepek/ozel-tansan-onkoloji-poliklinigi/)
- [Özel Tansan Onkoloji Polikliniği](https://oncotherm.com/maps/ozel-tansan-onkoloji-poliklinigi/)
- [Özel Tansan Onkoloji Polikliniği](https://oncotherm.com/de/karte/ozel-tansan-onkoloji-poliklinigi/)
- [Ospedale Civico di Carrara](https://oncotherm.com/maps/ospedale-civico-di-carrara/)
- [Ospedale Civico di Carrara](https://oncotherm.com/de/karte/ospedale-civico-di-carrara/)
- [Optimum Wellness Naturopathic Medical Clinic](https://oncotherm.com/maps/optimum-wellness-naturopathic-medical-clinic/)
- [Optimum Wellness Naturopathic Medical Clinic](https://oncotherm.com/de/karte/optimum-wellness-naturopathic-medical-clinic/)
- [OptiMed Clinic in National Cancer Institute of Ukraine](https://oncotherm.com/maps/optimed-clinic-in-national-cancer-institute-of-ukraine/)
- [OptiMed Clinic in National Cancer Institute of Ukraine](https://oncotherm.com/de/karte/optimed-clinic-in-national-cancer-institute-of-ukraine/)
- [Onkologische Tagesklinik Dr. med. Ferdinand Wurms](https://oncotherm.com/maps/onkologische-tagesklinik-dr-med-ferdinand-wurms/)
- [Onkologische Tagesklinik Dr. med. Ferdinand Wurms](https://oncotherm.com/de/karte/onkologische-tagesklinik-dr-med-ferdinand-wurms/)
- [OncoClinic Ltd](https://oncotherm.com/maps/oncoclinic-ltd/)
- [OncoClinic Ltd](https://oncotherm.com/de/karte/oncoclinic-ltd/)
- [Novac Clinic](https://oncotherm.com/maps/novac-clinic/)
- [Novac Clinic](https://oncotherm.com/de/karte/novac-clinic/)
- [New Hope Hospital](https://oncotherm.com/maps/new-hope-hospital/)
- [New Hope Hospital](https://oncotherm.com/de/karte/new-hope-hospital/)
- [New Breath Hospital](https://oncotherm.com/maps/new-breath-hospital/)
- [New Breath Hospital](https://oncotherm.com/de/karte/new-breath-hospital/)
- [New Anti Cancer Hospital](https://oncotherm.com/maps/new-anti-cancer-hospital/)
- [New Anti Cancer Hospital](https://oncotherm.com/de/karte/new-anti-cancer-hospital/)
- [Naturheilpraxis Gronau - Wieger Rekker - Praxis für Naturheilverfahren](https://oncotherm.com/maps/naturheilpraxis-gronau-wieger-rekker-praxis-fur-naturheilverfahren/)
- [Naturheilpraxis Gronau - Wieger Rekker - Praxis für Naturheilverfahren](https://oncotherm.com/de/karte/naturheilpraxis-gronau-wieger-rekker-praxis-fur-naturheilverfahren/)
- [Naturheilpraxis Dr. Langner](https://oncotherm.com/maps/naturheilpraxis-dr-langner/)
- [Naturheilpraxis Dr. Langner](https://oncotherm.com/de/karte/naturheilpraxis-dr-langner/)
- [Natural Love Deogyusan Care Hospital](https://oncotherm.com/maps/natural-love-deogyusan-care-hospital/)
- [Natural Love Deogyusan Care Hospital](https://oncotherm.com/de/karte/natural-love-deogyusan-care-hospital/)
- [Paracelsus Klinik Lustmühle AG](https://oncotherm.com/hu/terkepek/paracelsus-klinik-lustmuhle-ag/)
- [Paracelsus Stiftung Bad Liebenzell](https://oncotherm.com/hu/terkepek/paracelsus-stiftung-bad-liebenzell/)
- [Pohang Gidok Hospital](https://oncotherm.com/hu/terkepek/pohang-gidok-hospital/)
- [Port Moody Health - Integrative Medicine & Cancer Care](https://oncotherm.com/hu/terkepek/port-moody-health-integrative-medicine-cancer-care/)
- [Praxis Dr. Anton Leutz](https://oncotherm.com/hu/terkepek/praxis-dr-anton-leutz/)
- [Praxis Dr. Dieter Rixen und Dr. Nikolai U. Aldag](https://oncotherm.com/hu/terkepek/praxis-dr-dieter-rixen-und-dr-nikolai-u-aldag/)
- [Praxis Dr. Eloy Pulido](https://oncotherm.com/hu/terkepek/praxis-dr-eloy-pulido/)
- [Praxis Dr. rer. nat. Thomas Neßelhut](https://oncotherm.com/hu/terkepek/praxis-dr-rer-nat-thomas-neselhut/)
- [Praxis Dr. Stephan Wey](https://oncotherm.com/hu/terkepek/praxis-dr-stephan-wey/)
- [Praxis für Hyperthermie - Dr. Sahinbas](https://oncotherm.com/hu/terkepek/praxis-fur-hyperthermie-dr-sahinbas/)
- [Praxis für komplementäre Krebsintensivtherapie](https://oncotherm.com/hu/terkepek/praxis-fur-komplementare-krebsintensivtherapie/)
- [Praxis Margarete Eisenkolb-Sturm](https://oncotherm.com/hu/terkepek/praxis-margarete-eisenkolb-sturm/)
- [Praxis Prof. Dr. CanFeza SEZGİN](https://oncotherm.com/hu/terkepek/praxis-prof-dr-canfeza-sezgin/)
- [Praxis Prof.Dr.Teoman YANMAZ](https://oncotherm.com/hu/terkepek/praxis-prof-dr-teoman-yanmaz/)
- [Praxis Prof.Dr.Teoman YANMAZ](https://oncotherm.com/maps/praxis-prof-dr-teoman-yanmaz/)
- [Praxis Prof.Dr.Teoman YANMAZ](https://oncotherm.com/de/karte/praxis-prof-dr-teoman-yanmaz/)
- [Praxis Prof. Dr. CanFeza SEZGİN](https://oncotherm.com/maps/praxis-prof-dr-canfeza-sezgin/)
- [Praxis Prof. Dr. CanFeza SEZGİN](https://oncotherm.com/de/karte/praxis-prof-dr-canfeza-sezgin/)
- [Praxis Margarete Eisenkolb-Sturm](https://oncotherm.com/maps/praxis-margarete-eisenkolb-sturm/)
- [Praxis Margarete Eisenkolb-Sturm](https://oncotherm.com/de/karte/praxis-margarete-eisenkolb-sturm/)
- [Praxis für komplementäre Krebsintensivtherapie](https://oncotherm.com/maps/praxis-fur-komplementare-krebsintensivtherapie/)
- [Praxis für komplementäre Krebsintensivtherapie](https://oncotherm.com/de/karte/praxis-fur-komplementare-krebsintensivtherapie/)
- [Praxis für Hyperthermie - Dr. Sahinbas](https://oncotherm.com/maps/praxis-fur-hyperthermie-dr-sahinbas/)
- [Praxis für Hyperthermie - Dr. Sahinbas](https://oncotherm.com/de/karte/praxis-fur-hyperthermie-dr-sahinbas/)
- [Praxis Dr. Stephan Wey](https://oncotherm.com/maps/praxis-dr-stephan-wey/)
- [Praxis Dr. Stephan Wey](https://oncotherm.com/de/karte/praxis-dr-stephan-wey/)
- [Praxis Dr. rer. nat. Thomas Neßelhut](https://oncotherm.com/maps/praxis-dr-rer-nat-thomas-neselhut/)
- [Praxis Dr. rer. nat. Thomas Neßelhut](https://oncotherm.com/de/karte/praxis-dr-rer-nat-thomas-neselhut/)
- [Praxis Dr. Eloy Pulido](https://oncotherm.com/maps/praxis-dr-eloy-pulido/)
- [Praxis Dr. Eloy Pulido](https://oncotherm.com/de/karte/praxis-dr-eloy-pulido/)
- [Praxis Dr. Dieter Rixen und Dr. Nikolai U. Aldag](https://oncotherm.com/maps/praxis-dr-dieter-rixen-und-dr-nikolai-u-aldag/)
- [Praxis Dr. Dieter Rixen und Dr. Nikolai U. Aldag](https://oncotherm.com/de/karte/praxis-dr-dieter-rixen-und-dr-nikolai-u-aldag/)
- [Port Moody Health - Integrative Medicine & Cancer Care](https://oncotherm.com/maps/port-moody-health-integrative-medicine-cancer-care/)
- [Port Moody Health - Integrative Medicine & Cancer Care](https://oncotherm.com/de/karte/port-moody-health-integrative-medicine-cancer-care/)
- [Praxis Dr. Anton Leutz](https://oncotherm.com/maps/praxis-dr-anton-leutz/)
- [Praxis Dr. Anton Leutz](https://oncotherm.com/de/karte/praxis-dr-anton-leutz/)
- [Pohang Gidok Hospital](https://oncotherm.com/maps/pohang-gidok-hospital/)
- [Pohang Gidok Hospital](https://oncotherm.com/de/karte/pohang-gidok-hospital/)
- [Paracelsus Stiftung Bad Liebenzell](https://oncotherm.com/maps/paracelsus-stiftung-bad-liebenzell/)
- [Paracelsus Stiftung Bad Liebenzell](https://oncotherm.com/de/karte/paracelsus-stiftung-bad-liebenzell/)
- [Paracelsus Klinik Lustmühle AG](https://oncotherm.com/maps/paracelsus-klinik-lustmuhle-ag/)
- [Paracelsus Klinik Lustmühle AG](https://oncotherm.com/de/karte/paracelsus-klinik-lustmuhle-ag/)
- [Praxisgemeinschaft für Zelltherapie Duderstadt GmbH & Co. KG](https://oncotherm.com/hu/terkepek/praxisgemeinschaft-fur-zelltherapie-duderstadt-gmbh-co-kg/)
- [Praxisklinik Dr. Gassmann](https://oncotherm.com/hu/terkepek/praxisklinik-dr-gassmann/)
- [Praxisklinik Frank Daudert](https://oncotherm.com/hu/terkepek/praxisklinik-frank-daudert/)
- [Presbyterian Medical Center](https://oncotherm.com/hu/terkepek/presbyterian-medical-center/)
- [prio mensch - Privatpraxis für Integrative Onkologie Köln](https://oncotherm.com/hu/terkepek/prio-mensch-privatpraxis-fur-integrative-onkologie-koln/)
- [Privat Praxis Dr. med. Bozena Kilarski](https://oncotherm.com/hu/terkepek/privat-praxis-dr-med-bozena-kilarski/)
- [Privatpraxis Keisinger](https://oncotherm.com/hu/terkepek/privatpraxis-keisinger/)
- [Prunsoop Oriental Hospital](https://oncotherm.com/hu/terkepek/prunsoop-oriental-hospital/)
- [Pusan National University Hospital](https://oncotherm.com/hu/terkepek/pusan-national-university-hospital/)
- [Quality of Life Cancer Center](https://oncotherm.com/hu/terkepek/quality-of-life-cancer-center/)
- [Quantum Clinic](https://oncotherm.com/hu/terkepek/quantum-clinic/)
- [Radiotherapy Center, Novosibirskiy Research Institute of Circulation Pathology named after acad. Meshalkin](https://oncotherm.com/hu/terkepek/radiotherapy-center-novosibirskiy-research-institute-of-circulation-pathology-named-after-acad-meshalkin/)
- [Radiotherapy Center, Novosibirskiy Research Institute of Circulation Pathology named after acad. Meshalkin](https://oncotherm.com/maps/radiotherapy-center-novosibirskiy-research-institute-of-circulation-pathology-named-after-acad-meshalkin/)
- [Radiotherapy Center, Novosibirskiy Research Institute of Circulation Pathology named after acad. Meshalkin](https://oncotherm.com/de/karte/radiotherapy-center-novosibirskiy-research-institute-of-circulation-pathology-named-after-acad-meshalkin/)
- [Quantum Clinic](https://oncotherm.com/maps/quantum-clinic/)
- [Quantum Clinic](https://oncotherm.com/de/karte/quantum-clinic/)
- [Quality of Life Cancer Center](https://oncotherm.com/maps/quality-of-life-cancer-center/)
- [Quality of Life Cancer Center](https://oncotherm.com/de/karte/quality-of-life-cancer-center/)
- [Pusan National University Hospital](https://oncotherm.com/maps/pusan-national-university-hospital/)
- [Pusan National University Hospital](https://oncotherm.com/de/karte/pusan-national-university-hospital/)
- [Prunsoop Oriental Hospital](https://oncotherm.com/maps/prunsoop-oriental-hospital/)
- [Prunsoop Oriental Hospital](https://oncotherm.com/de/karte/prunsoop-oriental-hospital/)
- [Privat Praxis Dr. med. Bozena Kilarski](https://oncotherm.com/maps/privat-praxis-dr-med-bozena-kilarski/)
- [Privat Praxis Dr. med. Bozena Kilarski](https://oncotherm.com/de/karte/privat-praxis-dr-med-bozena-kilarski/)
- [Privatpraxis Keisinger](https://oncotherm.com/maps/privatpraxis-keisinger/)
- [Privatpraxis Keisinger](https://oncotherm.com/de/karte/privatpraxis-keisinger/)
- [prio mensch - Privatpraxis für Integrative Onkologie Köln](https://oncotherm.com/maps/prio-mensch-privatpraxis-fur-integrative-onkologie-koln/)
- [prio mensch - Privatpraxis für Integrative Onkologie Köln](https://oncotherm.com/de/karte/prio-mensch-privatpraxis-fur-integrative-onkologie-koln/)
- [Presbyterian Medical Center](https://oncotherm.com/maps/presbyterian-medical-center/)
- [Presbyterian Medical Center](https://oncotherm.com/de/karte/presbyterian-medical-center/)
- [Praxisklinik Frank Daudert](https://oncotherm.com/maps/praxisklinik-frank-daudert/)
- [Praxisklinik Frank Daudert](https://oncotherm.com/de/karte/praxisklinik-frank-daudert/)
- [Praxisklinik Dr. Gassmann](https://oncotherm.com/maps/praxisklinik-dr-gassmann/)
- [Praxisklinik Dr. Gassmann](https://oncotherm.com/de/karte/praxisklinik-dr-gassmann/)
- [Praxisgemeinschaft für Zelltherapie Duderstadt GmbH & Co. KG](https://oncotherm.com/maps/praxisgemeinschaft-fur-zelltherapie-duderstadt-gmbh-co-kg/)
- [Praxisgemeinschaft für Zelltherapie Duderstadt GmbH & Co. KG](https://oncotherm.com/de/karte/praxisgemeinschaft-fur-zelltherapie-duderstadt-gmbh-co-kg/)
- [Road Clinical Hospital](https://oncotherm.com/hu/terkepek/road-clinical-hospital/)
- [Russian Scientific Center of Roengenology and Radiology (RSCRR)](https://oncotherm.com/hu/terkepek/russian-scientific-center-of-roengenology-and-radiology-rscrr/)
- [S.C. ImunoMedica Provita S.R.L. Bucuresti](https://oncotherm.com/hu/terkepek/s-c-imunomedica-provita-s-r-l-bucuresti/)
- [Saira Memorial Hospital](https://oncotherm.com/hu/terkepek/saira-memorial-hospital/)
- [Schwerpunktpraxis für Komplementäre Onkologie - Dr. phil. Bausemer](https://oncotherm.com/hu/terkepek/schwerpunktpraxis-fur-komplementare-onkologie-dr-phil-bausemer/)
- [Semin S hospital](https://oncotherm.com/hu/terkepek/semin-s-hospital/)
- [Seoho Hadan Hospital](https://oncotherm.com/hu/terkepek/seoho-hadan-hospital/)
- [Seoul Cancer Care Hospital](https://oncotherm.com/hu/terkepek/seoul-cancer-care-hospital/)
- [Seoul National University Bundang Hospital](https://oncotherm.com/hu/terkepek/seoul-national-university-bundang-hospital/)
- [Seoul Songdo Hospital](https://oncotherm.com/hu/terkepek/seoul-songdo-hospital/)
- [Severance Hospital](https://oncotherm.com/hu/terkepek/severance-hospital/)
- [Shin Kong Wu Ho-Su Memorial Hospital](https://oncotherm.com/hu/terkepek/shin-kong-wu-ho-su-memorial-hospital/)
- [Shin Kong Wu Ho-Su Memorial Hospital](https://oncotherm.com/maps/shin-kong-wu-ho-su-memorial-hospital/)
- [Shin Kong Wu Ho-Su Memorial Hospital](https://oncotherm.com/de/karte/shin-kong-wu-ho-su-memorial-hospital/)
- [Severance Hospital](https://oncotherm.com/maps/severance-hospital/)
- [Severance Hospital](https://oncotherm.com/de/karte/severance-hospital/)
- [Seoul Songdo Hospital](https://oncotherm.com/maps/seoul-songdo-hospital/)
- [Seoul Songdo Hospital](https://oncotherm.com/de/karte/seoul-songdo-hospital/)
- [Seoul National University Bundang Hospital](https://oncotherm.com/maps/seoul-national-university-bundang-hospital/)
- [Seoul National University Bundang Hospital](https://oncotherm.com/de/karte/seoul-national-university-bundang-hospital/)
- [Seoul Cancer Care Hospital](https://oncotherm.com/maps/seoul-cancer-care-hospital/)
- [Seoul Cancer Care Hospital](https://oncotherm.com/de/karte/seoul-cancer-care-hospital/)
- [Seoho Hadan Hospital](https://oncotherm.com/maps/seoho-hadan-hospital/)
- [Seoho Hadan Hospital](https://oncotherm.com/de/karte/seoho-hadan-hospital/)
- [Semin S hospital](https://oncotherm.com/maps/semin-s-hospital/)
- [Semin S hospital](https://oncotherm.com/de/karte/semin-s-hospital/)
- [Schwerpunktpraxis für Komplementäre Onkologie - Dr. phil. Bausemer](https://oncotherm.com/maps/schwerpunktpraxis-fur-komplementare-onkologie-dr-phil-bausemer/)
- [Schwerpunktpraxis für Komplementäre Onkologie - Dr. phil. Bausemer](https://oncotherm.com/de/karte/schwerpunktpraxis-fur-komplementare-onkologie-dr-phil-bausemer/)
- [Saira Memorial Hospital](https://oncotherm.com/maps/saira-memorial-hospital/)
- [Saira Memorial Hospital](https://oncotherm.com/de/karte/saira-memorial-hospital/)
- [S.C. ImunoMedica Provita S.R.L. Bucuresti](https://oncotherm.com/maps/s-c-imunomedica-provita-s-r-l-bucuresti/)
- [S.C. ImunoMedica Provita S.R.L. Bucuresti](https://oncotherm.com/de/karte/s-c-imunomedica-provita-s-r-l-bucuresti/)
- [Road Clinical Hospital](https://oncotherm.com/maps/road-clinical-hospital/)
- [Road Clinical Hospital](https://oncotherm.com/de/karte/road-clinical-hospital/)
- [Singal Baekse Hospital](https://oncotherm.com/hu/terkepek/singal-baekse-hospital/)
- [Singyeongju Hospital](https://oncotherm.com/hu/terkepek/singyeongju-hospital/)
- [Soon Chun Hyang UnivSoon Chun Hyang University Hospital Cheonan Oncotherm Partnerersity Hospital Cheonan](https://oncotherm.com/hu/terkepek/soon-chun-hyang-univsoon-chun-hyang-university-hospital-cheonan-oncotherm-partnerersity-hospital-cheonan/)
- [Soram Clinic](https://oncotherm.com/hu/terkepek/soram-clinic/)
- [Spedali Civili di Brescia](https://oncotherm.com/hu/terkepek/spedali-civili-di-brescia/)
- [Stichting Hyperthermie / Baron G.A.](https://oncotherm.com/hu/terkepek/stichting-hyperthermie-baron-g-a/)
- [Tagesklinik Erzgesund](https://oncotherm.com/hu/terkepek/tagesklinik-erzgesund/)
- [THERA Praxisklinik](https://oncotherm.com/hu/terkepek/thera-praxisklinik/)
- [Thessaloniki Onco-Hyperthermia Clinic](https://oncotherm.com/hu/terkepek/thessaloniki-onco-hyperthermia-clinic/)
- [Tokyo Tsukishima Clinic](https://oncotherm.com/hu/terkepek/tokyo-tsukishima-clinic/)
- [Toyama University Hospital](https://oncotherm.com/hu/terkepek/toyama-university-hospital/)
- [Toyama University Hospital](https://oncotherm.com/maps/toyama-university-hospital/)
- [Toyama University Hospital](https://oncotherm.com/de/karte/toyama-university-hospital/)
- [Tokyo Tsukishima Clinic](https://oncotherm.com/maps/tokyo-tsukishima-clinic/)
- [Tokyo Tsukishima Clinic](https://oncotherm.com/de/karte/tokyo-tsukishima-clinic/)
- [Thessaloniki Onco-Hyperthermia Clinic](https://oncotherm.com/maps/thessaloniki-onco-hyperthermia-clinic/)
- [Thessaloniki Onco-Hyperthermia Clinic](https://oncotherm.com/de/karte/thessaloniki-onco-hyperthermia-clinic/)
- [THERA Praxisklinik](https://oncotherm.com/maps/thera-praxisklinik/)
- [THERA Praxisklinik](https://oncotherm.com/de/karte/thera-praxisklinik/)
- [Soram Clinic](https://oncotherm.com/maps/soram-clinic/)
- [Soram Clinic](https://oncotherm.com/de/karte/soram-clinic/)
- [Soon Chun Hyang UnivSoon Chun Hyang University Hospital Cheonan Oncotherm Partnerersity Hospital Cheonan](https://oncotherm.com/maps/soon-chun-hyang-univsoon-chun-hyang-university-hospital-cheonan-oncotherm-partnerersity-hospital-cheonan/)
- [Soon Chun Hyang UnivSoon Chun Hyang University Hospital Cheonan Oncotherm Partnerersity Hospital Cheonan](https://oncotherm.com/de/karte/soon-chun-hyang-univsoon-chun-hyang-university-hospital-cheonan-oncotherm-partnerersity-hospital-cheonan/)
- [Tri-Service General Hospital - Neihu Campus](https://oncotherm.com/hu/terkepek/tri-service-general-hospital-neihu-campus/)
- [Tsukiji Clinic COSMOS](https://oncotherm.com/hu/terkepek/tsukiji-clinic-cosmos/)
- [Tungs' Taichung Metroharbor Hospital - Wuqi Campus](https://oncotherm.com/hu/terkepek/tungs-taichung-metroharbor-hospital-wuqi-campus/)
- [Uni-Zentrum Naturheilkunde - Universitätsklinikum Freiburg](https://oncotherm.com/hu/terkepek/uni-zentrum-naturheilkunde-universitatsklinikum-freiburg/)
- [Unidad Oncothermia Barcelona](https://oncotherm.com/hu/terkepek/unidad-oncothermia-barcelona-2/)
- [Utsunomiya Central Clinic](https://oncotherm.com/hu/terkepek/utsunomiya-central-clinic/)
- [Veramed-Klinik am Wendelstein](https://oncotherm.com/hu/terkepek/veramed-klinik-am-wendelstein/)
- [Verita Life Mexico S.A. de C.V.](https://oncotherm.com/hu/terkepek/verita-life-mexico-s-a-de-c-v/)
- [VITALCLINICA](https://oncotherm.com/hu/terkepek/vitalclinica/)
- [Wonju Minjung Hospital](https://oncotherm.com/hu/terkepek/wonju-minjung-hospital/)
- [Wonju Minjung Hospital](https://oncotherm.com/maps/wonju-minjung-hospital/)
- [Wonju Minjung Hospital](https://oncotherm.com/de/karte/wonju-minjung-hospital/)
- [VITALCLINICA](https://oncotherm.com/maps/vitalclinica/)
- [VITALCLINICA](https://oncotherm.com/de/karte/vitalclinica/)
- [Verita Life Mexico S.A. de C.V.](https://oncotherm.com/maps/verita-life-mexico-s-a-de-c-v/)
- [Verita Life Mexico S.A. de C.V.](https://oncotherm.com/de/karte/verita-life-mexico-s-a-de-c-v/)
- [Veramed-Klinik am Wendelstein](https://oncotherm.com/maps/veramed-klinik-am-wendelstein/)
- [Veramed-Klinik am Wendelstein](https://oncotherm.com/de/karte/veramed-klinik-am-wendelstein/)
- [Utsunomiya Central Clinic](https://oncotherm.com/maps/utsunomiya-central-clinic/)
- [Utsunomiya Central Clinic](https://oncotherm.com/de/karte/utsunomiya-central-clinic/)
- [Unidad Oncothermia Barcelona](https://oncotherm.com/maps/unidad-oncothermia-barcelona-2/)
- [Unidad Oncothermia Barcelona](https://oncotherm.com/de/karte/unidad-oncothermia-barcelona-2/)
- [Tungs' Taichung Metroharbor Hospital - Wuqi Campus](https://oncotherm.com/maps/tungs-taichung-metroharbor-hospital-wuqi-campus/)
- [Tungs' Taichung Metroharbor Hospital - Wuqi Campus](https://oncotherm.com/de/karte/tungs-taichung-metroharbor-hospital-wuqi-campus/)
- [Uni-Zentrum Naturheilkunde - Universitätsklinikum Freiburg](https://oncotherm.com/maps/uni-zentrum-naturheilkunde-universitatsklinikum-freiburg/)
- [Uni-Zentrum Naturheilkunde - Universitätsklinikum Freiburg](https://oncotherm.com/de/karte/uni-zentrum-naturheilkunde-universitatsklinikum-freiburg/)
- [Tri-Service General Hospital - Neihu Campus](https://oncotherm.com/maps/tri-service-general-hospital-neihu-campus/)
- [Tri-Service General Hospital - Neihu Campus](https://oncotherm.com/de/karte/tri-service-general-hospital-neihu-campus/)
- [Wonju Severance Christian Hospital (Yonsei University Wonju College of Medicine)](https://oncotherm.com/hu/terkepek/wonju-severance-christian-hospital-yonsei-university-wonju-college-of-medicine/)
- [Wooridul Internal Medicine Hospital](https://oncotherm.com/hu/terkepek/wooridul-internal-medicine-hospital/)
- [Yongin Seoul Hospital](https://oncotherm.com/hu/terkepek/yongin-seoul-hospital/)
- [Yuan's General Hospital](https://oncotherm.com/hu/terkepek/yuans-general-hospital/)
- [Yuseong Sun Hospital](https://oncotherm.com/hu/terkepek/yuseong-sun-hospital/)
- [Zenith Hospital](https://oncotherm.com/hu/terkepek/zenith-hospital/)
- [Zentrum der erweiterten Medizin](https://oncotherm.com/hu/terkepek/zentrum-der-erweiterten-medizin/)
- [Zentrum für Naturheilverfahren Dr. Hartung](https://oncotherm.com/hu/terkepek/zentrum-fur-naturheilverfahren-dr-hartung/)
- [Zhongmei Hospital](https://oncotherm.com/hu/terkepek/zhongmei-hospital/)
- [Zentrum der erweiterten Medizin](https://oncotherm.com/maps/zentrum-der-erweiterten-medizin/)
- [Zentrum der erweiterten Medizin](https://oncotherm.com/de/karte/zentrum-der-erweiterten-medizin/)
- [Zenith Hospital](https://oncotherm.com/maps/zenith-hospital/)
- [Zenith Hospital](https://oncotherm.com/de/karte/zenith-hospital/)
- [Yuan's General Hospital](https://oncotherm.com/maps/yuans-general-hospital/)
- [Yuan's General Hospital](https://oncotherm.com/de/karte/yuans-general-hospital/)
- [Yuseong Sun Hospital](https://oncotherm.com/maps/yuseong-sun-hospital/)
- [Yuseong Sun Hospital](https://oncotherm.com/de/karte/yuseong-sun-hospital/)
- [Yongin Seoul Hospital](https://oncotherm.com/maps/yongin-seoul-hospital/)
- [Yongin Seoul Hospital](https://oncotherm.com/de/karte/yongin-seoul-hospital/)
- [Wooridul Internal Medicine Hospital](https://oncotherm.com/maps/wooridul-internal-medicine-hospital/)
- [Wooridul Internal Medicine Hospital](https://oncotherm.com/de/karte/wooridul-internal-medicine-hospital/)
- [Wonju Severance Christian Hospital (Yonsei University Wonju College of Medicine)](https://oncotherm.com/maps/wonju-severance-christian-hospital-yonsei-university-wonju-college-of-medicine/)
- [Wonju Severance Christian Hospital (Yonsei University Wonju College of Medicine)](https://oncotherm.com/de/karte/wonju-severance-christian-hospital-yonsei-university-wonju-college-of-medicine/)

## Klinikai publikációk

- [Modulated electrohyperthermia in locally advanced cervical cancer Results of an observational study of 95 patients](https://oncotherm.com/hu/klinikai-publikaciok/modulated-electrohyperthermia-in-locally-advanced-cervical-cancer-results-of-an-observational-study-of-95-patients/) - Abstract Abstract Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected from
- [Modulated electrohyperthermia in locally advanced cervical cancer Results of an observational study of 95 patients](https://oncotherm.com/clinical-publications/modulated-electrohyperthermia-in-locally-advanced-cervical-cancer-results-of-an-observational-study-of-95-patients/) - Abstract Abstract Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected from
- [Modulated electrohyperthermia in locally advanced cervical cancer Results of an observational study of 95 patients](https://oncotherm.com/de/klinische-publikationen/modulated-electrohyperthermia-in-locally-advanced-cervical-cancer-results-of-an-observational-study-of-95-patients/) - Abstract Abstract Most federation of gynecology and obstetrics stage II or higher locally advanced cervical cancer (LACC) patients are treated with concurrent chemoradiotherapy (CCRT); however, recurrence is high, and the prognosis is poor. In this observational retrospective study, data from LACC patients treated with CCRT alone or combined with modulated electrohyperthermia (mEHT) were collected from
- [Complex therapy of the not in sano respectable carcinoma of the pancreas – a pilot study](https://oncotherm.com/hu/klinikai-publikaciok/complex-therapy-of-the-not-in-sano-respectable-carcinoma-of-the-pancreas-a-pilot-study/)
- [Complex therapy of the not in sano respectable carcinoma of the pancreas – a pilot study](https://oncotherm.com/clinical-publications/complex-therapy-of-the-not-in-sano-respectable-carcinoma-of-the-pancreas-a-pilot-study/)
- [Complex therapy of the not in sano respectable carcinoma of the pancreas – a pilot study](https://oncotherm.com/de/klinische-publikationen/complex-therapy-of-the-not-in-sano-respectable-carcinoma-of-the-pancreas-a-pilot-study/)
- [Hoffnung bei Prostata-Beschwerden. Die neue Therapie ohne Messer](https://oncotherm.com/hu/klinikai-publikaciok/hoffnung-bei-prostata-beschwerden-die-neue-therapie-ohne-messer/)
- [Hoffnung bei Prostata-Beschwerden. Die neue Therapie ohne Messer](https://oncotherm.com/clinical-publications/hoffnung-bei-prostata-beschwerden-die-neue-therapie-ohne-messer/)
- [Hoffnung bei Prostata-Beschwerden. Die neue Therapie ohne Messer](https://oncotherm.com/de/klinische-publikationen/hoffnung-bei-prostata-beschwerden-die-neue-therapie-ohne-messer/)
- [Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer](https://oncotherm.com/hu/klinikai-publikaciok/deep-hyperthermia-with-radiofrequencies-in-patients-with-liver-metastases-from-colorectal-cancer/) - Abstract Patients at advanced stage of colorectal cancer with liver metastases have been treated with deep hyperthermia alone or in combination with chemotherapy (5-FU + FA + MMC). Hyperthermia was achieved by arrangements of capacitive electrodes with a radiofrequency field of 13.56 MHz (RF-DHT). This prospective open single-arm clinical study with 80 patients suffering from
- [Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer](https://oncotherm.com/clinical-publications/deep-hyperthermia-with-radiofrequencies-in-patients-with-liver-metastases-from-colorectal-cancer/) - Abstract Patients at advanced stage of colorectal cancer with liver metastases have been treated with deep hyperthermia alone or in combination with chemotherapy (5-FU + FA + MMC). Hyperthermia was achieved by arrangements of capacitive electrodes with a radiofrequency field of 13.56 MHz (RF-DHT). This prospective open single-arm clinical study with 80 patients suffering from
- [Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer](https://oncotherm.com/de/klinische-publikationen/deep-hyperthermia-with-radiofrequencies-in-patients-with-liver-metastases-from-colorectal-cancer/) - Abstract Patients at advanced stage of colorectal cancer with liver metastases have been treated with deep hyperthermia alone or in combination with chemotherapy (5-FU + FA + MMC). Hyperthermia was achieved by arrangements of capacitive electrodes with a radiofrequency field of 13.56 MHz (RF-DHT). This prospective open single-arm clinical study with 80 patients suffering from
- [Posttreatment Histology and Microcirculation Status of Osteogenic Sarcoma after a Neoadjuvant Chemo- and Radiotherapy in Combination with Local Electromagnetic Hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/posttreatment-histology-and-microcirculation-status-of-osteogenic-sarcoma-after-a-neoadjuvant-chemo-and-radiotherapy-in-combination-with-local-electromagnetic-hyperthermia/) - Abstract BACKGROUND: Many biological attributes of tumors (including regional blood flow and microcirculation) can deteriorate the homogeneity of heat distribution and temperature elevation during hyperthermia. We analyzed the connection between the microcirculation status of osteogenic sarcomas and the posttreatment histology after neoadjuvant chemotherapy, irradiation and local hyperthermia. PATIENTS AND METHODS: 62 patients with histologically verified
- [Posttreatment Histology and Microcirculation Status of Osteogenic Sarcoma after a Neoadjuvant Chemo- and Radiotherapy in Combination with Local Electromagnetic Hyperthermia](https://oncotherm.com/clinical-publications/posttreatment-histology-and-microcirculation-status-of-osteogenic-sarcoma-after-a-neoadjuvant-chemo-and-radiotherapy-in-combination-with-local-electromagnetic-hyperthermia/) - Abstract BACKGROUND: Many biological attributes of tumors (including regional blood flow and microcirculation) can deteriorate the homogeneity of heat distribution and temperature elevation during hyperthermia. We analyzed the connection between the microcirculation status of osteogenic sarcomas and the posttreatment histology after neoadjuvant chemotherapy, irradiation and local hyperthermia. PATIENTS AND METHODS: 62 patients with histologically verified
- [Posttreatment Histology and Microcirculation Status of Osteogenic Sarcoma after a Neoadjuvant Chemo- and Radiotherapy in Combination with Local Electromagnetic Hyperthermia](https://oncotherm.com/de/klinische-publikationen/posttreatment-histology-and-microcirculation-status-of-osteogenic-sarcoma-after-a-neoadjuvant-chemo-and-radiotherapy-in-combination-with-local-electromagnetic-hyperthermia/) - Abstract BACKGROUND: Many biological attributes of tumors (including regional blood flow and microcirculation) can deteriorate the homogeneity of heat distribution and temperature elevation during hyperthermia. We analyzed the connection between the microcirculation status of osteogenic sarcomas and the posttreatment histology after neoadjuvant chemotherapy, irradiation and local hyperthermia. PATIENTS AND METHODS: 62 patients with histologically verified
- [Transurethral hyperthermia in early stage prostate cancer](https://oncotherm.com/hu/klinikai-publikaciok/transurethral-hyperthermia-in-early-stage-prostate-cancer/) - Objective A treatment only has value if it can be demonstrated to be more effective than doing nothing. The major treatment for early prostate cancer (PC) is surgery or radiation. Unfortunately, none of these has been clearly shown to have a positive effect on long-term survival. In a study published in JAMA in 1997 a
- [Transurethral hyperthermia in early stage prostate cancer](https://oncotherm.com/clinical-publications/transurethral-hyperthermia-in-early-stage-prostate-cancer/) - Objective A treatment only has value if it can be demonstrated to be more effective than doing nothing. The major treatment for early prostate cancer (PC) is surgery or radiation. Unfortunately, none of these has been clearly shown to have a positive effect on long-term survival. In a study published in JAMA in 1997 a
- [Transurethral hyperthermia in early stage prostate cancer](https://oncotherm.com/de/klinische-publikationen/transurethral-hyperthermia-in-early-stage-prostate-cancer/) - Objective A treatment only has value if it can be demonstrated to be more effective than doing nothing. The major treatment for early prostate cancer (PC) is surgery or radiation. Unfortunately, none of these has been clearly shown to have a positive effect on long-term survival. In a study published in JAMA in 1997 a
- [Radiofrequency Transurethral Hyperthermia and complete Androgen Blockade. A Nonsurgical Approach to Treating Prostate Cancer](https://oncotherm.com/hu/klinikai-publikaciok/radiofrequency-transurethral-hyperthermia-and-complete-androgen-blockade-a-nonsurgical-approach-to-treating-prostate-cancer/)
- [Radiofrequency Transurethral Hyperthermia and complete Androgen Blockade. A Nonsurgical Approach to Treating Prostate Cancer](https://oncotherm.com/clinical-publications/radiofrequency-transurethral-hyperthermia-and-complete-androgen-blockade-a-nonsurgical-approach-to-treating-prostate-cancer/)
- [Radiofrequency Transurethral Hyperthermia and complete Androgen Blockade. A Nonsurgical Approach to Treating Prostate Cancer](https://oncotherm.com/de/klinische-publikationen/radiofrequency-transurethral-hyperthermia-and-complete-androgen-blockade-a-nonsurgical-approach-to-treating-prostate-cancer/)
- [Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer](https://oncotherm.com/hu/klinikai-publikaciok/whole-body-hyperthermia-in-combination-with-platinum-containing-drugs-in-patients-with-recurrent-ovarian-cancer-2/) - Abstract Background. Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in
- [Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer](https://oncotherm.com/clinical-publications/whole-body-hyperthermia-in-combination-with-platinum-containing-drugs-in-patients-with-recurrent-ovarian-cancer-2/) - Abstract Background. Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in
- [Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer](https://oncotherm.com/de/klinische-publikationen/whole-body-hyperthermia-in-combination-with-platinum-containing-drugs-in-patients-with-recurrent-ovarian-cancer-2/) - Abstract Background. Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in
- [Tolerability of external electro-hyperthermia in the treatment of solid tumors](https://oncotherm.com/hu/klinikai-publikaciok/tolerability-of-external-electro-hyperthermia-in-the-treatment-of-solid-tumors/)
- [Tolerability of external electro-hyperthermia in the treatment of solid tumors](https://oncotherm.com/clinical-publications/tolerability-of-external-electro-hyperthermia-in-the-treatment-of-solid-tumors/)
- [Tolerability of external electro-hyperthermia in the treatment of solid tumors](https://oncotherm.com/de/klinische-publikationen/tolerability-of-external-electro-hyperthermia-in-the-treatment-of-solid-tumors/)
- [The treatment of patients with high-grade malignant gliomas with RF-hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/the-treatment-of-patients-with-high-grade-malignant-gliomas-with-rf-hyperthermia/)
- [The treatment of patients with high-grade malignant gliomas with RF-hyperthermia](https://oncotherm.com/clinical-publications/the-treatment-of-patients-with-high-grade-malignant-gliomas-with-rf-hyperthermia/)
- [The treatment of patients with high-grade malignant gliomas with RF-hyperthermia](https://oncotherm.com/de/klinische-publikationen/the-treatment-of-patients-with-high-grade-malignant-gliomas-with-rf-hyperthermia/)
- [Malignus és benignus prosztatadaganatok hyperthermiája](https://oncotherm.com/hu/klinikai-publikaciok/malignus-es-benignus-prosztatadaganatok-hyperthermiaja/)
- [Malignus és benignus prosztatadaganatok hyperthermiája](https://oncotherm.com/clinical-publications/malignus-es-benignus-prosztatadaganatok-hyperthermiaja/)
- [Malignus és benignus prosztatadaganatok hyperthermiája](https://oncotherm.com/de/klinische-publikationen/malignus-es-benignus-prosztatadaganatok-hyperthermiaja/)
- [Thermo-Chemotherapie des fortgeschrittenen Pankreaskarzinoms. Ergebnisseeiner klinischen Anwendungsstudie](https://oncotherm.com/hu/klinikai-publikaciok/thermo-chemotherapie-des-fortgeschrittenen-pankreaskarzinoms-ergebnisseeiner-klinischen-anwendungsstudie/) - ABSTRACT: Oncothermia is a method of hyperthermia in oncology, controlling the locally applied deep heat by selectively targeting the cellular membrane of the malignant cells. The selection of the method is based on various biophysical and biochemical achievements. There are various differences between the malignant and healthy cells, which could be used for their selection
- [Thermo-Chemotherapie des fortgeschrittenen Pankreaskarzinoms. Ergebnisseeiner klinischen Anwendungsstudie](https://oncotherm.com/clinical-publications/thermo-chemotherapie-des-fortgeschrittenen-pankreaskarzinoms-ergebnisseeiner-klinischen-anwendungsstudie/) - ABSTRACT: Oncothermia is a method of hyperthermia in oncology, controlling the locally applied deep heat by selectively targeting the cellular membrane of the malignant cells. The selection of the method is based on various biophysical and biochemical achievements. There are various differences between the malignant and healthy cells, which could be used for their selection
- [Thermo-Chemotherapie des fortgeschrittenen Pankreaskarzinoms. Ergebnisseeiner klinischen Anwendungsstudie](https://oncotherm.com/de/klinische-publikationen/thermo-chemotherapie-des-fortgeschrittenen-pankreaskarzinoms-ergebnisseeiner-klinischen-anwendungsstudie/) - ABSTRACT: Oncothermia is a method of hyperthermia in oncology, controlling the locally applied deep heat by selectively targeting the cellular membrane of the malignant cells. The selection of the method is based on various biophysical and biochemical achievements. There are various differences between the malignant and healthy cells, which could be used for their selection
- [Lebermetastasen bei kolorektalen Karzinomen](https://oncotherm.com/hu/klinikai-publikaciok/lebermetastasen-bei-kolorektalen-karzinomen/)
- [Lebermetastasen bei kolorektalen Karzinomen](https://oncotherm.com/clinical-publications/lebermetastasen-bei-kolorektalen-karzinomen/)
- [Lebermetastasen bei kolorektalen Karzinomen](https://oncotherm.com/de/klinische-publikationen/lebermetastasen-bei-kolorektalen-karzinomen/)
- [Whole-body hyperthermia in combination with platinum containing drugs in patients with recurrent ovarian cancer](https://oncotherm.com/hu/klinikai-publikaciok/whole-body-hyperthermia-in-combination-with-platinum-containing-drugs-in-patients-with-recurrent-ovarian-cancer/) - Abstract BACKGROUND: Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in
- [Whole-body hyperthermia in combination with platinum containing drugs in patients with recurrent ovarian cancer](https://oncotherm.com/clinical-publications/whole-body-hyperthermia-in-combination-with-platinum-containing-drugs-in-patients-with-recurrent-ovarian-cancer/) - Abstract BACKGROUND: Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in
- [Whole-body hyperthermia in combination with platinum containing drugs in patients with recurrent ovarian cancer](https://oncotherm.com/de/klinische-publikationen/whole-body-hyperthermia-in-combination-with-platinum-containing-drugs-in-patients-with-recurrent-ovarian-cancer/) - Abstract BACKGROUND: Patients with advanced ovarian cancer have an enormous risk of relapse after primary therapy, and the prognosis for these patients remains bleak. Primary and acquired resistance of tumor cells to antineoplastic drugs is a major cause of the limited effectiveness of chemotherapy. The effect of whole-body hyperthermia (WBH) combined with platinum-containing chemotherapy in
- [Rebell gegen den Krebs. Biologische Intersivtherapie – Neue Hoffnung für Patienten?](https://oncotherm.com/hu/klinikai-publikaciok/rebell-gegen-den-krebs-biologische-intersivtherapie-neue-hoffnung-fur-patienten/)
- [Rebell gegen den Krebs. Biologische Intersivtherapie – Neue Hoffnung für Patienten?](https://oncotherm.com/clinical-publications/rebell-gegen-den-krebs-biologische-intersivtherapie-neue-hoffnung-fur-patienten/)
- [Rebell gegen den Krebs. Biologische Intersivtherapie – Neue Hoffnung für Patienten?](https://oncotherm.com/de/klinische-publikationen/rebell-gegen-den-krebs-biologische-intersivtherapie-neue-hoffnung-fur-patienten/)
- [Whole body hyperthermia combined with carboplatin/paclitaxel in patients with ovarian carcinoma – Phase-II-study](https://oncotherm.com/hu/klinikai-publikaciok/whole-body-hyperthermia-combined-with-carboplatin-paclitaxel-in-patients-with-ovarian-carcinoma-phase-ii-study/)
- [Whole body hyperthermia combined with carboplatin/paclitaxel in patients with ovarian carcinoma – Phase-II-study](https://oncotherm.com/clinical-publications/whole-body-hyperthermia-combined-with-carboplatin-paclitaxel-in-patients-with-ovarian-carcinoma-phase-ii-study/)
- [Whole body hyperthermia combined with carboplatin/paclitaxel in patients with ovarian carcinoma – Phase-II-study](https://oncotherm.com/de/klinische-publikationen/whole-body-hyperthermia-combined-with-carboplatin-paclitaxel-in-patients-with-ovarian-carcinoma-phase-ii-study/)
- [Bestrahlung der Prostata erhöht Rektum-Ca-Risiko](https://oncotherm.com/hu/klinikai-publikaciok/bestrahlung-der-prostata-erhoht-rektum-ca-risiko/)
- [Bestrahlung der Prostata erhöht Rektum-Ca-Risiko](https://oncotherm.com/clinical-publications/bestrahlung-der-prostata-erhoht-rektum-ca-risiko/)
- [Bestrahlung der Prostata erhöht Rektum-Ca-Risiko](https://oncotherm.com/de/klinische-publikationen/bestrahlung-der-prostata-erhoht-rektum-ca-risiko/)
- [Hyperthermia in combination with ACNU chemotherapy in the treatment of recurrent glioblastoma](https://oncotherm.com/hu/klinikai-publikaciok/hyperthermia-in-combination-with-acnu-chemotherapy-in-the-treatment-of-recurrent-glioblastoma/)
- [Hyperthermia in combination with ACNU chemotherapy in the treatment of recurrent glioblastoma](https://oncotherm.com/clinical-publications/hyperthermia-in-combination-with-acnu-chemotherapy-in-the-treatment-of-recurrent-glioblastoma/)
- [Hyperthermia in combination with ACNU chemotherapy in the treatment of recurrent glioblastoma](https://oncotherm.com/de/klinische-publikationen/hyperthermia-in-combination-with-acnu-chemotherapy-in-the-treatment-of-recurrent-glioblastoma/)
- [Malignes Melanom Stadium IV: Anwendung von regionaler Tiefenhyperthermie, Tamoxifen, Interferon-α und komplementären Therapien](https://oncotherm.com/hu/klinikai-publikaciok/malignes-melanom-stadium-iv-anwendung-von-regionaler-tiefenhyperthermie-tamoxifen-interferon-α-und-komplementaren-therapien/) - Einleitung Die Prognose von Patienten mit metastasiertem Melanom ist schlecht. Alle bisherigen Behandlungskonzepte sind unbefriedigend. Die mediane Überlebenszeit liegt in den meisten Studien zwischen 6 und 9 Monaten und das 5-Jahresüberleben bei nur 1 bis 2 %. Zytostatika ermöglichen Ansprechraten zwischen 10 und 20 % mit einem Anteil von kompletten Ansprechraten von bis zu 5 %. Am besten
- [Malignes Melanom Stadium IV: Anwendung von regionaler Tiefenhyperthermie, Tamoxifen, Interferon-α und komplementären Therapien](https://oncotherm.com/clinical-publications/malignes-melanom-stadium-iv-anwendung-von-regionaler-tiefenhyperthermie-tamoxifen-interferon-α-und-komplementaren-therapien/) - Einleitung Die Prognose von Patienten mit metastasiertem Melanom ist schlecht. Alle bisherigen Behandlungskonzepte sind unbefriedigend. Die mediane Überlebenszeit liegt in den meisten Studien zwischen 6 und 9 Monaten und das 5-Jahresüberleben bei nur 1 bis 2 %. Zytostatika ermöglichen Ansprechraten zwischen 10 und 20 % mit einem Anteil von kompletten Ansprechraten von bis zu 5 %. Am besten
- [Malignes Melanom Stadium IV: Anwendung von regionaler Tiefenhyperthermie, Tamoxifen, Interferon-α und komplementären Therapien](https://oncotherm.com/de/klinische-publikationen/malignes-melanom-stadium-iv-anwendung-von-regionaler-tiefenhyperthermie-tamoxifen-interferon-α-und-komplementaren-therapien/) - Einleitung Die Prognose von Patienten mit metastasiertem Melanom ist schlecht. Alle bisherigen Behandlungskonzepte sind unbefriedigend. Die mediane Überlebenszeit liegt in den meisten Studien zwischen 6 und 9 Monaten und das 5-Jahresüberleben bei nur 1 bis 2 %. Zytostatika ermöglichen Ansprechraten zwischen 10 und 20 % mit einem Anteil von kompletten Ansprechraten von bis zu 5 %. Am besten
- [Thermo-chemotherapy of the advanced pancreas carcinoma](https://oncotherm.com/hu/klinikai-publikaciok/thermo-chemotherapy-of-the-advanced-pancreas-carcinoma/) - Abstract The results of chemotherapy of pancreas carcinoma are still disappointing. In nearly all cases the disease progresses, response rates to cytotoxic therapy are low and the 5-year survival rate amounts to 1%. The purpose of the present study was to evaluate whether response rate, time to progression and survival time can be improved by
- [Thermo-chemotherapy of the advanced pancreas carcinoma](https://oncotherm.com/clinical-publications/thermo-chemotherapy-of-the-advanced-pancreas-carcinoma/) - Abstract The results of chemotherapy of pancreas carcinoma are still disappointing. In nearly all cases the disease progresses, response rates to cytotoxic therapy are low and the 5-year survival rate amounts to 1%. The purpose of the present study was to evaluate whether response rate, time to progression and survival time can be improved by
- [Thermo-chemotherapy of the advanced pancreas carcinoma](https://oncotherm.com/de/klinische-publikationen/thermo-chemotherapy-of-the-advanced-pancreas-carcinoma/) - Abstract The results of chemotherapy of pancreas carcinoma are still disappointing. In nearly all cases the disease progresses, response rates to cytotoxic therapy are low and the 5-year survival rate amounts to 1%. The purpose of the present study was to evaluate whether response rate, time to progression and survival time can be improved by
- [Behandlung des fortgeschrittenen Pankreaskarzinoms mit regionaler Hyperthermie und einer Zytostase mit Mitomycin- C und 5-Fluorouracil/ Folinsäure](https://oncotherm.com/hu/klinikai-publikaciok/behandlung-des-fortgeschrittenen-pankreaskarzinoms-mit-regionaler-hyperthermie-und-einer-zytostase-mit-mitomycin-c-und-5-fluorouracil-folinsaure/) - Zusammenfassung Hintergrund Das Pankreaskarzinom stellt für die onkologische Therapie nach wie vor eine große Herausforderung dar. Bisher lässt sich der fortschreitende Verlauf der Erkrankung kaum aufhalten, so dass die 5- Jahres- Überlebensrate unter 1% liegt. Aufgrund der niedrigen Ansprechraten einer zytostatischen Therapie soll die Wirksamkeit einer Chemotherapie mit Mitomycin C/ 5-Fluorouracil/ Folinsäure durch den Einsatz
- [Behandlung des fortgeschrittenen Pankreaskarzinoms mit regionaler Hyperthermie und einer Zytostase mit Mitomycin- C und 5-Fluorouracil/ Folinsäure](https://oncotherm.com/clinical-publications/behandlung-des-fortgeschrittenen-pankreaskarzinoms-mit-regionaler-hyperthermie-und-einer-zytostase-mit-mitomycin-c-und-5-fluorouracil-folinsaure/) - Zusammenfassung Hintergrund Das Pankreaskarzinom stellt für die onkologische Therapie nach wie vor eine große Herausforderung dar. Bisher lässt sich der fortschreitende Verlauf der Erkrankung kaum aufhalten, so dass die 5- Jahres- Überlebensrate unter 1% liegt. Aufgrund der niedrigen Ansprechraten einer zytostatischen Therapie soll die Wirksamkeit einer Chemotherapie mit Mitomycin C/ 5-Fluorouracil/ Folinsäure durch den Einsatz
- [Behandlung des fortgeschrittenen Pankreaskarzinoms mit regionaler Hyperthermie und einer Zytostase mit Mitomycin- C und 5-Fluorouracil/ Folinsäure](https://oncotherm.com/de/klinische-publikationen/behandlung-des-fortgeschrittenen-pankreaskarzinoms-mit-regionaler-hyperthermie-und-einer-zytostase-mit-mitomycin-c-und-5-fluorouracil-folinsaure/) - Zusammenfassung Hintergrund Das Pankreaskarzinom stellt für die onkologische Therapie nach wie vor eine große Herausforderung dar. Bisher lässt sich der fortschreitende Verlauf der Erkrankung kaum aufhalten, so dass die 5- Jahres- Überlebensrate unter 1% liegt. Aufgrund der niedrigen Ansprechraten einer zytostatischen Therapie soll die Wirksamkeit einer Chemotherapie mit Mitomycin C/ 5-Fluorouracil/ Folinsäure durch den Einsatz
- [Glioblastoma multiforme Grad IV: Regionale Tiefenhyperthermie, Antiangiogenese mit Thalidomid, Hochdosis-Ascorbinsäureinfusionen und komplementäre Therapie](https://oncotherm.com/hu/klinikai-publikaciok/glioblastoma-multiforme-grad-iv-regionale-tiefenhyperthermie-antiangiogenese-mit-thalidomid-hochdosis-ascorbinsaureinfusionen-und-komplementare-therapie/) - Einleitung Epidemiologisch werden primäre Hirntumoren in Deutschland mit einer Inzidenz von etwa 10/100 000 Einwohner und Jahr beobachtet. Im Erwachsenenalter sind hierbei bis zu 50 % aller Gehirntumoren den Gliomen zuzuordnen mit deutlichem Anstieg ab dem 65. Lebensjahr auf ca. 18/100 000 Einwohner [1], [2]. Männer erkranken statistisch gesehen häufiger als Frauen (m/w: 1,2-1,9/1). Die histologische Klassifikation,
- [Glioblastoma multiforme Grad IV: Regionale Tiefenhyperthermie, Antiangiogenese mit Thalidomid, Hochdosis-Ascorbinsäureinfusionen und komplementäre Therapie](https://oncotherm.com/clinical-publications/glioblastoma-multiforme-grad-iv-regionale-tiefenhyperthermie-antiangiogenese-mit-thalidomid-hochdosis-ascorbinsaureinfusionen-und-komplementare-therapie/) - Einleitung Epidemiologisch werden primäre Hirntumoren in Deutschland mit einer Inzidenz von etwa 10/100 000 Einwohner und Jahr beobachtet. Im Erwachsenenalter sind hierbei bis zu 50 % aller Gehirntumoren den Gliomen zuzuordnen mit deutlichem Anstieg ab dem 65. Lebensjahr auf ca. 18/100 000 Einwohner [1], [2]. Männer erkranken statistisch gesehen häufiger als Frauen (m/w: 1,2-1,9/1). Die histologische Klassifikation,
- [Glioblastoma multiforme Grad IV: Regionale Tiefenhyperthermie, Antiangiogenese mit Thalidomid, Hochdosis-Ascorbinsäureinfusionen und komplementäre Therapie](https://oncotherm.com/de/klinische-publikationen/glioblastoma-multiforme-grad-iv-regionale-tiefenhyperthermie-antiangiogenese-mit-thalidomid-hochdosis-ascorbinsaureinfusionen-und-komplementare-therapie/) - Einleitung Epidemiologisch werden primäre Hirntumoren in Deutschland mit einer Inzidenz von etwa 10/100 000 Einwohner und Jahr beobachtet. Im Erwachsenenalter sind hierbei bis zu 50 % aller Gehirntumoren den Gliomen zuzuordnen mit deutlichem Anstieg ab dem 65. Lebensjahr auf ca. 18/100 000 Einwohner [1], [2]. Männer erkranken statistisch gesehen häufiger als Frauen (m/w: 1,2-1,9/1). Die histologische Klassifikation,
- [A Phase II Clinical Study on Relapsed Malignant Gliomas Treated with Electro-hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/a-phase-ii-clinical-study-on-relapsed-malignant-gliomas-treated-with-electro-hyperthermia/) - Abstract The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients. Twelve patients with histologically diagnosed malignant glioma entered the study. Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma. All patients were pre-treated with temozolamide-based chemotherapy and
- [A Phase II Clinical Study on Relapsed Malignant Gliomas Treated with Electro-hyperthermia](https://oncotherm.com/clinical-publications/a-phase-ii-clinical-study-on-relapsed-malignant-gliomas-treated-with-electro-hyperthermia/) - Abstract The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients. Twelve patients with histologically diagnosed malignant glioma entered the study. Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma. All patients were pre-treated with temozolamide-based chemotherapy and
- [A Phase II Clinical Study on Relapsed Malignant Gliomas Treated with Electro-hyperthermia](https://oncotherm.com/de/klinische-publikationen/a-phase-ii-clinical-study-on-relapsed-malignant-gliomas-treated-with-electro-hyperthermia/) - Abstract The purpose of this study was to evaluate the activity and toxicity of electro-hyperthermia (ET) on relapsed malignant glioma patients. Twelve patients with histologically diagnosed malignant glioma entered the study. Eight patients had glioblastoma multiforme, two had anaplastic astrocytoma grade III and two had anaplastic oligodendroglioma. All patients were pre-treated with temozolamide-based chemotherapy and
- [Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas](https://oncotherm.com/hu/klinikai-publikaciok/retrospective-clinical-study-of-adjuvant-electro-hyperthermia-treatment-for-advanced-brain-gliomas/) - Summary Malignant gliomas represent about 70 % of all brain tumors. Despite advances in standard therapy consisting of surgery, radiation therapy and chemotherapy, gliomas remain an essentially fatal disease, with a median survival time of 10 to 12 months and a 2-year survival rate of 8 % to 12 %. Electro-hyperthermia applied either alone or in combination with
- [Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas](https://oncotherm.com/clinical-publications/retrospective-clinical-study-of-adjuvant-electro-hyperthermia-treatment-for-advanced-brain-gliomas/) - Summary Malignant gliomas represent about 70 % of all brain tumors. Despite advances in standard therapy consisting of surgery, radiation therapy and chemotherapy, gliomas remain an essentially fatal disease, with a median survival time of 10 to 12 months and a 2-year survival rate of 8 % to 12 %. Electro-hyperthermia applied either alone or in combination with
- [Retrospective clinical study of adjuvant electro-hyperthermia treatment for advanced brain-gliomas](https://oncotherm.com/de/klinische-publikationen/retrospective-clinical-study-of-adjuvant-electro-hyperthermia-treatment-for-advanced-brain-gliomas/) - Summary Malignant gliomas represent about 70 % of all brain tumors. Despite advances in standard therapy consisting of surgery, radiation therapy and chemotherapy, gliomas remain an essentially fatal disease, with a median survival time of 10 to 12 months and a 2-year survival rate of 8 % to 12 %. Electro-hyperthermia applied either alone or in combination with
- [Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: phase II study](https://oncotherm.com/hu/klinikai-publikaciok/deep-electro-hyperthermia-ehy-with-or-without-thermo-active-agents-in-patients-with-advanced-hepatic-cell-carcinoma-phase-ii-study/) - Background: Advanced HCC has no standard chemotherapy , all pts would be valuabled in clinical trials. We evaluated effectiveness and toxicity of capacitatively coupled low-frequency 13.56 MHz deep hyperthermia (Oncotherm-EHY 2000) treatment on chemo- refractory malignant primary liver cancer which underwent all other possible treatment. Methods: From February 2005 to July 2006, we enrolled 22 pts
- [Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: phase II study](https://oncotherm.com/clinical-publications/deep-electro-hyperthermia-ehy-with-or-without-thermo-active-agents-in-patients-with-advanced-hepatic-cell-carcinoma-phase-ii-study/) - Background: Advanced HCC has no standard chemotherapy , all pts would be valuabled in clinical trials. We evaluated effectiveness and toxicity of capacitatively coupled low-frequency 13.56 MHz deep hyperthermia (Oncotherm-EHY 2000) treatment on chemo- refractory malignant primary liver cancer which underwent all other possible treatment. Methods: From February 2005 to July 2006, we enrolled 22 pts
- [Deep electro-hyperthermia (EHY) with or without thermo-active agents in patients with advanced hepatic cell carcinoma: phase II study](https://oncotherm.com/de/klinische-publikationen/deep-electro-hyperthermia-ehy-with-or-without-thermo-active-agents-in-patients-with-advanced-hepatic-cell-carcinoma-phase-ii-study/) - Background: Advanced HCC has no standard chemotherapy , all pts would be valuabled in clinical trials. We evaluated effectiveness and toxicity of capacitatively coupled low-frequency 13.56 MHz deep hyperthermia (Oncotherm-EHY 2000) treatment on chemo- refractory malignant primary liver cancer which underwent all other possible treatment. Methods: From February 2005 to July 2006, we enrolled 22 pts
- [Sanfte Hilfen für die Prostata](https://oncotherm.com/hu/klinikai-publikaciok/sanfte-hilfen-fur-die-prostata/)
- [Sanfte Hilfen für die Prostata](https://oncotherm.com/clinical-publications/sanfte-hilfen-fur-die-prostata/)
- [Sanfte Hilfen für die Prostata](https://oncotherm.com/de/klinische-publikationen/sanfte-hilfen-fur-die-prostata/)
- [Prospective phase II trial for recurrent high-grade malignant gliomas with capacitive coupled low radiofrequency (LRF) deep hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/prospective-phase-ii-trial-for-recurrent-high-grade-malignant-gliomas-with-capacitive-coupled-low-radiofrequency-lrf-deep-hyperthermia/) - Abstract Treatment of malignant gliomas is in spite of many new approaches still disappointing. Median survival time (MST) of pts. with glioblastoma multiforme (GM) after diagnosis is 6 to 12 months. Surgery is treatment of first choice, but in most cases healing is not possible. The aims of surgery are tumor debulking or decompression of
- [Prospective phase II trial for recurrent high-grade malignant gliomas with capacitive coupled low radiofrequency (LRF) deep hyperthermia](https://oncotherm.com/clinical-publications/prospective-phase-ii-trial-for-recurrent-high-grade-malignant-gliomas-with-capacitive-coupled-low-radiofrequency-lrf-deep-hyperthermia/) - Abstract Treatment of malignant gliomas is in spite of many new approaches still disappointing. Median survival time (MST) of pts. with glioblastoma multiforme (GM) after diagnosis is 6 to 12 months. Surgery is treatment of first choice, but in most cases healing is not possible. The aims of surgery are tumor debulking or decompression of
- [Prospective phase II trial for recurrent high-grade malignant gliomas with capacitive coupled low radiofrequency (LRF) deep hyperthermia](https://oncotherm.com/de/klinische-publikationen/prospective-phase-ii-trial-for-recurrent-high-grade-malignant-gliomas-with-capacitive-coupled-low-radiofrequency-lrf-deep-hyperthermia/) - Abstract Treatment of malignant gliomas is in spite of many new approaches still disappointing. Median survival time (MST) of pts. with glioblastoma multiforme (GM) after diagnosis is 6 to 12 months. Surgery is treatment of first choice, but in most cases healing is not possible. The aims of surgery are tumor debulking or decompression of
- [Prostatakarzinom: Neue Aspekte für Diagnostik und Therapie](https://oncotherm.com/hu/klinikai-publikaciok/prostatakarzinom-neue-aspekte-fur-diagnostik-und-therapie/)
- [Prostatakarzinom: Neue Aspekte für Diagnostik und Therapie](https://oncotherm.com/clinical-publications/prostatakarzinom-neue-aspekte-fur-diagnostik-und-therapie/)
- [Prostatakarzinom: Neue Aspekte für Diagnostik und Therapie](https://oncotherm.com/de/klinische-publikationen/prostatakarzinom-neue-aspekte-fur-diagnostik-und-therapie/)
- [Clinical study for advanced pancreas cancer treated by oncothermia](https://oncotherm.com/hu/klinikai-publikaciok/clinical-study-for-advanced-pancreas-cancer-treated-by-oncothermia/) - Abstract Pancreas cancer (PCA) is an aggressive, common malignant tumor. We present two retrospective clinical studies of PCA done in two medical centers (HTT-MED Day-clinic and Peterfy Hospital). Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both centers and make a metaanalysis of
- [Clinical study for advanced pancreas cancer treated by oncothermia](https://oncotherm.com/clinical-publications/clinical-study-for-advanced-pancreas-cancer-treated-by-oncothermia/) - Abstract Pancreas cancer (PCA) is an aggressive, common malignant tumor. We present two retrospective clinical studies of PCA done in two medical centers (HTT-MED Day-clinic and Peterfy Hospital). Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both centers and make a metaanalysis of
- [Clinical study for advanced pancreas cancer treated by oncothermia](https://oncotherm.com/de/klinische-publikationen/clinical-study-for-advanced-pancreas-cancer-treated-by-oncothermia/) - Abstract Pancreas cancer (PCA) is an aggressive, common malignant tumor. We present two retrospective clinical studies of PCA done in two medical centers (HTT-MED Day-clinic and Peterfy Hospital). Both of the centers made the treatments by oncothermia in combination with the conventional tumor-therapies. We present the data from both centers and make a metaanalysis of
- [Clinical study for advanced non-small-cell lung-cancer treated by oncothermia](https://oncotherm.com/hu/klinikai-publikaciok/clinical-study-for-advanced-non-small-cell-lung-cancer-treated-by-oncothermia/) - Abstract The non-small-cell-lung-cancer (NSCLC) is a common malignant tumor, and generally not best candidates for hyperthermia due to the cooling effect of the breathing. We present two retrospective clinical studies for NSCLC done by two medical centers (HTT-MED Day-clinic and Peterfy Hospital) made by special modulated field electro-hyperthermia, called oncothermia. Both of the centers made
- [Clinical study for advanced non-small-cell lung-cancer treated by oncothermia](https://oncotherm.com/clinical-publications/clinical-study-for-advanced-non-small-cell-lung-cancer-treated-by-oncothermia/) - Abstract The non-small-cell-lung-cancer (NSCLC) is a common malignant tumor, and generally not best candidates for hyperthermia due to the cooling effect of the breathing. We present two retrospective clinical studies for NSCLC done by two medical centers (HTT-MED Day-clinic and Peterfy Hospital) made by special modulated field electro-hyperthermia, called oncothermia. Both of the centers made
- [Clinical study for advanced non-small-cell lung-cancer treated by oncothermia](https://oncotherm.com/de/klinische-publikationen/clinical-study-for-advanced-non-small-cell-lung-cancer-treated-by-oncothermia/) - Abstract The non-small-cell-lung-cancer (NSCLC) is a common malignant tumor, and generally not best candidates for hyperthermia due to the cooling effect of the breathing. We present two retrospective clinical studies for NSCLC done by two medical centers (HTT-MED Day-clinic and Peterfy Hospital) made by special modulated field electro-hyperthermia, called oncothermia. Both of the centers made
- [Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results](https://oncotherm.com/hu/klinikai-publikaciok/transcranial-electro-hyperthermia-combined-with-alkylating-chemotherapy-in-patients-with-relapsed-high-grade-gliomas-phase-i-clinical-results/) - Abstract Non-invasive loco-regional electro-hyperthermia (EHT) plus alkylating chemotherapy is occasionally used as salvage treatment in the relapse of patients with high-grade gliomas. Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. We performed a single-center prospective non-controlled single-arm Phase I trial. Main inclusion criteria were recurrent high-grade glioma WHO
- [Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results](https://oncotherm.com/clinical-publications/transcranial-electro-hyperthermia-combined-with-alkylating-chemotherapy-in-patients-with-relapsed-high-grade-gliomas-phase-i-clinical-results/) - Abstract Non-invasive loco-regional electro-hyperthermia (EHT) plus alkylating chemotherapy is occasionally used as salvage treatment in the relapse of patients with high-grade gliomas. Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. We performed a single-center prospective non-controlled single-arm Phase I trial. Main inclusion criteria were recurrent high-grade glioma WHO
- [Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results](https://oncotherm.com/de/klinische-publikationen/transcranial-electro-hyperthermia-combined-with-alkylating-chemotherapy-in-patients-with-relapsed-high-grade-gliomas-phase-i-clinical-results/) - Abstract Non-invasive loco-regional electro-hyperthermia (EHT) plus alkylating chemotherapy is occasionally used as salvage treatment in the relapse of patients with high-grade gliomas. Experimental data and retrospective studies suggest potential effects. However, no prospective clinical results are available. We performed a single-center prospective non-controlled single-arm Phase I trial. Main inclusion criteria were recurrent high-grade glioma WHO
- [Oncothermia: Emerging Therapy in Oncology](https://oncotherm.com/hu/klinikai-publikaciok/oncothermia-emerging-therapy-in-oncology/) - Abstract The healing effect of heat was already mentioned in the advanced cultures of the old Egypt (2400 B.C.), but only the medical professionals of the Greek Antique used this therapeutic approach consistently, acknowledged it and called it over-warming (in Greek: Hyperthermia). Oncothermia is a new paradigm which entails the generation of temperature gradient by
- [Oncothermia: Emerging Therapy in Oncology](https://oncotherm.com/clinical-publications/oncothermia-emerging-therapy-in-oncology/) - Abstract The healing effect of heat was already mentioned in the advanced cultures of the old Egypt (2400 B.C.), but only the medical professionals of the Greek Antique used this therapeutic approach consistently, acknowledged it and called it over-warming (in Greek: Hyperthermia). Oncothermia is a new paradigm which entails the generation of temperature gradient by
- [Oncothermia: Emerging Therapy in Oncology](https://oncotherm.com/de/klinische-publikationen/oncothermia-emerging-therapy-in-oncology/) - Abstract The healing effect of heat was already mentioned in the advanced cultures of the old Egypt (2400 B.C.), but only the medical professionals of the Greek Antique used this therapeutic approach consistently, acknowledged it and called it over-warming (in Greek: Hyperthermia). Oncothermia is a new paradigm which entails the generation of temperature gradient by
- [Neue Studie heizt Diskussion über den Wert von PSA-Tests an](https://oncotherm.com/hu/klinikai-publikaciok/neue-studie-heizt-diskussion-uber-den-wert-von-psa-tests-an/)
- [Neue Studie heizt Diskussion über den Wert von PSA-Tests an](https://oncotherm.com/clinical-publications/neue-studie-heizt-diskussion-uber-den-wert-von-psa-tests-an/)
- [Neue Studie heizt Diskussion über den Wert von PSA-Tests an](https://oncotherm.com/de/klinische-publikationen/neue-studie-heizt-diskussion-uber-den-wert-von-psa-tests-an/)
- [Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/successful-treatment-of-solitary-bone-metastasis-of-non-small-cell-lung-cancer-with-bevacizumab-and-hyperthermia/) - Abstract Non-small cell lung cancer (NSCLC) represents 85 % of all malignant lung cancers. In metastatic disease the principle goal of palliative therapy is to prolong survival with least toxicity and best patients’ quality of life. Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in
- [Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia](https://oncotherm.com/clinical-publications/successful-treatment-of-solitary-bone-metastasis-of-non-small-cell-lung-cancer-with-bevacizumab-and-hyperthermia/) - Abstract Non-small cell lung cancer (NSCLC) represents 85 % of all malignant lung cancers. In metastatic disease the principle goal of palliative therapy is to prolong survival with least toxicity and best patients’ quality of life. Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in
- [Successful Treatment of Solitary Bone Metastasis of Non-Small Cell Lung Cancer with Bevacizumab and Hyperthermia](https://oncotherm.com/de/klinische-publikationen/successful-treatment-of-solitary-bone-metastasis-of-non-small-cell-lung-cancer-with-bevacizumab-and-hyperthermia/) - Abstract Non-small cell lung cancer (NSCLC) represents 85 % of all malignant lung cancers. In metastatic disease the principle goal of palliative therapy is to prolong survival with least toxicity and best patients’ quality of life. Bevacizumab (BEV) has been approved as first line treatment in combination with platinum based chemotherapy and maintenance therapy in
- [Adjuvante Radiotherapie: Welcher Patient mit Prostatakarzinom profitiert?](https://oncotherm.com/hu/klinikai-publikaciok/adjuvante-radiotherapie-welcher-patient-mit-prostatakarzinom-profitiert/)
- [Adjuvante Radiotherapie: Welcher Patient mit Prostatakarzinom profitiert?](https://oncotherm.com/clinical-publications/adjuvante-radiotherapie-welcher-patient-mit-prostatakarzinom-profitiert/)
- [Adjuvante Radiotherapie: Welcher Patient mit Prostatakarzinom profitiert?](https://oncotherm.com/de/klinische-publikationen/adjuvante-radiotherapie-welcher-patient-mit-prostatakarzinom-profitiert/)
- [Für und Wider des Prostata-Karzinom-Screenings](https://oncotherm.com/hu/klinikai-publikaciok/fur-und-wider-des-prostata-karzinom-screenings/)
- [Für und Wider des Prostata-Karzinom-Screenings](https://oncotherm.com/clinical-publications/fur-und-wider-des-prostata-karzinom-screenings/)
- [Für und Wider des Prostata-Karzinom-Screenings](https://oncotherm.com/de/klinische-publikationen/fur-und-wider-des-prostata-karzinom-screenings/)
- [Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy](https://oncotherm.com/hu/klinikai-publikaciok/successful-treatment-of-advanced-ovarian-cancer-with-thermochemotherapy-and-adjuvant-immune-therapy/) - Abstract We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m2/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range
- [Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy](https://oncotherm.com/clinical-publications/successful-treatment-of-advanced-ovarian-cancer-with-thermochemotherapy-and-adjuvant-immune-therapy/) - Abstract We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m2/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range
- [Successful Treatment of Advanced Ovarian Cancer with Thermochemotherapy and Adjuvant Immune Therapy](https://oncotherm.com/de/klinische-publikationen/successful-treatment-of-advanced-ovarian-cancer-with-thermochemotherapy-and-adjuvant-immune-therapy/) - Abstract We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m2/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range
- [Treatment of advanced cervical cancer with complex chemoradio – hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/treatment-of-advanced-cervical-cancer-with-complex-chemoradio-hyperthermia/) - Abstract This single arm, retrospective, single institution study investigated intention to treat patients (n=72) with advanced cancer of cervix of uterus. The study was performed in 2001–2010, providing 331 sessions. All patients had radiotherapies as fractional radiotherapy and intracavital brachytherapy. Some patients (n=34) received chemotherapy (Cisplatin 40 mg/m2/week; concomitantly with tele-radiotherapy) as well. Complementary to
- [Treatment of advanced cervical cancer with complex chemoradio – hyperthermia](https://oncotherm.com/clinical-publications/treatment-of-advanced-cervical-cancer-with-complex-chemoradio-hyperthermia/) - Abstract This single arm, retrospective, single institution study investigated intention to treat patients (n=72) with advanced cancer of cervix of uterus. The study was performed in 2001–2010, providing 331 sessions. All patients had radiotherapies as fractional radiotherapy and intracavital brachytherapy. Some patients (n=34) received chemotherapy (Cisplatin 40 mg/m2/week; concomitantly with tele-radiotherapy) as well. Complementary to
- [Treatment of advanced cervical cancer with complex chemoradio – hyperthermia](https://oncotherm.com/de/klinische-publikationen/treatment-of-advanced-cervical-cancer-with-complex-chemoradio-hyperthermia/) - Abstract This single arm, retrospective, single institution study investigated intention to treat patients (n=72) with advanced cancer of cervix of uterus. The study was performed in 2001–2010, providing 331 sessions. All patients had radiotherapies as fractional radiotherapy and intracavital brachytherapy. Some patients (n=34) received chemotherapy (Cisplatin 40 mg/m2/week; concomitantly with tele-radiotherapy) as well. Complementary to
- [Oncothermia in HIV positive and negative locally advanced cervical cancer patients in South Africa](https://oncotherm.com/hu/klinikai-publikaciok/oncothermia-in-hiv-positive-and-negative-locally-advanced-cervical-cancer-patients-in-south-africa/) - Abstract Aim. Investigate the clinical, economic, and cellular effects of the addition of oncothermia to standard treatment for HIV-positive and -negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives. Evaluate the effect that the addition of oncothermia has on local disease control, progression-free survival, overall survival at 2 years, treatment toxicity,
- [Oncothermia in HIV positive and negative locally advanced cervical cancer patients in South Africa](https://oncotherm.com/clinical-publications/oncothermia-in-hiv-positive-and-negative-locally-advanced-cervical-cancer-patients-in-south-africa/) - Abstract Aim. Investigate the clinical, economic, and cellular effects of the addition of oncothermia to standard treatment for HIV-positive and -negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives. Evaluate the effect that the addition of oncothermia has on local disease control, progression-free survival, overall survival at 2 years, treatment toxicity,
- [Oncothermia in HIV positive and negative locally advanced cervical cancer patients in South Africa](https://oncotherm.com/de/klinische-publikationen/oncothermia-in-hiv-positive-and-negative-locally-advanced-cervical-cancer-patients-in-south-africa/) - Abstract Aim. Investigate the clinical, economic, and cellular effects of the addition of oncothermia to standard treatment for HIV-positive and -negative locally advanced cervical cancer patients in public healthcare in South Africa. Objectives. Evaluate the effect that the addition of oncothermia has on local disease control, progression-free survival, overall survival at 2 years, treatment toxicity,
- [Oncothermia Application for Various Malignant Diseases](https://oncotherm.com/hu/klinikai-publikaciok/oncothermia-application-for-various-malignant-diseases/) - ABSTRACT Oncothermia was introduced to our hospital in 2010. Our objective is to report results of 277 patients treated by oncothermia during 20 months. We present some characteristic cases and statistical study of the overall results. We concluded by stating the feasibility of oncothermia to treat high variety of malignant diseases also in their very
- [Oncothermia Application for Various Malignant Diseases](https://oncotherm.com/clinical-publications/oncothermia-application-for-various-malignant-diseases/) - ABSTRACT Oncothermia was introduced to our hospital in 2010. Our objective is to report results of 277 patients treated by oncothermia during 20 months. We present some characteristic cases and statistical study of the overall results. We concluded by stating the feasibility of oncothermia to treat high variety of malignant diseases also in their very
- [Oncothermia Application for Various Malignant Diseases](https://oncotherm.com/de/klinische-publikationen/oncothermia-application-for-various-malignant-diseases/) - ABSTRACT Oncothermia was introduced to our hospital in 2010. Our objective is to report results of 277 patients treated by oncothermia during 20 months. We present some characteristic cases and statistical study of the overall results. We concluded by stating the feasibility of oncothermia to treat high variety of malignant diseases also in their very
- [Lyme Disease and Oncothermia](https://oncotherm.com/hu/klinikai-publikaciok/lyme-disease-and-oncothermia/) - Abstract Lyme disease is a tick-borne disease with multiple organ failures, and systemic disorders. Dramatic change becomes apparent in the chronic phase of the disease. Chronic fatigue syndrome, lapse of concentration, depression, joint pain, and muscle pain are a few, but major clinical symptoms characterizing the disease. The human immune system is defenseless. Borrelia uses
- [Lyme Disease and Oncothermia](https://oncotherm.com/clinical-publications/lyme-disease-and-oncothermia/) - Abstract Lyme disease is a tick-borne disease with multiple organ failures, and systemic disorders. Dramatic change becomes apparent in the chronic phase of the disease. Chronic fatigue syndrome, lapse of concentration, depression, joint pain, and muscle pain are a few, but major clinical symptoms characterizing the disease. The human immune system is defenseless. Borrelia uses
- [Lyme Disease and Oncothermia](https://oncotherm.com/de/klinische-publikationen/lyme-disease-and-oncothermia/) - Abstract Lyme disease is a tick-borne disease with multiple organ failures, and systemic disorders. Dramatic change becomes apparent in the chronic phase of the disease. Chronic fatigue syndrome, lapse of concentration, depression, joint pain, and muscle pain are a few, but major clinical symptoms characterizing the disease. The human immune system is defenseless. Borrelia uses
- [Hypoxia Immunity, Metabolism and Hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/hypoxia-immunity-metabolism-and-hyperthermia/) - Abstract Hypoxia is common in solid tumors and in many other disease states such as myocardial infarction, stroke, bone fracture, and pneumonitis. Once hypoxia has developed, the undernourished and hypoxic cells trigger signals in order to obtain new blood vessels to satisfy their increasing demands and to resolve hypoxia. The principal signal activated is an
- [Hypoxia Immunity, Metabolism and Hyperthermia](https://oncotherm.com/clinical-publications/hypoxia-immunity-metabolism-and-hyperthermia/) - Abstract Hypoxia is common in solid tumors and in many other disease states such as myocardial infarction, stroke, bone fracture, and pneumonitis. Once hypoxia has developed, the undernourished and hypoxic cells trigger signals in order to obtain new blood vessels to satisfy their increasing demands and to resolve hypoxia. The principal signal activated is an
- [Hypoxia Immunity, Metabolism and Hyperthermia](https://oncotherm.com/de/klinische-publikationen/hypoxia-immunity-metabolism-and-hyperthermia/) - Abstract Hypoxia is common in solid tumors and in many other disease states such as myocardial infarction, stroke, bone fracture, and pneumonitis. Once hypoxia has developed, the undernourished and hypoxic cells trigger signals in order to obtain new blood vessels to satisfy their increasing demands and to resolve hypoxia. The principal signal activated is an
- [Oncothermia with chemotherapy in the patients with Small Cell Lung Cancer](https://oncotherm.com/hu/klinikai-publikaciok/oncothermia-with-chemotherapy-in-the-patients-with-small-cell-lung-cancer/) - Abstract Small-cell lung cancer (SCLC) is one of the most aggressive and lethal forms of lung cancers. Chemotherapy and radiotherapy would be standard modality for SCLC with median survival being less than 4 months only. Complementary treatment to chemotherapy is desired. Oncothermia will be one of the candidates to this addition. We have made a
- [Oncothermia with chemotherapy in the patients with Small Cell Lung Cancer](https://oncotherm.com/clinical-publications/oncothermia-with-chemotherapy-in-the-patients-with-small-cell-lung-cancer/) - Abstract Small-cell lung cancer (SCLC) is one of the most aggressive and lethal forms of lung cancers. Chemotherapy and radiotherapy would be standard modality for SCLC with median survival being less than 4 months only. Complementary treatment to chemotherapy is desired. Oncothermia will be one of the candidates to this addition. We have made a
- [Oncothermia with chemotherapy in the patients with Small Cell Lung Cancer](https://oncotherm.com/de/klinische-publikationen/oncothermia-with-chemotherapy-in-the-patients-with-small-cell-lung-cancer/) - Abstract Small-cell lung cancer (SCLC) is one of the most aggressive and lethal forms of lung cancers. Chemotherapy and radiotherapy would be standard modality for SCLC with median survival being less than 4 months only. Complementary treatment to chemotherapy is desired. Oncothermia will be one of the candidates to this addition. We have made a
- [Low back pain – complex approach of treatment by different CAM modalities (Acupuncture and other type of dry-needling, “Targeted RF non invasive physiotherapy” for low back pain).](https://oncotherm.com/hu/klinikai-publikaciok/low-back-pain-complex-approach-of-treatment-by-different-cam-modalities-acupuncture-and-other-type-of-dry-needling-targeted-rf-non-invasive-physiotherapy-for-low-back-pai/) - Abstract For at least 2,500 years, acupuncture has been an integral part of the traditional Chinese medicine. Recently, more people are diagnosed with chronic disease, and many of them are poorly treated with conventional therapies. Those frequently prefer other forms of complementary medical treatments. Based on the theory of homeostatic equilibrium being the basis of
- [Low back pain – complex approach of treatment by different CAM modalities (Acupuncture and other type of dry-needling, “Targeted RF non invasive physiotherapy” for low back pain).](https://oncotherm.com/clinical-publications/low-back-pain-complex-approach-of-treatment-by-different-cam-modalities-acupuncture-and-other-type-of-dry-needling-targeted-rf-non-invasive-physiotherapy-for-low-back-pai/) - Abstract For at least 2,500 years, acupuncture has been an integral part of the traditional Chinese medicine. Recently, more people are diagnosed with chronic disease, and many of them are poorly treated with conventional therapies. Those frequently prefer other forms of complementary medical treatments. Based on the theory of homeostatic equilibrium being the basis of
- [Low back pain – complex approach of treatment by different CAM modalities (Acupuncture and other type of dry-needling, “Targeted RF non invasive physiotherapy” for low back pain).](https://oncotherm.com/de/klinische-publikationen/low-back-pain-complex-approach-of-treatment-by-different-cam-modalities-acupuncture-and-other-type-of-dry-needling-targeted-rf-non-invasive-physiotherapy-for-low-back-pai/) - Abstract For at least 2,500 years, acupuncture has been an integral part of the traditional Chinese medicine. Recently, more people are diagnosed with chronic disease, and many of them are poorly treated with conventional therapies. Those frequently prefer other forms of complementary medical treatments. Based on the theory of homeostatic equilibrium being the basis of
- [Androtherm application for the Peyronie's Disease](https://oncotherm.com/hu/klinikai-publikaciok/androtherm-application-for-the-peyronies-disease/) - Abstract Peyronie's disease is characterized by a scarring fibrosis within the tunica albuginea of the penis that could lead to penile length loss, narrowing, curvature, erectile dysfunction, or pain with erection. This problem has recently no appropriate treatment. Our objective is to treat this kind of disease by a new kind of hyperthermia method.
- [Androtherm application for the Peyronie's Disease](https://oncotherm.com/clinical-publications/androtherm-application-for-the-peyronies-disease/) - Abstract Peyronie's disease is characterized by a scarring fibrosis within the tunica albuginea of the penis that could lead to penile length loss, narrowing, curvature, erectile dysfunction, or pain with erection. This problem has recently no appropriate treatment. Our objective is to treat this kind of disease by a new kind of hyperthermia method.
- [Androtherm application for the Peyronie's Disease](https://oncotherm.com/de/klinische-publikationen/androtherm-application-for-the-peyronies-disease/) - Abstract Peyronie's disease is characterized by a scarring fibrosis within the tunica albuginea of the penis that could lead to penile length loss, narrowing, curvature, erectile dysfunction, or pain with erection. This problem has recently no appropriate treatment. Our objective is to treat this kind of disease by a new kind of hyperthermia method.
- [Electrochemical Therapy of Tumors](https://oncotherm.com/hu/klinikai-publikaciok/electrochemical-therapy-of-tumors/) - ABSTRACT Application of electric current for the tumor destruction has a long time history. The theory of the direct galvanic current (galvanotherapy, GT) is worked out by B. Nordenstrom in the frame of biologically closed electric circuits (BCECs). Later, GT was extended by chemical considerations (EChT), and, starting with pioneering work of Professor Xin Yu
- [Electrochemical Therapy of Tumors](https://oncotherm.com/clinical-publications/electrochemical-therapy-of-tumors/) - ABSTRACT Application of electric current for the tumor destruction has a long time history. The theory of the direct galvanic current (galvanotherapy, GT) is worked out by B. Nordenstrom in the frame of biologically closed electric circuits (BCECs). Later, GT was extended by chemical considerations (EChT), and, starting with pioneering work of Professor Xin Yu
- [Electrochemical Therapy of Tumors](https://oncotherm.com/de/klinische-publikationen/electrochemical-therapy-of-tumors/) - ABSTRACT Application of electric current for the tumor destruction has a long time history. The theory of the direct galvanic current (galvanotherapy, GT) is worked out by B. Nordenstrom in the frame of biologically closed electric circuits (BCECs). Later, GT was extended by chemical considerations (EChT), and, starting with pioneering work of Professor Xin Yu
- [Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report](https://oncotherm.com/hu/klinikai-publikaciok/long-term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno-and-virotherapy-a-case-report/) - Abstract The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite
- [Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report](https://oncotherm.com/clinical-publications/long-term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno-and-virotherapy-a-case-report/) - Abstract The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite
- [Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report](https://oncotherm.com/de/klinische-publikationen/long-term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno-and-virotherapy-a-case-report/) - Abstract The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite
- [Sorafenib and locoregional deep electro‑hyperthermia in advanced hepatocellular carcinoma: A phase II study](https://oncotherm.com/hu/klinikai-publikaciok/sorafenib-and-locoregional-deep-electro‑hyperthermia-in-advanced-hepatocellular-carcinoma-a-phase-ii-study/) - Abstract. The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis and promotes apoptosis. Potential synergic antiangiogenic and proapoptotic effects represent the rationale for combining sorafenib with electro-hyperthermia (EHY) in HCC. A total of 21 patients (median age, 64 years; range, 55-73 years)
- [Sorafenib and locoregional deep electro‑hyperthermia in advanced hepatocellular carcinoma: A phase II study](https://oncotherm.com/clinical-publications/sorafenib-and-locoregional-deep-electro‑hyperthermia-in-advanced-hepatocellular-carcinoma-a-phase-ii-study/) - Abstract. The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis and promotes apoptosis. Potential synergic antiangiogenic and proapoptotic effects represent the rationale for combining sorafenib with electro-hyperthermia (EHY) in HCC. A total of 21 patients (median age, 64 years; range, 55-73 years)
- [Sorafenib and locoregional deep electro‑hyperthermia in advanced hepatocellular carcinoma: A phase II study](https://oncotherm.com/de/klinische-publikationen/sorafenib-and-locoregional-deep-electro‑hyperthermia-in-advanced-hepatocellular-carcinoma-a-phase-ii-study/) - Abstract. The standard treatment for advanced hepatocellular carcinoma (HCC) is sorafenib, a multikinase inhibitor of tumor cell proliferation and angiogenesis. Hyperthermia inhibits angiogenesis and promotes apoptosis. Potential synergic antiangiogenic and proapoptotic effects represent the rationale for combining sorafenib with electro-hyperthermia (EHY) in HCC. A total of 21 patients (median age, 64 years; range, 55-73 years)
- [The results of combination of ifosfamid and locoregional hyperthermia (EHY 2000) in patients with advanced abdominal soft-tissue sarcoma after relapse of first line chemotherapy](https://oncotherm.com/hu/klinikai-publikaciok/the-results-of-combination-of-ifosfamid-and-locoregional-hyperthermia-ehy-2000-in-patients-with-advanced-abdominal-soft-tissue-sarcoma-after-relapse-of-first-line-chemotherapy/) - Abstract From 2003 to 2011, 24 patients with advanced soft-tissue sarcoma with high-risk pretreated using first line chemotherapy with doxorubicin and recurrence disease were treated with chemotherapy (ifosfamide 3000mg/sqm, day 1–3) and locoregional hyperthermia (1 hour application with temperature between 41.5°C and 42°C, 3 days/week). The purpose was to evaluate the efficacy and safety of
- [The results of combination of ifosfamid and locoregional hyperthermia (EHY 2000) in patients with advanced abdominal soft-tissue sarcoma after relapse of first line chemotherapy](https://oncotherm.com/clinical-publications/the-results-of-combination-of-ifosfamid-and-locoregional-hyperthermia-ehy-2000-in-patients-with-advanced-abdominal-soft-tissue-sarcoma-after-relapse-of-first-line-chemotherapy/) - Abstract From 2003 to 2011, 24 patients with advanced soft-tissue sarcoma with high-risk pretreated using first line chemotherapy with doxorubicin and recurrence disease were treated with chemotherapy (ifosfamide 3000mg/sqm, day 1–3) and locoregional hyperthermia (1 hour application with temperature between 41.5°C and 42°C, 3 days/week). The purpose was to evaluate the efficacy and safety of
- [The results of combination of ifosfamid and locoregional hyperthermia (EHY 2000) in patients with advanced abdominal soft-tissue sarcoma after relapse of first line chemotherapy](https://oncotherm.com/de/klinische-publikationen/the-results-of-combination-of-ifosfamid-and-locoregional-hyperthermia-ehy-2000-in-patients-with-advanced-abdominal-soft-tissue-sarcoma-after-relapse-of-first-line-chemotherapy/) - Abstract From 2003 to 2011, 24 patients with advanced soft-tissue sarcoma with high-risk pretreated using first line chemotherapy with doxorubicin and recurrence disease were treated with chemotherapy (ifosfamide 3000mg/sqm, day 1–3) and locoregional hyperthermia (1 hour application with temperature between 41.5°C and 42°C, 3 days/week). The purpose was to evaluate the efficacy and safety of
- [Current Status of Oncothermia Therapy for Lung Cancer](https://oncotherm.com/hu/klinikai-publikaciok/current-status-of-oncothermia-therapy-for-lung-cancer/) - Abstract Lung cancer is one of the most common malignant tumors, and it has the highest death rate. Oncothermia is a feasible and successful treatment for lung cancer. Results show a remarkable survival benefit for patients, with a good quality of life. The treatment has no, or in some cases mild, side-effects and could decrease
- [Current Status of Oncothermia Therapy for Lung Cancer](https://oncotherm.com/clinical-publications/current-status-of-oncothermia-therapy-for-lung-cancer/) - Abstract Lung cancer is one of the most common malignant tumors, and it has the highest death rate. Oncothermia is a feasible and successful treatment for lung cancer. Results show a remarkable survival benefit for patients, with a good quality of life. The treatment has no, or in some cases mild, side-effects and could decrease
- [Current Status of Oncothermia Therapy for Lung Cancer](https://oncotherm.com/de/klinische-publikationen/current-status-of-oncothermia-therapy-for-lung-cancer/) - Abstract Lung cancer is one of the most common malignant tumors, and it has the highest death rate. Oncothermia is a feasible and successful treatment for lung cancer. Results show a remarkable survival benefit for patients, with a good quality of life. The treatment has no, or in some cases mild, side-effects and could decrease
- [Synergy between Oncothermia and Traditional Chinese Medicine](https://oncotherm.com/hu/klinikai-publikaciok/synergy-between-oncothermia-and-traditional-chinese-medicine/) - Abstract Aim of this article is to show the possibility and great advantage of the synergy of oncothermia with traditional Chinese medicine for treatment of malignant diseases based on the common basis of equilibrium demand. We use the re cognit io n of thedeviat ions fr om the com plex har monyof the org anismor its part for se lectionto
- [Synergy between Oncothermia and Traditional Chinese Medicine](https://oncotherm.com/clinical-publications/synergy-between-oncothermia-and-traditional-chinese-medicine/) - Abstract Aim of this article is to show the possibility and great advantage of the synergy of oncothermia with traditional Chinese medicine for treatment of malignant diseases based on the common basis of equilibrium demand. We use the re cognit io n of thedeviat ions fr om the com plex har monyof the org anismor its part for se lectionto
- [Synergy between Oncothermia and Traditional Chinese Medicine](https://oncotherm.com/de/klinische-publikationen/synergy-between-oncothermia-and-traditional-chinese-medicine/) - Abstract Aim of this article is to show the possibility and great advantage of the synergy of oncothermia with traditional Chinese medicine for treatment of malignant diseases based on the common basis of equilibrium demand. We use the re cognit io n of thedeviat ions fr om the com plex har monyof the org anismor its part for se lectionto
- [Long‑term remission of prostate cancer with extensive bone metastases upon immuno‑ and virotherapy: A case report](https://oncotherm.com/hu/klinikai-publikaciok/long‑term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno‑-and-virotherapy-a-case-report/) - Abstract The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite
- [Long‑term remission of prostate cancer with extensive bone metastases upon immuno‑ and virotherapy: A case report](https://oncotherm.com/clinical-publications/long‑term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno‑-and-virotherapy-a-case-report/) - Abstract The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite
- [Long‑term remission of prostate cancer with extensive bone metastases upon immuno‑ and virotherapy: A case report](https://oncotherm.com/de/klinische-publikationen/long‑term-remission-of-prostate-cancer-with-extensive-bone-metastases-upon-immuno‑-and-virotherapy-a-case-report/) - Abstract The present study reports the case of a patient with hormone-refractory metastatic prostate cancer who had failed standard therapy, but then achieved complete remission following combined treatment with local hyperthermia (LHT), Newcastle disease virus and dendritic cell (DC) vaccination, which was an unusual combination. In August 2005, the patient underwent a radical prostatectomy. Despite
- [Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer - preliminary results of a prospective trial](https://oncotherm.com/hu/klinikai-publikaciok/second-line-chemotherapy-with-gemcitabine-and-oxaliplatin-in-combination-with-loco-regional-hyperthermia-ehy-2000-in-patients-with-refractory-metastatic-pancreatic-cancer-preliminary-results-of-a/) - Abstract There is no standard treatment for second-line in patients with metastatic pancreatic cancer. The treatment with local hyperthermia (41–42°C) in order to enhance the activity gemcitabine-oxaliplatin on liver metastasis and primary advanced tumor was added as standard treatment. The primary objective was the response rate while the secondary objective were the safety of chemotherapy
- [Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer - preliminary results of a prospective trial](https://oncotherm.com/clinical-publications/second-line-chemotherapy-with-gemcitabine-and-oxaliplatin-in-combination-with-loco-regional-hyperthermia-ehy-2000-in-patients-with-refractory-metastatic-pancreatic-cancer-preliminary-results-of-a/) - Abstract There is no standard treatment for second-line in patients with metastatic pancreatic cancer. The treatment with local hyperthermia (41–42°C) in order to enhance the activity gemcitabine-oxaliplatin on liver metastasis and primary advanced tumor was added as standard treatment. The primary objective was the response rate while the secondary objective were the safety of chemotherapy
- [Second-line chemotherapy with gemcitabine and oxaliplatin in combination with loco-regional hyperthermia (EHY-2000) in patients with refractory metastatic pancreatic cancer - preliminary results of a prospective trial](https://oncotherm.com/de/klinische-publikationen/second-line-chemotherapy-with-gemcitabine-and-oxaliplatin-in-combination-with-loco-regional-hyperthermia-ehy-2000-in-patients-with-refractory-metastatic-pancreatic-cancer-preliminary-results-of-a/) - Abstract There is no standard treatment for second-line in patients with metastatic pancreatic cancer. The treatment with local hyperthermia (41–42°C) in order to enhance the activity gemcitabine-oxaliplatin on liver metastasis and primary advanced tumor was added as standard treatment. The primary objective was the response rate while the secondary objective were the safety of chemotherapy
- [Conventional cancer treatment alone or with regional hyperthermia for pain relief in lung cancer: A case–control study](https://oncotherm.com/hu/klinikai-publikaciok/conventional-cancer-treatment-alone-or-with-regional-hyperthermia-for-pain-relief-in-lung-cancer-a-case-control-study/) - Objective: To investigate the effect of combining conventional treatment with regional hyperthermia on cancer pain in lung cancer patients. Design: Case–control study. Setting: One Korean university hospital and three complementary cancer clinics. Main outcomes and measures: Main outcome was effective analgesic score (EAS, PI[1 + (M/10)], 1: anti-inflammatory drug consumption at a regular dosage, M: weekly dose (mg) of oral
- [Conventional cancer treatment alone or with regional hyperthermia for pain relief in lung cancer: A case–control study](https://oncotherm.com/clinical-publications/conventional-cancer-treatment-alone-or-with-regional-hyperthermia-for-pain-relief-in-lung-cancer-a-case-control-study/) - Objective: To investigate the effect of combining conventional treatment with regional hyperthermia on cancer pain in lung cancer patients. Design: Case–control study. Setting: One Korean university hospital and three complementary cancer clinics. Main outcomes and measures: Main outcome was effective analgesic score (EAS, PI[1 + (M/10)], 1: anti-inflammatory drug consumption at a regular dosage, M: weekly dose (mg) of oral
- [Conventional cancer treatment alone or with regional hyperthermia for pain relief in lung cancer: A case–control study](https://oncotherm.com/de/klinische-publikationen/conventional-cancer-treatment-alone-or-with-regional-hyperthermia-for-pain-relief-in-lung-cancer-a-case-control-study/) - Objective: To investigate the effect of combining conventional treatment with regional hyperthermia on cancer pain in lung cancer patients. Design: Case–control study. Setting: One Korean university hospital and three complementary cancer clinics. Main outcomes and measures: Main outcome was effective analgesic score (EAS, PI[1 + (M/10)], 1: anti-inflammatory drug consumption at a regular dosage, M: weekly dose (mg) of oral
- [The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study](https://oncotherm.com/hu/klinikai-publikaciok/the-effect-of-modulated-electro-hyperthermia-on-the-pharmacokinetic-properties-of-nefopam-in-healthy-volunteers-a-randomised-single-dose-crossover-open-label-study/) - Abstract PURPOSE: Nefopam is a widely available analgesic for the management of pain. The aim of this study was to reveal the effect of regional hyperthermia of the abdominal area on the pharmacokinetics of nefopam. MATERIALS AND METHODS: A randomised, single-dose, crossover, open-label study was conducted to reveal the effect of hyperthermia using modulated electro-hyperthermia
- [The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study](https://oncotherm.com/clinical-publications/the-effect-of-modulated-electro-hyperthermia-on-the-pharmacokinetic-properties-of-nefopam-in-healthy-volunteers-a-randomised-single-dose-crossover-open-label-study/) - Abstract PURPOSE: Nefopam is a widely available analgesic for the management of pain. The aim of this study was to reveal the effect of regional hyperthermia of the abdominal area on the pharmacokinetics of nefopam. MATERIALS AND METHODS: A randomised, single-dose, crossover, open-label study was conducted to reveal the effect of hyperthermia using modulated electro-hyperthermia
- [The effect of modulated electro-hyperthermia on the pharmacokinetic properties of nefopam in healthy volunteers: A randomised, single-dose, crossover open-label study](https://oncotherm.com/de/klinische-publikationen/the-effect-of-modulated-electro-hyperthermia-on-the-pharmacokinetic-properties-of-nefopam-in-healthy-volunteers-a-randomised-single-dose-crossover-open-label-study/) - Abstract PURPOSE: Nefopam is a widely available analgesic for the management of pain. The aim of this study was to reveal the effect of regional hyperthermia of the abdominal area on the pharmacokinetics of nefopam. MATERIALS AND METHODS: A randomised, single-dose, crossover, open-label study was conducted to reveal the effect of hyperthermia using modulated electro-hyperthermia
- [Results of Oncothermia Combined with Operation, Chemotherapy and Radiation Therapy for Primary, Recurrent and Metastatic Sarcoma](https://oncotherm.com/hu/klinikai-publikaciok/results-of-oncothermia-combined-with-operation-chemotherapy-and-radiation-therapy-for-primary-recurrent-and-metastatic-sarcoma/) - ABSTRACT Sarcomas are relatively rare malignancies; however, their huge variety and shortage of the effective therapies make this disease face huge challenge for oncology. It is recently shown that hyperthermia could be successfully applied even in high-risk cases in combination with the available gold-standard regiments. Our aim is to present various advanced cases treated with
- [Results of Oncothermia Combined with Operation, Chemotherapy and Radiation Therapy for Primary, Recurrent and Metastatic Sarcoma](https://oncotherm.com/clinical-publications/results-of-oncothermia-combined-with-operation-chemotherapy-and-radiation-therapy-for-primary-recurrent-and-metastatic-sarcoma/) - ABSTRACT Sarcomas are relatively rare malignancies; however, their huge variety and shortage of the effective therapies make this disease face huge challenge for oncology. It is recently shown that hyperthermia could be successfully applied even in high-risk cases in combination with the available gold-standard regiments. Our aim is to present various advanced cases treated with
- [Results of Oncothermia Combined with Operation, Chemotherapy and Radiation Therapy for Primary, Recurrent and Metastatic Sarcoma](https://oncotherm.com/de/klinische-publikationen/results-of-oncothermia-combined-with-operation-chemotherapy-and-radiation-therapy-for-primary-recurrent-and-metastatic-sarcoma/) - ABSTRACT Sarcomas are relatively rare malignancies; however, their huge variety and shortage of the effective therapies make this disease face huge challenge for oncology. It is recently shown that hyperthermia could be successfully applied even in high-risk cases in combination with the available gold-standard regiments. Our aim is to present various advanced cases treated with
- [Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance](https://oncotherm.com/hu/klinikai-publikaciok/oncolytic-newcastle-disease-virus-as-a-prospective-anti-cancer-therapy-a-biologic-agent-with-potential-to-break-therapy-resistance/) - Abstract INTRODUCTION: Oncolytic viruses (OVs) selectively replicate in tumor cells and cause cancer cell death. Most OVs in clinical studies are genetically engineered. In contrast, the avian Newcastle disease virus (NDV) is a naturally oncolytic RNA virus. While anti-viral immunity is considered a major problem in achieving maximal tumor cell killing by OVs, this review
- [Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance](https://oncotherm.com/clinical-publications/oncolytic-newcastle-disease-virus-as-a-prospective-anti-cancer-therapy-a-biologic-agent-with-potential-to-break-therapy-resistance/) - Abstract INTRODUCTION: Oncolytic viruses (OVs) selectively replicate in tumor cells and cause cancer cell death. Most OVs in clinical studies are genetically engineered. In contrast, the avian Newcastle disease virus (NDV) is a naturally oncolytic RNA virus. While anti-viral immunity is considered a major problem in achieving maximal tumor cell killing by OVs, this review
- [Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance](https://oncotherm.com/de/klinische-publikationen/oncolytic-newcastle-disease-virus-as-a-prospective-anti-cancer-therapy-a-biologic-agent-with-potential-to-break-therapy-resistance/) - Abstract INTRODUCTION: Oncolytic viruses (OVs) selectively replicate in tumor cells and cause cancer cell death. Most OVs in clinical studies are genetically engineered. In contrast, the avian Newcastle disease virus (NDV) is a naturally oncolytic RNA virus. While anti-viral immunity is considered a major problem in achieving maximal tumor cell killing by OVs, this review
- [The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case reports of four patients](https://oncotherm.com/hu/klinikai-publikaciok/the-outcome-of-the-chemotherapy-and-oncothermia-for-far-advanced-adenocarcinoma-of-the-lung-case-reports-of-four-patients/) - ABSTRACT Lung cancer is one of the most aggressive and lethal form of cancers. Patients with far advanced lung cancer are treated by chemotherapy with or without radiotherapy. However, median survival of these patients is less than 6 months. To increase survival and quality of life for these patients, various forms of complementary treatments have
- [The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case reports of four patients](https://oncotherm.com/clinical-publications/the-outcome-of-the-chemotherapy-and-oncothermia-for-far-advanced-adenocarcinoma-of-the-lung-case-reports-of-four-patients/) - ABSTRACT Lung cancer is one of the most aggressive and lethal form of cancers. Patients with far advanced lung cancer are treated by chemotherapy with or without radiotherapy. However, median survival of these patients is less than 6 months. To increase survival and quality of life for these patients, various forms of complementary treatments have
- [The Outcome of the Chemotherapy and Oncothermia for Far Advanced Adenocarcinoma of the Lung: Case reports of four patients](https://oncotherm.com/de/klinische-publikationen/the-outcome-of-the-chemotherapy-and-oncothermia-for-far-advanced-adenocarcinoma-of-the-lung-case-reports-of-four-patients/) - ABSTRACT Lung cancer is one of the most aggressive and lethal form of cancers. Patients with far advanced lung cancer are treated by chemotherapy with or without radiotherapy. However, median survival of these patients is less than 6 months. To increase survival and quality of life for these patients, various forms of complementary treatments have
- [Definitive radiotherapy with concurrent oncothermia for stage IIIB non‑small‑cell lung cancer: A case report](https://oncotherm.com/hu/klinikai-publikaciok/definitive-radiotherapy-with-concurrent-oncothermia-for-stage-iiib-non‑small‑cell-lung-cancer-a-case-report/) - Abstract Hyperthermia enhances the susceptibility of tumors to radiotherapy (RT) and chemotherapy. Oncothermia, also known as electro-hyperthermia, is a new treatment modality developed to overcome the problems of traditional hyperthermia by selectively delivering energy to the malignant tissues. The present study reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage
- [Definitive radiotherapy with concurrent oncothermia for stage IIIB non‑small‑cell lung cancer: A case report](https://oncotherm.com/clinical-publications/definitive-radiotherapy-with-concurrent-oncothermia-for-stage-iiib-non‑small‑cell-lung-cancer-a-case-report/) - Abstract Hyperthermia enhances the susceptibility of tumors to radiotherapy (RT) and chemotherapy. Oncothermia, also known as electro-hyperthermia, is a new treatment modality developed to overcome the problems of traditional hyperthermia by selectively delivering energy to the malignant tissues. The present study reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage
- [Definitive radiotherapy with concurrent oncothermia for stage IIIB non‑small‑cell lung cancer: A case report](https://oncotherm.com/de/klinische-publikationen/definitive-radiotherapy-with-concurrent-oncothermia-for-stage-iiib-non‑small‑cell-lung-cancer-a-case-report/) - Abstract Hyperthermia enhances the susceptibility of tumors to radiotherapy (RT) and chemotherapy. Oncothermia, also known as electro-hyperthermia, is a new treatment modality developed to overcome the problems of traditional hyperthermia by selectively delivering energy to the malignant tissues. The present study reports the outcome of combined oncothermia and RT in a 75-year-old patient with stage
- [Effect of modulated electrohyperthermia on the pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers](https://oncotherm.com/hu/klinikai-publikaciok/effect-of-modulated-electrohyperthermia-on-the-pharmacokinetics-of-oral-transmucosal-fentanyl-citrate-in-healthy-volunteers/) - Abstract PURPOSE: This study aimed to determine whether changes occur in fentanyl absorption and disposition when administered in conjunction with modulated electrohyperthermia (mEHT) treatment. METHODS: A randomized, single-dose, crossover, open-label study was used to investigate the effect of mEHT on the pharmacokinetic properties of fentanyl in 12 healthy volunteers. The 12 healthy volunteers were each
- [Effect of modulated electrohyperthermia on the pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers](https://oncotherm.com/clinical-publications/effect-of-modulated-electrohyperthermia-on-the-pharmacokinetics-of-oral-transmucosal-fentanyl-citrate-in-healthy-volunteers/) - Abstract PURPOSE: This study aimed to determine whether changes occur in fentanyl absorption and disposition when administered in conjunction with modulated electrohyperthermia (mEHT) treatment. METHODS: A randomized, single-dose, crossover, open-label study was used to investigate the effect of mEHT on the pharmacokinetic properties of fentanyl in 12 healthy volunteers. The 12 healthy volunteers were each
- [Effect of modulated electrohyperthermia on the pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers](https://oncotherm.com/de/klinische-publikationen/effect-of-modulated-electrohyperthermia-on-the-pharmacokinetics-of-oral-transmucosal-fentanyl-citrate-in-healthy-volunteers/) - Abstract PURPOSE: This study aimed to determine whether changes occur in fentanyl absorption and disposition when administered in conjunction with modulated electrohyperthermia (mEHT) treatment. METHODS: A randomized, single-dose, crossover, open-label study was used to investigate the effect of mEHT on the pharmacokinetic properties of fentanyl in 12 healthy volunteers. The 12 healthy volunteers were each
- [Complete Response of Locally Advanced (stage III) Rectal Cancer to Metabolically Supported Chemoradiotherapy with Hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/complete-response-of-locally-advanced-stage-iii-rectal-cancer-to-metabolically-supported-chemoradiotherapy-with-hyperthermia/) - Abstract Background: Locally advanced rectal cancer is defined as a rectal mass that cannot be resected without a high probability of leaving residual disease at the tumor site. While the standard treatment for locally advanced rectal cancer is chemoradiotherapy followed by surgery, this study reports a locally invasive rectal adenocarcinoma patient who achieved complete pathological
- [Complete Response of Locally Advanced (stage III) Rectal Cancer to Metabolically Supported Chemoradiotherapy with Hyperthermia](https://oncotherm.com/clinical-publications/complete-response-of-locally-advanced-stage-iii-rectal-cancer-to-metabolically-supported-chemoradiotherapy-with-hyperthermia/) - Abstract Background: Locally advanced rectal cancer is defined as a rectal mass that cannot be resected without a high probability of leaving residual disease at the tumor site. While the standard treatment for locally advanced rectal cancer is chemoradiotherapy followed by surgery, this study reports a locally invasive rectal adenocarcinoma patient who achieved complete pathological
- [Complete Response of Locally Advanced (stage III) Rectal Cancer to Metabolically Supported Chemoradiotherapy with Hyperthermia](https://oncotherm.com/de/klinische-publikationen/complete-response-of-locally-advanced-stage-iii-rectal-cancer-to-metabolically-supported-chemoradiotherapy-with-hyperthermia/) - Abstract Background: Locally advanced rectal cancer is defined as a rectal mass that cannot be resected without a high probability of leaving residual disease at the tumor site. While the standard treatment for locally advanced rectal cancer is chemoradiotherapy followed by surgery, this study reports a locally invasive rectal adenocarcinoma patient who achieved complete pathological
- [Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib](https://oncotherm.com/hu/klinikai-publikaciok/positive-response-of-a-primary-leiomyosarcoma-of-the-breast-following-salvage-hyperthermia-and-pazopanib/) - Primary sarcomas of the breast are rare tumors, accounting for less than 1% of all breast neoplasms. Leiomyosarcoma is an extremely rare subtype of breast sarcoma [1]. Prognoses for primary breast sarcoma are poor and treatment modalities are limited. Pazopanib is an oral, multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factors (VEGFs)
- [Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib](https://oncotherm.com/clinical-publications/positive-response-of-a-primary-leiomyosarcoma-of-the-breast-following-salvage-hyperthermia-and-pazopanib/) - Primary sarcomas of the breast are rare tumors, accounting for less than 1% of all breast neoplasms. Leiomyosarcoma is an extremely rare subtype of breast sarcoma [1]. Prognoses for primary breast sarcoma are poor and treatment modalities are limited. Pazopanib is an oral, multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factors (VEGFs)
- [Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib](https://oncotherm.com/de/klinische-publikationen/positive-response-of-a-primary-leiomyosarcoma-of-the-breast-following-salvage-hyperthermia-and-pazopanib/) - Primary sarcomas of the breast are rare tumors, accounting for less than 1% of all breast neoplasms. Leiomyosarcoma is an extremely rare subtype of breast sarcoma [1]. Prognoses for primary breast sarcoma are poor and treatment modalities are limited. Pazopanib is an oral, multitargeted tyrosine kinase inhibitor, with activity against vascular endothelial growth factors (VEGFs)
- [Stage IV Wilms tumor treated by Korean medicine, hyperthermia and thymosin-α1: A case report](https://oncotherm.com/hu/klinikai-publikaciok/stage-iv-wilms-tumor-treated-by-korean-medicine-hyperthermia-and-thymosin-α1-a-case-report/) - Abstract Introduction Wilms tumor is one of general solid cancers that occur in children, which carries a death rate of 7–8 in a million. The cure rate of Wilms tumor in the recent 30 years has dramatically been improved, but a proper remedy is still not prepared enough in terms of application in tumor therapy
- [Stage IV Wilms tumor treated by Korean medicine, hyperthermia and thymosin-α1: A case report](https://oncotherm.com/clinical-publications/stage-iv-wilms-tumor-treated-by-korean-medicine-hyperthermia-and-thymosin-α1-a-case-report/) - Abstract Introduction Wilms tumor is one of general solid cancers that occur in children, which carries a death rate of 7–8 in a million. The cure rate of Wilms tumor in the recent 30 years has dramatically been improved, but a proper remedy is still not prepared enough in terms of application in tumor therapy
- [Stage IV Wilms tumor treated by Korean medicine, hyperthermia and thymosin-α1: A case report](https://oncotherm.com/de/klinische-publikationen/stage-iv-wilms-tumor-treated-by-korean-medicine-hyperthermia-and-thymosin-α1-a-case-report/) - Abstract Introduction Wilms tumor is one of general solid cancers that occur in children, which carries a death rate of 7–8 in a million. The cure rate of Wilms tumor in the recent 30 years has dramatically been improved, but a proper remedy is still not prepared enough in terms of application in tumor therapy
- [Update on phase III randomized clinical trial investigating the effects of the addition of electro-hyperthermia to chemora-diotherapy for cervical cancer patients in South Africa](https://oncotherm.com/hu/klinikai-publikaciok/update-on-phase-iii-randomized-clinical-trial-investigating-the-effects-of-the-addition-of-electro-hyperthermia-to-chemora-diotherapy-for-cervical-cancer-patients-in-south-africa/) - Introduction The Electro-Hyperthermia trial an ongoing phase III randomised clinical trial being conducted at the Charlotte Maxeke Johannesburg Academic Hospital. The general aim is to determine the clinical effects of the addition of modulated electro-hyperthermia (EHT) to the standard treatment protocols for locally advanced cervical cancer patients in state healthcare in South Africa. The objectives
- [Update on phase III randomized clinical trial investigating the effects of the addition of electro-hyperthermia to chemora-diotherapy for cervical cancer patients in South Africa](https://oncotherm.com/clinical-publications/update-on-phase-iii-randomized-clinical-trial-investigating-the-effects-of-the-addition-of-electro-hyperthermia-to-chemora-diotherapy-for-cervical-cancer-patients-in-south-africa/) - Introduction The Electro-Hyperthermia trial an ongoing phase III randomised clinical trial being conducted at the Charlotte Maxeke Johannesburg Academic Hospital. The general aim is to determine the clinical effects of the addition of modulated electro-hyperthermia (EHT) to the standard treatment protocols for locally advanced cervical cancer patients in state healthcare in South Africa. The objectives
- [Update on phase III randomized clinical trial investigating the effects of the addition of electro-hyperthermia to chemora-diotherapy for cervical cancer patients in South Africa](https://oncotherm.com/de/klinische-publikationen/update-on-phase-iii-randomized-clinical-trial-investigating-the-effects-of-the-addition-of-electro-hyperthermia-to-chemora-diotherapy-for-cervical-cancer-patients-in-south-africa/) - Introduction The Electro-Hyperthermia trial an ongoing phase III randomised clinical trial being conducted at the Charlotte Maxeke Johannesburg Academic Hospital. The general aim is to determine the clinical effects of the addition of modulated electro-hyperthermia (EHT) to the standard treatment protocols for locally advanced cervical cancer patients in state healthcare in South Africa. The objectives
- [Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation](https://oncotherm.com/hu/klinikai-publikaciok/treatment-outcome-analysis-of-chemotherapy-combined-with-modulated-electro-hyperthermia-compared-with-chemotherapy-alone-for-recurrent-cervical-cancer-following-irradiation/) - The survival of patients with recurrent cervical cancer following irradiation remains poor. Chemotherapy combined with hyperthermia has been demonstrated to improve the response rate. The present study was performed to evaluate the effect of modulated electro‑hyperthermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation. A total of
- [Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation](https://oncotherm.com/clinical-publications/treatment-outcome-analysis-of-chemotherapy-combined-with-modulated-electro-hyperthermia-compared-with-chemotherapy-alone-for-recurrent-cervical-cancer-following-irradiation/) - The survival of patients with recurrent cervical cancer following irradiation remains poor. Chemotherapy combined with hyperthermia has been demonstrated to improve the response rate. The present study was performed to evaluate the effect of modulated electro‑hyperthermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation. A total of
- [Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation](https://oncotherm.com/de/klinische-publikationen/treatment-outcome-analysis-of-chemotherapy-combined-with-modulated-electro-hyperthermia-compared-with-chemotherapy-alone-for-recurrent-cervical-cancer-following-irradiation/) - The survival of patients with recurrent cervical cancer following irradiation remains poor. Chemotherapy combined with hyperthermia has been demonstrated to improve the response rate. The present study was performed to evaluate the effect of modulated electro‑hyperthermia combined with conventional chemotherapy compared with chemotherapy alone on recurrent cervical cancer previously treated with irradiation. A total of
- [Role of HIF-1α in response of tumors to a combination of hyperthermia and radiation in vivo](https://oncotherm.com/hu/klinikai-publikaciok/role-of-hif-1α-in-response-of-tumors-to-a-combination-of-hyperthermia-and-radiation-in-vivo/) - Abstract PURPOSE: Mild temperature hyperthermia (MTH) increases blood flow and oxygenation in tumours. On the other hand, high-dose-per-fraction irradiation damages blood vessels, decreases blood flow and increases hypoxia in tumours. The radiation-induced hypoxia in tumours activates hypoxia-inducible factor-1α (HIF-1α) and its target genes, such as vascular endothelial growth factor (VEGF), promoting revascularization and recurrence. In
- [Role of HIF-1α in response of tumors to a combination of hyperthermia and radiation in vivo](https://oncotherm.com/clinical-publications/role-of-hif-1α-in-response-of-tumors-to-a-combination-of-hyperthermia-and-radiation-in-vivo/) - Abstract PURPOSE: Mild temperature hyperthermia (MTH) increases blood flow and oxygenation in tumours. On the other hand, high-dose-per-fraction irradiation damages blood vessels, decreases blood flow and increases hypoxia in tumours. The radiation-induced hypoxia in tumours activates hypoxia-inducible factor-1α (HIF-1α) and its target genes, such as vascular endothelial growth factor (VEGF), promoting revascularization and recurrence. In
- [Role of HIF-1α in response of tumors to a combination of hyperthermia and radiation in vivo](https://oncotherm.com/de/klinische-publikationen/role-of-hif-1α-in-response-of-tumors-to-a-combination-of-hyperthermia-and-radiation-in-vivo/) - Abstract PURPOSE: Mild temperature hyperthermia (MTH) increases blood flow and oxygenation in tumours. On the other hand, high-dose-per-fraction irradiation damages blood vessels, decreases blood flow and increases hypoxia in tumours. The radiation-induced hypoxia in tumours activates hypoxia-inducible factor-1α (HIF-1α) and its target genes, such as vascular endothelial growth factor (VEGF), promoting revascularization and recurrence. In
- [A new strategy of cancer immunotherapy combining hyperthermia/oncolytic virus pretreatment with specific autologous anti-tumor vaccination - a review](https://oncotherm.com/hu/klinikai-publikaciok/a-new-strategy-of-cancer-immunotherapy-combining-hyperthermia-oncolytic-virus-pretreatment-with-specific-autologous-anti-tumor-vaccination-a-review/) - Abstract This review describes and explains a specific immunotherapy strategy that has been developed at the Immunological and Oncological Center Cologne in Germany. The strategy is based on many years of basic and translational research. It is a highly individualized approach to activate and target the patient’s immune system against the patient’s own tumor. In
- [A new strategy of cancer immunotherapy combining hyperthermia/oncolytic virus pretreatment with specific autologous anti-tumor vaccination - a review](https://oncotherm.com/clinical-publications/a-new-strategy-of-cancer-immunotherapy-combining-hyperthermia-oncolytic-virus-pretreatment-with-specific-autologous-anti-tumor-vaccination-a-review/) - Abstract This review describes and explains a specific immunotherapy strategy that has been developed at the Immunological and Oncological Center Cologne in Germany. The strategy is based on many years of basic and translational research. It is a highly individualized approach to activate and target the patient’s immune system against the patient’s own tumor. In
- [A new strategy of cancer immunotherapy combining hyperthermia/oncolytic virus pretreatment with specific autologous anti-tumor vaccination - a review](https://oncotherm.com/de/klinische-publikationen/a-new-strategy-of-cancer-immunotherapy-combining-hyperthermia-oncolytic-virus-pretreatment-with-specific-autologous-anti-tumor-vaccination-a-review/) - Abstract This review describes and explains a specific immunotherapy strategy that has been developed at the Immunological and Oncological Center Cologne in Germany. The strategy is based on many years of basic and translational research. It is a highly individualized approach to activate and target the patient’s immune system against the patient’s own tumor. In
- [Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer](https://oncotherm.com/hu/klinikai-publikaciok/efficacy-of-metabolically-supported-chemotherapy-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-for-stage-iv-triple-negative-breast-cancer/) - Abstract Triple-negative breast cancer (TNBC) is more aggressive and metastatic than other breast cancer types. Cytotoxic chemotherapy is presently the predominant systemic therapy for TNBC patients. This case report highlights the influence of metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT) in an overweight 29-year-old woman with stage IV
- [Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer](https://oncotherm.com/clinical-publications/efficacy-of-metabolically-supported-chemotherapy-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-for-stage-iv-triple-negative-breast-cancer/) - Abstract Triple-negative breast cancer (TNBC) is more aggressive and metastatic than other breast cancer types. Cytotoxic chemotherapy is presently the predominant systemic therapy for TNBC patients. This case report highlights the influence of metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT) in an overweight 29-year-old woman with stage IV
- [Efficacy of metabolically supported chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric oxygen therapy for stage IV triple-negative breast cancer](https://oncotherm.com/de/klinische-publikationen/efficacy-of-metabolically-supported-chemotherapy-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-for-stage-iv-triple-negative-breast-cancer/) - Abstract Triple-negative breast cancer (TNBC) is more aggressive and metastatic than other breast cancer types. Cytotoxic chemotherapy is presently the predominant systemic therapy for TNBC patients. This case report highlights the influence of metabolically supported chemotherapy (MSCT), ketogenic diet (KD), hyperthermia (HT), and hyperbaric oxygen therapy (HBOT) in an overweight 29-year-old woman with stage IV
- [The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer](https://oncotherm.com/hu/klinikai-publikaciok/the-safety-and-pharmacokinetics-of-high-dose-intravenous-ascorbic-acid-synergy-with-modulated-electrohyperthermia-in-chinese-patients-with-stage-iii-iv-non-small-cell-lung-cancer/) - Abstract Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. However, there are no safety and pharmacokinetics data in Chinese cancer patients. We carried out a clinical trial to evaluate the safety and pharmacokinetics of those methods in patients with stage III-IV non-small cell lung cancer (NSCLC). Blood
- [The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer](https://oncotherm.com/clinical-publications/the-safety-and-pharmacokinetics-of-high-dose-intravenous-ascorbic-acid-synergy-with-modulated-electrohyperthermia-in-chinese-patients-with-stage-iii-iv-non-small-cell-lung-cancer/) - Abstract Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. However, there are no safety and pharmacokinetics data in Chinese cancer patients. We carried out a clinical trial to evaluate the safety and pharmacokinetics of those methods in patients with stage III-IV non-small cell lung cancer (NSCLC). Blood
- [The safety and pharmacokinetics of high dose intravenous ascorbic acid synergy with modulated electrohyperthermia in Chinese patients with stage III-IV non-small cell lung cancer](https://oncotherm.com/de/klinische-publikationen/the-safety-and-pharmacokinetics-of-high-dose-intravenous-ascorbic-acid-synergy-with-modulated-electrohyperthermia-in-chinese-patients-with-stage-iii-iv-non-small-cell-lung-cancer/) - Abstract Ascorbic acid (AA) infusion and modulated electrohyperthermia (mEHT) are widely used by integrative cancer practitioners for many years. However, there are no safety and pharmacokinetics data in Chinese cancer patients. We carried out a clinical trial to evaluate the safety and pharmacokinetics of those methods in patients with stage III-IV non-small cell lung cancer (NSCLC). Blood
- [Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study](https://oncotherm.com/hu/klinikai-publikaciok/bevacizumab-based-chemotherapy-combined-with-regional-deep-capacitive-hyperthermia-in-metastatic-cancer-patients-a-pilot-study/) - Abstract As an angiogenesis inhibitor, bevacizumab has been investigated in combination with different chemotherapeutic agents, achieving an established role for metastatic cancer treatment. However, potential synergic anti-angiogenic effects of hyperthermia have not tested to date in literature. The aim of our study was to analyze efficacy, safety, and survival of anti-angiogenic-based chemotherapy associated to regional deep capacitive
- [Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study](https://oncotherm.com/clinical-publications/bevacizumab-based-chemotherapy-combined-with-regional-deep-capacitive-hyperthermia-in-metastatic-cancer-patients-a-pilot-study/) - Abstract As an angiogenesis inhibitor, bevacizumab has been investigated in combination with different chemotherapeutic agents, achieving an established role for metastatic cancer treatment. However, potential synergic anti-angiogenic effects of hyperthermia have not tested to date in literature. The aim of our study was to analyze efficacy, safety, and survival of anti-angiogenic-based chemotherapy associated to regional deep capacitive
- [Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study](https://oncotherm.com/de/klinische-publikationen/bevacizumab-based-chemotherapy-combined-with-regional-deep-capacitive-hyperthermia-in-metastatic-cancer-patients-a-pilot-study/) - Abstract As an angiogenesis inhibitor, bevacizumab has been investigated in combination with different chemotherapeutic agents, achieving an established role for metastatic cancer treatment. However, potential synergic anti-angiogenic effects of hyperthermia have not tested to date in literature. The aim of our study was to analyze efficacy, safety, and survival of anti-angiogenic-based chemotherapy associated to regional deep capacitive
- [Newer application of oncothermia to non-malignant diseases such as Dupuytren’s contracture of the hand and chronic lower back pain lasting more than 4 weeks](https://oncotherm.com/hu/klinikai-publikaciok/newer-application-of-oncothermia-to-non-malignant-diseases-such-as-dupuytrens-contracture-of-the-hand-and-chronic-lower-back-pain-lasting-more-than-4-weeks/) - ABSTRACT Oncothermia (OTM) is based on electromagnetic interactions with the living matter. Its nano-targeting approach establishes a new paradigm. OTM could be applied not only to treat malignancies but it is feasible to apply for other diseases too. OTH is well proven method from the laboratory level to the clinical applications, promoting the natural processes,
- [Newer application of oncothermia to non-malignant diseases such as Dupuytren’s contracture of the hand and chronic lower back pain lasting more than 4 weeks](https://oncotherm.com/clinical-publications/newer-application-of-oncothermia-to-non-malignant-diseases-such-as-dupuytrens-contracture-of-the-hand-and-chronic-lower-back-pain-lasting-more-than-4-weeks/) - ABSTRACT Oncothermia (OTM) is based on electromagnetic interactions with the living matter. Its nano-targeting approach establishes a new paradigm. OTM could be applied not only to treat malignancies but it is feasible to apply for other diseases too. OTH is well proven method from the laboratory level to the clinical applications, promoting the natural processes,
- [Newer application of oncothermia to non-malignant diseases such as Dupuytren’s contracture of the hand and chronic lower back pain lasting more than 4 weeks](https://oncotherm.com/de/klinische-publikationen/newer-application-of-oncothermia-to-non-malignant-diseases-such-as-dupuytrens-contracture-of-the-hand-and-chronic-lower-back-pain-lasting-more-than-4-weeks/) - ABSTRACT Oncothermia (OTM) is based on electromagnetic interactions with the living matter. Its nano-targeting approach establishes a new paradigm. OTM could be applied not only to treat malignancies but it is feasible to apply for other diseases too. OTH is well proven method from the laboratory level to the clinical applications, promoting the natural processes,
- [Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy](https://oncotherm.com/hu/klinikai-publikaciok/rescue-therapy-in-patient-with-glioblastoma-multiforme-combining-chemotherapy-hyperthermia-phytotherapy/) - Abstract Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surgically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 60-yearold woman suffering from recurrent glioblastoma who comes to my observation with no therapeutic options and treated with a combination of antiangiogenic
- [Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy](https://oncotherm.com/clinical-publications/rescue-therapy-in-patient-with-glioblastoma-multiforme-combining-chemotherapy-hyperthermia-phytotherapy/) - Abstract Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surgically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 60-yearold woman suffering from recurrent glioblastoma who comes to my observation with no therapeutic options and treated with a combination of antiangiogenic
- [Rescue Therapy in Patient with Glioblastoma Multiforme Combining Chemotherapy, Hyperthermia, Phytotherapy](https://oncotherm.com/de/klinische-publikationen/rescue-therapy-in-patient-with-glioblastoma-multiforme-combining-chemotherapy-hyperthermia-phytotherapy/) - Abstract Glioblastoma multiforme is a pathology that is poorly treatable and tends towards recurrence. If surgically unresectable, at least without macroscopically visible residue, the prognosis is severe. Here is the case of a 60-yearold woman suffering from recurrent glioblastoma who comes to my observation with no therapeutic options and treated with a combination of antiangiogenic
- [Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a 2-centre German cohort trial with systematic comparison](https://oncotherm.com/hu/klinikai-publikaciok/clinical-and-economic-evaluation-of-modulated-electrohyperthermia-concurrent-to-dose-dense-temozolomide-21-28-days-regimen-in-the-treatment-of-recurrent-glioblastoma-a-retrospective-analysis-of-a-2-c/) - Abstract OBJECTIVE: To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM). DESIGN: A cohort of 54 patients with recurrent GBM treated with ddTMZ+mEHT in 2000-2005 was systematically retrospectively compared with five pooled ddTMZ 21/28 days
- [Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a 2-centre German cohort trial with systematic comparison](https://oncotherm.com/clinical-publications/clinical-and-economic-evaluation-of-modulated-electrohyperthermia-concurrent-to-dose-dense-temozolomide-21-28-days-regimen-in-the-treatment-of-recurrent-glioblastoma-a-retrospective-analysis-of-a-2-c/) - Abstract OBJECTIVE: To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM). DESIGN: A cohort of 54 patients with recurrent GBM treated with ddTMZ+mEHT in 2000-2005 was systematically retrospectively compared with five pooled ddTMZ 21/28 days
- [Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21/28 days regimen in the treatment of recurrent glioblastoma: a retrospective analysis of a 2-centre German cohort trial with systematic comparison](https://oncotherm.com/de/klinische-publikationen/clinical-and-economic-evaluation-of-modulated-electrohyperthermia-concurrent-to-dose-dense-temozolomide-21-28-days-regimen-in-the-treatment-of-recurrent-glioblastoma-a-retrospective-analysis-of-a-2-c/) - Abstract OBJECTIVE: To assess the efficacy and cost-effectiveness of modulated electrohyperthermia (mEHT) concurrent to dose-dense temozolomide (ddTMZ) 21/28 days regimen versus ddTMZ 21/28 days alone in patients with recurrent glioblastoma (GBM). DESIGN: A cohort of 54 patients with recurrent GBM treated with ddTMZ+mEHT in 2000-2005 was systematically retrospectively compared with five pooled ddTMZ 21/28 days
- [Retrospective observational Clinical Study on Relapsed Malignant Gliomas Treated with Electro-Hyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/retrospective-observational-clinical-study-on-relapsed-malignant-gliomas-treated-with-electro-hyperthermia/) - ABSTRACT Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma. Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for
- [Retrospective observational Clinical Study on Relapsed Malignant Gliomas Treated with Electro-Hyperthermia](https://oncotherm.com/clinical-publications/retrospective-observational-clinical-study-on-relapsed-malignant-gliomas-treated-with-electro-hyperthermia/) - ABSTRACT Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma. Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for
- [Retrospective observational Clinical Study on Relapsed Malignant Gliomas Treated with Electro-Hyperthermia](https://oncotherm.com/de/klinische-publikationen/retrospective-observational-clinical-study-on-relapsed-malignant-gliomas-treated-with-electro-hyperthermia/) - ABSTRACT Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma. Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for
- [Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for treatment of peritoneal carcinomatosis with malignant ascites: a phase II randomized trial](https://oncotherm.com/hu/klinikai-publikaciok/local-modulated-electro-hyperthermia-in-combination-with-traditional-chinese-medicine-vs-intraperitoneal-chemoinfusion-for-treatment-of-peritoneal-carcinomatosis-with-malignant-ascites-a-phase-ii-ra/) - Abstract The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of local modulated electro-hyperthermia (mEHT) combined with the traditional Chinese medicine (TCM) 'Shi Pi' herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI). A
- [Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for treatment of peritoneal carcinomatosis with malignant ascites: a phase II randomized trial](https://oncotherm.com/clinical-publications/local-modulated-electro-hyperthermia-in-combination-with-traditional-chinese-medicine-vs-intraperitoneal-chemoinfusion-for-treatment-of-peritoneal-carcinomatosis-with-malignant-ascites-a-phase-ii-ra/) - Abstract The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of local modulated electro-hyperthermia (mEHT) combined with the traditional Chinese medicine (TCM) 'Shi Pi' herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI). A
- [Local modulated electro-hyperthermia in combination with traditional Chinese medicine vs. intraperitoneal chemoinfusion for treatment of peritoneal carcinomatosis with malignant ascites: a phase II randomized trial](https://oncotherm.com/de/klinische-publikationen/local-modulated-electro-hyperthermia-in-combination-with-traditional-chinese-medicine-vs-intraperitoneal-chemoinfusion-for-treatment-of-peritoneal-carcinomatosis-with-malignant-ascites-a-phase-ii-ra/) - Abstract The purpose of this study was to develop a safe and non-toxic alternative to the conventional conservative treatment of peritoneal carcinomatosis with malignant ascites (PCMA) by investigating the efficacy and safety of local modulated electro-hyperthermia (mEHT) combined with the traditional Chinese medicine (TCM) 'Shi Pi' herbal decoction, compared with standard intraperitoneal chemoinfusion (IPCI). A
- [Oncothermia-Booster (Targeted Radiofrequency) Treatment – in Some Non-Oncological Diseases as Special Physiotherapy](https://oncotherm.com/hu/klinikai-publikaciok/oncothermia-booster-targeted-radiofrequency-treatment-in-some-non-oncological-diseases-as-special-physiotherapy/) - Abstract Introduction: Oncothermia (OTM) is based on electromagnetic interactions with the living organism. Its nano-targeting approach [established a newer paradigm, which could be applied not only in case of malignancies but in any other diseases, when the non-selective conditions are existing. This technique by now is well proven from the simple laboratory level to the
- [Oncothermia-Booster (Targeted Radiofrequency) Treatment – in Some Non-Oncological Diseases as Special Physiotherapy](https://oncotherm.com/clinical-publications/oncothermia-booster-targeted-radiofrequency-treatment-in-some-non-oncological-diseases-as-special-physiotherapy/) - Abstract Introduction: Oncothermia (OTM) is based on electromagnetic interactions with the living organism. Its nano-targeting approach [established a newer paradigm, which could be applied not only in case of malignancies but in any other diseases, when the non-selective conditions are existing. This technique by now is well proven from the simple laboratory level to the
- [Oncothermia-Booster (Targeted Radiofrequency) Treatment – in Some Non-Oncological Diseases as Special Physiotherapy](https://oncotherm.com/de/klinische-publikationen/oncothermia-booster-targeted-radiofrequency-treatment-in-some-non-oncological-diseases-as-special-physiotherapy/) - Abstract Introduction: Oncothermia (OTM) is based on electromagnetic interactions with the living organism. Its nano-targeting approach [established a newer paradigm, which could be applied not only in case of malignancies but in any other diseases, when the non-selective conditions are existing. This technique by now is well proven from the simple laboratory level to the
- [PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study](https://oncotherm.com/hu/klinikai-publikaciok/pd-1-pd-l1-and-ctla-4-in-pregnancy-related-and-in-early-onset-breast-cancer-a-comparative-study/) - Abstract PURPOSE: We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors. METHODS: Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were
- [PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study](https://oncotherm.com/clinical-publications/pd-1-pd-l1-and-ctla-4-in-pregnancy-related-and-in-early-onset-breast-cancer-a-comparative-study/) - Abstract PURPOSE: We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors. METHODS: Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were
- [PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study](https://oncotherm.com/de/klinische-publikationen/pd-1-pd-l1-and-ctla-4-in-pregnancy-related-and-in-early-onset-breast-cancer-a-comparative-study/) - Abstract PURPOSE: We aimed to compare the immunohistochemical expression of PD-1, PD-L1 and CTLA-4 of pregnancy-related breast cancer (PRBC) and early onset non-PRBC (YWBC), and their prognosis prediction potential was correlated to that of conventional clinicopathological factors. METHODS: Twenty-one PRBC cases were paired with 21 YWBC in this matched case-control study. Immune-checkpoint markers (ICM) were
- [Comparing the Effectiveness of Pain Therapy (PT) and Modulated Electro-Hyperthermia (mEHT) Versus Pain Therapy Alone in Treating Patients With Painful Bony Metastases: an observational trial](https://oncotherm.com/hu/klinikai-publikaciok/comparing-the-effectiveness-of-pain-therapy-pt-and-modulated-electro-hyperthermia-meht-versus-pain-therapy-alone-in-treating-patients-with-painful-bony-metastases-an-observational-trial/) - Overview The aim of the trial is to compare the response, duration of pain relief and time to achieve pain relief after pain therapy (PT) with or without hyperthermia (mEHT) in patients with painful bony metastases. Cancer patients with bony metastases and a VAS score of ≥5 on a 0– 10 scale were treated with
- [Comparing the Effectiveness of Pain Therapy (PT) and Modulated Electro-Hyperthermia (mEHT) Versus Pain Therapy Alone in Treating Patients With Painful Bony Metastases: an observational trial](https://oncotherm.com/clinical-publications/comparing-the-effectiveness-of-pain-therapy-pt-and-modulated-electro-hyperthermia-meht-versus-pain-therapy-alone-in-treating-patients-with-painful-bony-metastases-an-observational-trial/) - Overview The aim of the trial is to compare the response, duration of pain relief and time to achieve pain relief after pain therapy (PT) with or without hyperthermia (mEHT) in patients with painful bony metastases. Cancer patients with bony metastases and a VAS score of ≥5 on a 0– 10 scale were treated with
- [Comparing the Effectiveness of Pain Therapy (PT) and Modulated Electro-Hyperthermia (mEHT) Versus Pain Therapy Alone in Treating Patients With Painful Bony Metastases: an observational trial](https://oncotherm.com/de/klinische-publikationen/comparing-the-effectiveness-of-pain-therapy-pt-and-modulated-electro-hyperthermia-meht-versus-pain-therapy-alone-in-treating-patients-with-painful-bony-metastases-an-observational-trial/) - Overview The aim of the trial is to compare the response, duration of pain relief and time to achieve pain relief after pain therapy (PT) with or without hyperthermia (mEHT) in patients with painful bony metastases. Cancer patients with bony metastases and a VAS score of ≥5 on a 0– 10 scale were treated with
- [Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study](https://oncotherm.com/hu/klinikai-publikaciok/modulated-electrohyperthermia-in-integrative-cancer-treatment-for-relapsed-malignant-glioblastoma-and-astrocytoma-retrospective-multicenter-controlled-study/) - Abstract BACKGROUND: There are interesting studies on glioma therapy with modulated electrohyperthermia (mEHT), which combines heat therapy with an electric field. Clinical researchers not only found the mEHT method feasible for palliation but also reported evidence of therapeutic response. PURPOSE: To study the efficacy and safety of mEHT for the treatment of relapsed malignant glioma
- [Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study](https://oncotherm.com/clinical-publications/modulated-electrohyperthermia-in-integrative-cancer-treatment-for-relapsed-malignant-glioblastoma-and-astrocytoma-retrospective-multicenter-controlled-study/) - Abstract BACKGROUND: There are interesting studies on glioma therapy with modulated electrohyperthermia (mEHT), which combines heat therapy with an electric field. Clinical researchers not only found the mEHT method feasible for palliation but also reported evidence of therapeutic response. PURPOSE: To study the efficacy and safety of mEHT for the treatment of relapsed malignant glioma
- [Modulated Electrohyperthermia in Integrative Cancer Treatment for Relapsed Malignant Glioblastoma and Astrocytoma: Retrospective Multicenter Controlled Study](https://oncotherm.com/de/klinische-publikationen/modulated-electrohyperthermia-in-integrative-cancer-treatment-for-relapsed-malignant-glioblastoma-and-astrocytoma-retrospective-multicenter-controlled-study/) - Abstract BACKGROUND: There are interesting studies on glioma therapy with modulated electrohyperthermia (mEHT), which combines heat therapy with an electric field. Clinical researchers not only found the mEHT method feasible for palliation but also reported evidence of therapeutic response. PURPOSE: To study the efficacy and safety of mEHT for the treatment of relapsed malignant glioma
- [The Induction of Immunogenic Cell Death (ICD) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma (GBM)](https://oncotherm.com/hu/klinikai-publikaciok/the-induction-of-immunogenic-cell-death-icd-during-maintenance-chemotherapy-and-subsequent-multimodal-immunotherapy-for-glioblastoma-gbm/) - Abstract The prognosis of Glioblastoma multiforme remains poor. Immunotherapy improved survival in a small fraction of patients. We studied the efficiency of multimodal immunotherapy as part of first line treatment for patients with GBM. Immunogenic Cell Death (ICD) was induced with Newcastle Disease Virus (NDV) and Modulated Electrohyperthermia (mEHT), and Dendritic Cell (DC) vaccinations loaded
- [The Induction of Immunogenic Cell Death (ICD) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma (GBM)](https://oncotherm.com/clinical-publications/the-induction-of-immunogenic-cell-death-icd-during-maintenance-chemotherapy-and-subsequent-multimodal-immunotherapy-for-glioblastoma-gbm/) - Abstract The prognosis of Glioblastoma multiforme remains poor. Immunotherapy improved survival in a small fraction of patients. We studied the efficiency of multimodal immunotherapy as part of first line treatment for patients with GBM. Immunogenic Cell Death (ICD) was induced with Newcastle Disease Virus (NDV) and Modulated Electrohyperthermia (mEHT), and Dendritic Cell (DC) vaccinations loaded
- [The Induction of Immunogenic Cell Death (ICD) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma (GBM)](https://oncotherm.com/de/klinische-publikationen/the-induction-of-immunogenic-cell-death-icd-during-maintenance-chemotherapy-and-subsequent-multimodal-immunotherapy-for-glioblastoma-gbm/) - Abstract The prognosis of Glioblastoma multiforme remains poor. Immunotherapy improved survival in a small fraction of patients. We studied the efficiency of multimodal immunotherapy as part of first line treatment for patients with GBM. Immunogenic Cell Death (ICD) was induced with Newcastle Disease Virus (NDV) and Modulated Electrohyperthermia (mEHT), and Dendritic Cell (DC) vaccinations loaded
- [The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma](https://oncotherm.com/hu/klinikai-publikaciok/the-effect-of-modulated-electro-hyperthermia-on-temperature-and-blood-flow-in-human-cervical-carcinoma/) - Abstract Introduction: Mild hyperthermia has been known to enhance the response of tumours to radiotherapy or chemotherapy by increasing tumour blood flow, thereby increasing tumour oxygenation or drug delivery. The purpose of this study was to assess the changes in temperature and blood flow in human cervical cancer in response to regional heating with modulated
- [The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma](https://oncotherm.com/clinical-publications/the-effect-of-modulated-electro-hyperthermia-on-temperature-and-blood-flow-in-human-cervical-carcinoma/) - Abstract Introduction: Mild hyperthermia has been known to enhance the response of tumours to radiotherapy or chemotherapy by increasing tumour blood flow, thereby increasing tumour oxygenation or drug delivery. The purpose of this study was to assess the changes in temperature and blood flow in human cervical cancer in response to regional heating with modulated
- [The effect of modulated electro-hyperthermia on temperature and blood flow in human cervical carcinoma](https://oncotherm.com/de/klinische-publikationen/the-effect-of-modulated-electro-hyperthermia-on-temperature-and-blood-flow-in-human-cervical-carcinoma/) - Abstract Introduction: Mild hyperthermia has been known to enhance the response of tumours to radiotherapy or chemotherapy by increasing tumour blood flow, thereby increasing tumour oxygenation or drug delivery. The purpose of this study was to assess the changes in temperature and blood flow in human cervical cancer in response to regional heating with modulated
- [Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth](https://oncotherm.com/hu/klinikai-publikaciok/combined-treatment-with-modulated-electro-hyperthermia-and-an-autophagy-inhibitor-effectively-inhibit-ovarian-and-cervical-cancer-growth/) - Abstract Purpose: Modulated electro-hyperthermia (mEHT), known as oncothermia, is an anticancer therapy that induces radiofrequency thermal damage to the cancer tissues. This study aimed to evaluate the potential effectiveness of mEHT as a therapeutic tool in ovarian and cervical cancer. Materials and methods: We used both tumor-bearing mice and ovarian and cervical OVCAR-3, SK-OV-3, HeLa
- [Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth](https://oncotherm.com/clinical-publications/combined-treatment-with-modulated-electro-hyperthermia-and-an-autophagy-inhibitor-effectively-inhibit-ovarian-and-cervical-cancer-growth/) - Abstract Purpose: Modulated electro-hyperthermia (mEHT), known as oncothermia, is an anticancer therapy that induces radiofrequency thermal damage to the cancer tissues. This study aimed to evaluate the potential effectiveness of mEHT as a therapeutic tool in ovarian and cervical cancer. Materials and methods: We used both tumor-bearing mice and ovarian and cervical OVCAR-3, SK-OV-3, HeLa
- [Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth](https://oncotherm.com/de/klinische-publikationen/combined-treatment-with-modulated-electro-hyperthermia-and-an-autophagy-inhibitor-effectively-inhibit-ovarian-and-cervical-cancer-growth/) - Abstract Purpose: Modulated electro-hyperthermia (mEHT), known as oncothermia, is an anticancer therapy that induces radiofrequency thermal damage to the cancer tissues. This study aimed to evaluate the potential effectiveness of mEHT as a therapeutic tool in ovarian and cervical cancer. Materials and methods: We used both tumor-bearing mice and ovarian and cervical OVCAR-3, SK-OV-3, HeLa
- [Nanoparticles and nanothermia for malignant brain tumors, a suggestion of treatment for further investigations](https://oncotherm.com/hu/klinikai-publikaciok/nanoparticles-and-nanothermia-for-malignant-brain-tumors-a-suggestion-of-treatment-for-further-investigations/) - Abstract The current treatment for brain tumors, such as glioblastoma multiforme (GBM), has not been developed enough yet in order to fully heal them. The main causes are the lack of specificity of the treatments, the difficulty of passage of drugs through the blood-brain barrier, heterogeneity and tumor aggressiveness, and widespread dissemination in the brain.
- [Nanoparticles and nanothermia for malignant brain tumors, a suggestion of treatment for further investigations](https://oncotherm.com/clinical-publications/nanoparticles-and-nanothermia-for-malignant-brain-tumors-a-suggestion-of-treatment-for-further-investigations/) - Abstract The current treatment for brain tumors, such as glioblastoma multiforme (GBM), has not been developed enough yet in order to fully heal them. The main causes are the lack of specificity of the treatments, the difficulty of passage of drugs through the blood-brain barrier, heterogeneity and tumor aggressiveness, and widespread dissemination in the brain.
- [Nanoparticles and nanothermia for malignant brain tumors, a suggestion of treatment for further investigations](https://oncotherm.com/de/klinische-publikationen/nanoparticles-and-nanothermia-for-malignant-brain-tumors-a-suggestion-of-treatment-for-further-investigations/) - Abstract The current treatment for brain tumors, such as glioblastoma multiforme (GBM), has not been developed enough yet in order to fully heal them. The main causes are the lack of specificity of the treatments, the difficulty of passage of drugs through the blood-brain barrier, heterogeneity and tumor aggressiveness, and widespread dissemination in the brain.
- [The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial](https://oncotherm.com/hu/klinikai-publikaciok/the-effect-of-modulated-electro-hyperthermia-on-local-disease-control-in-hiv-positive-and-negative-cervical-cancer-women-in-south-africa-early-results-from-a-phase-iii-randomised-controlled-trial/) - Background The global burden of cervical cancer remains high with the highest morbidity and mortality rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has shown to improve treatment outcomes. This is an analysis of the local control results at six months post-treatment of patients enrolled in an ongoing study investigating the effects
- [The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial](https://oncotherm.com/clinical-publications/the-effect-of-modulated-electro-hyperthermia-on-local-disease-control-in-hiv-positive-and-negative-cervical-cancer-women-in-south-africa-early-results-from-a-phase-iii-randomised-controlled-trial/) - Background The global burden of cervical cancer remains high with the highest morbidity and mortality rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has shown to improve treatment outcomes. This is an analysis of the local control results at six months post-treatment of patients enrolled in an ongoing study investigating the effects
- [The effect of modulated electro-hyperthermia on local disease control in HIV-positive and -negative cervical cancer women in South Africa: Early results from a phase III randomised controlled trial](https://oncotherm.com/de/klinische-publikationen/the-effect-of-modulated-electro-hyperthermia-on-local-disease-control-in-hiv-positive-and-negative-cervical-cancer-women-in-south-africa-early-results-from-a-phase-iii-randomised-controlled-trial/) - Background The global burden of cervical cancer remains high with the highest morbidity and mortality rates reported in developing countries. Hyperthermia as a chemo- and radiosensitiser has shown to improve treatment outcomes. This is an analysis of the local control results at six months post-treatment of patients enrolled in an ongoing study investigating the effects
- [Integrative Therapeutic Options for Treating Stage Four Breast Cancer](https://oncotherm.com/hu/klinikai-publikaciok/integrative-therapeutic-options-for-treating-stage-four-breast-cancer/) - Abstract Traditional Western medicine treats breast cancer – the most commonly occurring cancer in women with some combination of surgery, chemotherapy and/or radiation therapy. Few doctors’ council their patients to use complementary modalities and some forbid their use. However, complementary therapies in the form of agents or activities that minimize exposure to toxins, detoxify the
- [Integrative Therapeutic Options for Treating Stage Four Breast Cancer](https://oncotherm.com/clinical-publications/integrative-therapeutic-options-for-treating-stage-four-breast-cancer/) - Abstract Traditional Western medicine treats breast cancer – the most commonly occurring cancer in women with some combination of surgery, chemotherapy and/or radiation therapy. Few doctors’ council their patients to use complementary modalities and some forbid their use. However, complementary therapies in the form of agents or activities that minimize exposure to toxins, detoxify the
- [Integrative Therapeutic Options for Treating Stage Four Breast Cancer](https://oncotherm.com/de/klinische-publikationen/integrative-therapeutic-options-for-treating-stage-four-breast-cancer/) - Abstract Traditional Western medicine treats breast cancer – the most commonly occurring cancer in women with some combination of surgery, chemotherapy and/or radiation therapy. Few doctors’ council their patients to use complementary modalities and some forbid their use. However, complementary therapies in the form of agents or activities that minimize exposure to toxins, detoxify the
- [Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer](https://oncotherm.com/hu/klinikai-publikaciok/phase-i-ii-clinical-trial-of-modulated-electro-hyperthermia-treatment-in-patients-with-relapsed-refractory-or-progressive-heavily-treated-ovarian-cancer/) - Abstract Objective: To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT) treatment and to reveal whether mEHT treatment is feasible and effective as second-line therapy in recurrent and progressive ovarian cancer. Methods: Patients were treated with mEHT with dose escalation during the first cycle (two sessions each week for three weeks) to determine the MTD.
- [Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer](https://oncotherm.com/clinical-publications/phase-i-ii-clinical-trial-of-modulated-electro-hyperthermia-treatment-in-patients-with-relapsed-refractory-or-progressive-heavily-treated-ovarian-cancer/) - Abstract Objective: To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT) treatment and to reveal whether mEHT treatment is feasible and effective as second-line therapy in recurrent and progressive ovarian cancer. Methods: Patients were treated with mEHT with dose escalation during the first cycle (two sessions each week for three weeks) to determine the MTD.
- [Phase I/II clinical trial of modulated electro-hyperthermia treatment in patients with relapsed, refractory or progressive heavily treated ovarian cancer](https://oncotherm.com/de/klinische-publikationen/phase-i-ii-clinical-trial-of-modulated-electro-hyperthermia-treatment-in-patients-with-relapsed-refractory-or-progressive-heavily-treated-ovarian-cancer/) - Abstract Objective: To determine the maximal tolerated dose (MTD) of modulated electro-hyperthermia (mEHT) treatment and to reveal whether mEHT treatment is feasible and effective as second-line therapy in recurrent and progressive ovarian cancer. Methods: Patients were treated with mEHT with dose escalation during the first cycle (two sessions each week for three weeks) to determine the MTD.
- [Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients](https://oncotherm.com/hu/klinikai-publikaciok/modulated-electro-hyperthermia-as-palliative-treatment-for-pancreatic-cancer-a-retrospective-observational-study-on-106-patients/) - Abstract Background: Pancreatic adenocarcinoma has a poor prognosis, resulting in a
- [Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients](https://oncotherm.com/clinical-publications/modulated-electro-hyperthermia-as-palliative-treatment-for-pancreatic-cancer-a-retrospective-observational-study-on-106-patients/) - Abstract Background: Pancreatic adenocarcinoma has a poor prognosis, resulting in a
- [Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients](https://oncotherm.com/de/klinische-publikationen/modulated-electro-hyperthermia-as-palliative-treatment-for-pancreatic-cancer-a-retrospective-observational-study-on-106-patients/) - Abstract Background: Pancreatic adenocarcinoma has a poor prognosis, resulting in a
- [Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer](https://oncotherm.com/hu/klinikai-publikaciok/long-term-survival-outcomes-of-metabolically-supported-chemotherapy-with-gemcitabine-based-or-folfirinox-regimen-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-metastatic/) - Abstract Background: Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell. Objectives: This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric
- [Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer](https://oncotherm.com/clinical-publications/long-term-survival-outcomes-of-metabolically-supported-chemotherapy-with-gemcitabine-based-or-folfirinox-regimen-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-metastatic/) - Abstract Background: Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell. Objectives: This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric
- [Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer](https://oncotherm.com/de/klinische-publikationen/long-term-survival-outcomes-of-metabolically-supported-chemotherapy-with-gemcitabine-based-or-folfirinox-regimen-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-metastatic/) - Abstract Background: Despite introduction of new chemotherapeutic agents, outcomes of patients with metastatic pancreatic cancer are still poor. Metabolically supported chemotherapy (MSCT) is a novel approach targeting dysregulated energy mechanism of the tumor cell. Objectives: This study aimed to examine the efficacy of metabolically supported administration of chemotherapy combined with ketogenic diet, hyperthermia, and hyperbaric
- [Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy](https://oncotherm.com/hu/klinikai-publikaciok/breaking-therapy-resistance-an-update-on-oncolytic-newcastle-disease-virus-for-improvements-of-cancer-therapy/) - Abstract Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus(NDV)asabiologicalagentwithpotentialtobreaktherapyresistance. Thisavianviruscombines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11describedimmunestimulatoryproperties. FiftyyearsofclinicalapplicationofNDVgivewitnessto the high safety profile of this biological agent.
- [Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy](https://oncotherm.com/clinical-publications/breaking-therapy-resistance-an-update-on-oncolytic-newcastle-disease-virus-for-improvements-of-cancer-therapy/) - Abstract Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus(NDV)asabiologicalagentwithpotentialtobreaktherapyresistance. Thisavianviruscombines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11describedimmunestimulatoryproperties. FiftyyearsofclinicalapplicationofNDVgivewitnessto the high safety profile of this biological agent.
- [Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy](https://oncotherm.com/de/klinische-publikationen/breaking-therapy-resistance-an-update-on-oncolytic-newcastle-disease-virus-for-improvements-of-cancer-therapy/) - Abstract Resistance to therapy is a major obstacle to cancer treatment. It may exist from the beginning, or it may develop during therapy. The review focusses on oncolytic Newcastle disease virus(NDV)asabiologicalagentwithpotentialtobreaktherapyresistance. Thisavianviruscombines, upon inoculation into non-permissive hosts such as human, 12 described anti-neoplastic effects with 11describedimmunestimulatoryproperties. FiftyyearsofclinicalapplicationofNDVgivewitnessto the high safety profile of this biological agent.
- [Thermal and Nonthermal Effects of Radiofrequency on Living State and Applications as an Adjuvant with Radiation Therapy](https://oncotherm.com/hu/klinikai-publikaciok/thermal-and-nonthermal-effects-of-radiofrequency-on-living-state-and-applications-as-an-adjuvant-with-radiation-therapy/) - Abstract One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a rarely applied oncotherapy because of controversial results and complicated control. The challenge in clinical studies of oncological hyperthermia is the disharmony of the local response and local control
- [Thermal and Nonthermal Effects of Radiofrequency on Living State and Applications as an Adjuvant with Radiation Therapy](https://oncotherm.com/clinical-publications/thermal-and-nonthermal-effects-of-radiofrequency-on-living-state-and-applications-as-an-adjuvant-with-radiation-therapy/) - Abstract One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a rarely applied oncotherapy because of controversial results and complicated control. The challenge in clinical studies of oncological hyperthermia is the disharmony of the local response and local control
- [Thermal and Nonthermal Effects of Radiofrequency on Living State and Applications as an Adjuvant with Radiation Therapy](https://oncotherm.com/de/klinische-publikationen/thermal-and-nonthermal-effects-of-radiofrequency-on-living-state-and-applications-as-an-adjuvant-with-radiation-therapy/) - Abstract One of the most frequently applied bioelectromagnetic effects is the deep heating of living species with electromotive force energy. Despite its long history, hyperthermia is a rarely applied oncotherapy because of controversial results and complicated control. The challenge in clinical studies of oncological hyperthermia is the disharmony of the local response and local control
- [Fluctuations hypothesize the new explanation of meridians in living systems](https://oncotherm.com/hu/klinikai-publikaciok/fluctuations-hypothesize-the-new-explanation-of-meridians-in-living-systems/) - Abstract Biosystems are complex. Their physiology is well-controlled with various negative feedback signals and processes, it describes by opposite interfering effects which are characterized in the Eastern philosophy by Yin-Yang (Y-Y) pairs. Y-Y pairs could be described by the promoter-suppressor pairs in a wide range of physiologic signals creating the homeostasis of the complex system.
- [Fluctuations hypothesize the new explanation of meridians in living systems](https://oncotherm.com/clinical-publications/fluctuations-hypothesize-the-new-explanation-of-meridians-in-living-systems/) - Abstract Biosystems are complex. Their physiology is well-controlled with various negative feedback signals and processes, it describes by opposite interfering effects which are characterized in the Eastern philosophy by Yin-Yang (Y-Y) pairs. Y-Y pairs could be described by the promoter-suppressor pairs in a wide range of physiologic signals creating the homeostasis of the complex system.
- [Fluctuations hypothesize the new explanation of meridians in living systems](https://oncotherm.com/de/klinische-publikationen/fluctuations-hypothesize-the-new-explanation-of-meridians-in-living-systems/) - Abstract Biosystems are complex. Their physiology is well-controlled with various negative feedback signals and processes, it describes by opposite interfering effects which are characterized in the Eastern philosophy by Yin-Yang (Y-Y) pairs. Y-Y pairs could be described by the promoter-suppressor pairs in a wide range of physiologic signals creating the homeostasis of the complex system.
- [Defining Characteristics of Nodal Disease on PET/CT Scans in Patients With HIV-Positive and-Negative Locally Advanced Cervical Cancer in South Africa](https://oncotherm.com/hu/klinikai-publikaciok/defining-characteristics-of-nodal-disease-on-pet-ct-scans-in-patients-with-hiv-positive-and-negative-locally-advanced-cervical-cancer-in-south-africa/) - Abstract Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim is to identify differences in presentation and characteristics of FDG-avid lymph nodes between HIV-positive and HIV-negative locally advanced cervical cancer (LACC) patients in our clinical setting. We evaluated 250 pre-treatment 18F-FDG PET/CT imaging studies from women screened for a phase III randomised controlled
- [Defining Characteristics of Nodal Disease on PET/CT Scans in Patients With HIV-Positive and-Negative Locally Advanced Cervical Cancer in South Africa](https://oncotherm.com/clinical-publications/defining-characteristics-of-nodal-disease-on-pet-ct-scans-in-patients-with-hiv-positive-and-negative-locally-advanced-cervical-cancer-in-south-africa/) - Abstract Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim is to identify differences in presentation and characteristics of FDG-avid lymph nodes between HIV-positive and HIV-negative locally advanced cervical cancer (LACC) patients in our clinical setting. We evaluated 250 pre-treatment 18F-FDG PET/CT imaging studies from women screened for a phase III randomised controlled
- [Defining Characteristics of Nodal Disease on PET/CT Scans in Patients With HIV-Positive and-Negative Locally Advanced Cervical Cancer in South Africa](https://oncotherm.com/de/klinische-publikationen/defining-characteristics-of-nodal-disease-on-pet-ct-scans-in-patients-with-hiv-positive-and-negative-locally-advanced-cervical-cancer-in-south-africa/) - Abstract Literature reports increased FDG nodal uptake in HIV-positive patients. Our aim is to identify differences in presentation and characteristics of FDG-avid lymph nodes between HIV-positive and HIV-negative locally advanced cervical cancer (LACC) patients in our clinical setting. We evaluated 250 pre-treatment 18F-FDG PET/CT imaging studies from women screened for a phase III randomised controlled
- [Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic nonsmall cell lung cancer](https://oncotherm.com/hu/klinikai-publikaciok/feasibility-study-of-metabolically-supported-chemotherapy-with-weekly-carboplatin-paclitaxel-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-metastatic-nonsmall-cell-lung-c/) - ABSTRACT Background: Previous evidence suggests that metabolically supported chemotherapy (MSCT), ketogenic diet, hyperthermia and hyperbaric oxygen therapy (HBOT) could all target vulnerabilities of cancer cells. This study aimed to evaluate the efficacy and the tolerability of this combination therapy in the treatment of stage IV non-small cell lung cancer (NSCLC). Methods: Forty-four NSCLC patients with
- [Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic nonsmall cell lung cancer](https://oncotherm.com/clinical-publications/feasibility-study-of-metabolically-supported-chemotherapy-with-weekly-carboplatin-paclitaxel-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-metastatic-nonsmall-cell-lung-c/) - ABSTRACT Background: Previous evidence suggests that metabolically supported chemotherapy (MSCT), ketogenic diet, hyperthermia and hyperbaric oxygen therapy (HBOT) could all target vulnerabilities of cancer cells. This study aimed to evaluate the efficacy and the tolerability of this combination therapy in the treatment of stage IV non-small cell lung cancer (NSCLC). Methods: Forty-four NSCLC patients with
- [Feasibility study of metabolically supported chemotherapy with weekly carboplatin/paclitaxel combined with ketogenic diet, hyperthermia and hyperbaric oxygen therapy in metastatic nonsmall cell lung cancer](https://oncotherm.com/de/klinische-publikationen/feasibility-study-of-metabolically-supported-chemotherapy-with-weekly-carboplatin-paclitaxel-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-metastatic-nonsmall-cell-lung-c/) - ABSTRACT Background: Previous evidence suggests that metabolically supported chemotherapy (MSCT), ketogenic diet, hyperthermia and hyperbaric oxygen therapy (HBOT) could all target vulnerabilities of cancer cells. This study aimed to evaluate the efficacy and the tolerability of this combination therapy in the treatment of stage IV non-small cell lung cancer (NSCLC). Methods: Forty-four NSCLC patients with
- [Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients](https://oncotherm.com/hu/klinikai-publikaciok/analysis-of-the-effects-of-meht-on-the-treatmentrelated-toxicity-and-quality-of-life-of-hiv-positive-cervical-cancer-patients/) - ABSTRACT Introduction: HIV infection is associated with increased treatment-related toxicity and worse outcomes in locally advanced cervical cancer patients (LACC), especially in resource-constrained settings. Local control (LC) in a phase III randomized, controlled trial investigating modulated electro-hyperthermia (mEHT) on LACC patients in South Africa (ethics registration: M120477/M190295), was significantly higher in participants randomized to receive chemoradiotherapy
- [Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients](https://oncotherm.com/clinical-publications/analysis-of-the-effects-of-meht-on-the-treatmentrelated-toxicity-and-quality-of-life-of-hiv-positive-cervical-cancer-patients/) - ABSTRACT Introduction: HIV infection is associated with increased treatment-related toxicity and worse outcomes in locally advanced cervical cancer patients (LACC), especially in resource-constrained settings. Local control (LC) in a phase III randomized, controlled trial investigating modulated electro-hyperthermia (mEHT) on LACC patients in South Africa (ethics registration: M120477/M190295), was significantly higher in participants randomized to receive chemoradiotherapy
- [Analysis of the effects of mEHT on the treatmentrelated toxicity and quality of life of HIV-positive cervical cancer patients](https://oncotherm.com/de/klinische-publikationen/analysis-of-the-effects-of-meht-on-the-treatmentrelated-toxicity-and-quality-of-life-of-hiv-positive-cervical-cancer-patients/) - ABSTRACT Introduction: HIV infection is associated with increased treatment-related toxicity and worse outcomes in locally advanced cervical cancer patients (LACC), especially in resource-constrained settings. Local control (LC) in a phase III randomized, controlled trial investigating modulated electro-hyperthermia (mEHT) on LACC patients in South Africa (ethics registration: M120477/M190295), was significantly higher in participants randomized to receive chemoradiotherapy
- [A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer](https://oncotherm.com/hu/klinikai-publikaciok/a-randomized-phase-ii-trial-of-best-supportive-care-with-or-without-hyperthermia-and-vitamin-c-for-heavily-pretreated-advanced-refractory-non-small-cell-lung-cancer/) - Abstract Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage
- [A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer](https://oncotherm.com/clinical-publications/a-randomized-phase-ii-trial-of-best-supportive-care-with-or-without-hyperthermia-and-vitamin-c-for-heavily-pretreated-advanced-refractory-non-small-cell-lung-cancer/) - Abstract Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage
- [A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non-small-cell lung cancer](https://oncotherm.com/de/klinische-publikationen/a-randomized-phase-ii-trial-of-best-supportive-care-with-or-without-hyperthermia-and-vitamin-c-for-heavily-pretreated-advanced-refractory-non-small-cell-lung-cancer/) - Abstract Our previous study indicated that intravenous vitamin C (IVC) treatment concurrent with modulated electrohyperthermia (mEHT) was safe and improved the quality of life (QoL) of non-small-cell lung cancer (NSCLC) patients. The aim of this trial was to further verify the efficacy of the above combination therapy in previously treated patients with refractory advanced (stage
- [Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients](https://oncotherm.com/hu/klinikai-publikaciok/potentiation-of-the-abscopal-effect-by-modulated-electro-hyperthermia-in-locally-advanced-cervical-cancer-patients/) - ABSTRACT Background: A Phase III randomized controlled trial investigating the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced cervical cancer patients is being conducted in South Africa (Human Research Ethics Committee approval: M1704133; ClincialTrials.gov ID: NCT03332069). Two hundred and ten participants were randomized and 202 participants were eligible for six month local disease control evaluation. Screening 18F-FDG
- [Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients](https://oncotherm.com/clinical-publications/potentiation-of-the-abscopal-effect-by-modulated-electro-hyperthermia-in-locally-advanced-cervical-cancer-patients/) - ABSTRACT Background: A Phase III randomized controlled trial investigating the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced cervical cancer patients is being conducted in South Africa (Human Research Ethics Committee approval: M1704133; ClincialTrials.gov ID: NCT03332069). Two hundred and ten participants were randomized and 202 participants were eligible for six month local disease control evaluation. Screening 18F-FDG
- [Potentiation of the Abscopal Effect by Modulated Electro-Hyperthermia in Locally Advanced Cervical Cancer Patients](https://oncotherm.com/de/klinische-publikationen/potentiation-of-the-abscopal-effect-by-modulated-electro-hyperthermia-in-locally-advanced-cervical-cancer-patients/) - ABSTRACT Background: A Phase III randomized controlled trial investigating the addition of modulated electro-hyperthermia (mEHT) to chemoradiotherapy for locally advanced cervical cancer patients is being conducted in South Africa (Human Research Ethics Committee approval: M1704133; ClincialTrials.gov ID: NCT03332069). Two hundred and ten participants were randomized and 202 participants were eligible for six month local disease control evaluation. Screening 18F-FDG
- [Survival Outcomes of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Advanced Gastric Cancer](https://oncotherm.com/hu/klinikai-publikaciok/survival-outcomes-of-metabolically-supported-chemotherapy-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-advanced-gastric-cancer/) - Abstract: Background: Survival outcomes are still far from being satisfactory in patients with advanced gastric cancer, despite availability of novel chemotherapeutic regimens. Aim: This study evaluated the outcomes of patients with advanced gastric cancer who received chemotherapy along with additional treatment modalities targeting multiple tumor cell vulnerabilities. Materials and Methods: A total of 24 patients
- [Survival Outcomes of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Advanced Gastric Cancer](https://oncotherm.com/clinical-publications/survival-outcomes-of-metabolically-supported-chemotherapy-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-advanced-gastric-cancer/) - Abstract: Background: Survival outcomes are still far from being satisfactory in patients with advanced gastric cancer, despite availability of novel chemotherapeutic regimens. Aim: This study evaluated the outcomes of patients with advanced gastric cancer who received chemotherapy along with additional treatment modalities targeting multiple tumor cell vulnerabilities. Materials and Methods: A total of 24 patients
- [Survival Outcomes of Metabolically Supported Chemotherapy Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Advanced Gastric Cancer](https://oncotherm.com/de/klinische-publikationen/survival-outcomes-of-metabolically-supported-chemotherapy-combined-with-ketogenic-diet-hyperthermia-and-hyperbaric-oxygen-therapy-in-advanced-gastric-cancer/) - Abstract: Background: Survival outcomes are still far from being satisfactory in patients with advanced gastric cancer, despite availability of novel chemotherapeutic regimens. Aim: This study evaluated the outcomes of patients with advanced gastric cancer who received chemotherapy along with additional treatment modalities targeting multiple tumor cell vulnerabilities. Materials and Methods: A total of 24 patients
- [Feasibility of Modulated Electro-Hyperthermia in Preoperative Treatment for Locally Advanced Rectal Cancer: Early Phase 2 Clinical Results](https://oncotherm.com/hu/klinikai-publikaciok/feasibility-of-modulated-electro-hyperthermia-in-preoperative-treatment-for-locally-advanced-rectal-cancer-early-phase-2-clinical-results/) - Abstract: Despite advances in the multimodal approach for rectal cancer, treatment-related side effects remain an important issue. From this perspective, a prospective trial was performed to investigate the feasibility of modulated electro-hyperthermia (mEHT) as a concomitant boost to preoperative chemoradiation in locally advanced rectal cancer. Seventy-six patients with cT3-4 or cT2N+ rectal cancer were enrolled
- [Feasibility of Modulated Electro-Hyperthermia in Preoperative Treatment for Locally Advanced Rectal Cancer: Early Phase 2 Clinical Results](https://oncotherm.com/clinical-publications/feasibility-of-modulated-electro-hyperthermia-in-preoperative-treatment-for-locally-advanced-rectal-cancer-early-phase-2-clinical-results/) - Abstract: Despite advances in the multimodal approach for rectal cancer, treatment-related side effects remain an important issue. From this perspective, a prospective trial was performed to investigate the feasibility of modulated electro-hyperthermia (mEHT) as a concomitant boost to preoperative chemoradiation in locally advanced rectal cancer. Seventy-six patients with cT3-4 or cT2N+ rectal cancer were enrolled
- [Feasibility of Modulated Electro-Hyperthermia in Preoperative Treatment for Locally Advanced Rectal Cancer: Early Phase 2 Clinical Results](https://oncotherm.com/de/klinische-publikationen/feasibility-of-modulated-electro-hyperthermia-in-preoperative-treatment-for-locally-advanced-rectal-cancer-early-phase-2-clinical-results/) - Abstract: Despite advances in the multimodal approach for rectal cancer, treatment-related side effects remain an important issue. From this perspective, a prospective trial was performed to investigate the feasibility of modulated electro-hyperthermia (mEHT) as a concomitant boost to preoperative chemoradiation in locally advanced rectal cancer. Seventy-six patients with cT3-4 or cT2N+ rectal cancer were enrolled
- [Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice](https://oncotherm.com/hu/klinikai-publikaciok/suppression-of-metastatic-melanoma-growth-in-lung-by-modulated-electro-hyperthermia-monitored-by-a-minimally-invasive-heat-stress-testing-approach-in-mice/) - Simple Summary The lung is the most frequent site of distant melanoma metastases. Metastases of melanoma in the lungs offer a very poor prognosis, with a 5-year survival rate of below 10%. Hyperthermic therapies including modulated electro-hyperthermia (mEHT) in clinical settings have been used to improve the efficacy of radiotherapy, chemotherapy, and immunotherapy of tumors.
- [Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice](https://oncotherm.com/clinical-publications/suppression-of-metastatic-melanoma-growth-in-lung-by-modulated-electro-hyperthermia-monitored-by-a-minimally-invasive-heat-stress-testing-approach-in-mice/) - Simple Summary The lung is the most frequent site of distant melanoma metastases. Metastases of melanoma in the lungs offer a very poor prognosis, with a 5-year survival rate of below 10%. Hyperthermic therapies including modulated electro-hyperthermia (mEHT) in clinical settings have been used to improve the efficacy of radiotherapy, chemotherapy, and immunotherapy of tumors.
- [Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice](https://oncotherm.com/de/klinische-publikationen/suppression-of-metastatic-melanoma-growth-in-lung-by-modulated-electro-hyperthermia-monitored-by-a-minimally-invasive-heat-stress-testing-approach-in-mice/) - Simple Summary The lung is the most frequent site of distant melanoma metastases. Metastases of melanoma in the lungs offer a very poor prognosis, with a 5-year survival rate of below 10%. Hyperthermic therapies including modulated electro-hyperthermia (mEHT) in clinical settings have been used to improve the efficacy of radiotherapy, chemotherapy, and immunotherapy of tumors.
- [Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia](https://oncotherm.com/hu/klinikai-publikaciok/putative-abscopal-effect-in-three-patients-treated-by-combined-radiotherapy-and-modulated-electrohyperthermia/) - ABSTRACT Purpose: True abscopal responses from radiation therapy are extremely rare; the combination of immune checkpoint inhibitors with radiation therapy has led to more reports of the abscopal effect, but even in this setting, the genuine magnitude remains unknown and is still considered generally uncommon. We report the occurrence of what appears to be putative, durable
- [Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia](https://oncotherm.com/clinical-publications/putative-abscopal-effect-in-three-patients-treated-by-combined-radiotherapy-and-modulated-electrohyperthermia/) - ABSTRACT Purpose: True abscopal responses from radiation therapy are extremely rare; the combination of immune checkpoint inhibitors with radiation therapy has led to more reports of the abscopal effect, but even in this setting, the genuine magnitude remains unknown and is still considered generally uncommon. We report the occurrence of what appears to be putative, durable
- [Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia](https://oncotherm.com/de/klinische-publikationen/putative-abscopal-effect-in-three-patients-treated-by-combined-radiotherapy-and-modulated-electrohyperthermia/) - ABSTRACT Purpose: True abscopal responses from radiation therapy are extremely rare; the combination of immune checkpoint inhibitors with radiation therapy has led to more reports of the abscopal effect, but even in this setting, the genuine magnitude remains unknown and is still considered generally uncommon. We report the occurrence of what appears to be putative, durable
- [Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer](https://oncotherm.com/hu/klinikai-publikaciok/beneficial-effects-of-modulated-electro-hyperthermia-during-neoadjuvant-treatment-for-locally-advanced-rectal-cancer/) - Purpose: Modulated electro-hyperthermia (mEHT) may enhance the tumor response, although the effectiveness of combined neoadjuvant therapy remains unclear. Therefore, we investigated the role of mEHT with neoadjuvant therapy for locally advanced rectal cancer. Materials and methods: Clinical data were analyzed for 120 patients who received neoadjuvant treatment for locally advanced rectal cancer (T3/4 or Nþ, M0) from May
- [Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer](https://oncotherm.com/clinical-publications/beneficial-effects-of-modulated-electro-hyperthermia-during-neoadjuvant-treatment-for-locally-advanced-rectal-cancer/) - Purpose: Modulated electro-hyperthermia (mEHT) may enhance the tumor response, although the effectiveness of combined neoadjuvant therapy remains unclear. Therefore, we investigated the role of mEHT with neoadjuvant therapy for locally advanced rectal cancer. Materials and methods: Clinical data were analyzed for 120 patients who received neoadjuvant treatment for locally advanced rectal cancer (T3/4 or Nþ, M0) from May
- [Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer](https://oncotherm.com/de/klinische-publikationen/beneficial-effects-of-modulated-electro-hyperthermia-during-neoadjuvant-treatment-for-locally-advanced-rectal-cancer/) - Purpose: Modulated electro-hyperthermia (mEHT) may enhance the tumor response, although the effectiveness of combined neoadjuvant therapy remains unclear. Therefore, we investigated the role of mEHT with neoadjuvant therapy for locally advanced rectal cancer. Materials and methods: Clinical data were analyzed for 120 patients who received neoadjuvant treatment for locally advanced rectal cancer (T3/4 or Nþ, M0) from May
- [Marked local and distant response of heavily treated breast cancer with cardiac metastases treated by combined low dose radiotherapy, low dose immunotherapy and hyperthermia: a case report](https://oncotherm.com/hu/klinikai-publikaciok/marked-local-and-distant-response-of-heavily-treated-breast-cancer-with-cardiac-metastases-treated-by-combined-low-dose-radiotherapy-low-dose-immunotherapy-and-hyperthermia-a-case-report/) - Abstract: Breast cancer (BC) with cardiac metastases (CMs) is often associated with poor prognosis due to late stage of diagnosis. Palliative radiotherapy (RT) for CMs is generally used for symptomatic treatment and to maintain normal cardiac function. Palliative RT with hyperthermia (HT) or immunotherapy have been reported to be effective in prolonging the overall survival
- [Marked local and distant response of heavily treated breast cancer with cardiac metastases treated by combined low dose radiotherapy, low dose immunotherapy and hyperthermia: a case report](https://oncotherm.com/clinical-publications/marked-local-and-distant-response-of-heavily-treated-breast-cancer-with-cardiac-metastases-treated-by-combined-low-dose-radiotherapy-low-dose-immunotherapy-and-hyperthermia-a-case-report/) - Abstract: Breast cancer (BC) with cardiac metastases (CMs) is often associated with poor prognosis due to late stage of diagnosis. Palliative radiotherapy (RT) for CMs is generally used for symptomatic treatment and to maintain normal cardiac function. Palliative RT with hyperthermia (HT) or immunotherapy have been reported to be effective in prolonging the overall survival
- [Marked local and distant response of heavily treated breast cancer with cardiac metastases treated by combined low dose radiotherapy, low dose immunotherapy and hyperthermia: a case report](https://oncotherm.com/de/klinische-publikationen/marked-local-and-distant-response-of-heavily-treated-breast-cancer-with-cardiac-metastases-treated-by-combined-low-dose-radiotherapy-low-dose-immunotherapy-and-hyperthermia-a-case-report/) - Abstract: Breast cancer (BC) with cardiac metastases (CMs) is often associated with poor prognosis due to late stage of diagnosis. Palliative radiotherapy (RT) for CMs is generally used for symptomatic treatment and to maintain normal cardiac function. Palliative RT with hyperthermia (HT) or immunotherapy have been reported to be effective in prolonging the overall survival
- [Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study](https://oncotherm.com/hu/klinikai-publikaciok/modulated-electro-hyperthermic-meht-treatment-in-the-therapy-of-inoperable-pancreatic-cancer-patients-a-single-center-case-control-study/) - Abstract: Our present oncological treatment arsenal has limited treatment options for pancreatic ductal adenocarcinoma (PDAC). Extended reviews have shown the benefits of hyperthermia for PDAC, supporting the perspectives with the improvements of the treatment possibilities. METHODS: A retrospective single-center case-control study was conducted with the inclusion of 78 inoperable PDAC patients. Age-, sex-, chemotherapy-, stage-, and
- [Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study](https://oncotherm.com/clinical-publications/modulated-electro-hyperthermic-meht-treatment-in-the-therapy-of-inoperable-pancreatic-cancer-patients-a-single-center-case-control-study/) - Abstract: Our present oncological treatment arsenal has limited treatment options for pancreatic ductal adenocarcinoma (PDAC). Extended reviews have shown the benefits of hyperthermia for PDAC, supporting the perspectives with the improvements of the treatment possibilities. METHODS: A retrospective single-center case-control study was conducted with the inclusion of 78 inoperable PDAC patients. Age-, sex-, chemotherapy-, stage-, and
- [Modulated Electro-Hyperthermic (mEHT) Treatment in the Therapy of Inoperable Pancreatic Cancer Patients—A Single-Center Case-Control Study](https://oncotherm.com/de/klinische-publikationen/modulated-electro-hyperthermic-meht-treatment-in-the-therapy-of-inoperable-pancreatic-cancer-patients-a-single-center-case-control-study/) - Abstract: Our present oncological treatment arsenal has limited treatment options for pancreatic ductal adenocarcinoma (PDAC). Extended reviews have shown the benefits of hyperthermia for PDAC, supporting the perspectives with the improvements of the treatment possibilities. METHODS: A retrospective single-center case-control study was conducted with the inclusion of 78 inoperable PDAC patients. Age-, sex-, chemotherapy-, stage-, and
- [The first experience of application of remote radiotherapy in combination with hyperthermia (oncothermia) in the treatment of patients with primary gliomas of the brain of a high degree of malignancy](https://oncotherm.com/hu/klinikai-publikaciok/the-first-experience-of-application-of-remote-radiotherapy-in-combination-with-hyperthermia-oncothermia-in-the-treatment-of-patients-with-primary-gliomas-of-the-brain-of-a-high-degree-of-malignancy/) - Abstract High-grade brain gliomas are characterized by a rapid clinical course and a 2-year survival rate of 8-12%. Despite the improvement of methods of surgery, radiotherapy (RT), and systemic drug therapy, it is still not possible to significantly increase the overall and relapse-free survival in patients withth is neuro-oncological pathology, and the combination of RT
- [The first experience of application of remote radiotherapy in combination with hyperthermia (oncothermia) in the treatment of patients with primary gliomas of the brain of a high degree of malignancy](https://oncotherm.com/clinical-publications/the-first-experience-of-application-of-remote-radiotherapy-in-combination-with-hyperthermia-oncothermia-in-the-treatment-of-patients-with-primary-gliomas-of-the-brain-of-a-high-degree-of-malignancy/) - Abstract High-grade brain gliomas are characterized by a rapid clinical course and a 2-year survival rate of 8-12%. Despite the improvement of methods of surgery, radiotherapy (RT), and systemic drug therapy, it is still not possible to significantly increase the overall and relapse-free survival in patients withth is neuro-oncological pathology, and the combination of RT
- [The first experience of application of remote radiotherapy in combination with hyperthermia (oncothermia) in the treatment of patients with primary gliomas of the brain of a high degree of malignancy](https://oncotherm.com/de/klinische-publikationen/the-first-experience-of-application-of-remote-radiotherapy-in-combination-with-hyperthermia-oncothermia-in-the-treatment-of-patients-with-primary-gliomas-of-the-brain-of-a-high-degree-of-malignancy/) - Abstract High-grade brain gliomas are characterized by a rapid clinical course and a 2-year survival rate of 8-12%. Despite the improvement of methods of surgery, radiotherapy (RT), and systemic drug therapy, it is still not possible to significantly increase the overall and relapse-free survival in patients withth is neuro-oncological pathology, and the combination of RT
- [Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system](https://oncotherm.com/hu/klinikai-publikaciok/evidence-based-tools-to-improve-efficiency-of-currently-administered-oncotherapies-for-tumors-of-the-hepatopancreatobiliary-system/) - Hepatopancreatobiliary tumors are challenging to treat, and the advanced or metastatic forms have a very low 5-year survival rate. Several drug combinations have been tested, and new therapeutic approaches have been introduced in the last decades, including radiofrequency and heat based methods. Hyperthermia is the artificial heating of tumors by various biophysical methods that may
- [Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system](https://oncotherm.com/clinical-publications/evidence-based-tools-to-improve-efficiency-of-currently-administered-oncotherapies-for-tumors-of-the-hepatopancreatobiliary-system/) - Hepatopancreatobiliary tumors are challenging to treat, and the advanced or metastatic forms have a very low 5-year survival rate. Several drug combinations have been tested, and new therapeutic approaches have been introduced in the last decades, including radiofrequency and heat based methods. Hyperthermia is the artificial heating of tumors by various biophysical methods that may
- [Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system](https://oncotherm.com/de/klinische-publikationen/evidence-based-tools-to-improve-efficiency-of-currently-administered-oncotherapies-for-tumors-of-the-hepatopancreatobiliary-system/) - Hepatopancreatobiliary tumors are challenging to treat, and the advanced or metastatic forms have a very low 5-year survival rate. Several drug combinations have been tested, and new therapeutic approaches have been introduced in the last decades, including radiofrequency and heat based methods. Hyperthermia is the artificial heating of tumors by various biophysical methods that may
- [Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial](https://oncotherm.com/hu/klinikai-publikaciok/modulated-electro‑hyperthermia-with-weekly-paclitaxel-or-cisplatin-in-patients-with-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-the-kgog-3030-tr/) - The study (KGOG 3030) aimed to evaluate the safety of modulated electro‑hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into the paclitaxel or cisplatin arm at a 1:1 ratio. Patients received
- [Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial](https://oncotherm.com/clinical-publications/modulated-electro‑hyperthermia-with-weekly-paclitaxel-or-cisplatin-in-patients-with-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-the-kgog-3030-tr/) - The study (KGOG 3030) aimed to evaluate the safety of modulated electro‑hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into the paclitaxel or cisplatin arm at a 1:1 ratio. Patients received
- [Modulated electro‑hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial](https://oncotherm.com/de/klinische-publikationen/modulated-electro‑hyperthermia-with-weekly-paclitaxel-or-cisplatin-in-patients-with-recurrent-or-persistent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal-carcinoma-the-kgog-3030-tr/) - The study (KGOG 3030) aimed to evaluate the safety of modulated electro‑hyperthermia (mEHT) therapy with weekly administration of paclitaxel or cisplatin in female patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. A total of 12 patients were randomized into the paclitaxel or cisplatin arm at a 1:1 ratio. Patients received
- [“Oncothermia” (Modulated electro-hyperthermia) ― Present status and future development](https://oncotherm.com/hu/klinikai-publikaciok/oncothermia-modulated-electro-hyperthermia-―-present-status-and-future-development/) - Modulated electro-hyperthermia (mEHT) ‒ trade name: Oncothermia ‒ is an emerging curative treatment method in oncological hyperthermia. Although mEHT is similar to other classic hyperthermia methods to utilize temperature rise in tumor, there are several features; i.e. use precise impedance-matched, capacitive-coupled 13.56 MHz radiofrequency (RF) with amplitude modulation, in order to keep the tumor temperature below
- [“Oncothermia” (Modulated electro-hyperthermia) ― Present status and future development](https://oncotherm.com/clinical-publications/oncothermia-modulated-electro-hyperthermia-―-present-status-and-future-development/) - Modulated electro-hyperthermia (mEHT) ‒ trade name: Oncothermia ‒ is an emerging curative treatment method in oncological hyperthermia. Although mEHT is similar to other classic hyperthermia methods to utilize temperature rise in tumor, there are several features; i.e. use precise impedance-matched, capacitive-coupled 13.56 MHz radiofrequency (RF) with amplitude modulation, in order to keep the tumor temperature below
- [“Oncothermia” (Modulated electro-hyperthermia) ― Present status and future development](https://oncotherm.com/de/klinische-publikationen/oncothermia-modulated-electro-hyperthermia-―-present-status-and-future-development/) - Modulated electro-hyperthermia (mEHT) ‒ trade name: Oncothermia ‒ is an emerging curative treatment method in oncological hyperthermia. Although mEHT is similar to other classic hyperthermia methods to utilize temperature rise in tumor, there are several features; i.e. use precise impedance-matched, capacitive-coupled 13.56 MHz radiofrequency (RF) with amplitude modulation, in order to keep the tumor temperature below
- [Clinical study of modulated electro‑hyperthermia for advanced metastatic breast cancer](https://oncotherm.com/hu/klinikai-publikaciok/clinical-study-of-modulated-electro‑hyperthermia-for-advanced-metastatic-breast-cancer/) - Abstract. Modulated electro‑hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance‑matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim
- [Clinical study of modulated electro‑hyperthermia for advanced metastatic breast cancer](https://oncotherm.com/clinical-publications/clinical-study-of-modulated-electro‑hyperthermia-for-advanced-metastatic-breast-cancer/) - Abstract. Modulated electro‑hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance‑matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim
- [Clinical study of modulated electro‑hyperthermia for advanced metastatic breast cancer](https://oncotherm.com/de/klinische-publikationen/clinical-study-of-modulated-electro‑hyperthermia-for-advanced-metastatic-breast-cancer/) - Abstract. Modulated electro‑hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance‑matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim
- [Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients](https://oncotherm.com/hu/klinikai-publikaciok/modulated-electro-hyperthermia-in-stage-iii-and-iv-pancreatic-cancer-results-of-an-observational-study-on-158-patients/) - Abstract BACKGROUND An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy (CHT) and radiotherapy for the treatment of pancreatic cancer; in particular, the use of modulated electrohyperthermia (mEHT) results in increased survival and tumor response. AIM To compare outcomes of CHT alone or in association with mEHT for the
- [Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients](https://oncotherm.com/clinical-publications/modulated-electro-hyperthermia-in-stage-iii-and-iv-pancreatic-cancer-results-of-an-observational-study-on-158-patients/) - Abstract BACKGROUND An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy (CHT) and radiotherapy for the treatment of pancreatic cancer; in particular, the use of modulated electrohyperthermia (mEHT) results in increased survival and tumor response. AIM To compare outcomes of CHT alone or in association with mEHT for the
- [Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients](https://oncotherm.com/de/klinische-publikationen/modulated-electro-hyperthermia-in-stage-iii-and-iv-pancreatic-cancer-results-of-an-observational-study-on-158-patients/) - Abstract BACKGROUND An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy (CHT) and radiotherapy for the treatment of pancreatic cancer; in particular, the use of modulated electrohyperthermia (mEHT) results in increased survival and tumor response. AIM To compare outcomes of CHT alone or in association with mEHT for the
- [Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas](https://oncotherm.com/hu/klinikai-publikaciok/meta-analysis-of-modulated-electro-hyperthermia-and-tumor-treating-fields-in-the-treatment-of-glioblastomas/) - Simple Summary Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (
- [Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas](https://oncotherm.com/clinical-publications/meta-analysis-of-modulated-electro-hyperthermia-and-tumor-treating-fields-in-the-treatment-of-glioblastomas/) - Simple Summary Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (
- [Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas](https://oncotherm.com/de/klinische-publikationen/meta-analysis-of-modulated-electro-hyperthermia-and-tumor-treating-fields-in-the-treatment-of-glioblastomas/) - Simple Summary Glioblastoma is a highly aggressive brain tumor, which has a very poor 5-year survival rate (

## Munkatársak

- [Ács Balázs](https://oncotherm.com/hu/munkatarsak/acs-balazs/) - Ács Balázs több évtizedes tapasztalattal rendelkezik az orvostechnológiai fejlesztések területén, ügyvezetőként és tulajdonosként irányítja mind az Egyesült Arab Emirátusok beli, német, mind a magyar Oncotherm cégeket (Oncotherm Medical Trading - FZCO, Oncotherm Kft és Oncotherm GmbH) többségi tulajdonosa az Egyesült Arab Emirátusok beli Oncotherm MENA vállalatnak és az Ács Medical Holding által alapított vállalkozásokat irányítja
- [Herr Balázs Ács](https://oncotherm.com/de/kollegen/herr-balazs-acs/) - Herr Balázs Ács verfügt über jahrzehntelange Erfahrung im Bereich der medizintechnischen Entwicklung, sowohl als Geschäftsführer und Eigentümer der deutschen, ungarischen und in der Vereingten Arabischen Emiraten Oncotherm-Gesellschaften (Oncotherm GmbH, Oncotherm Kft und Oncotherm Medical Trading FZCO), Mehrheitseigentümer des UAE Oncotherm MENA-Unternehmens als auch der von der Ács Medical Holding gegründeten Unternehmen (SCA Holding Kft, SCA
- [Mr Balázs Ács](https://oncotherm.com/team/acs-balazs/) - Mr Balázs Ács has several decades of experience in the field of medical technology developments. He is the CEO and owner of the United Arab Emirates, German and Hungarian Oncotherm companies (Oncotherm Medical Trading - FZCO, Oncotherm Kft. and Oncotherm GmbH) majority owner of the UAE Oncotherm MENA company and the businesses founded by Ács
- [Prof. Dr. András Szász](https://oncotherm.com/de/kollegen/prof-dr-szasz-andras/) - Prof. Dr. András Szász ist der Entwickler der Oncothermie-Methode (modulierte Elektro-Hyperthermie, mEHT) und Gründer der Oncotherm-Unternehmensgruppe. Im Laufe seiner Karriere hat er an mehreren renommierten Universitäten gearbeitet. Derzeit ist er auch Professor an der Ungarischen Universität für Agrar- und Biowissenschaften in Gödöllő, wissenschaftlicher Leiter der Oncotherm-Gruppe und macht die Oncotherm-Methode auf internationalen Veranstaltungen noch bekannter.
- [Prof. Dr. András Szász](https://oncotherm.com/team/prof-dr-szasz-andras/) - Prof. Dr. András Szász invented the method of Oncothermia (modulated electro-hyperthermia, mEHT) and the founder of the Oncotherm company group. He worked at many renowned universities during his career. He is still active as a university professor at the Hungarian University of Agriculture and Life Sciences in Gödöllő, the scientific manager of the Oncotherm group,
- [Prof. Dr. Szász András](https://oncotherm.com/hu/munkatarsak/prof-dr-szasz-andras/) - Prof. Dr. András Szász az Oncothermia (modulált elektro-hipertermia, mEHT) módszer kifejlesztője és az Oncotherm cégcsoport megalapítója. Pályája során számos neves egyetemen tevékenykedett. Jelenleg is a Gödöllői Magyar Agrár- és Élettudományi Egyetem egyetemi tanára, az Oncotherm cégcsoport tudományos vezetőviselője és a nemzetközi eseményeken az Oncothermia módszertanát teszi még ismertebbé a világban. Több mint 450 tudományos publikáció
- [Mr János Szücs](https://oncotherm.com/team/mr-janos-szucs/) - Mr János Szücs is the Engineering manager of Oncotherm Kft. He is a certified mechanical engineer and lecturer at the Faculty of Mechanical Engineering of Budapest University of Technology and Economics. He has more than 15 years of experience in many areas of development and production. As the Head of Engineering he is responsible for
- [Frau Anikó Bertók](https://oncotherm.com/de/kollegen/bertok-aniko/) - Als Qualitätsmanagerin ist Frau Anikó Bertók für die Etwicklung, Implementierung, Effektivität und kontinuierliche Verbesserung des Qualitätsmanagementsystems in Übereinstimmung mit den Anforderungen von Behörden und Kunden verantwortlich. Sie bringt jahrzehntelange Erfahrung bei Oncotherm ein und stellt die Wirksamkeit des Managementsystems sicher.
- [Ms Anikó Bertók](https://oncotherm.com/team/bertok-aniko/) - As the Head of Quality Mr Anikó Bertók is responsible for the implementation and maintenance of the quality management system. With decades of expertise, she supports Oncotherm and ensures the effectiveness of the management system in order to meet regulatory and customer requirements.
- [Bertók Anikó](https://oncotherm.com/hu/munkatarsak/bertok-aniko/) - Minőségirányítási vezetőként a minőségirányítási rendszer megvalósításáért és fenntartásáért felel. Több évtizedes szakértelmével támogatja az Oncotherm-et, gondoskodik az irányítási rendszer hatékonyságáról a szabályozói és vevői követelményeknek való megfelelés érdekében.
- [Dr. Marcell Szász](https://oncotherm.com/de/kollegen/dr-szasz-marcell/) - Dr. Marcell Szász erhielt seinen medizinischen Abschluss (2006), seinen Doktortitel (2012) und seine Habilitation an der Semmelweis-Universität (2020). Er arbeitete als Gastforscher an der Karlsuniversität Prag (CZ), der Charité in Berlin (DE), der Johns Hopkins University, der Harvard Medical School und der University of Chicago School of Medicine (USA). 2014 erhielt er den Facharzt für
- [Dr. Carrie Minnaar](https://oncotherm.com/de/kollegen/dr-carrie-minnaar/) - Dr. Carrie Minnaar hat sich seit 2009 auf die hyperthermische Onkologie spezialisiert, hat an mehreren viel beachteten klinischen Studien teilgenommen und führt derzeit laufende Forschungsarbeiten in diesem Bereich durch. Ihre Forschung konzentriert sich auf die Verbesserung der Ergebnisse in ressourcenbeschränkten Umgebungen in Afrika. Zu Ihren Arbeiten gehört eine Phase-III-Studie mit positiven Ergebnissen bei der Verwendung
- [Szücs János](https://oncotherm.com/hu/munkatarsak/szucs-janos/) - Szücs János az Oncotherm Kft. mérnökségének vezetője. Okleveles Gépészmérnök és a Budapesti Műszaki és Gazdaságtudományi Egyetem Gépészmérnöki karának oktatója, több mint 15 éves tapasztalat rendelkezik a fejlesztés és gyártás számos területén. Szücs János úr feladata a mérnöki csapatok működésének koordinálása és szervezése, valamint a gyártással és minőségbiztosítással való együttműködés elősegítése, valamint az Oncotherm beszállítóval történő
- [Herr János Szücs](https://oncotherm.com/de/kollegen/herr-janos-szuecs/) - Herr János Szücs ist der technische Leiter der Oncotherm Kft. Er ist diplomierter Maschinenbauingenieur und Dozent an der Fakultät für Maschinenbau der Budapester Universität für Technologie und Wirtschaft. Er verfügt über mehr als 15 Jahre Erfahrung in vielen Bereichen der Entwicklung und Produktion. Als technischer Leiter ist er verantwortlich für die Koordination und Organisation der
- [Herr József Szarvas](https://oncotherm.com/de/kollegen/herr-jozsef-szarvas/) - Herr József Szarvas ist als Produktionsleiter für für die Koordination von Produktions- und Logistikaufgaben zuständig, um die Einhaltung von Qualität und Terminen zu gewährleisten. Er ist für die Verbesserung der Betriebsabläufe unseres Unternehmens durch das Management und die Optimierung der Fertigungsprozesse sowie für den effizienten Betrieb der Lieferkette und die Pflege der Lieferantenbeziehungen verantwortlich.
- [Dr. Olivér Szász](https://oncotherm.com/de/kollegen/dr-szasz-oliver/) - Dr. Olivér Szász ist Honorarprofessor an der Szent István Universität, Berater und Miteigentümer von Oncotherm Kft. in Ungarn und Berater für die Oncotherm GmbH in Deutschland. Er promovierte in Elektrotechnik mit der Entwicklung der Oncotherm-Methode und -Hilfsmittel. Er verfügt über hervorragende Kenntnisse und Erfahrungen in der Softwareentwicklung. Dieses Wissen kam auch der Oncotherm-Gruppe zugute. Seine
- [Dr. Marcell Szász](https://oncotherm.com/team/dr-szasz-marcell/) - Dr. Marcell Szász graduated as a M.D. (2006) and earned his Ph.D. (2012) and habilitation (2020) degrees from Semmelweis University, Budapest, Hungary. He has been a visiting scholar at the medical faculties of Charles University in Prague (CZ), Charité University in Berlin (DE), The Johns Hopkins University, Harvard Medical School and The University of Chicago
- [Dr. Carrie Minnaar](https://oncotherm.com/team/dr-carrie-minnaar/) - Dr. Carrie Minnaar specialises in hyperthermic oncology since 2009 and is well-recognised for her ongoing clinical trials in this field. Dr Minnaar’s research is focused on improving outcomes in resource constrained settings in Africa. Her work includes a positive phase III trial using modulated electro hyperthermia (mEHT) combined with chemoradiotherapy, several published papers on the
- [Mr József Szarvas](https://oncotherm.com/team/szarvas-jozsef/) - Mr József Szarvas is the Production manager of Oncotherm Kft. He is responsible for the overall production and logistics. His role is to manage operations to keep deadlines and he co-ordinates the suppliers.
- [Dr. Olivér Szász](https://oncotherm.com/team/dr-szasz-oliver/) - Dr. Olivér Szász is an honorary associate professor at Szent István University, a consultant and co-owner of Oncotherm Kft. in Hungary and Oncotherm GmbH in Germany. He completed a doctorate in electrical engineering with the development of Oncotherm’s method and tools. He has outstanding knowledge and experience in software development. This knowledge also provided benefits
- [Dr. Szász Olivér](https://oncotherm.com/hu/munkatarsak/dr-szasz-oliver/) - Dr. Szász Olivér a Szent István Egyetem címzetes egyetemi docense, tanácsadó és résztulajdonos a magyarországi Oncotherm Kft.-nél, a németországi Oncotherm GmbH-nál. Elektrotechnikából szerzett doktori fokozatot, az Oncotherm módszerével és eszközeinek fejlődésével együtt nőtt fel. Kimagasló tudással és tapasztalattal rendelkezik a software fejlesztési területen és ezt kamatoztataja is az Oncotherm csoport hasznára. Munkája egyben a hobbija
- [Szarvas József](https://oncotherm.com/hu/munkatarsak/szarvas-jozsef/) - Szarvas József felelősségi körébe tartozik a gyártási és logisztikai feladatok összehangolása a megfelelő minőség és határidők teljesítésének biztosítása érdekében. A gyártási folyamatok irányításán és optimalizálásán keresztül fejleszti a vállalatunk működését, továbbá az ellátási lánc hatékony operációjáért és a beszállítói kapcsolatok fenntartásáért felel.
- [Dr. Szász Marcell](https://oncotherm.com/hu/munkatarsak/dr-szasz-marcell/) - Dr. Szász Marcell orvosi diplomát (2006), Ph.D fokozatot (2012) szerzett, majd 2020-ban habilitált a Semmelweis Egyetemen. Vendégkutatóként dolgozott a Prágai Károly Egyetem (CZ), a berlini Charité Egyetem (DE), a Johns Hopkins Egyetem, a Harvard Medical School és a Chicagói Egyetem orvosi karán (USA). Patológia szakvizsgával rendelkezik (2014), az orvosi onkológia munkatársa. Érdeklődési köre elsősorban a
- [Dr. Carrie Minnaar](https://oncotherm.com/hu/munkatarsak/dr-carrie-minnaar/) - Dr. Carrie Minnaar 2009 óta specializálódott hipertermiás onkológia területére, számos elismert klinikai vizsgálatban vett részt és jelenleg is folyamatosan kutat ezen a területen. Kutatása az afrikai erőforrások szűkös környezetében elért eredmények javítására összpontosít. Munkásságához tartozik egy pozitív eredményeket hozó fázis III vizsgálat, amelyben modulált elektrohipertermiát (mEHT) alkalmazott kemoradioterápiával kombinálva. Emellett számos publikációt jelentetett meg a

## Kategóriák

- [Hírek](https://oncotherm.com/hu/hirek/)
- [News](https://oncotherm.com/news/)
- [Társadalmi felelősségvállalás](https://oncotherm.com/hu/tarsadalmi-felelossegvallalas/)
- [Corporate Social Responsibility](https://oncotherm.com/corporate-social-responsibility/)
- [Események](https://oncotherm.com/hu/esemenyek/)
- [Events](https://oncotherm.com/events/)
- [Neuigkeiten](https://oncotherm.com/de/neuigkeiten/)
- [Veranstaltungen](https://oncotherm.com/de/veranstaltungen/)
- [CSR Veranstaltungen](https://oncotherm.com/de/csr-veranstaltungen/)

## Tags

- [HU](https://oncotherm.com/hu/)
- [EN](https://oncotherm.com/)
- [DE](https://oncotherm.com/de/)

## Partner típusok

- [Oncothermia klinikák](https://oncotherm.com/hu/map/oncothermia-klinikak/)
- [Disztribútorok](https://oncotherm.com/hu/map/disztributorok/)
- [Képzési központok](https://oncotherm.com/hu/map/kepzesi-kozpontok/)
- [Oncothermia Clinics](https://oncotherm.com/map/oncothermia-clinics/)
- [Distributor Partnerships](https://oncotherm.com/map/distributor-partnerships/)
- [Research Partnerships](https://oncotherm.com/map/research-partnerships/)
- [Distributoren](https://oncotherm.com/de/map/distributoren/)
- [Oncothermie Praxen/Kliniken](https://oncotherm.com/de/map/oncothermie-praxen-kliniken/)
- [Forschungspartnerschaften](https://oncotherm.com/de/map/forschungspartnerschaften/)

## Munkatárs kategóriák

- [Menedzsment](https://oncotherm.com/hu/munkatars-kategoria/menedzsment/)
- [Tudományos munkatársak](https://oncotherm.com/hu/munkatars-kategoria/tudomanyos-munkatarsak/)
- [Mérnökség](https://oncotherm.com/hu/munkatars-kategoria/mernokseg/)
- [Gyártás](https://oncotherm.com/hu/munkatars-kategoria/gyartas/)
- [Minőségirányítás](https://oncotherm.com/hu/munkatars-kategoria/minosegiranyitas/)
- [Management](https://oncotherm.com/munkatars-kategoria/management/)
- [Scientific leaders](https://oncotherm.com/munkatars-kategoria/scientific-leaders/)
- [Production](https://oncotherm.com/munkatars-kategoria/production/)
- [Engineering](https://oncotherm.com/munkatars-kategoria/engineering/)
- [Quality management](https://oncotherm.com/munkatars-kategoria/quality-management/)
- [Produktion](https://oncotherm.com/de/munkatars-kategoria/produktion/)
- [Geschäftsführung](https://oncotherm.com/de/munkatars-kategoria/geschaeftsfuehrung/)
- [Technik](https://oncotherm.com/de/munkatars-kategoria/technik/)
- [Qualitätsmanagement](https://oncotherm.com/de/munkatars-kategoria/qualitaetsmanagement/)
- [Wissenschaftliche Leiter](https://oncotherm.com/de/munkatars-kategoria/wissenschaftliche-leiter/)